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Introduction 
As always, it is a pleasure 
to present the Health 
Protection Surveillance Centre 
epidemiological report which 
provides an analysis of the most 
important infectious diseases 
affecting Ireland during 2013.  
The publication of this report 
has been slightly delayed due 
to the prioritisation of work to develop guidance in 
response to the Ebola epidemic in West Africa. At the 
time of writing the outbreak continues in West Africa, 
highlighting the continued need for vigilance related to 
emerging infectious diseases. 
During 2013, measles continues to decline thanks to the 
continued improvement in uptake of the MMR vaccine 
and to the prompt investigation and control measures 
enacted by Departments of Public Health throughout 
the country. Four measles outbreaks were notified in 
2013 with 20 cases occurring in a school outbreak in 
the South-East. 2013 was the first year in which we 
had no cases of rubella in Ireland. While the World 
Health Organization (WHO) requires full laboratory 
investigation of all suspected rubella cases to confirm 
elimination of rubella in Ireland, this is, nonetheless, 
an important milestone in the fight against infectious 
diseases. 
In 2013 meningococcal disease increased by almost 
a quarter (23%) compared to levels reported in 
2012. However, the numbers of cases have declined 
dramatically in comparison to those seen at the peak 
of meningococcal disease during the late 1990s. The 
new Men B vaccine was used in Ireland for the first 
time in 2013, to control an outbreak of meningitis 
in an extended Irish traveller family. There was no 
change in the incidence of confirmed cases of invasive 
pneumococcal disease (IPD) in 2013. Despite reductions 
in the IPD burden in childhood, increases in non PCV7 
serotypes in other age groups continued. It is important 
that all IPD isolates are sent for typing to enable 
informed national decisions on pneumococcal vaccine 
selection. 
1,835 cases of Clostridium difficile infection (CDI) were 
notified during 2013. This represents a national crude 
incidence rate of 41.3 cases per 100,000 population, 
which is similar to the rate reported in 2012 (41.1).
The updated National Clinical Guidelines on the 
Surveillance, Diagnosis and Management of CDI in 
Ireland were published in 2013 and endorsed by the 
National Clinical Effectiveness Committee. The updated 
guidelines may be accessed on the HPSC website at:
www.hpsc.ie/A-Z/Gastroenteric/Clostridiumdifficile/
Guidelines/ 
Acute hospital use of alcohol-based hand rub increased 
by 10% in 2013 and biannual results of hand hygiene 
compliance audits continued to improve, although 
falling slightly short of a 90% compliance target set by 
HSE for 2013. 
Data on antimicrobial consumption is mixed, with a 
reduction in hospital but an increase in the community 
and Ireland ranked seventh highest for outpatient 
consumption of 27 European countries with reliable 
data.
   
It is welcome to see that for the seventh consecutive 
year, the proportion of S. aureus blood stream 
infections attributable to MRSA further declined 
to 20.3%. Unfortunately, antimicrobial resistance in 
other pathogens, such as Enterobacteriaceae (e.g., 
Escherichia coli and Klebsiella pneumoniae) and 
Enterococcus faecium has increased. In 2013, the 
Antimicrobial Resistance and Microbial Ecology group at 
NUI Galway alerted the Health Protection Surveillance 
Centre (HPSC) to the detection of two multi-drug 
resistant K. pneumoniae clones causing both infection 
and colonisation in patients attending a number of Irish 
hospitals and a national outbreak control team was 
established in October 2013 to evaluate this emerging 
threat. In response to the changing epidemiology of 
these multi-drug resistant organisms, the guidelines 
for the prevention and control of multi-drug resistant 
organisms developed under the auspices of the Royal 
College of Physicians of Ireland were further updated in 
July 2014.  
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The report on influenza during the 2013/2014 season 
highlights once again the number of patients with 
underlying risk conditions who were admitted to 
hospital without a history of influenza vaccination and 
who were not treated with antivirals.  This report also 
includes information on influenza vaccine uptake in 
hospitals and long term care facilities (LTCF). There was 
a seven percent increase in uptake in hospital staff to 
24.4% and an 8.4% increased uptake in staff working 
in LTCF to 22.8%. These figures remain well below 
the target of 40% set by the Health Service Executive 
(HSE). However some individual hospitals and LTCF 
have exceeded the target demonstrating that with 
strong local leadership significant improvements are 
possible. Influenza continues to place a considerable 
burden on the health services each year and we need to 
improve on the uptake of influenza vaccine and the use 
of anti–viral agents in order to reduce influenza-related 
morbidity and mortality.
Most group A streptococcal infections cause relatively 
mild illnesses, such as acute sore throat, scarlet fever 
and impetigo. However, they can also cause severe 
illness. The increase in the number of cases of invasive 
group A streptococcal infection (iGAS) first noted in 
2012 was maintained in 2013 and is noted in all parts of 
the country. Of the 168 patients with iGAS in 2013, 44 
required ICU admission and 39 required surgery. There 
were 16 deaths where iGAS was considered either 
a main or contributory cause of death. Worldwide, 
increases in the severity of iGAS disease have been 
associated with increases in prevalence of emm types 
1 and 3. These types now account for 53% of GAS 
isolates typed in Ireland in 2013. Ongoing surveillance is 
essential to enable early interventions for contacts and 
early detection of clusters.
The national rate of tuberculosis remained stable at 
8.2 per 100,000 and the rate in the indigenous Irish 
population was also stable at 5.5 per 100,000. However 
outbreaks continue to occur with seven reported in 
2012 and 12 in 2013, placing considerable pressure on 
public health departments. 
Campylobacter is the commonest bacterial cause of 
gastroenteritis in Ireland and Europe. The high rate of 
broiler contamination with campylobacter continues 
to be a cause of concern. Ireland has the highest rate 
of cryptosporidiosis in Europe. Cryptosporidiosis is a 
disease of rural areas with animal contact and the use of 
non-public water supplies featuring among cases. This 
is similar to the epidemiology of verotoxigenic E.Coli, 
where we also, unfortunately, continue to have the 
highest reported rate in Europe. 
Consumption of frozen berries was implicated as the 
source of a large multinational outbreak of hepatitis A in 
2013 that affected Ireland as well as other countries in 
Europe. The Food Safety Authority of Ireland has issued 
advice to boil all imported frozen berries for at least one 
minute prior to consumption. More rare causes of food 
poisoning included a case of botulism associated with 
exposure to pet turtles/ turtle feed. 
During 2013, 13 cases of Lyme neuroborreliosis were 
notified in Ireland. As it is estimated that 10% of cases 
of Lyme disease are complicated by neuroborreliosis 
it is estimated that around 130 cases of Lyme 
disease occurred in that year. There continues to be 
considerable controversy in many countries including 
Ireland around the diagnosis and management of Lyme 
disease. There is further information for both the public 
and professionals on the HPSC website 
www.hpsc.ie/A-Z/Vectorborne/LymeDisease/ 
Hepatitis C is a major cause of liver disease worldwide. 
The overall prevalence of chronic hepatitis C in Ireland is 
comparable to other Northern European countries, and 
is estimated to be between 0.5 and 1.2%. Recently new 
combination therapies have achieved high success rates 
in clearing the virus. This, combined with data showing 
the declining incidence of hepatitis C in Ireland, 
indicates there may be grounds for optimism in relation 
to tackling hepatitis C.
The overall trend in HIV cases has been relatively stable 
at 7.5 per 100,000 population. Sex between men 
remains the commonest mode of transmission (46%), 
followed by heterosexual transmission (38%). People 
who inject drugs now only account for 5% of newly 
diagnosed cases. However in 2013, 50% of new HIV 
diagnoses were late. More emphasis on the benefits of 
early testing and ready access to testing are needed to 
reduce these numbers thereby benefiting not only the 
individuals affected but also reducing the likelihood of 
transmission to others.  
Once again I would like to express my gratitude to all 
those who provide data and participate in committees 
and to staff in HPSC and elsewhere in the HSE. This 
report is a testament to all of those who are managing 
to do more with less and continue to support the 
prevention and control of infectious disease in Ireland. 
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In 2013, 41 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (0.9/100,000 total 
population). This is identical to the number reported in 
the previous year, but still considerably higher than the 
28 cases reported in 2010 (figure 1). No imported cases 
were reported in 2013.
The main change in 2013, when compared to 2012, 
is the increase in the number of non-typeable/non-
capsular strains from 26 to 32 (figure 1). No other 
noteworthy change in the overall number of cases due 
to other serotypes has been observed since 2004 apart 
from the decline in the proportion of type b cases and 
the corresponding rise of non-typeable/non-capsular 
strains (figure 1).
Non-typeable/non-capsular cases accounted for the 
majority of the invasive H. influenzae cases notified in 
2013 (78.0%, n=32/41). The remaining cases were due 
to H. influenzae type f (7.3%; n=3), type b (4.9%; n=2), 
type e (2.4%; n=1), not type b (2.4%; n=1) and isolates 
that were not typed (4.9%; n=2), with the latter two 
cases being diagnosed by PCR testing only. The cases 
ranged in age from three months to 99 years (median 
59 years). The incidence rates were highest in infants 
<1 year (4.1/100,000) and those aged 1 to 4 years 
(2.2/100,000) (table 1).
Cases occurring in children <10 years of age (n=11) and 
in elderly adults 65+ years of age (n=15) accounted for 
63.4% of all invasive H. influenzae notifications in 2013 
(table 1). One notable trend since 2004 is the increase 
in the overall proportion of cases 65+ years of age 
from 26.3% to 36.6% in 2013 compared to the decline 
in those aged between 5 and 64 years from 47.4% to 
39.0% (figure 2).
The highest frequency of cases tend to occur in the 1 
to 4 year age group, after which it falls sharply before 
rising steadily again across all 5-year age groups >=55 
years (figure 3). One consistent finding over the 2004 
to 2013 period has been the predominance of non-
typeable cases in most age groups (figure 3).
In 2013, the number of male cases (n=11) was just over 
a third of that of females (n=30), resulting in a male 
to female ratio of 0.37:1.0, considerably less than the 
1.13:1.0 ratio for the 2004 to 2013 period (figure 4).
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2013: 41
Number of cases, 2012: 41
Number of cases, 2011: 44
Crude incidence rate, 2012:0.9/100,000
Summary
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Figure 1. Number of invasive H. influenzae cases and proportion of cases attributable to type b and non-typeable strains with 
95% confidence intervals, Ireland, 2004-2013
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Incidence of disease in 2013 was highest in the HSE M 
area (1.42/100,000) with the lowest in the HSE E area 
(0.62/100,000) (table 2). No HSE area had an incidence 
rate that was significantly different from the national 
rate (figure 5) and no imported cases were reported in 
2013.
Apart from the years 2004, 2007, 2008 and 2011, H. 
influenzae cases have tended to occur most often in the 
first quarter of each calendar year (figure 6). 
Figure 7 shows how over the period 2009 to 2013 the 
proportion of non-typeable cases with septicaemia 
tends to fall between the age groups 5 to 24 and 65+ 
years. A breakdown by clinical diagnosis for all cases 
by age group between 2004 and 2013 is presented in 
Table 2. 
Five deaths were reported in 2013. The age range was 
3 months to 99 years. A non-typeable infection was 
recorded with each death, but only one was reported to 
have been caused directly by the infection.
In 2013, two cases of H. influenzae type b (Hib) 
occurred, both were two years of age and both were 
unvaccinated. In the previous year, three cases of Hib 
occurred, two of whom were <5 years of age: one 
was unvaccinated and the other was incompletely 
vaccinated having received only three doses of the Hib 
vaccine; the remaining third case occurred in an adult 
aged 45 to 49 years and was unvaccinated.
Between Q3-2007 and Q4-2013, only one true Hib 
vaccine failure was reported, highlighting the continuing 
positive impact that the Hib booster catch up campaign 
has had in Ireland. 
Since September 2008, the Hib booster dose has 
been administered at 13 months of age as part of the 
routine childhood immunisation schedule in addition 
to the three doses given during infancy (at 2, 4 and 6 
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Figure 2. Percentage and number of cases of invasive H. influenzae cases by age group 
and year, Ireland, 2004-2013
Table 1. Number and incidence rates of invasive H. influenzae cases by serotype, Ireland, 2013
Age Group Type b Type e Type f
Not 
type b
Non-typeable/
non-capsular
Not Typed* Total ASIR of Hib
ASIR of all H. 
influenzae
<1 0 0 0 0 3 0 3 0.00 4.14
1-4 2 0 0 0 4 1 7 0.62 2.18
5-9 0 0 0 0 1 0 1 0.00 0.33
10-14 0 0 0 0 0 0 0 0.00 0.00
15-19 0 0 0 0 0 0 0 0.00 0.00
20-24 0 0 0 0 0 1 1 0.00 0.13
25-34 0 1 1 0 3 0 5 0.00 0.72
35-44 0 0 0 0 2 0 2 0.00 0.35
45-54 0 0 0 0 0 0 0 0.00 0.00
55-64 0 0 1 0 6 0 7 0.00 1.31
65+ 0 0 1 1 13 0 15 0.00 0.33
All Ages 2 1 3 1 32 2 41 0.04 0.89
CIR 0.04 0.02 0.07 0.02 0.70 0.04 0.89 - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000 population
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Table 2. Number of invasive H. influenzae cases by clinical diagnosis, Ireland, 2004-2013
Clinical Diagnosis 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Septicaemia 8 14 13 6 3 9 9 11 11 14
Pneumonia 5 0 3 6 3 8 5 12 12 4
Meningitis 3 9 3 2 2 2 1 3 2 2
Meningitis & septicaemia 1 0 1 0 1 1 1 1 1 0
Bacteraemia (without focus) 1 0 1 1 2 0 0 3 5 6
Epiglottitis 1 3 3 1 1 0 2 0 0 3
Cellulitis 1 1 2 1 1 0 0 1 0 0
Septic arthritis 0 1 0 0 1 0 0 0 0 0
Osteomyelitis 1 0 0 0 0 0 0 0 0 0
Other 1 2 1 0 0 0 0 3 4 7
Not specified 16 4 11 14 8 23 10 10 6 5
Total 38 34 38 31 22 43 28 44 41 41
% Known Clinical Diagnosis 57.9% 88.2% 71.1% 54.8% 63.6% 46.5% 64.3% 77.3% 85.4% 87.8%
 Table 3. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, Ireland, 2004-2013
HSE Area 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
HSE E 1.07 1.00 0.87 0.80 0.53 0.74 0.56 1.11 1.11 0.62
HSE M 1.19 1.19 0.40 1.19 0.79 1.06 0.35 1.06 0.35 1.42
HSE MW 0.83 0.28 0.83 0.55 0.83 2.11 0.53 0.53 1.05 0.79
HSE NE 0.25 1.27 0.25 0.00 0.00 0.23 0.45 1.59 0.91 1.36
HSE NW 0.42 0.00 2.11 0.42 0.00 0.39 0.39 0.77 0.77 1.16
HSE SE 1.08 0.43 0.87 1.08 0.65 1.00 1.00 0.80 1.21 1.00
HSE S 1.13 0.32 1.29 0.32 0.64 1.20 1.05 0.30 0.60 0.90
HSE W 0.48 1.45 0.72 1.45 0.48 1.12 0.22 1.35 0.45 0.90
Ireland 0.90 0.80 0.90 0.73 0.52 0.94 0.61 0.96 0.89 0.89
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Figure 3. Number of H. influenzae cases by agegroup and type*, Ireland, 2004-
2013
* Typed includes b, e, f, not-b types
months of age). Furthermore, vaccination is routinely 
recommended for those at increased risk of Hib disease 
due to underlying medical conditions or treatments.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 27th August, 
2014. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Figure 4. Percentage of H. influenzae cases by type* and 
gender, Ireland, 2004-2013
* Typed includes b, e, f, not-b types
Figure 5. Crude incidence rates per 100,000 population with 
95% confidence intervals for H. influenzae notifications by HSE 
area, Ireland, 2013
Figure 6. Number of H. influenzae cases by year/quarter and 
gender, Ireland, 2004-2013
-17-HPSC Annual Epidemiological Report 2013 1. Vaccine Preventable Diseases
1 1 1 1 0 1
3 3 7 8
7 11
2
0
2
2 4 20
0
2
2
1 3 4
2
1
0
1
1 4
1
3 3 8 6 19
0%
25%
50%
75%
100%
<1 1-4 5-24 25-44 45-64 65+
P
er
ce
nt
ag
e 
of
 C
as
es
Age Group
Meningitis and Meningitis & Septicaemia Septicaemia
Pneumonia Bacteraemia (without focus)
Other* Not specified
Figure 7. Percentage of H. influenzae non-typeable cases by age 
group and clinical diagnosis, Ireland, 2009-2013 (excludes two 
cases of unknown age)
*Other category includes cellulitis, epiglottitis, septic arthritis 
and osteomyelitis and other not specified
There were 51 measles cases (1.1/100,000) in 2013. This 
is a decline compared to previous years (figure 1).
In 2013, the largest number of cases and the highest 
crude incidence rate was in the HSE SE (table 1). 
Twenty of the cases in the HSE SE were notified during 
October to mid November and were associated with 
a school outbreak. These 20 outbreak cases ranged in 
age from one year to five years with a mean age and a 
median age of four years. The majority (80%, n=16/20) 
of the cases were vaccinated with one dose of MMR. 
Measles positive samples from six of the 20 cases were 
genotyped by the NVRL and were genotype D8.
In 2013, the second highest number of cases and crude 
incidence rate was in the HSE E (table 1). Nine of the 
cases in the HSE E were notified in May and were 
associated with an outbreak in an extended family. 
The nine outbreak cases ranged in age from one year 
to 17 years with a mean age and median age of seven 
years. Five of the nine cases were unvaccinated; three 
were reported to have one dose of MMR while the 
vaccination status of one case was unknown. All three 
vaccinated with one dose of MMR were vaccinated 
between three and 10 days prior to onset. As the 
incubation period for measles ranges from seven to 
21 days from exposure to onset of fever these three 
cases were probably incubating measles at the time of 
vaccination. The measles virus from one of the cases was 
genotyped by the NVRL and was genotype D4.
Two other localised measles outbreaks were notified 
during 2013. One of these was an outbreak in a private 
house with two ill; one of these cases was genotyped 
by the NVRL and was genotype D4. One was a travel 
related (United Kingdom) family outbreak with two ill; 
measles virus from both of these cases were genotyped 
by the NVRL and were genotype D8.
Of the 51 measles cases in 2013, 16% (n=8) were 
classified as possible, 20% (n=10) were classified as 
probable while 65% (n=33) were classified as confirmed, 
giving a crude confirmed incidence rate of 0.7 per 
100,000 population.
1.2 Measles 
Summary
Number of cases, 2013: 51
Number of confirmed cases, 2013: 33                                 
Crude incidence rate, 2013: 1.1/100,000
Crude confirmed incidence rate, 2013: 0.7/100,000
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Figure 1. Number of measles cases by year, 2000-2013
The 51 measles cases ranged in age from six months to 
35 years; the mean age was six years and the median 
age was four years. The largest number of cases and the 
highest age specific incidence rates were in those aged 
3-4 years (figures 2 and 3). Of the 51 measles cases, 
51% (n=26) were female and 49% (n=25) were male.
Laboratory results were provided for 37 cases in 2013. 
Sixty-five percent (n=33/51) of cases were laboratory 
test positive for measles. Four cases were laboratory 
negative for measles, however, for two of these the 
specimens were not taken at the optimal time following 
disease onset. Two of the cases that were laboratory 
negative for measles were known to have a specimen 
collected at the optimal time; both of these cases were 
recorded as epidemiologically linked to a laboratory 
confirmed case.
Isolates from 13 cases were genotyped by the NVRL. 
Eleven were genotype D8 and two were genotype D4.
The country of infection was recorded as Ireland for 
43 cases, United Kingdom for three cases and was 
unknown or not reported for five cases.
Measles vaccine in Ireland is available as part of the 
combined measles mumps rubella (MMR) vaccine. 
In Ireland, vaccination with the first dose of MMR 
is routinely recommended at twelve months of age 
and the second dose at four to five years of age. A 
MMR catch up campaign started in October 2012 and 
continued during 2013. During the MMR catch up 
campaign the HSE offered a dose of MMR vaccine to 
second level students and primary school children who 
had not completed (or were not sure they had) their two 
dose MMR vaccination schedule.
Vaccination data were reported for 90% (n=46/51) of 
measles cases in 2013. Twenty-nine percent (n=15/51) 
of cases were unvaccinated; of these only six percent 
(n=3/51) were less than 12 months of age.
Fifty-three percent (n=27/51) of cases were reported 
to have one dose of MMR vaccine; the majority (93%, 
n=25/27) of these were less than six years of age. Eighty 
one percent (n=22/27) of those reported to have one 
dose of MMR were classified as confirmed or probable. 
Ninety three percent (n=26/27) with one dose of 
MMR had a vaccination date reported. Fifteen percent 
(n=4/26) of these were vaccinated between one and 
10 days prior to onset and were probably incubating 
measles at the time of vaccination.
Four cases (8%, n=4/51) were reported as having 
received two doses of MMR. Three of these cases had 
both vaccination dates reported; one of these was 
vaccinated with the second dose one day prior to onset. 
One of the cases with two MMR doses was classified as 
confirmed.
Five cases were reported as hospitalised, representing 
ten percent (n=5/51) of all cases. The mean age of 
hospitalised cases was 10 years while the median age 
was four years (range two to 35 years). All five cases 
were classified as confirmed. Length of hospitalisation 
was reported for all five cases with a median duration 
of stay of four days (range one to seven days). One 
hospitalised case had no MMR details reported, one 
was unvaccinated, two cases had one dose of MMR and 
one case had two doses of MMR.
Reported complications of measles included pneumonia 
(2%, n=1/43) and ear infection (n=2).
Of the 51 cases, the setting where the case most likely 
acquired measles was reported as home (29%, n=15), 
primary school (24%, n=12), overseas (6%, n=3), day-
care or pre-school (2%, n=1), work (2% n=1), and was 
unreported for the remainder (37%, n=19).
The figures presented above are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 10th September 2014, 
however, this report excludes two cases that were 
laboratory negative for measles and were not 
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Table 1. Number of measles cases and the crude incidence 
rate per 100,000 population (CIR) by HSE Area in 2013
HSE Area Number CIR
HSE E 19 1.2
HSE M 1 0.4
HSE MW 2 0.5
HSE NE 1 0.2
HSE NW 1 0.4
HSE SE 22 4.4
HSE S 2 0.3
HSE W 3 0.7
Total 53 1.1
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epidemiologically linked to a confirmed measles case. 
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR. 
WHO require information on discarded measles cases 
ie measles cases investigated and who were found not 
to meet the case definition. A method for capturing the 
number of these cases is in place since July 1st 2013. 
The HSE Areas reported the number of discarded CIDR 
cases to HPSC. For July to December 2013 41 cases 
were discarded from CIDR as following investigation 
they were not considered to be measles cases. 
Discarded cases are not available in CIDR for reporting 
and are therefore not included in the analysis above.
Figure 3. The age specific incidence rate (per 100,000) of 
measles cases in 2013 by case classification
Figure 2. Number of measles cases in 2013 by age group and 
case classification
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In 2013, 81 cases (1.8/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This represents a 22.7% increase on the previous year 
when 66 cases (1.4/100,000) were reported. However, 
over the past decade the trend has been downward: in 
1999 there were 536 cases (14.8/100,000). The number 
of cases reported in 2013 compared to 1999 reflects a 
decline in incidence of almost 85%.
Of the 81 cases notified in 2013, 74 (91.3%) were case 
classified as confirmed, one (1.2%) as probable and 
six (7.4%) as possible. Confirmation of diagnosis by 
laboratory testing of cases has improved with time. 
In 2013, 93.8% (n=76/81) of cases were confirmed by 
laboratory testing in comparison to 83.0% (n=445/536) 
in 1999.
Typically, most cases in 2013 were diagnosed by blood/
CSF culture testing, blood/CSF PCR testing or by 
detection of Gram negative diplococci in skin lesions/
culture or in CSF specimens. Isolation of the organism 
from non-sterile sites (such as the eye, nose or throat) in 
clinically compatible cases is considered a possible case. 
In 2013, 39 of the 74 confirmed cases (52.7%) were 
laboratory tested by PCR testing alone and another 
11 confirmed cases (14.9%) were diagnosed by culture 
of sterile specimens alone. Among the remaining 24 
(32.4%) confirmed cases, all were diagnosed by both 
culture and PCR testing of sterile specimens.
Of all the 81 cases in 2013, none had a positive skin 
lesion, throat or nose culture test result or a positive 
serology or skin lesion microscopy test result. There 
were however, two positive eye culture test results and 
four CSF positive microscopy test results.
In 2013, male cases (n=44) exceeded female cases 
(n=37), resulting in a male to female ratio of 1.2:1.0, 
following a consistent pattern observed since 2005. 
IMD cases in 2013 ranged in age from one month to 
84 years (median age of 4 years). The incidence of IMD 
was highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 year 
of age (35.9/100,000; n=26), followed by children in the 
1 to 4 year (7.4/100,000; n=21), and 15 to 19 year age 
groups (3.2/100,000; n=9) (table 1, figure 1). 
Figure 2 presents the number of IMD cases by gender 
and age group between 1999 and 2013 and shows the 
decline in numbers across all of the age groups, with 
the steepest declines observed in the <1, 5 to 9 and 10 
to 24 year age groups following the introduction of the 
meningococcal C conjugate (MCC) vaccine in late 2000.
The overall incidence of IMD in Ireland in 2013 was 
highest in the HSE SE area (2.4/100,000) with the 
lowest in the HSE S area (1.4/100,000) (table 2). No 
1.3  Meningococcal Disease     
Summary
Number of cases, 2013: 81
Number of cases, 2012: 66
Number of cases, 2011: 94
Crude incidence rate, 2013:1.8/100,000
Table 1. Number of cases, deaths, age-group specific incidence rates per 1000,000 population (calculated using Census 2011 
denominator data) and case fatality ratios of IMD, Ireland, 2013
Age Group No. Cases ASIR No. Deaths %CFR
<1 26 35.9 1 3.8%
1-4 21 7.4 0 0.0%
5-9 8 2.5 0 0.0%
10-14 2 0.7 0 0.0%
15-19 9 3.2 0 0.0%
20-24 3 1.0 0 0.0%
25+ 12 0.4 3 25.0%
All ages 81 1.8 4 4.9%
ASIR, age specific incidence rate per 100,000 population 
%CFR, case fatality ratio
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HSE area had an incidence rate that was significantly 
different from the national rate (figure 3). There was one 
imported case in 2013 from the United States.
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2013 and 
accounted for 68 of the 81 (84.0%) notifications (figure 
4). Since 2003 serogroup B has consistently accounted 
for more than 80% of annual IMD notifications (figure 4). 
Apart from the year 2003, IMD cases have tended 
to occur most frequently in the first quarter of each 
calendar year (figure 5). 
When serogroup B cases since 2009 by clinical diagnosis 
are viewed, the proportion of cases with septicaemia 
only decreases between the 1 to 4 and 25+ year age 
groups, but the opposite trend occurs with meningitis 
only cases (figure 6).
Figure 1. Age-specific rates per 100,000 population for invasive meningococcal disease 
(IMD), Ireland, 1999-2013
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Table 2. Age specific incidence rates per 100,000 population (calculated using Census 2011 denominator data) of IMD by HSE 
area and age group, Ireland, 2013
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
HSE E 26.9 10.2 0.9 1.0 2.1 0.8 0.6 1.7
HSE M 20.7 5.2 18.2 0.0 0.0 0.0 0.0 2.1
HSE MW 35.1 4.4 0.0 0.0 12.2 0.0 0.4 1.8
HSE NE 26.0 6.4 0.0 0.0 0.0 7.9 0.4 1.6
HSE NW 77.1 6.3 5.3 0.0 0.0 0.0 0.0 1.9
HSE SE 65.4 9.7 0.0 0.0 6.4 0.0 0.6 2.4
HSE S 29.9 2.5 2.2 0.0 4.9 0.0 0.5 1.4
HSE W 45.3 7.6 3.2 3.4 0.0 0.0 0.0 1.6
Ireland 35.9 7.4 2.5 0.7 3.2 1.0 0.4 1.8
Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year for meningococcal B and C disease, Ireland, 1999-2013
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
2010 93 4 4.3% 4 0 0.0%
2011 84 2 2.4% 2 0 0.0%
2012 58 1 1.7% 0 0 0.0%
2013 68 4 5.9% 1 0 0.0%
%CFR, case fatality ratio
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IMD due to serogroup C (MenC) has remained at very 
low levels over the last decade with five cases or less 
occurring annually. In 2013, only one meningococcal 
C case was notified (table 3); it occurred in an eight 
year old child with no risk factors reported and who 
had received three primary childhood doses of the 
MCC vaccine by the time she was eight months of age 
and was therefore considered a true vaccine failure for 
her age cohort. Before 2013, there had been no true 
vaccine failures since 2009 when three failures were 
reported. Between 2005 and 2008, one true vaccine 
failure was reported in each year.
The low numbers of MenC cases and the rarity of MCC 
vaccine failures over the past decade is a measure of the 
positive impact of the vaccination programme since first 
introduced in October 2000. Prior to the introduction of 
the MCC vaccine, serogroup C incidence rate in 1999 
was 3.7/100,000 population. 
There were four IMD related notified deaths in 2013 
(case fatality ratio of 4.9%), double the number in the 
previous year (table 1). This compares to an annual 
average of 5.6 deaths between 2005 and 2011. In 2013, 
the %CFR was highest amongst cases 65+ years of age 
(40.0%) as a result of two deaths among five cases. The 
next highest %CFR was 33.1% (n=1/3) due to a death in 
an adult aged 40-44 years.
All of the IMD deaths in 2013 were due to serogroup 
B disease (age range 7 months to 81 years). This is in 
marked contrast to the 13 deaths due to serogroup B 
out of all 25 deaths reported in 2000. In the same year, 
11 deaths were due to serogroup C disease. The decline 
in deaths associated with meningococcal disease since 
2000 has been significant, partly due to the decrease in 
MenC cases as a result of the vaccination programme 
and also partly due to the decline in meningococcal B 
disease (table 3). 
Despite a marked decline in the overall incidence over 
the past decade, IMD is still an important public health 
concern due to its associated severity, high mortality 
rate and serious adverse sequelae. Effective vaccination 
Figure 2. Number of IMD cases by gender and age group in Ireland, 1999-
2013 (excludes one case with unknown gender details)
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Figure 4. Number of IMD notifications in Ireland by serogroup and proportion of 
cases attributable to serogroup B with 95% confidence intervals, Ireland, 1999-2013
is necessary for the complete prevention and control of 
IMD. Effective vaccines are available against serogroups 
A, C, W135 and Y forms of the disease. In 2012, a 
recombinant multicomponent vaccine (4CMenB) 
against serogroup B disease was recommended 
for approval by the European Medicines Agency. 
Marketing authorisation for the vaccine was granted in 
January 2013 for both child and adult administration. 
The decision regarding introducing this vaccine into 
the national immunisation programme is still under 
consideration at the time of writing, but in August 2014, 
the National Immunisation Advisory Committee (NIAC) 
issued recommended guidelines relating to this vaccine, 
details of which are available at http://www.hse.ie/eng/
health/immunisation/hcpinfo/guidelines/
An outbreak of meningococcal disease in an extended 
Irish Traveller family across three HSE areas was 
reported in 2013. Eight cases of disease within this 
extended family group with epidemiological links 
were identified between March 2010 and November 
2013. All eight cases survived and were aged between 
5 and 46 months, and were either a cousin or sibling 
of another case. This outbreak was notable in that 
appropriate chemoprophylaxis had been given to the 
relevant nuclear family members and close contacts 
following each notification. Neisseria meningitidis 
isolates from six cases were highly related, belonging 
to the ST-41/44 clonal complex, and shared the porA 
designation 7-2,4. In November 2013, the outbreak 
control team (incorporating staff from public health 
departments, the Health Protection Surveillance Centre 
and the Irish Meningococcal and Meningitis Reference 
Laboratory) recommended that directly observed 
ciprofloxacin chemoprophylaxis be administered 
simultaneously to the extended family, and that the 
four component 4CMenB vaccine be administered to 
family members aged 2 months to 23 years inclusive 
in an effort to prevent further cases occurring among 
members of this family. At the time of writing, the 
combination of directly observed ciprofloxacin 
chemoprophylaxis and use of 4CMenB vaccine 
has controlled the outbreak with no further cases 
diagnosed.
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Figure 5. Number of IMD cases by quarter and serogroup, Ireland, 1999-2013
In 2014 (at the time of writing this report) new 
changes to the routine MenC vaccination programme 
are planned. Recent studies undertaken in the 
United Kingdom have identified waning immunity 
to serogroup C disease following infant vaccination 
in early childhood. Protection given by vaccination 
at 12 months also wanes by the teenage years, but 
vaccination later in childhood provides higher levels 
of antibody that persist for longer.1-4 There is also 
evidence that shows that MCC vaccination significantly 
reduces nasopharyngeal carriage of the serogroup C 
meningococcus, providing indirect protection through 
herd immunity.5-6 In recognition of waning immunity, 
NIAC has recommended a booster dose of the MCC 
vaccine for those considered at increased risk of MenC 
disease. Since 2011 the MCC vaccine booster has 
been recommended for close contacts of cases if their 
last dose was more than one year before and since 
August 2014, NIAC now recommends an adolescent 
booster at 12-13 years (http://www.hse.ie/eng/health/
immunisation/hcpinfo/guidelines/). The adolescent 
booster will be introduced into the 2014/2015 school 
immunisation programme and will be provided to 
students in the first year of secondary level school.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 27th August, 
2014. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
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Mumps
There were 223 (4.9/100,000) mumps cases notified 
in 2013. This is higher than 2012 when 163 cases 
were notified and 2011 when 165 cases were notified 
but a decline compared to the years 2008/2009 and 
2004/2005 when large outbreaks occurred (figure 1). 
The number of cases notified in 2013 is fivefold higher 
compared to the years 1998 to 2003 when there was an 
average of 43 cases notified each year.
In 2013, of the 223 mumps cases notified 36% (n=80) 
were classified as confirmed, three percent (n=6) as 
probable and 61% (n=137) were classified as possible.
The largest number of cases was notified in the HSE E 
while the highest crude incidence rate was in the HSE E 
and HSE SE (table 1).
In 2013, the median age of cases was 20 years and the 
mean age was 23 years with cases ranging in age from 
one to 84 years. The number of cases by age group and 
the age specific incidence rates are shown in figures 2 
and 3. The highest age specific incidence rates were 
in those 0-4 years and 20-24 years. Of the 223 mumps 
cases, 43% (n=97) were female and 57% (n=126) were 
male.
Mumps vaccine in Ireland is available as part of the 
combined measles mumps rubella (MMR) vaccine. 
In Ireland, vaccination with the first dose of MMR 
is routinely recommended at twelve months of age 
and the second dose at four to five years of age. A 
MMR catch up campaign started in October 2012 and 
continued during 2013. During the MMR catch up 
campaign the HSE offered a dose of MMR vaccine to 
second level students and primary school children who 
had not completed (or were not sure they had) their two 
dose MMR vaccination schedule.
Of the 223 mumps cases, 17% (n=37) were 
unvaccinated, 24% (n=53) had one dose of the 
measles-mumps-rubella vaccine (MMR), 24% (n=54) 
1.4 Mumps 
Summary
Number of cases, 2013: 223
Number of cases, 2012: 163
Crude incidence rate, 2013: 4.9/100,000
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were reported to have received two doses of MMR, 
one percent (n=2) were reported to have three doses 
of MMR while for 35% (n=77) of cases the number of 
doses of MMR was not reported. The vaccination date 
was reported for 75% (n=40/53) of cases reported to 
have received one dose of MMR. Both vaccination 
dates were reported for 37% (n=20/54) of cases 
vaccinated with two doses of MMR; one of these was 
vaccinated one day prior to onset. The vaccination 
dates were available for one of the cases given three 
doses of MMR. Thirty-one percent (n=17/54) of the 
cases reported to have received two doses of MMR 
were classified as confirmed; 35% (n=6/17) of these 
cases had both MMR vaccination dates reported. Both 
cases reported to have received three MMR doses were 
classified as possible cases.
Ten cases were hospitalised, representing four percent 
(n=10/223) of all cases and six percent (n=10/168) of 
cases where hospitalisation data were provided. The 
number of days hospitalised was reported for six of 
the hospitalised cases; the median number of days 
hospitalised was three days (range one to 12 days). 
Reported complications of mumps included orchitis 
(8%, n=6/75), mastitis (1%, n=1/130), pancreatitis (1%, 
n=1/132), deafness (1%, n=1/134), aggravated adenoids 
(n=1), back pain (n=1), dehydration (n=1) and painful 
ear (n=1).
The setting where the case most likely acquired 
mumps was reported for 27% (n=61/223) of cases. The 
identified settings for these cases were: social setting 
for 14% (n=31/223) of cases; family/household for four 
percent (n=10/223); work for four percent (n=9/223); 
day-care/preschool for two percent (n=4/223); primary 
school for one percent (n=3/223); university/college 
for one percent (n=2/223); international travel for 0.4% 
(n=1/223); and secondary school for 0.4% (n=1/223) of 
cases.
The country of infection was recorded as Ireland for 112 
cases, Brazil for one case, Malta for one case, Sudan 
for one case, United Kingdom for two cases and was 
unknown/not specified for 106 cases.
Five localised outbreaks of mumps were notified during 
2013 with a total of 11 associated cases of illness. The 
outbreak locations included a school (with three ill), a 
university/college (with two ill), a community outbreak 
(with two ill) and two of the outbreaks were associated 
with a private house (with two ill in each outbreak).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 4th September 
2014. These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.  
Figure 2. Number of notified mumps cases in 2013 by age 
group and case classification
Figure 3. The age specific incidence rates (per 100,000) of 
notified mumps cases in 2013
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Table 1. Number of mumps cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2013
HSE Area Number CIR
HSE E 101 6.2
HSE M 13 4.6
HSE MW 17 4.5
HSE NE 13 2.9
HSE NW 10 3.9
HSE SE 30 6.0
HSE S 20 3.0
HSE W 19 4.3
Total 223 4.9
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Apart from Neisseria meningitidis, which is the most 
common cause of bacterial meningitis in Ireland, other 
pathogens cause this disease, including those caused 
by non-notifiable organisms. For information on invasive 
meningococcal disease (Neisseria meningitidis), see 
that chapter within this report. Information on bacterial 
meningitis caused by specified notifiable diseases 
is summarised below and further pathogen-specific 
data are available in the relevant chapter. The figures 
presented in this chapter are based on data extracted 
from the Computerised Infectious Disease Reporting 
(CIDR) system on 27th August, 2014. These figures may 
differ from those published previously due to ongoing 
updating of notification data on CIDR. 
Bacterial meningitis caused by diseases not otherwise 
specified (NOS):
In total, 21 cases of meningitis under this disease 
category were notified in 2013, none of whom died. 
Six of the 21 (28.6%) cases were case classified 
as confirmed, five as probable (23.8%) and ten as 
possible (47.6%) (table 1). The causative pathogens 
were identified in 28.6% (n=6/21) of cases, which is 
considerably less than the annual average observed 
between 2008 and 2012 at 48% (table 2).
Prior to 1st January 2012, all cases of Group B 
streptococcus, also known as S. agalactiae, were 
notifiable under the ‘Bacterial Meningitis (NOS)’ disease 
category. In 2012, this changed when Streptococcus 
agalactiae in children < 90 days of age was notifiable 
in its own right, including those which were meningitis-
related. This has meant that the overall number of 
bacterial meningitis (NOS) cases has, as a result, fallen 
in both 2013 and 2012 compared to previous years. 
In other words, without this change there would have 
been five and 11 extra cases reported under the 
Bacterial meningitis (NOS) category in 2013 and 2012, 
respectively (table 2). Furthermore, there is evidence of 
an additional 23 possible meningitis-related cases of this 
disease in this same age group during 2012 and 2013 
where Streptococcus agalactiae was either isolated 
from or detected in CSF specimens from patients that 
were not clinically categorised as having ‘meningitis’. 
These 23 cases have been excluded from Table 3, which 
is a summary breakdown of all bacterial meningitis 
cases by their causative pathogen (both specified and 
not specified types except for meningococcal disease) 
between 2008 and 2013.
Among the bacterial meningitis (NOS) cases notified in 
2013 were four caused by Escherichia coli (age range 1 
week to 63 years; none of which had serotype details), 
one caused by Streptococcus salivarius in a one year old 
and another by Streptococcus agalactiae in an elderly 
adult. There were 15 other cases whose causative 
organism was not identified. No deaths were reported.
Bacterial meningitis caused by specified notifiable 
diseases:
Haemophilus influenzae
Two cases of meningitis due to H. influenzae were 
notified in 2013, one of which was attributable to a 
non-typeable/non-capsulated strain and another that 
was not typed. The age range was 22 to 32 years. 
One death was reported, but the actual cause was 
not known. See Table 3 and the chapter on invasive H. 
influenzae disease for further details.
Listeria species
Two cases of listeriosis meningitis were notified in 2013: 
both had a serotype 4b infection, one was aged 60 to 
64 years with an underlying medical condition and the 
other was a two week old infant. See Table 3 and the 
chapter on listeriosis disease for further details.
Streptococcus pneumoniae
In 2013, 32 cases of pneumococcal meningitis were 
notified, compared to 37 in the previous year. The 
age range of the 32 cases was one month to 85 
years (median 52 years). Four (12.5%) pneumococcal 
meningitis related deaths were reported in 2013 with 
an age range of 4 to 85 years (median 50 years) and all 
caused by the infection itself. 
Of the 32 cases in 2013, five were vaccinated with the 
1.5  Other Forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Bacterial meningitis, not otherwise specified (NOS)
Number of cases, 2013: 21
Number of cases, 2012: 29
Number of cases, 2011: 35
Crude incidence rate, 2013: 0.5/100,000
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Table 1. Number and percentage of bacterial meningitis (NOS) cases reported by cases classification, Ireland, 2008-2013
Case Classification 2008 2009 2010 2011 2012 2013 2008-2013
Confirmed 22 17 21 18 12 6 133
Probable 12 8 7 4 5 5 72
Possible 6 15 14 13 12 10 146
Total 40 40 42 35 29 21 351
% Confirmed 55.0% 42.5% 50.0% 51.4% 41.4% 28.6% 37.9%
Note: Streptococcus agalactiae < 90 days of age excluded from 2012, 2013 figures
Table 2. Number and percentage of bacterial meningitis (NOS) cases reported with and without an identified causative 
organism, Ireland, 2008-2013
Causative Organism 2008 2009 2010 2011 2012 2013 2008-2013
Known 23 15 21 20 11 6 133
Unknown/Not specified 17 25 21 15 18 15 218
Total 40 40 42 35 29 21 351
% Known 57.5% 37.5% 50.0% 57.1% 37.9% 28.6% 37.9%
Note: Streptococcus agalactiae < 90 days of age excluded from 2012, 2013 figures
Table 3. Annual notifications of bacterial meningitis (specified and NOS) except meningococcal disease, Ireland, 2008-2013
Notified under Causative organism 2008 2009 2010 2011 2012 2013 2008-2013
Haemophilus influenzae disease (invasive) Haemophilus influenzae 3 3 2 4 3 2 17
Leptospirosis Leptospira spp. 2 1 0 1 1 0 5
Listerosis Listeria spp. 3 1 3 2 2 2 13
Salmonellosis Salmonella enteritidis 0 1 0 0 0 0 1
Streptococcus pneumoniae infection 
(invasive)
Streptococcus 
pneumoniae
27 22 16 23 37 32 157
Streptococcus Group A infection (invasive) 
(iGAS)
Streptococcus pyogenes 2 0 2 0 1 3 8
Streptococcus Group B infection (invasive) 
(Group B Strep) < 90 days of age
Streptococcus agalactiae† NA NA NA NA 11 5 16
Tuberculosis* Mycobacterium spp.* 6 8 9 2 3 2 30
Total Bacterial Meningitis, specified  43 36 32 32 58 46 247
Bacterial Meningitis, not otherwise 
specified
Streptococcus 
agalactiae**
6 7 11 16 0 1 41
Escherichia coli 11 3 2 1 7 4 28
Staphylococcus aureus 3 2 6 2 1 0 14
Enterococcus faecalis 1 1 0 0 0 0 2
Streptococcus bovis 
biotype II/2
0 2 0 0 0 0 2
Citrobacter koseri 1 0 0 0 0 0 1
Enterococcus faecium 0 0 0 0 1 0 1
Group C Streptococcus 0 0 0 0 1 0 1
Klebsiella oxytoca 0 0 0 1 0 0 1
Mycoplasma pneumoniae 0 0 1 0 0 0 1
Serratia liquefaciens 1 0 0 0 0 0 1
Staphylococcus aureus & 
Staphylococcus capitis
0 0 0 0 1 0 1
Staphylococcus capitis 0 0 1 0 0 0 1
Streptococcus salivarius 0 0 0 0 0 1 1
Unknown 2 1 1 1 2 1 8
Not specified 15 24 20 14 16 14 103
Total Bacterial Meningitis, not otherwise 
specified
 40 40 42 35 29 21 207
Total Bacterial Meningitis, specified and 
not otherwise specified
 83 76 74 67 87 67 454
*Tuberculosis meningitis figure for 2013 is provisional
**Streptococcus agalactiae for all ages between 2008 and 2011 and for cases > 90 days of age only in 2012 and 2013
†Streptococcus agalactiae < 90 days of age in 2012 and 2013 figures do not include 23 meningitis-related cases where the 
causative organism was isolated from or detected in CSF specimens from patients that were not clinically categorised as having 
‘meningitis’
NA not applicable 
PCV7, PCV13 or PPV23 vaccines only or a combination 
of them, two were incompletely vaccinated with PCV13, 
24 were unvaccinated and the vaccination status of 
one case was not reported. Two deaths were reported 
among these 32 cases: one was aged 65+ years, had 
a type 6B infection and had received one dose of the 
PPV23 vaccine and had been on immunosuppressive 
therapy; the other was aged 1 to 4 years, had received 
three doses of the PCV7 vaccine plus one dose of 
the PPV23 vaccine, had no risk factors reported and 
had a type 3 infection (which is covered by the PPV23 
vaccine). Four cases could not have been prevented by 
vaccination as the serotypes involved were not covered 
by any vaccine, but there were 12 others that could 
have potentially been prevented. Additional details are 
presented in Table 4. See also a separate chapter on 
invasive pneumococcal disease for further details.
Streptococcus agalactiae < 90 days of age (also known 
as Group B streptococcus)
Five cases of meningitis causing Group B streptococcus 
infection were notified in 2013; their age range was one 
day to one month with no deaths reported. See Table 
3 and the chapter on invasive Group B streptococcal 
infections disease for further details.
Mycobacterium species
In 2013, two tuberculosis meningitis cases were notified 
(provisional at the time of writing). Cases ranged in age 
from 35 to 49 years. See the chapter on tuberculosis for 
further details.
Table 4. Details of the 32 pneumococcal meningitis cases reported, Ireland, 2013
Age 
Group 
(years)
Died Vaccinated
No. of 
Vaccine 
Doses 
Received
No. of 
PCV7 / 
Prevenar 
7 Doses
No. of PCV13 
/ Prevenar 13 
Doses
No. of 
PPV23 / 
Pneumovax 
23  Doses
Serotype 
of 
Infection
Potentially 
Vaccine 
Preventable
Serotype Covered 
by Vaccine Type
<1
 Y 3  3  NA  NA
 I 1  1  NA  NA
 I 1  1  7F  
PCV7, PCV13, 
PPV23
 N 0    7F Y
PCV7, PCV13, 
PPV23
1-4
 Y 3 2 1  NA  NA
Y Y 4 3  1 3  PCV13, PPV23
5-9  Y 3 3   NA  NA
15-19
 N 0    3 Y PCV13, PPV23
 N 0    10A Y PPV23
30-34
 N 0    35F  No
 N 0    NA  NA
Y N 0    NA  NA
35-39
 N 0    7F Y
PCV7, PCV13, 
PPV23
 N 0    6C  No
40-44  N 0    14 Y
PCV7, PCV13, 
PPV23
45-49  N 0    7F Y
PCV7, PCV13, 
PPV23
55-59
 N 0    7F Y PCV13, PPV23
 N 0    NA  NA
 N 0    NA  NA
 N 0    14 Y
PCV7, PCV13, 
PPV23
 N 0    22F Y PPV23
60-64
 N 0    23A  No
 N 0    NA  NA
 N 0    22F Y PPV23
65+
Y Y 1   1 6B  
PCV7, PCV13, 
PPV23
 N 0    NA  NA
 N 0    31  No
Y N 0    NA  NA
 N 0    19F Y
PCV7, PCV13, 
PPV23
 N 0    NA  NA
 N 0    18C Y
PCV7, PCV13, 
PPV23
 U NA    23B  No
NA=not applicable or not available; Vaccinated: Y=Yes, N=No, U=Unknown, I=Incompletely vaccinated
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Pertussis
Following an increase in pertussis in 2012 with 458 
notifications, pertussis declined in 2013 with 174 cases 
(3.8/100,000) notified (figures 1 and 2). The majority (62%) 
of cases were notified in the first five months of 2013 
(figure 3).
Of the 174 cases in 2013, 64% (n=112) were classified as 
confirmed, five percent (n=9) were classified as probable 
and 30% (n=53) were classified as possible.
The largest number of cases was notified in the HSE E 
while the highest crude incidence rate was in the HSE SE 
(table 1).
In 2013, the largest number of cases (n=51/174, 29%) 
and the highest age-specific incidence rate (70/100,000) 
were in children aged less than one year with a quarter 
(n=43/174, 25%) of all cases aged less than six months 
(figures 4 and 5). Fifty-two percent of cases (n=90) were 
female and 48% (n=84) were male.
One death occurred in a child aged less than one year; this 
child was reported to have several underlying conditions.
In Ireland it is recommended that children be vaccinated 
with an acellular pertussis containing vaccine at two, four 
and six months of age and a booster dose at four to five 
years of age. In 2008, the National Immunisation Advisory 
1.6 Pertussis
Summary
Number of cases, 2013: 174
Number of cases, 2012: 458
Crude incidence rate, 2013: 3.8/100,000
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Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2013
1948-June 2000 data collated by DoHC
July 2000-2013 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2013
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Committee (NIAC) recommended a booster with low dose 
acellular pertussis vaccine for children aged 11-14 years. 
The adolescent pertussis booster was introduced into the 
school programme, in 19 LHOs, in 2011 and to all schools 
in 2012. In August 2012, an additional pertussis booster 
was recommended for health care workers and pregnant 
women; please see www.immunisation.ie for additional 
information on pertussis vaccination recommendations.
In 2013, the vaccination status was reported for nearly two 
thirds (n=111/174, 64%) of pertussis cases. Twenty eight 
percent of cases (n=49/174) were unvaccinated; these 
cases ranged in age from three weeks to 62 years, with 
63% (n=31/49) of these cases aged less than six months. 
Twenty-seven percent of the unvaccinated cases (n=13/49) 
were less than two months of age and were therefore not 
eligible for pertussis vaccine in the Irish schedule.
Fourteen percent (n=25/174) of cases were reported as 
incompletely vaccinated, with 40% (n=10/25) of these less 
than six months of age and were therefore not eligible for 
three doses of pertussis vaccine in the Irish schedule.
Twenty-one percent (n=37/174) of cases were reported 
as completely vaccinated for their age; 54% (n=20/37) of 
these were reported to have had three doses of pertussis 
vaccine, 27% (n=10/37) were reported as having four 
doses while the number of doses was not specified for the 
remainder.
Ten localised pertussis outbreaks were notified during 
2013, with 28 associated cases of illness. Nine were family 
outbreaks (with 25 ill) and one was a school outbreak (with 
three ill).
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 5th September 2014. These 
figures may differ slightly from those published previously 
due to ongoing updating of notification data on CIDR.
Figure 3. Number of notified pertussis cases in 2013 by month of notification
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Table 1. Number of pertussis cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2013
HSE Area Number CIR
HSE E 68 4.2
HSE M 4 1.4
HSE MW 11 2.9
HSE NE 8 1.8
HSE NW 8 3.1
HSE SE 39 7.8
HSE S 23 3.5
HSE W 13 2.9
Total 174 3.8
Figure 4. Number of notified pertussis cases in 2013 by age 
group and case classification.
‘Mo’ in graph indicates months i.e. 0-5 months and 6-11 
months, the remaining age groups are in years
Figure 5. The age specific incidence rate (per 100,000 
population) of notified pertussis cases in 2013 by case 
classification
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During 2013, there was interrupted endemic 
transmission of rubella in Ireland with zero cases of 
rubella identified in 2013. In 2012 there was also 
interrupted endemic transmission of rubella. Of the 
nine cases notified in 2012, none were confirmed, eight 
were possible and the one probable case had country of 
infection recorded as United Kingdom.
All rubella cases, including suspected cases, should 
be notified to the local Department of Public Health. 
Accurate and detailed information on all notified rubella 
cases is needed to monitor progress towards the WHO 
European Measles and Rubella Elimination Strategy (for 
2015). During 2013 enhanced surveillance of rubella 
using the Computerised Infectious Disease Reporting 
(CIDR) system was implemented.
The diagnosis of rubella based solely on clinical signs 
and symptoms is often unreliable because there are 
many other causes of fever and rash illness which 
may resemble rubella infection. Therefore, diagnostic 
samples (serum, oral fluid, urine) should always be 
obtained from patients in order to accurately diagnose 
rubella. Since 2012 the laboratory criteria for case 
confirmation of rubella requires the identification 
of rubella virus specific IgG antibody response in 
serum or saliva or detection of rubella virus nucleic 
acid in a clinical specimen or isolation of rubella virus 
from a clinical specimen. Isolation of rubella virus is 
not routinely performed in Ireland but can be done 
following consultation with the laboratory. Laboratory 
results always need to be interpreted according to the 
vaccination status and history of recent vaccination. 
Since 2012 the laboratory criteria for a probable case 
requires the identification of rubella virus specific IgM 
antibody response; again laboratory results need to be 
interpreted according to the vaccination status. (For a 
case to meet the probable case classification they must 
meet the clinical criteria and be either epidemiologically 
linked to a confirmed case or meet the laboratory 
criteria for a probable case.) When rubella in pregnancy 
is suspected, further confirmation of a positive rubella 
IgM result is required (e.g. a rubella specific IgG avidity 
test showing a low avidity). In certain situations, such as 
confirmed rubella outbreaks detection of rubella virus 
IgM can be considered confirmatory in non-pregnant 
cases.
The figures presented in this summary are based on 
data extracted from the CIDR system on 18th September 
2014. These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
WHO require information on discarded rubella cases ie 
rubella cases investigated and who were found not to 
meet the case definition. A method for capturing the 
number of discarded cases is in place since July 1st 2013. 
The HSE Areas reported the number of discarded CIDR 
cases to HPSC. For July to December 2013 nine cases 
were discarded from CIDR as following investigation 
they were not considered to be rubella cases.
1.7 Rubella
Summary
Number of cases, 2013: 0
Number of cases, 2012: 9
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Background
Invasive Streptococcus pneumoniae infection is a 
notifiable disease in Ireland; clinicians and laboratories 
are legally obliged to notify this infection.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.  
IPD includes meningitis and bloodstream infection (BSI) 
with and without pneumonia. 
A number of different initiatives are in place in Ireland 
for the surveillance of IPD.  Data on IPD notifications 
are collated in the Computerised Infectious Disease 
Reporting (CIDR) system.  Enhanced surveillance of 
IPD notifications is undertaken by Departments of 
Public Health, particularly of children and adolescents 
<15 years, and these data are also collated in CIDR.  A 
separate surveillance strand (EARS-Net project) involving 
the microbiology laboratories and the HPSC is used to 
monitor in detail the antimicrobial resistance profiles 
of invasive S. pneumoniae isolates from blood and/
or CSF.  Since April 2007, the National Pneumococcal 
Typing Laboratory has provided a typing service to Irish 
laboratories for all invasive S. pneumoniae isolates.  This 
is a collaborative project involving the Royal College of 
Surgeons in Ireland/Beaumont Hospital, the Children’s 
University Hospital, Temple Street and the HPSC. In 
addition, since August 2012 HPSC is participating in a 
European Centre for Disease Prevention and Control 
(ECDC) project called SpID-net. The project aims to 
strengthen or set up long term active population based 
IPD surveillance in order to estimate the impact of the 
pneumococcal conjugate vaccines in children less than 
five years of age in Europe.
In September 2008, the 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced into the Irish 
infant immunisation schedule at 2, 6 and 12 months of 
age.  A catch-up campaign was also implemented at that 
time, targeting children <2 years of age.  In December 
2010, PCV13 replaced PCV7 in the infant schedule. 
Uptake of three doses of PCV by 24 months of age for 
2013 was 91%.
Notification data for IPD was extracted from CIDR on 
30th June 2014. These figures may differ slightly from 
those previously published due to ongoing updating 
of notification data on CIDR.  For the 2012 and 2013 
notifications, the 2012 HPSC case definition for IPD was 
used.  In brief, isolation or detection of S. pneumoniae 
from a normally sterile site was classified as confirmed; 
detection of S. pneumoniae antigen from urine was 
classified as possible case. Since 2012 the previously 
used probable case definition is no longer applicable 
and any case in which S. pneumonia antigen is detected 
from urine (previously defined as a probable case) is now 
classified as possible, and antigen detection from a sterile 
site is now categorized as confirmed. 
Results
All IPD notifications
In 2013, 638 cases of IPD (13.9/100,000) were notified in 
Ireland, a significant increase compared with 2012 (427 
cases; 9.3/100000). This increase is related to an increase 
in the number of possible cases notified in comparison to 
2012 (239 possible cases in 2013 versus 80 possible cases 
in 2012).
In 2013, 54% (n=345) of notifications were classified as 
confirmed and 46% (n=293) as possible. The majority 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of confirmed cases in 2013: 345
Number of confirmed cases in 2012: 347
Number of deaths in 2013: 24
Number of deaths in 2012: 37
Crude incidence rate of confirmed cases in 2013:  
7.5/100,000
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Figure 1.  Number of confirmed invasive pneumococcal 
disease (IPD) notifications by typing status and the incidence 
rate (IR) of confirmed IPD with 95% confidence intervals, 
2008-2013
Data source: CIDR
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of possible cases (91%) were notified by HSE-SE, HSE 
E and HSE MW (n=128/293; n=81/293 and n=59/293, 
respectively).  These figures do not necessarily indicate 
a higher burden of IPD in these areas relative to other 
areas, but more likely reflects an increase in the use of 
urinary antigen tests being used and therefore more 
reports of positive urinary antigen cases from these areas. 
Confirmed IPD notifications
Focusing specifically on the confirmed IPD notifications, 
345 cases were notified in 2013 (7.5/100,000; 95% CI 
6.8 - 8.3/100,000),unchanged compared with 2012 
(7.6/100,000; 95% CI 6.8 - 8.4/100,000; 347 cases) 
(Figure 1). In 2013, the incidence of confirmed IPD in 
2013 declined by 21% compared with 2008 (9.5/100,000; 
95% CI 8.6 – 10.5/100,000; 404 cases; p<0.05) (Figure 1).
In 2013, 80% of the confirmed IPD notifications had an 
isolate submitted for serotyping, somewhat less than 
the proportion of cases in 2012 (85%) but the same as 
the proportion in both 2008 and 2009 when 79% of 
notifications had an isolate typed (Figure 1).  In 2013 
however, 36% of notifications (14/39) relating to children 
<5 years of age did not have an isolate submitted 
for serotyping.  For seven of the 14 the cases were 
confirmed by PCR only and no isolate was available. For 
the remaining seven isolates from a sterile site, no sample 
was available for typing.
Incidence rates by HSE area ranged from 3.9 per 100,000 
in HSE-M to 10.5 per 100,000 in HSE-NW, with the high 
incidence in the HSE MW, HSE NE and HSE-SE (Figure 
2).  However, the incidence rates in each of the eight HSE 
areas were not statistically different from the national 
one.
A clinical diagnosis was reported for 146 of the 345 
confirmed cases (42%), which included BSI with 
pneumonia (n=93), meningitis (n=32), and other BSI for 
the remainder (n=21).
More cases occurred in males (n=179,52%) than in 
females. . Cases ranged in age from 1 month to 100 
years, with an average age of 56.7 years (median age 64 
years).  Those aged 65 years and older accounted for half 
of the cases (50%, n=171). The age specific incidence 
rate (ASIR) was highest in those 85 years of age and older 
(61.6/100,000; n=36), followed by those in the 75-84 
years age group (42.4/100,000; n=73) and the 65-74 year 
age group (20.3/100,000; n=62) (Figure 3).  In children 
< 2 years of age the ASIR was 11.7 cases per 100,000 
population (n=17).  A statistically significant decline 
(72%) in IPD incidence was seen in this age group when 
compared with 2008 (42/100,000; n=52; p<0.0001), 
highlighting the positive impact of the introduction of 
PCV7 in September 2008 to the infant schedule followed 
by PCV13 in December 2010(Figure 3). 
The medical risk factor field was completed for 98 
(28%) confirmed cases; 38 cases (11%) did not have an 
identified risk factor; for the remainder this information 
was either unknown or not specified.  Based on the 
98 cases for whom this information was reported, 85 
(69%) had an underlying medical risk factor, with some 
patients having multiple risk factors.  The main risk 
factors reported included immunosuppressive condition 
or therapies (n=29), chronic lung disease (n=32), chronic 
heart disease (n=26), chronic liver disease (n=5) and renal 
diseases (n=10). It should also be noted that being aged 
65 years and older was also a recognised IPD risk factor; 
171 cases in 2013 were in this age group.  Apart from 
their age, 51 cases in this age group also had a reported 
medical risk factor.
IPD death notifications
Outcome was reported in 30% (n=194) of the IPD 
notifications in 2013 versus 47% in 2012. Therefore, these 
figures may not accurately estimate the burden of IPD 
in terms of mortality. Based on the data available, 31 
deaths in individuals with IPD in 2013 were reported.  In 
2013 the cause of death was reported as directly due to 
IPD in eight cases, not due to IPD in five cases and for 
Figure 2.  Incidence rate of confirmed invasive pneumococcal 
disease notifications by HSE area, 2013
Data source: CIDR
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Figure 3.  Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2013
Data source: CIDR
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the remaining 16, the cause of death was not specified 
or was unknown.  Twenty four deaths occurred in 
adults, ranging in age from 32-100 years and one death 
occurred in a four year age child. All twenty four deaths 
were in confirmed cases. 
The apparent increase in IPD death notifications in 2013 
and 2012 (24 cases in 2013 and 37 cases in 2012 versus 
11 cases in 2011) is most likely related to the additional 
information that was available by linking CIDR data to 
the Enhanced Surveillance of Blood Stream Infections 
(ESBI) database. Using BSI data it was possible to identify 
missing information on outcome in CIDR and then the 
CIDR database was updated by HSE areas. 
Impact of pneumococcal conjugate vaccines (PCV)
Data from the National Pneumococcal Typing Laboratory 
were used to assess the impact of introducing PCV on 
the distribution of S. pneumoniae serotypes associated 
with IPD and on the burden of IPD in Ireland.  In 2013, 
of the 345 confirmed IPD notifications reported in CIDR, 
276 had isolates sent for typing (80%).  Twelve percent of 
IPD infections were due to serotypes covered by PCV7 
(4, 6B, 9V, 14, 18C, 19F and 23F), 39% were associated 
with the six additional serotypes included in PCV13 (1, 3, 
5, 6A, 7F and 19A) and the remaining 49% of infections 
were due to non-vaccine types (NVTs).  
Since introducing PCV7 to the Irish childhood 
immunisation schedule towards the end of 2008, there 
has been a 20% reduction in the overall burden of IPD 
disease.  Reductions in the incidence of IPD due to PCV7 
serotypes have been seen in all age groups (Figure 4a).  
Overall, the incidence of IPD due to PCV7 serotype 
has significantly declined in 2013 compared with 2008 
(80% decline, p<0.001).  The greatest impact has been 
seen in children <2 years of age where the incidence 
due to PCV7 serotypes has declined by 97% (p<0.001) 
(Figure 4a).  In 2013 the incidence of disease due to the 
additional six serotypes covered by the PCV13 declined 
by 64% in children <2 years of age compared with 2008 
(Figure 4b).  This decline was not observed in any of the 
other age groups, but rather the incidence of disease 
associated with these additional six serotypes increased 
compared with previous years (Figure 4b).  An increase in 
incidence due to the non vaccine types (NVTs) was also 
seen in 2013 compared with 2008. However, in those 
aged 65 years and greater, a decrease in incidence was 
observed in 2013 compared with 2012. There has been 
little change in the incidence of NVTs among other age 
groups (Figure 4c).  
The predominant serotypes in circulation in 2013, 
were 7F and 19A (both included in PCV13), followed 
by serotypes 22F (NVT), 3 (included in PCV13) and 14 
(included in PCV7 and PCV13).  In children <2 years of 
age, the predominant serotypes were 7F (included in 
PCV13), 22F and 10A (both NVTs) accounting for a half of 
the isolates serotyped in this age group (Figure 5).
For ongoing updates, see “Slides – Impact of 
PCV in Ireland” at http://www.hpsc.ie/hpsc/A-Z/
VaccinePreventable/PneumococcalDisease/
PostersPresentations/
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Figure 4.  Age specific incidence rate by age group of 
confirmed invasive pneumococcal disease cases due to (a) 
PCV7 serotypes, (b) the additional six serotypes covered by 
PCV13 and (c) non-vaccine types , 2008-2013
Data source: National Pneumococcal Typing Laboratory
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PCV vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, three PCV vaccine failures were 
reported in 2013, all due to serotype 19A (PCV 13). 
Since 2008, a total of seven vaccine failures have been 
reported in addition to the three reported in 2013, two 
in 2010 (19F and 14) and two in 2012 (19F and 19A. 
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2013, the proportion of penicillin non-susceptible 
invasive S. pneumoniae (PNSP) was 20.7%, (2.3% and 
18.3% with high and intermediate level resistance, 
respectively) while 17.9% of isolates were resistant to 
erythromycin (Data source: HPSC/EARS-Net Ireland).  
This compares to 19.6% and 16.9% in 2012 respectively. 
In the UK, the PNSP proportion in 2013 was 4.9% (0.5% 
and 4.4%, with high and intermediate level resistance, 
respectively). 
In 2013, Ireland had one of the highest proportions of 
PNSP in Europe, ranking 10th out of 29 countries overall.  
Although, 35 different serotypes were identified in 
2013, only 13 serotypes were associated with penicillin 
non-susceptiblity. The predominant PNSP serotypes in 
2013 were 19A, 14 and 35B whereas in 2008 serotypes 
9V and 14 were the leading ones. For details on the 
antimicrobial resistance patterns of S. pneumoniae, 
please see the chapter on Antimicrobial Resistance 
within this report. 
Discussion
Although there was no significant changes in the 
incidence of confirmed cases of IPD in Ireland in 2013 
compared with 2012, since its introduction in 2008, 
PCV7 has had a significant impact in reducing the overall 
burden of the disease in the total population.  There has 
been a decline in IPD in all age groups due to serotypes 
covered by PCV7, indicating the indirect/herd immunity 
effect the vaccine confers on the population.  The 
greatest impact has been in children <2 years of age 
where disease incidence due to PCV7 serotypes has 
fallen by over 97%.  The impact due to additional six 
serotypes covered by PCV13 vaccine was observed in 
children <2 years of age, amongst whom the reduction in 
the incidence of disease was 64%.
However, despite reductions in the IPD burden during 
childhood, the incidence of disease due to non-PCV7 
serotypes has increased in other age groups.  There has 
been a shift in the prevalent serotypes associated with 
invasive disease.  Serotypes 7F, 19A, and 22F were the 
predominant serotypes identified in 2013.  
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in 
Ireland, it is crucial that laboratories continue to send 
all invasive S. pneumoniae isolates for typing to the 
National Pneumococcal Typing Laboratory.  Although 
80% of confirmed notifications had an isolate submitted 
for serotyping in 2013, 20% (n=69) did not, including 
14 cases in children <5 years of age.  In seven of these 
14 cases an isolate was not available for typing and 
confirmation was by PCR only.  Serotype information is 
unavailable for 36% of confirmed notifications in this age 
group and the absence of this data is of concern.
Continued good quality IPD surveillance including the 
monitoring of invasive S. pneumoniae serotypes is 
crucial in identifying any epidemiological changes in 
the disease, in assessing the impact of PCV13 on public 
health and in guiding further vaccination strategies, as 
newer expanded valency vaccines become available.  For 
example, due to the incomplete data we do not know 
the impact of IPD on mortality and this is a key metric 
in assessing the true impact of this disease and the 
effectiveness of interventions, including new vaccines.
Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age group 
(years) in Ireland, 2013
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: National Pneumococcal Typing Laboratory
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HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College 
of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project since 2000. During the 2013/2014 influenza 
season, 60 general practices (located in all HSE-Areas) 
were recruited to report electronically, on a weekly 
basis, the number of patients who consulted with 
influenza-like illness (ILI). Sentinel GPs were requested 
to send a combined nose and throat swab to the NVRL 
on one ILI patient per week. The NVRL also tested 
respiratory non-sentinel specimens, referred mainly from 
hospitals. 
Other surveillance systems set up to monitor ILI/
influenza activity include:
•   Surveillance of all calls to GP out-of-hours (OOHs) 
centres, monitored for self-reported influenza. These 
data were provided by HSE-NE.  
•   Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System 
(CIDR) in Ireland. 
•   Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years.   
•   Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza 
•   Surveillance of all reported influenza-associated 
deaths. 
•   A network of sentinel hospitals reporting admissions 
data.
The data presented in this summary were based on all 
data reported to HPSC by the 28th November 2014. 
Due to the current legislation regarding the registration 
of deaths in Ireland; there can be significant delays 
between the date of death and the registration of 
deaths and subsequent reporting to HPSC. Further 
information on the registration of deaths in Ireland is 
available on the General Register Office website.  
Sentinel GP Clinical Data
Influenza activity in Ireland was moderate during 
the 2013/2014-influenza season, with sentinel GP 
ILI consultation rates peaking at 54.1 per 100,000 
population during week 9 2014 (late February/
early March) (figure 1). ILI rates first increased above 
baseline levels (21.0/100,000) during week 6 2014 and 
remained there for eight consecutive weeks, a shorter 
period than for the previous season (2012/2013). The 
highest age specific ILI rates were reported in the 5-14 
year age group (peaking at 71.6/100,000), followed 
by those aged 15-64 years (59.3/100,000), 0-4 years 
(56.6/100,000) and those aged 65 years or older 
(46.8/100,000).
Virological Data - Influenza
The NVRL tested 581 sentinel specimens for influenza 
virus during the 2013/2014 season. Two hundred and 
seventy-five (47.3%) sentinel specimens were positive 
for influenza: 264 influenza A (160 A(H3), 98 A(H1)
pdm09 and 6 A not subtyped) and 11 influenza B. 
Data on underlying medical conditions and vaccination 
status were reported from the sentinel GP network 
for 54 confirmed influenza cases. Of these 54 cases 
reported with underlying medical conditions and known 
vaccination status, 82% were not vaccinated. 
The NVRL tested 8391 non-sentinel respiratory 
specimens during the 2013/2014 season, 1283 (15.3%) 
of which were positive for influenza: 1269 influenza A 
(797 A(H3), 369 A(H1)pdm09 and 103 A (not subtyped)) 
and 14 influenza B. 
Influenza A(H3) was the predominant influenza virus 
circulating during the 2013/2014 season, co-circulating 
with influenza A(H1)pdm09. Influenza A accounted for 
98.4% of all influenza positive specimens and influenza 
B for 1.6%. Of the 1424 influenza A sentinel and non-
sentinel specimens that were subtyped, influenza A(H3) 
accounted for 67.2% and influenza A(H1)pdm09 for 
32.8%. 
2.1 Influenza and Other Respiratory Viruses
Summary
2013/2014 influenza season summary:
Peak influenza-like illness rate: 54.1 / 100,000 population
Total confirmed influenza cases hospitalised: 693
Total confirmed influenza cases admitted to ICU: 83
Total influenza-associated deaths: 43 
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For the 2013/2014 influenza season, the National 
Virus Reference Laboratory (NVRL) genetically and/or 
antigenically characterised 156 influenza specimens (87 
A(H3), 61 A(H1)pdm09 and 8 B). Further confirmatory 
testing was conducted on specimens by the WHO 
Collaborating Centre for Reference and Research on 
Influenza, Mill Hill. All influenza A(H1)pdm09 specimens 
sequenced clustered closely with the Group 6 strain A/
St. Petersburg/27/2011. Viruses in this genetic clade 
remain antigenically similar to the clade representative 
vaccine strain A/California/7/2009. All influenza A(H1)
pdm09 viruses successfully isolated and antigenically 
characterised by the NVRL during the 2013/2014 
season were similar to the A/California/07/2009 vaccine 
strain. Influenza A(H3) viruses sequenced by the NVRL 
all clustered with the A/Texas/50/2012 subgroup 3C. 
Antigenic characterisation determined that the majority 
of viruses characterised throughout the season were 
antigenically similar to the A/Texas/50/2012 H3N2 
2013/2014 vaccine strain. Of the few influenza B viruses 
characterised, seven belonged to the B/Yamagata 
lineage (the same lineage as the influenza B virus 
included in the 2013/2014 vaccine) and one belonged 
to the B/Victoria lineage (clustering closely with B/
Brisbane/60/2008). 
Virological Data - Other respiratory viruses 
During the 2013/2014 season, of 8391 non-sentinel 
specimens tested by the NVRL, 675 (8.0%) positive 
detections of respiratory syncytial virus (RSV) were 
reported, peaking (at 32.7% positivity) during week 
1 2014. A total of 114 (1.4%) positive detections of 
human metapneumovirus (hMPV) were reported, with 
the majority of these detected in January and February 
2014. Seventy-seven (0.9%) positive detections of 
adenovirus were reported, 47 (0.6%) parainfluenza virus 
type 1 (PIV-1), 28 (0.3%) PIV-2, 24 (0.3%) PIV-3 and 1 
(0.01%) PIV-4, during the 2013/2014 season.  
Of the 581 sentinel specimens tested during the 
2013/2014 season, 7 (1.2%) were positive for RSV, 6 
(1.0%) were positive for hMPV, 2 (0.3%) adenovirus, 3 
(0.5%) for PIV-1, 3 (0.5%) for PIV-2 and one (0.2%) for 
PIV-3.   
Outbreaks, GP OOHs & Sentinel hospital data
Fifty-nine influenza outbreaks were reported during 
the 2013/2014 influenza season; all were associated 
with influenza A (53 A(H3), 1 A(H1)pdm09 and 5 A - 
not subtyped). Over 40% of all influenza outbreaks 
were reported from HSE-E (table 1). The majority of 
outbreaks were associated with the elderly/those 
with intellectual disabilities, in health care facilities/
residential institutions. In total 28 deaths were 
recorded associated with these 59 outbreaks, 13 
deaths linked with these outbreaks were officially 
reported as influenza-associated deaths. It is probable 
that the actual number of influenza-associated deaths 
linked with these outbreaks exceeds this number. 
Vaccination status was reported for patients from 26 
healthcare facilities/residential institutions, with over 
90% (1020/1126) of patients vaccinated prior to these 
outbreaks. Vaccination status was reported for staff from 
17 healthcare facilities/residential institutions, with only 
28.7% (316/1101) of staff reported as vaccinated prior 
to these outbreaks.  
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Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold rate, and number of positive influenza 
A and B specimens tested by the NVRL, by influenza week and season. 
Source: Clinical ILI data from ICGP and virological data from the NVRL.
A further 19 acute respiratory infection (ARI) general 
outbreaks (the majority reported as negative for 
influenza) were reported during the 2013/2014 influenza 
season, two associated with hMPV, four with RSV and 13 
associated with unidentified pathogens. 
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 8 2014 
at 4.3% (one week prior to the peak in sentinel GP ILI 
consultation rates). During the peak of activity, each 
service received on average, one call per hour relating 
to influenza.
Hospital respiratory admissions in sentinel hospitals 
were at elevated levels for eight weeks, between weeks 
52 2013 and 7 2014, coinciding with increased RSV and 
influenza activity. Respiratory admissions peaked during 
week 7 2014, with 386 respiratory admissions reported. 
Total emergency admissions reported from sentinel 
hospitals were also elevated during the period of peak 
influenza activity, peaking at 2946.  
Influenza and RSV notifications
A total of 1718 confirmed influenza notifications were 
reported on CIDR during the 2013/2014 influenza 
season. Of the 1718 notifications, 909 (52.9%) were 
influenza A(H3), 467 (27.2%) were influenza A (H1)
pdm2009, 306 (17.8%) were influenza A (not subtyped) 
and 36 (2.1%) were influenza B. A total of 1770 RSV 
notifications were reported on CIDR during the 
2013/2014 season, peaking at 264 during week 1 2014. 
Confirmed influenza cases hospitalised 
Six hundred and ninety-three cases with confirmed 
influenza were reported as hospitalised during the 
2013/2014 influenza season. The highest age specific 
rate in hospitalised cases for the 2013/2014 season was 
in those less than one year of age (58.0 per 100,000 
population), followed by those aged 65 years and older 
(48.6 per 100,000) (table 2). Of the 693 hospitalised 
cases, 349 (50.4%) were influenza A(H3), 191 (27.6%) 
were influenza A(H1)pdm09, 142 (20.5%) were influenza 
A (not subtyped) and 11 (1.6%) were influenza B. 
Enhanced surveillance hospital data on 0-14 year age 
group 
A total of 247 confirmed influenza cases aged between 
0 and 14 years were notified on CIDR for the 2013/2014 
influenza season, 169 (68.4%) of these cases were 
hospitalised. One hundred and sixty-six cases (98.2%) 
were positive for influenza A [83 A(H3), 46 A(H1)
pdm09 and 37 A (not subtyped)] and three (1.8%) was 
positive for influenza B. The median age of cases was 
2 years. Over 67% of cases were aged between 0 and 
4 years, with one quarter of cases aged less than one 
year. Enhanced surveillance data was available for 129 
(76.3%) cases. The most frequently reported symptoms 
included: fever (80.6%), cough (76.0%), gastroenteric 
manifestations (30.2%) and fatigue (31.0%). 
Complications were reported for 43.4% of cases; of 
these cases more than one complication was reported 
for 30.4% of cases. The most frequently reported 
complications included secondary bacterial pneumonia, 
primary influenza viral pneumonia and other respiratory 
complications. The median length of stay in hospital 
was 3 days (ranging from 1 - 50 days). Approximately, 
36% of cases were reported as having an underlying 
medical condition, with chronic respiratory disease 
(including asthma), immunosuppression, conditions that 
can compromise respiratory function and other medical 
conditions being the most frequently reported. In 
addition, three cases were reported as being premature. 
Of the 39 cases with reported underlying medical 
conditions and known vaccination status, 95% were not 
vaccinated. Approximately, 22.5% of cases (25/111) 
commenced antiviral treatment and 77.5% (86/111) of 
cases did not. Nineteen cases were admitted to critical 
care units (for further details, see below). 
Confirmed influenza cases admitted to ICU  
Of the 693 hospitalised confirmed influenza cases, 83 
(12.0%) were admitted to critical care (64 adults and 19 
paediatric cases). Nineteen cases aged between 0 and 
15 years were reported from paediatric hospitals. Of 
the 83 critical care cases, 31 (37.3%) were infected with 
influenza A(H3), 42 (50.6%) with influenza A(H1)pdm09, 
8 (9.6%) influenza A (not subtyped) and 2 (2.4%) with 
influenza B. Age specific rates for patients admitted to 
critical care units were highest in those aged less than 
1 year of age (8.3 per 100,000 population) followed 
by those aged 65 years and over (4.5 per 100,000 
population) (table 2). The median age in years for 
paediatric cases was 4, and 59 years for adult cases. 
Fifty-five (55/62, 88.7%) adults and 14 (14/19, 73.7%) 
paediatric cases had pre-existing medical conditions. 
Pre-existing medical conditions were unknown for two 
adults. The most frequently reported underlying medical 
conditions for adults were chronic respiratory disease 
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Table 1: Number of influenza outbreaks by HSE-Area for the 2013/2014 influenza season (n=59).* 
HSE-Area No. of outbreaks Total number ill
Total number hospi-
talised
Total number dead
Total number lab 
confirmed
HSE-E 24 514 121 13 146
HSE-M 2 10 0 1 5
HSE-MW 4 41 23 0 13
HSE-NE 6 90 12 0 18
HSE-NW 4 30 11 0 14
HSE-SE 7 154 11 6 26
HSE-S 9 110 18 7 2
HSE-W 3 40 2 1 12
Total 59 989 198 28 236
*It should be noted that only 13/28 of the deaths reported in these outbreaks were officially reported as influenza-associated deaths.
(34/55, 61.8%), followed by chronic heart disease 
(18/55, 32.7%), and chronic neurological disease (12/55, 
21.8%). Four adult cases were pregnant. Twenty-four 
(37.5%) adult cases were reported as current/former 
smokers and five (7.8%) adult cases were reported 
to have alcohol related disease. The most frequently 
reported underlying medical conditions for paediatric 
cases were respiratory disease (7/14; 50%) and 
neurological/neuromuscular conditions (7/14, 50%). 
Fifty-seven (57/60, 95.0%) adults and four (4/5, 80.0%) 
paediatric cases were ventilated during their stay in 
critical care units. Ventilation status was unknown for 
four adult cases and 14 paediatric cases. The median 
length of stay in critical care for adult cases was 9 days 
(ranging from 1 - 55 days) and for paediatric cases 8.0 
days (ranging from 1 - 61 days). Of the 55 cases with 
underlying medical conditions and known vaccination 
status, 63.6% were not vaccinated. Vaccination status 
was known for 11 paediatric cases with underlying 
medical conditions, none of these cases were 
vaccinated. Twenty-seven (27/83, 32.5%) confirmed 
influenza cases admitted to critical care units died, 22 
of these deaths were reported as due to influenza.
Mortality data 
During the 2013/2014 influenza season, of the 1718 
confirmed influenza cases notified, 54 (3.2%) cases 
died. Influenza was reported as a cause of death for 
43 cases†. The case classification of influenza was 
confirmed for 40 of these cases, probable for two and 
possible for one. Of the 40 cases with known virology, 
20 were associated with influenza A(H3), 13 with 
influenza A(H1)pdm09, six influenza A (not subtyped) 
and one with influenza B. The median age of cases 
who died during the 2013/2014 influenza season was 
75 years, ranging from 0-95 years. Almost one third 
of these influenza-associated deaths were linked 
to influenza outbreaks. Cumulative excess all-cause 
mortality was high in those aged 65 years and older, 
between weeks 6 and 9 2014 and again during weeks 
15 and 16 2014. 
Summary tables of confirmed influenza hospitalised and 
critical care cases and influenza-associated deaths for 
all ages are detailed in tables 2, 3 & 4.
Overview of the 2013/2014 season 
During the 2013/2014 influenza season, overall 
influenza activity was at moderate levels. Sentinel GP ILI 
consultation rates were above baseline levels for eight 
consecutive weeks, a shorter period than the previous 
season. The predominant circulating influenza virus was 
influenza A(H3), which was co-circulating with influenza 
A(H1)pdm09. Higher influenza positivity levels were 
reported during the period of peak activity, compared 
to recent seasons. An increase in influenza severity 
was also observed relative to recent influenza seasons 
with a higher number of hospitalisations, critical care 
admissions and influenza-associated deaths reported. 
The highest age specific rates in hospitalised cases 
were in those aged less than 1 year and those aged 
65 years and over. There was a significant increase 
in hospitalisation rates for those aged 65 years and 
over, at 48.6/100,000, compared to 19.1/100,000 
in 2012/2013 and 6.7/100,000 in 2011/2012. As 
with previous seasons, the majority of cases with 
underlying medical conditions and known vaccination 
status admitted to hospital (data only available for 
paediatric cases) and/or critical care units (adult and 
paediatric cases) were not vaccinated. This highlights 
the importance of promoting influenza vaccination 
for those in risk groups to prevent influenza-related 
morbidity and mortality.1
The number of acute respiratory outbreaks reported 
during the 2013/2014 influenza season remained 
at high levels, similar to the 2012/2013 season. The 
majority of these outbreaks were caused by influenza. 
These outbreaks mainly affected the elderly and those 
with intellectual disabilities in residential care facilities. 
Cumulative excess all-cause mortality was high in 
the elderly during the 2013/2014 season, coinciding 
with increased reporting of confirmed influenza A(H3) 
outbreaks. Reported influenza vaccination status of 
patients/clients in these outbreaks was high, whilst 
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Table 2: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2013/2014 influenza season. Age 
specific rates are based on the 2011 CSO census.
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 42 58.0 6 8.3
1-4 67 23.6 6 2.1
5-14 52 8.3 6 1.0
15-24 25 4.3 1 0.2
25-34 70 9.3 4 0.5
35-44 68 9.0 13 1.9
45-54 38 6.6 9 1.6
55-64 71 15.3 14 3.0
65+ 260 48.6 24 4.5
Total 693 15.1 83 1.8
† Influenza-associated deaths include all deaths where influenza is reported as the primary/main cause of death by the physician or if influenza 
is listed anywhere on the death certificate as the cause of death.
vaccination status of staff was low, further highlighting 
the need to improve influenza vaccine uptake amongst 
health-care workers in order to reduce influenza-
related morbidity and mortality. Further information 
on seasonal influenza vaccine uptake in hospitals and 
long term care facilities is available in the Immunisation 
uptake chapter of the HPSC Annual Epidemiological 
Report, 2013.  
Globally, as reported by the WHO, the majority of 
influenza A viruses characterised during the 2013/2014 
influenza season were antigenically similar to those 
contained in the WHO recommended 2013/2014 
trivalent influenza vaccine. Of the influenza B viruses 
characterised globally, both the B/Yamagata and B/
Victoria lineages circulated. For the 2014/2015 influenza 
season in the northern hemisphere, WHO have 
recommended trivalent influenza vaccines contain the 
following strains: an A/California/7/2009(H1N1)pdm09-
like virus; an A/Texas/50/2012 (H3N2)-like virus; a B/
Massachusetts/2/2012-like virus.2
HPSC will continue ongoing collaborative work with 
the National Virus Reference Laboratory (NVRL) for the 
early detection of novel respiratory viruses, such as 
Middle East Respiratory Syndrome coronavirus (MERS-
CoV), avian-origin influenza A(H7N9) and enterovirus 
EV-D68. Surveillance procedures for these viruses 
will remain in place while the risk remains. Further 
information on these novel viruses is available on the 
HPSC and ECDC websites. 
For the 2014/2015 influenza season, existing 
surveillance systems in Ireland have been strengthened. 
A number of additional measures have been put 
in place to improve the surveillance of influenza/ILI 
outbreaks, including the inclusion of a category for 
Acute Respiratory outbreaks on Ireland’s Computerised 
Infectious Disease Reporting System (CIDR). HPSC 
are focusing on improving influenza vaccine uptake 
data on severe influenza cases, outbreaks, health 
care workers and those in risk groups for influenza. 
Additional projects not detailed in this report include an 
all-cause mortality monitoring project associated with 
the European mortality monitoring group (EuroMOMO) 
and the European influenza vaccine effectiveness study 
(I-MOVE project). Efforts have been made to increase 
patient participation in the I-MOVE project in order to 
improve Irish and international estimates on influenza 
vaccine effectiveness. Data from all of these surveillance 
systems will assist in guiding the management and 
control of influenza and any future epidemics or 
pandemics.  www.hpsc.ie
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Table 3: Summary table of confirmed influenza cases hospitalised and admitted to critical care units for all ages by influenza 
season: 2009-2014. It should be noted that risk factor data were not available for hospitalised cases in all age groups (with the 
exception of the pandemic period). Rates are based on the 2011 CSO census.
Hospitalised  Admitted to ICU
Pandemic 
period 2010/2011 2011/2012 2012/2013 2013/2014
Pandemic 
period 2010/2011 2011/2012 2012/2013 2013/2014
Total cases 1059 968 147 469 693 100 121 15 39 83
Crude rate 
/100,000 pop. 
23.1 21.1 3.2 10.2 15.1 2.2 2.6 0.3 0.8 1.8
Age range 
(years)
0-84 0-97 0-92 0-99 0-98 0-79 0-80 0-80 0-88 0-88
Median age 
(years)
17 29 27 32 51 34 49 60 39 50
Females 
533 529 83 267 398 50 64 12 19 34
50.3% 54.6% 56.5% 56.9% 57.4% 50.0% 52.9% 80.0% 48.7% 41.0%
Cases with risk 
factor
507
No data No data No data No data
81 90 13 35 69
47.9% 81.0% 74.4% 86.7% 89.7% 83.1%
Table 4: Summary table of influenza-associated deaths for all ages by influenza season: 2009-2014. Rates are based on the 2011 
CSO census.
Influenza-associated deaths
Pandemic period 2010/2011 2011/2012 2012/2013 2013/2014
Total cases 29 38 13 32 43
Crude rate /100,000 
pop. 
0.6 0.8 0.3 0.7 0.9
Age range (years) 8-83 2-83 81-98 0-95 0-97
Median age (years) 54 57 88 86 80
Females 
15 18 5 16 22
51.7% 47.4% 38.5% 50.0% 51.2%
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In 2013, there were 14 cases of Legionnaires’ disease 
notified in Ireland, a rate of 3.1 per million population, 
a slight decrease from the rate of 3.3 per million seen 
in 2012. One death was reported but was not directly 
attributed to Legionnaires’ disease.
Ten cases were reported from HSE East, two from HSE 
South East and one each from HSE Midlands and HSE 
Mid-Western areas.
The majority of the cases were male (64.3%). The 
median age was 56 years with a range from 38 to 78 
years.
All fourteen cases were classified as confirmed. The 
diagnosis of all fourteen cases was made by urinary 
antigen test (UAT) and two had the organism cultured. 
The organism involved in the 14 cases confirmed by 
UAT and cultured in the two cases was Legionella 
pneumophila serogroup 1. Monocloncal subtyping 
information was not available. 
Nine cases were travel-associated. Countries of travel 
included Ireland (1), Italy (1), Spain (4), the UK (2) and 
the USA (1). Two of these cases were linked to travel 
related clusters. The remaining five cases were assumed 
to be community acquired.
No real seasonality was observed in 2013 as described 
in Figure 1.
2.2 Legionellosis
Summary
Number of cases in 2013: 14
Crude incidence rate: 3.1 per million
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Table 1. Number of Legionnaires’ disease cases per million population in Ireland, 2006-2013
Age group (years) 2006 2007 2008 2009 2010 2011 2012 2013
<30 0 1 0 0 1 0 0 0
30-39 0 3 0 0 0 0 1 1
40-49 7 4 2 0 2 0 1 3
50-59 2 2 3 2 1 1 1 4
60-69 1 3 4 3 3 4 6 1
70+ 2 2 2 2 4 2 6 5
Total 12 15 11 7 11 7 15 14
CIR 2.8 3.5 2.6 1.5 2.4 1.5 3.3 3.1
For details of denominator data used, please see Explanatory Notes section at the end of this document
Figure 1. Number of Legionnaires’ disease cases by month of 
notification in Ireland, 2013
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Invasive Group A Streptococcal Disease
Summary
2013 total number of cases = 168
2013 crude incidence rate = 3.66 per 100,000 
population
Notifications
In 2013, 168 cases of invasive group A streptococcal 
(iGAS) disease were notified, which   corresponds with 
a rate of 3.66 iGAS cases per 100,000 population [95% 
confidence interval (CI): 3.13 – 4.26 per 100,000]. The 
2013 iGAS rate was higher than in 2012 (3.66 versus 
2.66 [95% CI: 2.21 – 3.17 per 100,000]). However, the 
increase is not considered to be statistically significant 
as the confidence intervals overlap. 
The majority (n = 158; 94%) were classified as confirmed 
cases: patients with group A streptococcus (GAS; 
Streptococcus pyogenes), isolated from a sterile site. 
The remaining ten were classified as probable cases: 
patients with streptococcal toxic shock syndrome (STSS) 
or necrotising fasciitis and GAS isolated from a non-
sterile site (e.g. throat, sputum, vagina).
Patient demographics
Of the 168 cases, 95 (57%) were male. The mean age of 
patients with iGAS was 41 years (range = 1 month – 93 
years) and iGAS was more common in young children 
and older adults (Figure 1). 
Geographic spread and seasonal variation
Table 1 displays the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2009 to 2013. 
While HSE East accounted for the highest number 
of reported cases in 2013 (n=67), HSE West had the 
highest CIR (4.27 per 100,000 population). In all HSE 
areas except the Midlands, both numbers of cases and 
CIRs increased. HSE Mid-West reported the largest 
annual increase (two-fold on 2012).
In 2013, the peak months were April (17 cases), May 
(26 cases) and July (18 cases).  As in previous years, the 
peak period occurred during the first half of the year 
(Figure 2). Upon annual review of cumulative monthly 
data, the increase in notifications was first noted from 
April 2012 (Figure 3). Data presented here are based on 
the date the case was notified to public health, not on 
the date the case was first detected.
Isolate details
Of confirmed cases, GAS was isolated from a sterile site 
in 147, with a source site not reported for the remaining 
11. GAS was isolated primarily from blood cultures 
(n=107; 73%), abscesses (n=15), deep tissue (n=9), joints 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
2013 total number of cases = 168
2013 crude incidence rate = 3.66 per 100,000 
population
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Figure 1.  Age and sex specific rates of iGAS disease in 2013
(n=10), pleural fluid (n=3), peritoneal fluid (n=2) and 
cerebrospinal fluid (CSF) (n=1).  For four cases, GAS was 
isolated from another sterile site in addition to blood: 
deep tissue (n=3) and joint (n=1). 
For the 10 probable cases, GAS was isolated from non-
sterile sites, including sputum, swabs and wound tissue.
Typing data, based on sequencing of the emm genes 
that encode the M protein (the major virulence factor), 
were available on 140 isolates submitted from 30 
laboratories: emm-types 1 (n=41; 29%), 3 (n=33; 24%), 
89 (n=13; 9%) and 28 (n=8; 6%) comprised 69% of all 
the isolates typed. Twenty-one other emm-types (each 
represented by four isolates or less) were also detected. 
Of the 28 patients with STSS for whom emm-typing was 
undertaken, nine GAS isolates belonged to emm1 (32%) 
and nine to emm3 (32%). 
Enhanced surveillance data
Enhanced data were provided for 155 (92%) of the 168 
iGAS cases, which is higher than in 2012 (87%, 106 of 
122 cases). The source laboratory could be ascertained 
for all cases. As in previous years, there was wide 
variation in completeness of enhanced data reporting. 
Table 2 summarises characteristics of iGAS cases in 
Ireland from 2008 to 2013.
Clinical details
Clinical presentation data were provided for 141 cases 
(84%). As in previous years, bacteraemia (n=111 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(n=45) were the commonest presentations, followed 
by STSS (n=32; eight of which were implied based on 
the information provided on the clinical presentation), 
pneumonia (n=24), necrotising fasciitis (n=10), septic 
arthritis (n=10), puerperal sepsis (n=6), peritonitis (n=4), 
myositis (n=3), erysipelas (n=3) and meningitis (n=3). 
Note that an iGAS case could have more than one 
clinical manifestation of infection.
  
Risk factors
Risk factor data were provided for 140 iGAS cases 
(83%). Risk factors included; presence of skin or wound 
lesions (n=55), age ≥65 years (n=50), malignancy 
(n=23), diabetes mellitus (n=16), steroid use (n=11), 
alcoholism (n=6), childbirth (n=6), injecting drug use 
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Figure 2.  Monthly distribution of iGAS cases, 2009-2013
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area (2009-2013) 
HSE Area 2009 2010 2011 2012 2013
 n   CIR    n   CIR    n   CIR    n   CIR    n   CIR    
HSE-E 32 1.98 22 1.36 29 1.79 51 3.15 67 4.14
HSE-M 2 0.71 2 0.71 5 1.77 7 2.48 7 2.48
HSE-MW 5 1.32 6 1.58 6 1.58 8 2.11 16 4.22
HSE-NE 3 0.68 7 1.59 1 0.23 11 2.50 14 3.18
HSE-NW 1 0.39 8 3.10 2 0.77 5 1.94 6 2.32
HSE-SE 8 1.20 5 1.00 7 1.41 16 3.22 21 4.22
HSE-S 5 1.00 12 1.81 12 1.81 14 2.11 18 2.71
HSE-W 4 0.90 6 1.35 5 1.12 10 2.25 19 4.27
IRELAND 60 1.31 68 1.48 67 1.46 122 2.66 168 3.66
CIR for 2009 calculated using the 2006 census; CIRs for 2010-2013 calculated using the 2011 census
Change from previous reports: error in calculation of rates for HSE-SE and HSE-S for 2010-2012, corrected rates are highlighted in red
(IDU) (n=5), varicella infection (n=5) and non-steroidal 
anti-inflammatory drug (NSAID) use (n=4). Note that an 
iGAS case could have more than one risk factor. No risk 
factors were identified for 37 cases. 
Among the patients with STSS, risk factor data were 
provided for 28 cases. Risk factors associated with 
iGAS disease and STSS included age ≥65 years (n=12), 
presence of skin or wound lesions (n=10), steroid 
use (n=7), alcoholism (n=4), diabetes mellitus (n=4), 
malignancy (n=4), IDU (n=3) and NSAID use (n=3). 
Note that cases could have one or more associated risk 
factors. No risk factors were identified for eight STSS 
cases.
Clinical management/Severity
Surgical intervention was required for 39 patients 
(aged 10 months – 86 years), which reflects an increase 
compared to 26 in 2012. This included six patients with 
STSS, three patients with necrotising fasciitis and three 
patients with both STSS and necrotising fasciitis.
Among patients requiring surgical intervention, risk 
factor data were provided for 36 cases. Risk factors 
included; skin and wound lesions (n=20), age ≥65 years 
(n=5), diabetes mellitus (n=3), malignancy (n=2), steroid 
use (n=2), IDU (n=1) and varicella (n=1). Note that an 
iGAS case requiring surgery could have more than 
one risk factor. No risk factors were identified for 14 
patients.
Forty-four patients (aged 1 – 86 years) required 
intensive care unit (ICU) admission, which reflects 
an increase compared to 40 in 2012. This included 
20 patients with STSS, four patients with necrotising 
fasciitis and three patients with both STSS and 
necrotising fasciitis.
Among patients admitted to an ICU, risk factor data 
were provided for 39. Risk factors included; age ≥65 
years (n=16), skin and wound lesions (n=15), diabetes 
mellitus (n=4), malignancy (n=4), steroid use (n=4), 
childbirth (n=3), alcoholism (n=2), IDU (n=2) and 
NSAID use (n=1). Note that an iGAS case requiring ICU 
admission could have more than one risk factor. No risk 
factors were identified for ten patients. Length of ICU 
stay was provided for 27 cases. The median length of 
ICU stay was four days (range = 1 – 8). 
Other epidemiological information
Five cases (including three with STSS) were reported as 
hospital-acquired (compared to three in 2012). 
In 2013, two iGAS outbreaks were notified: one family 
outbreak and one hospital outbreak, both with two 
people ill (compared to just one family outbreak in 
2012). There was one additional hospital GAS outbreak 
(non-invasive) reported in 2013.
 
Outcome
Outcome at seven-days following GAS isolation was 
reported for 107 cases: 
•   89 were still alive 
•   16 patients had died, where GAS was the main or 
contributory cause of death
 •   One additional patient had died, but GAS was not a 
cause of death
The seven-day case fatality rate (CFR) for iGAS disease 
was 15% in 2013, which is higher than in 2012 (12%).
Of 32 STSS cases, outcome at seven-days was reported 
for 26. Of those, there were ten deaths due to GAS 
(CFR = 38%).  
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Figure 3.  Cumulative monthly numbers of iGAS cases, 2009-2013.
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Table 2. Characteristics of iGAS cases in Ireland (2008-2013).
YEAR
2008 2009 2010 2011 2012 2013
Notifications
Total iGAS cases notified 70 60 68 67 122 168
iGAS incidence rate per 100,000 population 1.65 1.31 1.48 1.46 2.66 3.66
Cases for which Enhanced data provided* (%) 44 (63%) 44 (73%) 61 (90%) 60 (90%) 106 (87%) 155 (92%)
Patient Demographics
Male (%) 37 (53%) 34 (57%) 36 (53%) 28 (42%) 59 (48%) 95 (57%)
M:F ratio 1.12:1 1.31:1 1.13:1 0.72:1 0.94:1 1.31:1
Mean age 45 47 49 43 44 41
Median age 47 48 39 49 42 41
Age range 0-89 0-95 0-97 0-97 0-92 0-93
Paediatric cases (aged <18 years) (%) 16 (23%) 13 (22%) 10 (15%) 15 (22%) 28 (23%) 45 (27%)
Older cases (aged 65+ years) (%) 18 (26%) 21 (35%) 22 (32%) 22 (33%) 42 (34%) 50 (30%)
Clinical Presentation†
Data on Clinical Presentation (%) 39 (56%) 42 (70%) 59 (87%) 58 (87%) 103 (84%) 141 (84%)
Streptococcal Toxic Shock-like Syndrome (STSS) without NF (%) 6 (15%) 3 (7%) 7 (12%) 4 (7%) 22 (21%) 28 (20%)
Necrotising fasciitis (NF) without STSS (%) 3 (8%) 1 (2%) 2 (3%) 1 (2%) 2 (2%) 6 (4%)
STSS and NF (%) 1 (3%) 4 (10%) 2 (3%) 2 (3%) 4 (4%) 4 (3%)
Bacteraemia with focal presentations (%) 23 (59%) 14 (33%) 27 (46%) 30 (52%) 42 (41%) 45 (32%)
Bacteraemia with no focal presentations (%) 3 (8%) 18 (43%) 20 (34%) 15 (26%) 21 (20%) 35 (25%)
Other focal presentations with no bacteraemia (%) 3 (8%) 2 (5%) 1 (2%) 6 (10%) 12 (12%) 23 (16%)
Bacteraemia (%) 33 (85%) 39 (93%) 55 (93%) 52 (90%) 80 (78%) 111 (75%)
Other focal presentations:
Cellulitis (%) 17 (44%) 13 (31%) 22 (37%) 24 (41%) 41 (40%) 45 (32%)
STSS (%) 7 (18%) 7 (17%) 9 (15%) 6 (10%) 26 (25%) 32 (23%)
Pneumonia (%) 6 (15%) 2 (5%) 10 (17%) 8 (14%) 17 (17%) 24 (17%)
Septic arthritis (%) 6 (15%) 2 (5%) 2 (3%) 2 (3%) 7 (7%) 10 (7%)
Myositis (%) 2 (5%) 2 (5%) 2 (3%) 0 (0%) 4 (4%) 3 (2%)
Necrotising fasciitis (%) 4 (10%) 5 (12%) 4 (7%) 3 (5%) 6 (6%) 10 (7%)
Puerperal sepsis (%) 5 (13%) 2 (5%) 4 (7%) 5 (9%) 6 (4%) 6 (4%)
Peritonitis (%) 0 (0%) 0 (0%) 1 (2%) 3 (5%) 1 (1%) 4 (3%)
Erysipelas (%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 3 (3%) 3 (2%)
Meninigtis (%) 2 (5%) 0 (0%) 2 (3%) 1 (2%) 3 (3%) 3 (2%)
Risk Factors†
Data on Risk Factors (%) 37 (53%) 36 (60%) 49 (72%) 49 (73%) 98 (80%) 140 (83%)
Skin lesions/wounds (%) 15 (41%) 16 (44%) 16 (33%) 20 (41%) 34 (35%) 55 (39%)
Diabetes (%) 5 (14%) 3 (8%) 8 (16%) 7 (14%) 5 (5%) 16 (11%)
Varicella (%) 2 (5%) 2 (6%) 2 (4%) 2 (4%) 9 (9%) 5 (4%)
Malignancy (%) 3 (8%) 6 (17%) 6 (12%) 6 (12%) 10 (10%) 23 (16%)
Alcoholism (%) 1 (3%) 0 (0%) 3 (6%) 1 (2%) 5 (5%) 6 (4%)
Injecting drug user (%) 2 (5%) 3 (8%) 6 (12%) 3 (6%) 6 (6%) 5 (4%)
Steroid use (%) 4 (11%) 1 (3%) 2 (4%) 1 (2%) 8 (8%) 11 (8%)
Childbirth (%) 5 (14%) 2 (6%) 4 (8%) 5 (10%) 6 (6%) 6 (4%)
Non-steroid anti-inflammatory drug use (%) 3 (8%) 0 (0%) 6 (12%) 1 (2%) 2 (2%) 4 (3%)
No identified risk factor (%) 11 (30%) 10 (28%) 12 (24%) 12 (24%) 25 (26%) 47 (34%)
Outcome at 7 days
Data on outcome at 7 days (%) 27 (39%) 30 (50%) 43 (63%) 43 (64%) 65 (53%) 107 (64%)
RIP/GAS main cause or contributory (%) 1 (4%) 2 (7%) 4 (9%) 5 (12%) 8 (12%) 16 (15%)
STSS cases: Data on outcome at 7 days (%) 6 (86%) 6 (86%) 8 (89%) 5 (83%) 17 (65%) 26 (81%)
STSS cases: RIP/GAS main cause or contributory (%) 1 (17%) 1 (17%) 2 (25%) 1 (20%) 6 (35%) 10 (38%)
Severity
Data on Admission to ITU (%) 39 (56%) 40 (67%) 57 (84%) 57 (85%) 99 (81%) 152 (90%)
Admitted to ITU (%) 7 (18%) 16 (40%) 14 (25%) 11 (19%) 40 (40%) 44 (29%)
Data on Surgical Intervention (%) 32 (46%) 28 (47%) 49 (72%) 45 (67%) 86 (70%) 135 (80%)
Surgical Intervention Required (%) 9 (28%) 8 (29%) 12 (24%) 8 (18%) 26 (30%) 39 (29%)
Typing
iGAS isolates that were typed (%) 109 (89%) 140 (83%)
emm1 (%) 53 (49%) 41 (29%)
emm3 (%) 4 (4%) 33 (24%)
emm12 (%) 10 (10%) 3 (3%)
emm28 (%) 8 (7%) 8 (6%)
emm89 (%) 4 (4%) 13 (9%)
Otheremm-types (%) 30 (27%) 42 (29%)
* Degree of completion of enhanced surveillance forms varies from case to case: information may not be available on all variables/categories,
thus calculations of percentages take into account only those cases for which data are provided
†Note: A patient may have more than one clinical presentation or risk factor
Of 39 cases requiring surgical intervention, outcome at 
seven-days was reported for 27. Of those, there were 
four deaths due to GAS (CFR = 15%). 
Of 44 cases admitted to ICU, outcome at seven-days 
was reported for 32. Of those, there were ten deaths 
due to GAS (CFR = 31%). One additional patient died, 
but GAS was not a cause of death.
Antimicrobial susceptibility
In 2013, antimicrobial susceptibility data were reported 
on 126 GAS isolates (103 from blood and 23 from 
other specimens) by 20 laboratories via the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net). All isolates tested were susceptible to penicillin 
(n=110) and vancomycin (n=88).  Resistance to 
erythromycin was reported in five (5%) of 104 isolates, 
to clindamycin in one (2%) of 51 isolates and to 
tetracycline in three (7%) of 43 isolates.
CONCLUSION
In 2013, 168 cases of iGAS infection were notified in 
Ireland, the highest annual number reported to date, 
representing an increase of 38% on 2012 (n=122). The 
CIR increased from 2.66 (2012) to 3.66 per 100,000 
(2013), but this was not found to be statistically 
significant. 
iGAS is a potentially life-threatening disease. In 2013, 
the CFR was 15% for all iGAS infections and even 
higher for patients admitted to ICU (31%) or presenting 
with STSS (38%). In 2012 and 2013, more patients 
presented with STSS than in previous years: 26 and 32 
cases, respectively, compared with 6-9 cases in each of 
the previous four years.
emm-typing was undertaken on a national basis for 
the first time in 2012, with the establishment of a GAS 
typing service by the Epidemiology and Molecular 
Biology Unit (EMBU) at the Children’s University 
Hospital, Temple St. In 2013, two emm types, emm1 
and emm3 (together representing 74 of 140 isolates), 
comprised 53% of all isolates typed, compared with 
just one emm type, emm1 (53 of 109 isolates), which 
comprised 49% of all isolates in 2012. Certain emm 
types, including emm1 and emm3, are associated 
with STSS, and STSS in turn is strongly associated 
with increased mortality. The changes observed in the 
predominant emm types in circulation in just one year 
and in the clinical presentations over the last couple of 
years highlight the dynamic nature of iGAS infection. 
Ongoing surveillance is essential, specifically 
completion of the enhanced data questionnaire, to 
gain a greater understanding of iGAS, to enable early 
detection of clusters/outbreaks, to ensure prompt 
implementation of infection prevention and control 
precautions and appropriate management of contacts. 
Epidemiological typing as provided by EMBU is another 
vital element to increase insight into GAS infection 
in Ireland, as certain emm types are associated with 
greater morbidity and mortality.
Antimicrobial susceptibility data confirm that iGAS 
remains susceptible to penicillin and that penicillin 
should continue to be the treatment of choice for iGAS. 
HPSC thanks participating microbiology laboratories 
and public health departments for their ongoing 
contribution to the iGAS enhanced surveillance scheme. 
All microbiology laboratories are encouraged:
•   to return enhanced iGAS surveillance forms for every 
patient with iGAS 
•   to submit all iGAS isolates to the Epidemiology and 
Molecular Biology Unit (EMBU), Children’s University 
Hospital, Temple St for emm-typing 
•   to submit antimicrobial susceptibility data on all iGAS 
cases along with EARS-Net quarterly returns
The enhanced surveillance form can be downloaded 
from the HPSC web site at:
http://www.hpsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/SurveillanceForms/
Further information on iGAS disease in Ireland, 
including factsheets for patients and contacts, 
national guidelines and a new quarterly report, is 
available at: http://www.ndsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 21st July 2014. 
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Background
Invasive group B streptococcal (iGBS; Streptococcus 
agalactiae) infections in infants <90 days old or 
stillborn infants have been notifiable in Ireland via the 
Computerised Infectious Diseases Reporting (CIDR) 
system since January 2012.
In neonates two syndromes exist:
•  Early-onset disease (EOD; age at onset/diagnosis <7 
days old)
•  Late-onset disease (LOD; age at onset/diagnosis 7-89 
days old)
Both include sepsis, pneumonia and meningitis. Stillbirth 
associated with isolation/detection of Streptococcus 
agalactiae from the placenta or amniotic fluid is also 
notifiable.
Notifications
In 2013, there were 66 iGBS cases, of which 42 and 24 
cases represented EOD and LOD, respectively (Figure 
1 and Table 1). The EOD and LOD rates were 0.61 
and 0.35 per 1,000 live births, respectively (68,930 live 
births, CSO 2013 data obtained from 
http://www.cso.ie/en/media/csoie/releasespublications/
documents/vitalstats/2013/vstats_q42013.pdf) 
Twenty cases presented with meningitis (meningitis was 
specifically mentioned as a case presentation for five 
cases and inferred from 15 cases where the specimen 
type tested included CSF).
Three of the reported cases in 2013 were associated 
with stillbirth.
The figures presented in this summary are based on 
data extracted from CIDR on 17th July 2014. 
2.4  Invasive Group B Streptococcal 
Infections
Summary
2013 total number of cases = 66 
•  42 cases of early-onset disease (EOD)
• 24 cases of  late-onset disease (LOD)
2013 EOD rate per 1,000 live births = 0.61
2013 LOD rate per 1,000 live births = 0.35
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Figure 1. Distribution of cases of invasive Group B streptococcal infection by age (in 
days) at time of onset/diagnosis in 2013: early-onset disease (<7 days) and late-onset 
disease (7-89 days)
Table 1. Annual breakdown, including rates, of iGBS cases by 
disease syndrome
Year
Disease syndrome
2012 2013
n (%) Rate* n (%) Rate*
EOD 58 (75%) 0.80 42 (64%) 0.61
LOD 19 (25%) 0.26 24 (36%) 0.35
Total 77 1.07 66 0.96
* Incidence rate per 1,000 live births
[Live births in the Republic of Ireland (source: www.cso.ie): 2012, 72,225; 
2013, 68,930
In 2012, 359 cases of tuberculosis (TB) were notified 
in Ireland, corresponding to a crude notification rate 
of 7.8 per 100,000 population, a decrease compared 
to 2011 (9.0/100,000 population). A summary of the 
epidemiology of TB in Ireland during 2012 is shown in 
table 1 while the number of cases and crude incidence 
rates from 1991 to 2013* with three-year moving 
averages are shown in figure 1. 
The highest crude incidence rate was reported by 
HSE-S (10.2/100,000 population) while the lowest rate 
was reported by HSE-SE (5.0/100,000 population). 
Cases ranged in age from 4 months to 90 years of age, 
with a median age of 40 years. The highest age-specific 
rate in 2012 occurred among those aged 25-34 years 
(10.5/100,000 population) followed by those aged 65 
years and over (10.3/100,000 population). The rate 
among males (9.5/100,000 population) was higher than 
that among females (6.1/100,000 population). Rates 
among males were higher than females for all age 
groups except in the 15-24 year age group (8.6/100,000 
population in females compared to 7.6/100,000 
population in males). The highest rate among males 
(15.1/100,000 population) was in the group aged 55-64 
years while the highest rate in females (10.1/100,000 
population) was in the 25-34 year age group. The male 
to female ratio (1.5:1) reported in 2012 was consistent 
with the ratio reported in previous years. 
Geographic origin
During 2012, 44.6% (160 cases) of TB cases were born 
outside Ireland, a slight decrease from the proportion 
reported in 2011 (46.7%). The crude rate in the foreign-
born population decreased from 25.2 per 100,000 
population in 2011 to 20.9 per 100,000 population in 
2012. The crude rate in the indigenous population was 
5.2 per 100,000 population in 2012, which decreased 
slightly compared to 5.7 per 100,000 population 
reported in 2011. There was a notable difference in age 
2.5 Tuberculosis, 2012
Summary
Number of cases in 2012: 359
Crude incidence rate in 2012: 7.8/100,000
Number of cases in 2013*: 381
Crude incidence rate in 2013*:8.3/100,000
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  Data for 2013 are provisional data which may change significantly following validation
Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2013* and 
3-year moving averages, 1992-2012
Number of cases 3 year moving average - Cases Crude Rate per 100,000 population 
between those born in Ireland and those born outside 
Ireland, with a median age of 51 years and 33 years 
respectively. 
Site of infection 
Pulmonary TB was reported in 255 (71.0%) cases and 
104 (29.0%) had exclusively extrapulmonary disease. Of 
the extrapulmonary cases reported in 2012, there were 
three cases of TB meningitis corresponding to a rate of 
0.07 per100,000 population (0.7 per million population).
Microbiology
Of the 359 cases reported in 2012, 79.1% (284 cases) 
were culture confirmed. Of the 284 culture confirmed 
cases, species identification showed M. tuberculosis in 
96.1% (272 cases), M. tuberculosis complex‡ in 1.1% (3 
cases) M. africanum in 1.4% (4 cases), M. bovis in 1.4% 
(4 cases) and M. canettii in 0.4% (1 case). Of the 255 
cases with a pulmonary component, 217 (85.1%) were 
reported as culture confirmed, and 118 (46.3%) were 
reported as smear positive. 
Drug sensitivity 
Information on antibiotic sensitivity testing was available 
for 278 (97.9%) of the 284 culture confirmed cases. Of 
these, resistance was documented in 22 (7.9%) cases, 
five (1.4% of total cases) of which were MDR-TB cases. 
Mono-resistance to isoniazid was recorded in 10 cases 
and to streptomycin in five. Further details on the 
resistance profiles of TB cases reported in 2012 will be 
available in the HPSC Report on the Epidemiology of TB 
in Ireland, 2012 (www.hpsc.ie).
Outcome
In 2012, information on treatment outcome was 
provided for 77.7% (279) of cases, a slight increase 
compared to 75.1% in 2011. Treatment outcome was 
reported as completed for 218 (60.7%) cases, 17 were 
still on treatment (4.7%), 17 (4.7%) cases died, 16 
(4.5%) were lost to follow up, seven cases transferred 
out (1.9%), four (1.1%) had treatment interrupted. Four 
(1.1%) of the 17 deaths were reported as attributable to 
TB. During 2012, the reported treatment success rate 
was 67.9% for new culture confirmed pulmonary TB 
cases and 67.1% for new smear-positive pulmonary TB 
cases. 
Outbreaks 
The introduction of the amendment to the Infectious 
Disease Regulations 1981 on January 1st 2004, made 
outbreaks, unusual clusters or changing patterns of 
illness statutorily notifiable by medical practitioners and 
clinical directors of laboratories to the medical officer of 
health. Standard reporting procedures for surveillance 
of TB outbreaks were formally agreed in 2007. 
During 2012, seven outbreaks of TB were reported to 
HSPC, with 25 reported cases of active TB, four with 
latent TB infection (LTBI) and six hospitalisations. Two 
outbreaks each were reported by HSE-M and HSE-S and 
one outbreak each was reported by HSE-MW, -SE and 
-W. There were three general outbreaks, one of which 
occurred in an extended family, one in a community 
setting and the remaining general outbreak involved 
more than one location. There were also four family 
outbreaks, all of which occurred in private houses. The 
number of outbreaks reported during 2012 remained 
stable in comparison to 2011, however the number of 
cases of LTBI reported as associated with the outbreaks 
decreased. Figure 2 shows a summary of reported 
TB outbreaks from 2004 to 2013 by year of outbreak, 
number of active TB cases and number of persons with 
LTBI. Please note that numbers of LTBI for outbreaks 
reported during 2012 are provisional and may increase 
as outbreak investigations continue.
Provisional 2013 data
There were 381 cases of TB provisionally notified in 
2013, corresponding to a crude rate of 8.3 per 100,000 
population. It is important to note that these data are 
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‡Species of mycobacteria not specified when reported
†Country of birth was unknown for 3 cases
Table 1: Summary of the epidemiology of TB in Ireland, 2012
Parameter Number % of Total cases
Total number of cases 359
Crude notification rate per 100,000 7.8
Cases in indigenous population† 196 54.6
Cases in foreign-born persons† 160 44.6
Culture positive cases 284 79.1
Pulmonary cases 255 71.0
Smear positive pulmonary cases 118 46.3
Multi-drug resistant cases 5 1.4
Mono-resistant to isoniazid 10 2.8
Deaths attributable to TB 4 1.1
Outcomes reported in cases 279 77.7
TB meningitis cases 3 0.8
provisional and may change significantly following 
validation. 
Of the 381 cases provisionally notified in 2013, 
•   Pulmonary TB was diagnosed in 229 cases (60.1%), 
extrapulmonary TB in 128 cases (33.6%) and 
pulmonary and extrapulmonary TB in 24 cases (6.3%) 
•   Of the 253 cases with a pulmonary disease 
component, 203 (80.3%) were culture positive and 
130 (51.4%) were smear positive
•   There were two cases of TB meningitis provisionally 
notified corresponding to a rate of 0.04 per 100,000 
population (0.44 permillion population)
•   There were 205 (53.8%) cases born in Ireland, 169 
(44.4%) were foreign-born and country of birth was 
not reported for 7 (1.8%) cases
•   There were 139 cases (36.5%) notified in females, 240 
cases (63.0%) in males while sex was unknown for the 
remaining two cases (0.5%)
•   The mean age of cases was 42.4 years (range: 0 to 88 
years)
•   Resistance was reported in 27 cases, 19 of which were 
mono-resistant to isoniazid 
•   Four cases of MDR-TB were reported during 2013 
•   Twenty (74.0%) of the 27 resistant cases (including all 
four MDR cases) were born outside Ireland 
•   There were 12 TB outbreaks reported to HPSC 
during 2013, with 42 active TB cases, 174 cases of 
latent TB infection and 17 hospitalisations. No deaths 
were reported from these outbreaks. Please note 
that numbers of LTBI for outbreaks reported during 
2013 are provisional and may increase as outbreak 
investigations continue.
Further details on the epidemiology of TB cases 
reported in 2012 will be available in the HPSC Report on 
the Epidemiology of TB in Ireland, 2012 (www.hpsc.ie). 
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Figure 2: TB outbreak summary by year, 2004-2013*
* Data for 2013 are provisional data which may change significantly following validation
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Chickenpox-hospitalised cases
The Health Act, 1947 entitles the Minister for Health 
to declare by regulation diseases that are infectious, 
covered by legislation and that require notification to 
a Medical Officer of Health. The infectious diseases 
notifiable in Ireland are regulated in the 1981 Infectious 
Diseases Regulations. The amendment S.I. No. 452 of 
2011 to these regulations specified for the first time 
the disease chickenpox, hospitalised cases only, as 
notifiable. Chickenpox is caused by varicella-zoster 
virus. The case definition is available at www.hpsc.ie.
In 2013, 53 (1.2/100,000) hospitalised chickenpox cases 
were notified in Ireland compared to 80 (1.7/100,000) 
in 2012. The largest number of cases and largest 
crude incidence rate was in the HSE E (table 1). Of 
the 53 cases, 37 (70%) were classified as confirmed, 
three (6%) as probable and 13 (25%) as possible. The 
largest number of cases was in the age group 3-4 years 
followed by those <1 year (figure 1). The highest age 
specific incidence rate was in the age group <1 year 
followed by 3-4 years (figure 2). Of the 53 cases, 28 
(53%) were male, 24 (45%) were female while gender 
was not reported for one case (2%).
Chickenpox/varicella outbreaks
The amendment S.I. No. 707 of 2003 to the infectious 
disease regulations specified that unusual clusters 
or changing patterns of illness that may be of 
public health concern must be reported. Therefore, 
outbreaks of chickenpox must be notified regardless of 
hospitalisation status. One outbreak of chickenpox was 
notified in 2013. This outbreak occurred in a crèche with 
eight ill.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 30th July 2014. 
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
2.6 Chickenpox-hospitalised cases
Summary
Number of cases, 2013: 53
Crude incidence rate, 2013: 1.2/100,000
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Figure 1. Number of notified hospitalised chickenpox cases in 
2013 by age group and case classification
Figure 2. The age specific incidence rate (per 100,000 
population) of notified hospitalised chickenpox cases in 2013 
by case classification
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Table 1. Number of notified hospitalised chickenpox cases and 
the crude incidence rate per 100,000 population (CIR) by HSE 
Area in 2013
HSE Area Number CIR
HSE E 32 2.0
HSE M 2 0.7
HSE MW 6 1.6
HSE NE 2 0.5
HSE NW 1 0.4
HSE SE 1 0.2
HSE S 7 1.1
HSE W 2 0.4
Total 53 1.2
HPSC Annual Epidemiological Report 2013
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03
Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations (while some cases were included in the 
former category of “Food Poisoning
(bacterial other than Salmonella)”). It is an acute 
zoonotic bacterial disease characterised by diarrhoea, 
abdominal pain, malaise, fever, nausea and vomiting. 
Symptoms generally last for only a few days. 
Campylobacteriosis is the commonest bacterial cause 
of gastroenteritis in Ireland and Europe. In the EU it is 
estimated that 9.2 million cases occur annually, resulting 
in a public health impact of 0.35 million disability 
adjusted life years (DALYs) per year and an annual cost 
of approximately €2.4 billion.1
During 2008, a European Union-wide baseline survey of 
Campylobacter in broiler batches and broiler carcasses 
was carried out by The European Food Safety Authority 
(EFSA). This survey found that 75.8% of broiler carcasses 
sampled were contaminated with Campylobacter while 
98% of Irish broiler carcasses sampled were positive 
for Campylobacter.2 EFSA currently estimates that 
handling, preparation and consumption of broiler meat 
may account for 20-30% of human campylobacteriosis 
while 50-80% of cases may be attributed to the broiler 
reservoir as a whole.3 The importance of poultry meat 
as a source of human Campylobacter infection was 
supported by the food-borne outbreak data reported 
to EFSA during 2012, where 44.0% of food-borne 
outbreaks of campylobacteriosis (with strong evidence 
and a specified food item) were poultry related.4 In 
response to such evidence, the food Safety Authority 
of Ireland (FSAI) published “Recommendations for a 
Practical Control Programme for Campylobacter in the 
Poultry Production and Slaughter Chain” during 2011.5
Findings of an all-Ireland case control study that 
investigated risk factors for sporadic Campylobacter 
infections showed that consuming chicken and lettuce, 
and eating in takeaways were important risk factors for 
contracting the disease in Ireland. Contact with sheep, 
3.1 Campylobacter 
Summary
Number of cases: 2,275
Crude incidence rate: 49.6/100,000
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Figure 1: Campylobacteriosis 2013 CIR compared to 2004-2012 mean CIR by HSE area (CIDR)
peptic ulcer, hiatus hernia and lower bowel problems 
were also independently associated with infection. 
However, mains water supply showed protective effect 
from contracting the illness.6
During 2013, levels of campylobacteriosis remained 
elevated with 2,275 notifications reported to HPSC. 
This corresponded to a crude incidence rate of 
49.6/100,000 population, which is comparable with the 
2012 European crude incidence rate of 55.5 per 100,000 
population.7 
Historically, variation in campylobacteriosis crude 
incidence rates (CIRs) has been reported between HSE 
areas. During 2013, the highest CIRs occurred in HSE-
SE (68.9/100,000 population) and HSE-S (57.6/100,000 
population). The lowest CIR was reported by HSE-
NE (35.2/100,000 population). Figure 1 compares 
the campylobacteriosis CIRs in 2013 with the mean 
campylobacteriosis incidence rates for 2004 to 2012 by 
HSE area. 
Campylobacteriosis occurs in all age groups with the 
highest rate of notification reported in the 0-4 year 
age group. This preponderance in younger children 
is a well described characteristic of the disease and is 
also observed at European level. The highest European 
notification rate during 2012 was reported in males in 
the 0-4 year age group (157.5/100,000 population).7
In Ireland between 2004 and 2012, the highest mean 
ASIR occurred in the 0-4 year age group (159.0/100,000 
population) followed by the 25-34 year age group 
(41.4/100,000 population) and the 15-24 year age group 
(40.1/100,000 population). A comparison of the mean 
age-specific incidence rate between 2004-2012 and 
the age-specific rate in 2013 showed an increase of 
>40% in the 55-64 year age group (43.1%) and those 
aged 65 years and older (50.8%). Figure 2 compares the 
campylobacteriosis age specific rates (ASIR) for 2013 
with the mean campylobacteriosis ASIR for 2004 to 
2012. 
During 2013, 47.1% of all cases were female, 52.5% of 
cases were male and sex was not reported for 0.4% of 
cases. Further analysis of the age-sex distribution of 
campylobacteriosis cases shows that the highest ASIRs 
for both males and females were observed in the 0-4 
year and 65 years and older age groups. 
Campylobacteriosis has a well-documented seasonal 
distribution with a peak in summer. In Ireland, 
campylobacteriosis notifications typically peak during 
May to August. While there was the usual warm-season 
peak in campylobacteriosis notifications in 2013, a 
smaller secondary peak also occurred during October. 
This represented an increase of 27.7% compared to the 
mean number of notifications during the same period in 
2004-2013. Figure 3 compares the monthly number of 
campylobacteriosis notifications for 2013 to the mean 
monthly number of campylobacteriosis notifications 
between 2004 and 2013. 
All of the cases notified in Ireland during 2013 were 
laboratory confirmed. However, as there is currently 
no national reference facility for routine typing of 
Campylobacter isolates, information on Campylobacter 
species is strikingly incomplete. In 2013, 31.7% (n=721) 
of isolates were speciated. Of the 721 speciated 
isolates, 90.7% of isolates were C. jejuni, 8.7% were 
C. coli, 0.3% were C. upsaliensis while C. lari and C. 
laridis each accounted for 0.1%. The remaining 68.3% 
(n=1,554) of Campylobacter isolates identified were not 
further speciated. 
During 2013, there were seven outbreaks of 
campylobacteriosis reported to HPSC with 16 
associated cases of illness. Six outbreaks were family 
outbreaks occurring in private houses, as is typical of 
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Figure 2: Campylobacteriosis ASIR 2013 compared to 2004-2012 mean ASIR (CIDR)
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previous years. Three reported mode of transmission as 
person to person, one reported mode of transmission 
as other, while mode of transmission was unknown for 
the remaining two outbreaks. One general outbreak 
was also reported in a community hospital/long stay 
facility and mode of transmission was unknown. During 
2012, 19 European countries reported 501 food-borne 
outbreaks of campylobacteriosis which accounted for 
9.3% of the total food-borne outbreaks reported to 
EFSA. These outbreaks comprised 1,801 associated 
cases of illness and 197 hospitalisations.4
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Figure 3: Campylobacteriosis notifications by month during 2013 compared to mean monthly 
notifications 2004-2012 (CIDR)
Table 1: Campylobacteriosis outbreaks summary, 2013 (CIDR)
Outbreak location Mode of 
transmission
Number outbreaks Number ill Number hospitalised Number dead
Comm. hosp. /long-stay unit Unknown 1 2 0 0
Private house Person to person 3 7 0 0
Private house Other 1 2 0 0
Private house Unknown 2 5 0 0
Total 7 16 0 0
Cryptosporidiosis
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faecal-oral route, with both ani-
mals and humans serving as potential reservoirs. Human 
cryptosporidiosis became a notifiable disease in Ireland 
in 2004, and the case definition in use is published on 
the HPSC website. 
In 2013, 514 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 11.2 per 100,000 
population (95% CI 10.2-12.2), with 38.4% of notified 
cases reported as hospitalised for their illness. There 
were no reported deaths.
This was a 7% decrease on the number of cases notified 
in 2012 (Figure 1), being the fourth highest annual crude 
incidence rate since the disease became notifiable in 
2004. In 2011 (the most recent year for which data are 
available), the ECDC reported an incidence rate overall 
of 2.31 per 100,000 population in the European Union, 
with Ireland reporting the highest rate among those 
countries reporting on this disease at the time.1 Other 
countries with relatively high incidence rates among EU 
Member States in 2011 were the United Kingdom at 5.4 
per 100,000 and Sweden at 4.1 per 100,000.
Consistent with previous years, the highest reported 
incidence was in children under 5 years, with around 80 
cases per 100,000 population in this age group (Figure 
2). While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference in 
risk between adults and children.
The crude incidence (CIR) rates by HSE area for 2013 
are reported in Figure 3. As in previous years, there 
was a strong urban-rural divide, with the HSE E having 
a much lower reported incidence rate (1.5 per 100,000) 
than all other HSE areas. The HSE  NW and HSE W 
reported the highest crude incidence rates this year 
(23.2 and 23.4 per 100,000 respectively). Compared to 
2012, five areas reported decreased incidence rates, but 
any differences compared to 2012 were not statistically 
significant. 
As in previous years, the highest number of cases was 
recorded in spring (Figure 4).
Risk factors
Reviewing case-based enhanced surveillance data, 
3.2 Cryptosporidiosis
Summary
Number of cases, 2013: 514
Number of cases, 2012: 556
Crude incidence rate, 2013: 11.2/100,000
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Figure 1: Annual number and crude incidence rate 
cryptosporidiosis, Ireland 2004-2013    
Figure 2: Age-specific incidence rate cryptosporidiosis, Ireland 
2013
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exposure to farm animals or their faeces either by virtue 
of residence on a farm or by visiting a farm during the 
potential incubation period was common among cases; 
61.2% of cases reported either or both of these expo-
sures (Table 1). This is consistent with the low incidence 
of cryptosporidiosis among residents in the largely 
urban HSE E population and the higher incidence re-
corded in more rural parts of the country. 
Unlike salmonellosis, foreign travel plays only a minor 
role in cryptosporidiosis in Ireland (Table 1), with the 
majority of infections acquired indigenously (96.6%). 
Although, like the United Kingdom, a higher proportion 
of cases from late summer/early autumn were reported 
as being acquired abroad (Figure 5).
The proportion of cases reporting other exposures such 
as swimming pool visits and exposure to pets were simi-
lar to last year.
Table 2 shows the distribution of notified cases by home 
water supply type. It appears that persons who are not 
served by public water supplies have an increased risk 
of cryptosporidiosis as they are over-represented among 
the cases relative to the distribution of households 
by water supply type nationally; this was particularly 
noticeable for private well users. However, it should be 
borne in mind that persons whose household drinking 
water is not from a public supply are more likely to be 
rural dwellers who may also have a higher likelihood of 
exposure to farm animals and rural environments which 
is also likely to increase their risk. 
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Figure 3: Regional crude incidence rates cryptosporidiosis, 
Ireland 2010-2013. 
Figure 4. Seasonal distribution of cryptosporidiosis cases, 
Ireland 2013 compared to the mean for 2010-2012
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Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=113.5, P<0.001
Table 1: Number of cases (and percentage of cases where information available) where selected risk factors were 
reported for cryptosporidiosis cases, Ireland 2013 
Risk factor Yes (% of known) No Unknown/Not Specified Total
Travel 15 (3.4%) 430 69 514
Lives/cared for on farm 166 (37.9%) 272 76 514
Visited farm 106 (27.7%) 276 132 514
Lives/works on or visited farma 249 (61.2%) 158 107 514
Swimming pool visit 93 (22.6%) 319 102 514
Pets 260 (65.0%) 140 114 514
Other water based activities 25 (6.9%) 336 153 514
aComposite of 2 previous variables
Table 2: Number of cases (and percentage of cases where information available) by home water supply type compared to the 
number and percentage of households in Ireland by water supply type, Ireland 2013
Home water supply of 
notified cases
Number 
of cases
% of known
No. households served by these 
water supply types in the general 
population 2011 (Census 2011)
% of known
Fishers exact 
P value
Group water scheme (private) 27 6.2% 45,774 2.9%
<0.001
Group water scheme (public) 41 9.4% 144,428 9.0%
Other 2 0.5% 2,080 0.1%
Private well 119 27.2% 161,532 10.1%
Public water supply 248 56.8% 1,247,185 77.9%
Unknown 11
Not specified 66 48,409
Total 514 1,649,408 100%
Outbreaks
In 2013, there were six general and 22 family 
outbreaks in total (Figure 6). The increase in the 
number of outbreaks since 2011 is most likely due 
to increased recognition of small family outbreaks 
following the introduction of enhanced surveillance for 
cryptosporidiosis cases late in 2010. 
Among the six general outbreaks were three drinking 
water mediated outbreaks (Figure 7). This is a reversal 
of the trend which saw fewer waterborne general 
outbreaks reported since 2008. All three outbreaks 
were reported by HSE W. There were 29 ill in total, with 
4 persons admitted to hospital. 
Two additional general outbreaks were reported 
associated with swimming pools; these are the first 
swimming pool related cryptosporidiosis outbreaks 
reported in Ireland since outbreaks became notifiable in 
2004. Both were small in size; a total of five cases were 
reported and none were hospitalised. 
All 22 family outbreaks in 2013 occurred in private 
homes. The most common mode of transmission 
reported was person-to-person spread; six family 
outbreaks resulted in 12 illnesses. The second most 
common transmission route reported in family 
outbreaks was animal contact with three outbreaks 
(13 persons ill); contact with diarrhoeal cattle was the 
suspected for one of these outbreaks. The transmission 
route was unknown for the remaining 13 family 
outbreaks (Table 3 and Figure 8). 
Summary
The crude incidence of cryptosporidiosis in Ireland in 
2013 was marginally lower than the rate in 2012, but 
remains high relative to most other EU countries.The 
seasonal, age and regional distribution in incidence 
reported in 2013 was also typical of previous years; 
consistently there has been a higher incidence in 
springtime, in young children and in non HSE E areas. 
Person-to-person spread appears to be an important 
mode of transmission within family outbreaks, while 
both enhanced surveillance data and outbreak 
surveillance data are consistent with animal contact 
being an important risk factor for cryptosporidiosis in 
Ireland. Unlike in the United Kingdom, travel-associated 
disease is reported infrequently, and is likely to be a 
minor contributor to transmission, as is transmission 
associated with food.
From the enhanced information on CIDR, exposure to 
water from non-public supplies appears to present a 
higher risk of cryptosporidiosis; persons who are not 
served by public water supplies were over-represented 
among the cases relative to the distribution of 
households by water supply type nationally. However, 
while there were fewer general waterborne outbreaks 
reported between 2008 and 2012 relative to earlier 
years, three general waterborne outbreaks occurred 
in 2013.The EPA drinking water reports provide 
information on improvements in the public water supply 
sector in relation to Cryptosporidium.2
Figure 5. Seasonal distribution of cryptosporidiosis cases by 
Country of Infection, Ireland 2013
Figure 6: Number of cryptosporidiosis outbreaks notified by 
type, Ireland 2004-2013
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Table 3: Number of outbreaks and number ill by transmission route and location, Ireland 2013
Outbreak location
Person-to-person Waterborne Animal contact UNK/Not specified Total
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
Private house 6 12 3 13 13 30 22 55
Community outbreak 3 29 3 29
Swimming pool 2 5 2 5
Creche 1 4 1 4
Total 7 16 5 34 3 13 13 30 28 93
1. ECDC. 2013. Annual epidemiological report; Reporting on 2011 
surveillance data and 2012 epidemic intelligence data. Available 
at http://ecdc.europa.eu/en/publications/Publications/Annual-
Epidemiological-Report-2013.pdf 
2. EPA. 2012. The Provision and Quality of Drinking Water in 
Ireland A Report for the Year 2012. available at   
http://www.epa.ie/pubs/reports/water/drinking/  
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Figure 7: Number of general cryptosporidiosis outbreaks by 
transmission route and year, Ireland 2004-2013
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as Animal contact. Person-to-person outbreaks include only 
those outbreaks reported as being due only to person-to-person 
transmission. Note: two waterborne outbreaks in 2013 were reported 
as recreational waterborne outbreaks rather than drinking waterborne 
outbreaks
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Figure 8: Number of cryptosporidiosis outbreaks 
notified by reported transmission route, Ireland 
2004-2013
Note: In this figure, reported transmission routes were grouped 
for simplicity. Any outbreak where food contributed was 
reported as foodborne, any outbreak where water contributed 
was reported as waterborne, any outbreak where animal contact 
contributed was reported as Animal contact. Person-to-person 
outbreaks include only those outbreaks reported as being due 
only to person-to-person transmission.
Introduction
The reported verotoxigenic E. coli (VTEC) incidence rate 
in Ireland is generally high relative to other European 
countries. In 2012 (the latest year for which data are 
published), the overall VTEC incidence rate in the 
European Union was 1.15 per 100,000.1 For many years, 
Ireland has reported the highest VTEC incidence rate of 
any Member State in the EU, except in 2011 Germany 
reported the highest rate due to a large VTEC O104 
outbreak linked with fenugreek seeds.2-3 
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-7 Other important transmission 
routes identified internationally include food (often 
minced beef products or fresh produce such as lettuce 
and spinach), and contact with infected animals or 
contaminated environments.3, 8-9
Materials and Methods
Infection with verotoxigenic E. coli became a notifiable 
disease in 2012; prior to that VTEC were notifiable 
under the category Enterohaemorrhagic E. coli (EHEC) 
since 2004. Enhanced epidemiological information was 
supplied as in previous years by HSE personnel, and 
the VTEC National Reference Laboratory at the Public 
Health Laboratory HSE Dublin Mid Leinster (VTEC-
NRL at PHL HSE DML) provided VTEC confirmation 
and typing data. Data from all sources are maintained 
in the Computerised Infectious Disease Reporting 
(CIDR) system. Outbreaks of VTEC are notifiable since 
2004 and data are provided to CIDR by regional public 
health departments. The data used in this report were 
extracted from CIDR on 7th July 2014.
Data from the Central Statistics Office (CSO) 2011 
census were used to provide denominators for the 
calculation of national, regional and age-specific 
incidence rates in 2013.
Results
Incidence
In 2013, there were 702 notifications of VTEC, equating 
to a crude incidence rate (CIR) of 15.3 per 100,000 
(95% CI 14.2-16.4). This compares to an overall rate 
of 12.1 per 100,000 in 2012, an increase of 27%. 569 
notifications in 2013 were reported as confirmed cases 
(CIR 12.40 95% CI 11.38-13.42), 130 were probable and 
there were 3 cases reported in the possible case class. 
The criteria under which notified cases were reported 
in 2013 under the VTEC case definition is outlined in 
Table 1. As the classification of VTEC cases changed 
significantly upon the amendment of the Irish VTEC case 
definition in 2012, it is not valid to directly compare the 
number of notifications by case classification with the 
period before 2012. 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2013: 702
Crude incidence rate, 2013: 15.3/100,000
Number of VTEC-associated HUS 2013: 31
Number of VTEC cases, 2012: 554
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Table 1. Number of VTEC notifications by criteria for notification, Ireland 2013
Notification criteria Confirmed Probable Possible Total
Culture confirmationa 471 111  582
Laboratory confirmation by PCRb 97 11 108
Serodiagnosis (valid for HUS only) 1  1
Reported solely on the basis of epidemiological link  8 8
Clinical HUS not meeting lab or epi criteria  3 3
Total 569 130 3 702
aSymptomatic culture confirmed cases are classified as confirmed cases, while asymptomatic culture confirmed cases are 
classified as probable cases
b Symptomatic PCR-confirmed cases are classified as confirmed cases, while asymptomatic PCR-confirmed cases are 
classified as probable cases
Of the 691 cases with laboratory evidence of infection, 
215 cases were reported as being infected with E. 
coli O157 (4.7 per 100,000 (95% CI 4.1-5.3), 212 with 
E. coli O26 (4.6 per 100,000 (95% CI 4.0-5.2), 255 
with other VTEC strains, and 9 cases had mixed VTEC 
infections, being infected with more than one VTEC 
strain. Of the 8 probable cases reported on the basis 
of an epidemiological link to a confirmed case, 4 were 
linked to E. coli O157 outbreaks, and 4 were linked to E. 
coli O26 outbreaks. Figure 1 illustrates the distribution 
of VTEC cases in Ireland by serogroup since 1999. 
The serogroup distribution this year represents a 6.6% 
decrease in O157 infections, a 2.4% increase in O26 
infections, and a 180% increase in other non-O157 
infections compared to 2012.
Severity of illness
Five hundred and seventy-nine of the 702 notified 
cases were symptomatic (82.5%), 234 (40.4%) of which 
developed bloody diarrhoea (43.8% when only cases 
with this variable completed are included). Thirty-one 
individuals (4.4%) developed HUS, a decrease of 3% 
on 2012. There was one death in a confirmed VTEC 
case and one death in a possible VTEC case; four other 
persons diagnosed in 2014 with VTEC infection died, 
but their deaths were not due to VTEC. Where reported 
(n=680), 242 (35.6%) of notified cases were hospitalised 
(42.0% of symptomatic cases). 
Twelve HUS cases were infected with E. coli O157, with 
a further two HUS case infected with both VTEC O157 
and VTEC O26. Five had laboratory evidence of VTEC 
O26 infection, two had VTEC O55 infections, and seven 
were infected with other VTEC strains (Table 2). The 
remaining three HUS cases were reported as possible 
VTEC notifications. HUS cases ranged in age from 10 
months to 81 years, with 25 of the 31 cases being less 
than 10 years. Eighteen were sporadic cases, nine were 
part of family outbreaks (including two cases in one 
household), and four were part of general outbreaks 
(including two in one small community outbreak).  
Seasonal distribution
Figure 2 shows the seasonal distribution of notifications 
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Figure 1. Annual number of confirmed and probable VTEC 
cases by serogroup, Ireland 1999-2013
Note: For simplicity in this figure, cases with mixed VTEC O157/other 
serogroup infections are included in the data for O157, as are probable 
cases linked to known E. coli O157 outbreaks. Non-O157 data includes 
cases with mixed non-O157 infections and probable cases linked to 
known O26 outbreaks
Figure 2. Seasonal distribution of VTEC notifications, Ireland 
2013 compared to the mean number of notifications 2010-
2012
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Table 2. Number of VTEC notifications by infecting serogroup and verotoxin and HUS status, Ireland 2013
Serogroupa HUS non-HUS Total
O157 VT1b 0 1 1
O157 VT2 or epi-linked to O157 VT2 outbreak 11 178 189
O157 VT1+VT2 or epi-linked to O157 VT1+VT2 outbreak 3 32 35
O26 VT1 or epi-linked to O26 VT1 outbreak 1 102 103
O26 VT2 or epi-linked to O26 VT2 outbreak 0 10 10
O26 VT1+VT2 or epi-linked to O26 VT1+VT2 outbreak 3 102 105
O26 serodiagnosed 1 0 1
Other VT1 1 114 115
Other VT2 7 80 87
Other VT1+ VT2 1 52 53
No organism 3 - 3
Total 31 671 702
aFor simplicity mixed infections were recorded as O157 if at least one strain was O157, as O26 if at least one strain was O26 but not O157, 
and as Other if only non-O157 non-O26 strains were detected. 
bOne case was reported as positive for vt1 and O157 by PCR; it is possible that these genes were not detected from the same strain
in 2013 relative to the mean monthly number of cases 
in the years 2010-2012. Despite the very large increase 
in the number of notifications, the typical summer 
seasonal peak was maintained, but was slightly higher 
than previously in the early part of the summer the 
peak months were May and August, followed by July, 
September and October.
Like 2012, there was variation in the seasonal 
distribution by serogroup, with VTEC O157 showing 
the typical peak in numbers in late summer; in contrast, 
VTEC O26 notifications peaked in May and July during 
2013 (Figure 3). Other non-O157 serogroups were also 
more common in early summer in 2013.
Regional distribution
While the overall VTEC incidence rate nationally 
increased significantly compared to 2012, examining 
by VTEC serogroup showed that the increase was due 
to a large significant increase in the reported rate of 
non-O157 infections, while the reported rate for VTEC 
O157 actually decreased although not significantly.
Reviewing at the regional incidence rates for VTEC 
O157, the reported incidence rates by area were not 
significantly different compared to 2012. The HSE E 
reported a rate significantly lower than all other areas 
in 2013, while the rate for the HSE NE was significantly 
lower than for four of the other HSE areas.
The crude rate for non-O157 infections was higher 
than for VTEC O157 in six HSE areas (Table 3; Figure 
4). There were significant increases in the reported 
incidence of non-O157 for three HSE areas: the HSE 
E, HSE MW and HSE SE; this is likely to have been 
influenced at least in part by changes in local diagnostic 
practices. 
The highest VTEC incidence rate overall were reported 
in the HSE MW followed by the HSE SE, where the rates 
were two to two and half times the national crude rate 
(Table 3). Atypically, the HSE NE reported the lowest 
overall crude incidence rate (Table 3), followed closely 
by the HSE E and HSE NW. The reported incidence 
rates in these three areas were significantly lower than 
the rates reported in the other five areas. 
The relative ranking of HSE areas by overall VTEC 
incidence was fairly similar to the the ranking of areas 
by HUS incidence rate suggesting that the differences 
observed are likely to be a reasonable reflection of the 
true differences in risk between HSE areas. 
Age-sex distribution
As in previous years, the highest reported age-specific 
incidence rate was in the 0-4 years age group (~ 80 per 
100,000). Incidence rates were higher among females in 
all age groups over 25 years, and were slightly higher in 
males than females in the 0-4 year age group (Figure 5).
Laboratory typing
In 2013, the serogroup and verotoxin profiles of VTEC 
isolates/samples referred to the PHL HSE Dublin Mid 
Leinster, Cherry Orchard Hospital are displayed in Table 
4. The most common serogroup reported was VTEC 
O157 (n=215), closely followed by VTEC O26 (n=213). 
Among the other serogroups listed by the World Health 
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Figure 3: Seasonal distribution of VTEC notifications by 
serogroup, Ireland 2013
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Table 3. Number and crude incidence rate VTEC by serogroup and HSE area, and number and crude incidence rate VTEC-
associated HUS by HSE area, Ireland 2013
HSE-area a Number [CIR (95% CI)] VTEC 
O157 b
Number [CIR (95% CI)] non-
O157 VTEC c
Number [CIR (95% CI)] all 
VTEC d
Number [CIR (95% CI)] VTEC-
associated HUS
E 34 [2.1 (1.4-2.8)] 53 [3.3 (2.4-4.2)] 89 [5.5 (4.4-6.6)] 5 [0.3 (0.0-0.6]
M 20 [7.1 (4.0-10.2)] 50 [17.7 (12.8-22.6)] 70 [24.8 (19.0-30.6)] 2 [0.7 (-0.3-1.7)]
MW 29 [7.7 (4.9-10.4)] 122 [32.2 (26.5-37.9)] 151 [39.8 (33.5-46.2)] 4 [1.1 (0.0-2.1)]
NE 13 [3.0 (1.4-4.6)] 2 [0.5 (-0.2-1.1)] 15 [3.4 (1.7-5.1)] 2 [0.5 (-0.2-1.1)]
NW 12 [4.7 (2.0-7.3)] 4 [1.6 (0.0-3.1)] 16 [6.2 (3.2-9.2)] 0 [0.0 (0.0-0.0)]
SE 36 [7.2 (4.9-9.6)] 111 [22.3 (18.2-26.5)] 148 [29.7 (25.0-34.5)] 10 [2.0 0.8-3.3)]
S 45 [6.8 (4.8-8.8)] 66 [9.9 (7.54-12.3)] 111 [16.7 (13.6-19.8)] 4 [0.6 (0.0-1.2)]
W 36 [8.1 (5.4-10.7)] 66 [14.8 (11.2-18.4)] 102 [22.9 (18.5-27.4)] 4 [0.9 (0.0-1.8)]
IE 225 [4.9 (4.2-5.5)] 474 [10.4(9.4-11.3)] 702 [15.3 (14.2-16.4 31 {0.7 (0.4-0.9)]
aRates per 100,000 calculated using CSO census 2011 for denominator data
b For simplicity, cases with mixed VTEC O157/other serogroup infections are included in the data for O157, as are probable cases linked to known 
E. coli O157 outbreaks. 
c Non-O157 data includes cases with mixed non-O157 infections and probable cases linked to known O26 outbreaks. 
d Possible cases (i.e. those with no associated organism are also included in this column), and therefore the total in this column will not always be 
the sum of the previous two columns.
Organisation as having the highest association with HUS 
internationally, there were eighteen VTEC O103 cases, 
seven VTEC O111, and seventeen VTEC O145. There 
was a large increase in the variety of other non-O157 
serogroups reported, and in the number of cases 
infected with ungroupable strains (this included those 
cases diagnosed by PCR only). 
As usual among VTEC O157 in Ireland, isolates 
containing the genes for verotoxin 2 (vt2) were more 
common (84%) than strains containing both vt1 and vt2. 
VTEC O26 strains containing only vt1 made up 47% of all 
VTEC O26 reported, with 48% of VTEC O26 containing 
the genes for both vt1 and vt2, and those containing 
vt2 making up the remaining 5% of VTEC O26. vt2-
containing strains made up the majority of O145 strains 
(82%), vt1-containing strains made up the majority of 
O103 strains (89%), while VTEC O111 strains comprised 
both vt1-containing (57%) and vt1+vt2-containing (43%) 
strains. 
Risk factors
Under enhanced surveillance for VTEC, risk factor 
information is routinely collected on VTEC notifications 
(Table 5).
Exposure to farm animals or their faeces and exposure to 
private well water were relatively common among cases; 
36.7% and 35.0% reported these exposures respectively, 
although both were less commonly reported than in 
2012. According to CSO data, in the general population, 
around 10.1% of households are served by private wells, 
indicating that, on a national basis, exposure to private 
wells appears to be more common among VTEC cases 
than among the general population.
Unlike salmonellosis, foreign travel plays only a minor 
role in VTEC infection in Ireland, with the overwhelming 
majority of infections acquired indigenously. 
Where the information was available, around a quarter of 
VTEC cases in 2013 were reported to attend a Childcare 
Facility (CCF). When these analyses were restricted to 
notified VTEC under five years of age, over half reported 
attendance at a childcare facility. This is higher than the 
proportion of children in the general population who use 
non-parental childcare (42%) as reported by the Central 
Statistics Office.10
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in 
our understanding of VTEC transmission in Ireland. 
Ninety-six VTEC outbreaks were notified in 2013, which 
included 315 of the 702 VTEC notifications. 29 outbreaks 
were due to VTEC O157, 43 to VTEC O26, eight were 
mixed VTEC strain outbreaks, and 16 were caused by 
other VTEC strains. 
The majority of outbreaks (83%) were family outbreaks, 
with sixteen general outbreaks notified. The 80 family 
outbreaks resulted in 133 persons becoming ill, an 
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Figure 4: Crude incidence rate VTEC O157 and non-O157, 
Ireland 2013
Table 4. Serotype and verotoxin (vt) profiles associated with 
laboratory confirmed VTEC cases, as determined at the VTEC-
NRL at PHL HSE DML in 2013 
Sero-
group 
vt1 vt1+vt2 vt2 N/A Total
O157 1a 34 180 215
O26 100 102 10 1b 213
O103 16 2 18
O145 2 1 14 17
O111 4 3 7
O55 1 5 6
O91 1 4 1 6
O146 4 1 5
O84 4 4
O5 3 3
O113 3 3
O182 3 3
O153 3 3
O105c 2 2
O104 1 1 2
O117 1 1 2
O130 2 2
O165 1 1 2
O178 1 1
O159 1 1
O78 1 1
O180 1 1
O98 1 1
O181 1 1
O76 1 1
O118 1 1
O8 1 1
O2 1 1
O73 1 1
O108 1 1
O101 1 1
O140 1 1
O74 1 1
O166 1 1
Un-
group-
able
70 34 49 153
Mixed in-
fections
~ ~ ~ 9
Total 218 190 282 1 691
aOne case was reported as positive for vt1 and O157 by PCR; it is 
possible that these genes were not detected from the same strain
bNo vt type for one VTEC O26 case, as diagnosed by serodiagnosis
average of 1.7 (range 1-5) persons ill per outbreak, 
while the sixteen general outbreaks resulted in 88 
persons becoming ill, an average of 5.5 (range 1 to 31) 
persons ill per outbreak. 
Seventy-seven outbreaks occurred in private homes, 
seven involved childcare facilities, six were community 
outbreaks (note: two of these also involved childcare 
facilities), two involved extended families, one was 
travel-related, one was in a community hospital/long 
stay unit, and the locations for two outbreaks was not 
specified. 
The suspected modes of transmission are listed in Table 6.
Person-to-person spread is consistently the most 
common mode of VTEC transmission reported in 
Ireland, particularly between young children, and 
was suspected to have played a role in 46 (48%) 
VTEC outbreaks in 2012 in which 105 persons were 
reported ill (Table 6 and Figure 5). Thirty seven of these 
outbreaks were reported as being solely due to person-
to-person transmission, including five of the outbreaks 
which occurred in CCFs. 
The second most common transmission route was 
Animal/Environmental contact, which was reported 
to have contributed to 10 outbreaks (10.4%) with 15 
persons ill. All were family outbreaks in private houses. 
This is the largest annual number of VTEC outbreaks 
due to this transmission route since outbreaks became 
notifiable in 2004 (Figure 6). There are few details 
available, however, exposure to calves was mentioned 
in one outbreak, exposure to sheep in another, and 
exposure to farm manure in a third.
The third most common transmission route reported 
was waterborne transmission, which was reported to 
have contributed to 8 outbreaks (8.3%) with 16 persons 
ill. This is fewer than half the number of waterborne 
VTEC outbreaks reported in 2012. Two were general 
outbreaks and six were family outbreaks; these 8 
outbreaks were linked to 7 domestic private wells, and 
one group water scheme. For one outbreak, VTEC other 
than that identified in the outbreak cases was detected 
in the implicated supply. Evidence was circumstantial 
for the water supplies suspected in the remaining 
outbreaks. For the six family outbreaks, the location 
was reported as private house. One general outbreak 
in a childcare facility was reported as waterborne plus 
person to person spread; initial transmission to the 
index case in the CCF was by waterborne transmission 
at home, with onward person-to-person transmission 
within the CCF. The second general outbreak was a 
small community outbreak associated with a group 
water scheme.
Five outbreaks (51 persons ill in total) were reported as 
being suspected to be foodborne, three general and 
two family outbreaks. In one small community outbreak 
in HSE MW with two persons ill, microbiological and 
descriptive epidemiological evidence implicated an 
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Figure 5. Age-sex distribution VTEC notifications, Ireland 2013
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Table 5. Number of cases of VTEC (and percentage where known) for selected risk factors, Ireland 2013
Risk factor Number ‘Yes’ and % where 
reported
Number ‘No’ and % where 
reported
Number where risk factor was 
unknown or not reported
Food suspected 42 (8.4%) 457 (91.6%) 203
Exposure to farm animals or their faeces 231 (36.7%) 398 (63.3%) 73
Exposure to private well watera 223 (35.0%) 413 (65.0%) 66
Travel-associatedb 16 (2.4%) 651 (97.6%) 35
Attendance at a CCFc 155 (26.5%) 430 (73.5%) 117
Attendance at a CCFc (among <5 yrs) 146 (55.7%) 116 (44.3%) 41
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bInferred from CIDR core variable Country of Infection
c CCF=Childcare Facility
unpasteurised cheese. This is the first time in Ireland 
where there has been strong evidence implicating a raw 
milk cheese in a foodborne VTEC outbreak. 
Two further general community foodborne outbreaks 
were notified with 45 persons ill (51 laboratory 
confirmed cases) between them. Both were national 
outbreaks, and evidence of the microbiological link 
between cases was based on detailed laboratory typing 
undertaken at the VTEC Reference Laboratory at Cherry 
Orchard Hospital. Cases were diffusely distributed; and 
although no evidence was obtained suggesting any 
particular food as the source, foodborne transmission 
was suspected given the geographical spread of the 
primary cases and the absence of other exposures 
common to all which might explain the outbreak. For 
one of these outbreaks, approximately half of cases in 
the outbreak appear to result from secondary spread in 
a childcare facility. A further small family outbreak was 
suspected to be due to the consumption of raw milk at 
home, while the remaining foodborne family outbreak 
was associated with exposure in Africa.
For 38% (n=36) of VTEC outbreaks in 2013, the 
transmission route was reported as unknown or not 
specified (Table 6 and Figure 6).
In sporadic case investigations, a further seven private 
supplies investigated as possible sources were positive 
for VTEC either by culture or PCR. In two instances, the 
strains detected were similar to those identified in the 
associated human cases.
Summary
There was a statistically significant increase in the 
number of VTEC notifications in 2013 relative to 2012. 
The great majority of this increase was accounted for 
by non-O157 non-O26 VTEC cases, which increased 
by 180% relative to 2012, coinciding with continuing 
changes in diagnostics in primary hospital laboratories 
during this time. In contrast, the incidence of VTEC 
O157 actually decreased in 2013 although not 
significantly. 
Guidance for Laboratory Diagnosis of Human 
Verotoxigenic E. coli Infection developed by The 
Laboratory Sub-Group of the VTEC Sub-Committee 
of the HPSC Scientific Advisory Committee was issued 
in September 2014. It is anticipated that this will 
further contribute to a coordinated approach to VTEC 
diagnosis in Ireland.11
Within the European Union, the latest available data 
shows that the overall incidence rate for confirmed 
VTEC cases in Europe in 2012 was 1.15 (range 0.0-
8.99).1 Ireland, Luxembourg, Sweden and Denmark 
reported the highest confirmed incidence rates at that 
time. It seems likely when the data are available across 
Europe for 2013, that Ireland will have one of the 
highest reported incidence rates in Europe again.
Foodborne transmission was the first recognised 
transmission route for VTEC infection historically, with 
minced beef, unpasteurised dairy products, and fresh 
produce consumed raw all having been implicated 
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Figure 6. Number of VTEC outbreaks by suspected 
transmission route and year, Ireland 2004-2013
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any other outbreak where animal contact contributed 
was reported as Animal contact. Person-to-person outbreaks include 
only those outbreaks reported as being due only to person-to-person 
transmission.
Table 6. VTEC outbreaks by suspected mode of transmission, Ireland 2013 
Transmission Route Number of  outbreaks Number ill Number of associated CIDR 
Events
Person-to-person 37 76 102
Foodborne 3 34 35
Person-to-person and Foodborne 1 14 19
Waterborne 7 12 19
Person-to-person and Animal Contact 7 11 17
Person-to-person and Waterborne 1 4 9
Animal contact 2 2 4
Environmental / Fomite 1 2 3
Foodborne and Animal Contact 1 3 2
Unknown 31 57 90
Not Specified 5 6 15
Total 96 221 315
in outbreaks across the world. Foodborne outbreaks 
typically comprise a small percentage of the total 
number of VTEC outbreaks in Ireland; in 2013, they 
made up 5% of outbreaks, however, they caused a 
disproportionately high proportion of VTEC outbreak 
cases (23%). This was largely due to the occurrence of 
two nationally distributed community outbreaks which 
were suspected to be foodborne but for which the 
source of infection was not established. Both outbreaks 
were caused by strains of VTEC O157 VT2 strains (the 
most common VTEC variant reported historically in 
Ireland), and molecular typing of VTEC isolates at the 
VTEC Reference Laboratory was key in determining 
which cases occurring around the country were 
included/excluded from each of the two outbreaks. 
For the first time in Ireland, there was strong evidence 
implicating a food product in a VTEC outbreak; 
an unpasteurised cheese was implicated in a small 
outbreak with two persons ill in the HSE MW. A 
thorough investigation was undertaken, alerts were 
issued and the implicated product was withdrawn 
from sale. Also in 2013, a small family outbreak was 
suspected to be due to consumption of unpasteurised 
milk at home. 
Unusually, animal/environmental contact was reported 
as the second most common route of transmission for 
VTEC outbreaks in 2013. This has long been recognised 
as a risk factor for VTEC infection,8-9 and cases due to 
this transmission route are not unexpected in Ireland 
given the large cattle population, the high proportion 
of rural dwellers, and the large number of farming 
families. Fortunately, none of these animal contact 
outbreaks were associated with public venues such as 
open farms, and so the numbers of people affected 
were small. Advice is available on the HPSC website on 
how to minimise the risk of gastrointestinal infections 
following exposure to farm animals and environments, 
and for the safe recreational use of farmland.12
In 2013, contaminated drinking water contributed to 
fewer outbreaks that in 2012. As in previous years, all 
drinking water associated outbreaks reported were 
linked with private water supplies. Exposure to water 
from contaminated untreated or poorly treated private 
water supplies has historically been recognized as a 
strong risk factor for VTEC infection in Ireland.6,7 This 
has been particularly pronounced following periods 
of heavy rainfall. The lower number of outbreaks in 
2013 is likely to have been influenced by lower rainfall 
levels and less contamination of private water sources. 
The HSE and EPA have both developed resources for 
owners of private wells, providing advice on private 
well maintenance.13-14
Transmission by person-to-person spread, however, 
remained the most common transmission route 
reported in VTEC outbreaks (48% of outbreaks), as 
usual being most frequently associated with private 
house and childcare facility outbreaks. Handwashing 
and exclusion of cases in risk groups from high risk 
settings remains a key prevention measures for VTEC.15
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from 
person to person via the faecal-oral route and is 
associated with poor hygiene and sanitation. Common 
source outbreaks due to contaminated food or water 
also occur.
The incidence of hepatitis A in Ireland has been low 
in recent years and remained low in 2013, with 50 
cases notified (figure 1). This corresponds to a crude 
notification rate of 1.1/100,000 population. Although 
this rate was higher than in 2012, when 30 cases were 
notified, the increase was due to two large outbreaks, 
which accounted for two thirds of the 2013 cases. Case 
classification was reported for all cases. Forty seven 
were laboratory confirmed and three were classified as 
probable. The notification rates for each HSE area are 
shown in figure 2.
3.4 Hepatitis A
Summary
Number of cases, 2013: 50
Crude notification rate, 2013: 1.1/100,000 population
Number of cases, 2012: 30
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Figure 1. Number of hepatitis A notifications, 1998-2013
Figure 2. Hepatitis A notification rates/100,000 population, by HSE area, 2013
Fifty four percent of cases were female (n=27) and 46% 
were male (n=23). The highest notifications rates were 
in adults, with 76% of cases aged between 25 and 64 
years (figure 3).
Thirty five cases were reported as infected in Ireland. 
Nine cases were linked to travel outside of Ireland and 
a further five had a history of recent travel outside of 
Ireland but could also have been infected in Ireland. 
Country of infection was not known for the remaining 
case.
Six hepatitis A outbreaks were reported in 2013. The 
largest involved 23 adult cases (15 confirmed primary, 4 
confirmed secondary, 3 possible primary and 1 possible 
secondary) in multiple HSE areas. A case control study 
was undertaken and the outbreak was found to be 
associated with the consumption of frozen berries. The 
hepatitis A genotype (1A) and sequence were identical 
to that in a large multi-national European outbreak, 
which was also associated with frozen berries. In 
September 2014, the Food Safety Authority of Ireland 
reiterated earlier advice to boil all imported frozen 
berries for at least a minute prior to consumption 
(http://www.fsai.ie/news_centre/press_releases/
hepatitis_a_frozen_berries_advice_08092014.html).
A further outbreak involving two adult cases was 
associated with frozen berries consumed in Italy. The 
genotype and sequence were also identical to that in 
the multi-national European outbreak described above.
An outbreak in HSE NE affected six adults and four 
children. The index case had travelled to Asia and 
was likely to have been infected there. The remaining 
cases were contacts infected through person-to-person 
transmission in Ireland. 
A smaller outbreak in HSE NW affected two adults 
and one teenager. The index case had travelled to the 
United Kingdom within the exposure period but could 
also have been infected in Ireland. Another outbreak 
in HSE E involved one adult and one child. The country 
of infection was Ireland, but no source of infection 
was identified. The remaining outbreak involved two 
adults who had travelled to Egypt and was linked to 
an outbreak affecting people from several European 
countries.
In recent years, large hepatitis A outbreaks due 
to agricultural produce such as frozen berries1, 
pomegranate seeds2, and semi-dried tomatoes3 
have been reported internationally. This illustrates 
the importance of compliance with good hygiene, 
agricultural and manufacturing practices in all countries 
exporting agricultural products, particularly those that 
are usually consumed raw.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 15th September 
2014. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR.
1. European Centre for Disease Control and Prevention, 
Stockholm, 2013. Rapid Outbreak Assessment - 
Update: Outbreak of hepatitis A virus infection in Italy and Ireland, 9 
July 2013. Available at:
http://ecdc.europa.eu/en/publications/Publications/ROA-update_
HAV_Italy_Ireland-final.pdf
2. Collier MG, Khudyakov YE, Selvage D3, Adams-Cameron 
M, Epson E, Cronquist A et al. Outbreak of hepatitis A in the USA 
associated with frozen pomegranate arils imported from Turkey: an 
epidemiological case study. Lancet Infect Dis. 2014 Oct;14(10):976-81. 
3. Donnan EJ, Fielding JE, Gregory JE, Lalor K, Rowe S, 
Goldsmith P et al. A multistate outbreak of hepatitis A associated 
with semidried tomatoes in Australia, 2009. Clin Infect Dis. 2012 
Mar;54(6):775-81.
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Figure 3. Hepatitis A age and sex-specific notification rates/100,000 population, 2013
Rotavirus is the commonest global cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant. Three 
primary serogroups of rotaviruses infect humans; A, B 
and C; A being the commonest infecting serogroup. 
Given the universal distribution of rotavirus, the 
numbers of notifications will always represent an 
underestimate of the true incidence and are likely to 
be more reflective of habits of presentation to medical 
practitioners and of styles of investigation, notification 
and testing.
Since 2004, rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the 
Acute Infectious Gastroenteritis (AIG) disease category. 
Prior to 2004, rotavirus caress were notified in the 
former notification category of “Gastroenteritis in 
children under two years”. In April 2008 the case 
definition of AIG was amended specifying definitions 
for both rotavirus and the newly notifiable Clostridium 
difficile associated disease. On 4th May 2008, these 
amended definitions formally replaced the previous 
3.5 Rotavirus
Summary
Number of cases:  2,514
Crude incidence rate:   54.8/100,000 population
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Figure 1: Rotavirus 2013 CIR compared to 2004-2012 mean CIR by HSE area (CIDR).
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AIG case classification. Rotavirus became notifiable as 
a disease in its own right under the Infectious Diseases 
(Amendment) Regulations 2011 (S.I. No. 452 of 2011).
Rotavirus case definition:
A case of rotavirus infection is defined as a patient with 
acute onset of vomiting followed by watery diarrhoea 
with fever, which typically lasts between three and eight 
days, AND one of the following laboratory criteria for 
diagnosis:
• Detection of rotavirus by antigen assay
• Detection of rotavirus-specific RNA
• Detection of rotavirus by electron microscopy
• Isolation of rotavirus
During 2013, there were 2,514 cases of rotavirus 
notified in Ireland, corresponding to a national crude 
incidence rate (CIR) of 54.8 per 100,000 population and 
representing a decrease of 5.2% compared to 2012.
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIRs were 
observed in HSE-M (116.9/100,000 population) and 
HSE-SE (84.2/100,000 population). The lowest regional 
CIR was observed in HSE-E at 31.0 per 100,000 and 
Figure 2: Rotavirus notifications by month during 2013 compared to mean monthly notifications, 2004-2012 (CIDR).
Figure 3: Number of cases of rotavirus in children less than two years of age by year, 2001 to 2013
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HSE-MW at 44.8 per 100,000 population. Figure 1 
illustrates the rotavirus CIR by HSE area for 2013 
compared to the mean CIR during 2004-2012.
Rotavirus infection has a well-documented seasonal 
pattern in Ireland with the number of cases typically 
peaking during March to May. During 2013, rotavirus 
notifications peaked during April (n=787) and May 
(n=740). Figure 2 illustrates the seasonal variation 
in rotavirus cases by month of notification for 2013 
compared to the mean monthly number of notifications 
reported during 2004 to 2012.
Rotavirus is the most common cause of acute 
gastroenteritis in children worldwide with children 
generally affected in the first 2-3 years of life. In 2013, 
66.6% (n=1,674) of cases were aged two years or 
under. From 2004 to 2013, data shows that the peak 
incidence of clinical disease occurred in the 6-18 month 
age group, with 54.4% of total notifications in this 
age group. Figure 3 presents the number of cases of 
rotavirus in children less than two years of age by year, 
2001 to 2013.
During 2013, 1,163 cases (46.3%) were female and 
1,342 (53.4%) were male. Sex was not reported for 9 
(0.4%) cases. This represented a ratio of females: males 
of 0.9:1.2, which was similar to the ratio observed in 
previous years.
One outbreak of rotavirus was notified during 2013 
with two cases of associated illness, both of whom were 
hospitalised. This was a family outbreak that occurred in 
a private home with mode of transmission reported as 
person to person spread.
Salmonellosis
Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. S. 
Typhi and S. Paratyphi can cause enteric fever, a severe 
systemic life threatening condition, but these are not 
common in Ireland and are almost invariably travel-
associated.
The common reservoirs for non-typhoidal Salmonella 
are the intestinal tract of domestic and wild animals 
(including birds), which may result in a variety of 
foodstuffs, of both animal and plant origin, becoming 
contaminated with faecal organisms either directly 
or indirectly. The organism may also be transmitted 
through direct contact with infected animals or humans 
or faecally contaminated environments. Infected food 
handlers may also act as a source of contamination for 
foodstuffs.1 Of particular concern is the number of cases 
of infection associated with direct contact with reptiles 
kept as companion animals.  
Incidence and clinical features
There were 324 cases of salmonellosis notified in 2013, 
up 3% compared to 2012 (Figure 1). Among cases with 
information on symptoms, 96.8% were reported to have 
diarrhoea (274/283), 30.4% bloody diarrhoea (78/257), 
52.5% vomiting (134/255), 65.7% nausea (140/213), 
79.8% abdominal pain (194/243), 70.6% fever (156/221) 
and 38.0% headache (65/171). Almost 40% of cases 
required hospital admission (119/299), with no reported 
fatalities.
This equates to a national crude incidence rate (CIR) for 
salmonellosis of 7.1 per 100,000 population. The annual 
CIR has remained consistently low over the last five 
years (mean 7.2 per 100,000; range 6.8-7.8 per 100,000) 
compared to the previous five years (mean CIR 9.9 per 
100,000 range 8.1-10.8). 
Figure 2 illustrates the regional variation in CIR during 
2013 compared to 2012. The highest CIR in 2013 
occurred in HSE MW and the lowest in HSE E and HSE 
SE. However, the rates were not statistically significantly 
different either between HSE areas in 2013, or 
comparing between 2013 and 2012 by region.  
The number of male cases was marginally higher than 
3.6 Salmonella 
Summary
Number of confirmed cases: 324
Number of probable cases: 0
Crude incidence rate: 7.1/100,000
Figure 1: Salmonellosis notifications and crude incidence rate per 100,000 population by year of notification, 
Ireland 2004-2013. [Data source: CIDR]
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Figure 2. Regional CIR 2013 vs 2012, salmonellosis. [Data source: CIDR]
Figure 3: Salmonellosis notifications and age specific incidence rate per 100,000 population by age group (years) 
and sex, Ireland 2013. [Data source: CIDR]
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for females in 2013 (male:female ratio=1.13:1.0); this is 
consistent with previous years. 
Overall, the highest age-specific incidence rate was 
in children under 5 years of age; this is likely to be, 
at least in part, a reflection of clinicians more readily 
seeking clinical samples in that age group. Specifically, 
the incidence rates were higher in males than females 
in all age groups less than 15 years; among adults, 
age-specific incidence rates were comparable between 
the sexes except in the age group 25-34 years where 
females predominated.  
NSSLRL data:
The National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) based in Galway has 
been providing reference services nationally since 2000. 
In 2013, the NSSLRL analysed 332 human non-typhoidal 
Salmonella isolates referred for further typing. 
Table 1 lists the top 12 serotypes detected during 
2013. S. Typhimurium* (n=129) was the most common 
serotype, followed by S. Enteritidis (n=49). S. 
Typhimurium has been the most common serotype 
since 2008. 
Figure 4 shows the trend in referral of isolates to 
NSSLRL by organism over time. S Enteritidis case 
numbers have been in steep decline since 2008, and 
in 2013, these decreased by further 12% (Figure 4). 
In contrast, both S Typhimurium and Other serotypes 
increased by 6% and 20% respectively relative to 2012, 
although numbers of both have been relatively stable 
the last four years. 
The NSSLRL conducted phage typing analysis on all 129 
S. Typhimurium and all 53 S. Enteritidis isolates.
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Figure 4. Annual number of non-typhoidal Salmonella isolates referred to NSSLRL by 
serotype, 2000-2013. [Data source: NSSLRL] 
0
50
100
150
200
250
300
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Nu
m
be
r o
f n
on
-ty
ph
oi
da
l i
so
la
te
s 
re
ce
iv
ed
 a
t 
NS
SL
RL
 
year
Typhimurium* Enteritidis Other
Phage type DT193 (n=39) comprised over 30% of all 
S. Typhimurium strains; this is the highest annual total 
of phage type DT193 cases reported since records 
began in 2000 (Figure 5). Other currently important S 
Typhimurium phage types included Untypable (14.0%) 
and DT104b (8.5%). Both DT193 and Untypable have 
increased gradually over the last 5-6 years, while the 
numbers of DT104b and DT104 in 2013 represent a 
substantial reduction compared to 10 years ago.
Phage types PT14b (22.4%), PT8 (16.3%), and PT1 
(16.3%) were the most common types observed among 
S. Enteritidis isolates (Figure 6). 
Of the 332 non-typhoidal isolates analysed for 
antimicrobial resistance, 191 (57.5%) were fully 
susceptible to all antimicrobials tested. The remaining 
151 isolates exhibited some degree of antimicrobial 
resistance. 39 isolates exhibited resistance to five or 
more antimicrobials, the most common pattern of 
which was ampicillin, chloramphenicol, streptomycin, 
sulphadiazine and tetracycline (ACSSuT, n=20). The 
majority of isolates exhibiting this level of resistance 
were S. Typhimurium (32/39, 82%). Overall, the 
commonest resistance pattern† seen was resistance to 
ampicillin, streptomycin, sulphadiazine and tetracycline 
(ASSuT, n=42, 12.7% of isolates); this pattern was almost 
exclusively identified in S. Typhimurium isolates (41/42 
ASSuT resistant strains were S. Typhimurium). Resistance 
to nalidixic acid (Na, n=21, 6.3% of isolates) was the 
most common AMR profile among S. Enteritidis isolates 
(30.6% of S. Enteritidis strains). 
The NSSLRL’s Annual Report 2013 provides a more 
detailed analysis of clinical Salmonella typing results and 
a comparison with isolates from non-human sources.2 
Foreign travel as a risk factor for salmonellosis in 
Ireland
The variable ‘Country of infection’ was completed on 
CIDR for over 90% of notifications in 2013, up from 86% 
in 2012 and 78% in 2011. In the following analyses, we 
have defined travel-associated cases as those where a 
country of infection other then Ireland was reported, and 
indigenous as those where the country of infection was 
recorded as Ireland. 
Travel abroad during the incubation period is a strong 
risk factor for salmonellosis in Ireland. Of the two 
hundred and ninety-three cases where the ‘country 
of infection’ variable was completed, 177 cases were 
acquired in Ireland (65.5%); this compares with 2012 
when 55.5% of cases with known travel status were 
indigenous. Among cases acquired abroad, the most 
common countries of infection reported were: Spain 
(n=27), Thailand (n=14), India (n=8) and Nigeria (n=7). 
The popularity of a country as a travel destination is 
likely to be an important factor in determining the 
Table 1: Number and percentage of non-typhoidal  human 
Salmonella isolates by serotype, Ireland 2013
Salmonella serotype Number of 
isolates
% Isolates
Typhimurium 76 22.9%
Monophasic Typhimuriuma 53 16.0%
Enteritidis 49 14.9%
Infantis 14 4.2%
Dublin 12 3.6%
Newport 11 3.2%
Unnamed 10 3.0%
Agama 6 1.8%
Montevideo 5 1.5%
Stanley 5 1.5%
Virchow 5 1.5%
Anatum 5 1.5%
Other 81 24.4%
Total 332 100.0
aThis terms is applied for this table to isolates with the antigenic 
formula 4,[5],12:i:- as there is persuasive evidence that these are over-
whelmingly comprised of variants of S. Typhimurium
[Data source: NSSLRL]
†Where A= Ampicillin, C= Chloramphenicol, Na = Nalidixic acid, S= Streptomycin, Su= Sulphonamide and T= Tetracycline
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Figure 5. Annual number of S. Typhimurium isolates referred to NSSLRL by phage type, 
2000-2013. [Data source: NSSLRL]
Figure 6. Annual number of S. Enteritidis isolates referred to NSSLRL by phage type, 
2000-2013. [Data source: NSSLRL]
Figure 7: Salmonellosis notifications by month of notification and travel history, 2013 [Data source: CIDR]
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number of cases associated with each country. 
Salmonella notifications peaked in the period July to 
October; with highest numbers of both indigenous and 
travel-associated cases occurring during this period 
(Figure 7). A second shorter peak in May comprised 
largely indigenous cases. 
Indigenous cases were more common in quarter 4 
than at this time of year than in the previous two 
years (Figure 8), in part due to a number of general 
indigenous outbreaks during Q4 2013 –see outbreak 
section below.
When serotyping data were analysed by travel history, 
almost half of all indigenous cases were infected with 
S. Typhimurium (or monophasic S. Typhimurium), with 
‘Other’ serotypes making up a further 43.5% of cases 
(Table 2). Just 7.3% of indigenous cases were due to 
S. Enteritidis. In contrast, S. Enteritidis features more 
prominently among travel-associated cases (25.9%). 
Specifically, cases with travel to Spain were more evenly 
split between Typhimurium, Enteritidis and ‘Other’ 
serotypes (9:10:8), whereas ‘Other’ serotypes featured 
exclusively among infections associated with India and 
Nigeria.
Travel-associated cases were also notable in that they 
formed a higher proportion of cases in adult age groups 
between 20 and 64 years (Figure 9).
Other risk factor data
As travel-associated cases are likely to have different 
exposures to indigenous cases, the analyses undertaken 
of other risk factor information focuses solely on known 
indigenous cases (n=177). It should be noted that in 
most instances, there are no comparable data for the 
population as a whole in order to make inferences 
about the relative importance of these factors as risks 
for salmonellosis in Ireland, however, some observations 
can be made. 
In general, the quality of public water supplies in Ireland 
is better than that of domestic wells and other private 
water supplies (EPA). The difference in the proportion of 
salmonellosis cases served by non-public water supplies 
Table 2: Number and percentage Salmonellosis notifications by serotype and travel history, 2013 [Data source: CIDR]
Salmonella serotype Indigenous N (%) Travel associated N (%) Travel history unknown N (%)
S. Typhimurium* 85 (48.0%) 27 (23.3%) 13 (41.9%)
S. Enteritidis 13 (7.3%) 30 (25.9%) 5 (16.1%)
Other serotypes 77 (43.5%) 58 (50.0%) 12 (50.0%)
Serotype not specified 2 (1.1%) 1 (0.9%) 1 (3.2%)
All serotypes (n) 177 (100%) 116 (100.0%) 31 (100%)
Table 3. Number of cases of indigenous salmonellosis cases (and percentage where known) for selected risk factors, Ireland 2013
Yes (% of Known) No (% of Known) Unk/not specified Total
Did case eat outside home 3 days PTO? 66 (46.5%) 76 (53.5%) 35 177
Contact with person with GI symptoms in 3 days PTO? 19 (12.4%) 134 (77.6%) 24 177
Contact with pet animals 3 days PTO? 84 (51.2%) 80 (48.8%) 13 177
Contact with farm animals 3 days PTO? 24 (15.3%) 133 (84.7%) 20 177
Home not on public water supply 33 (20.4%) 129 (79.6%) 15 177
Attends pre-school 10 (6.1%) 153 (93.9%) 14 177
Attends pre-school (cases under 5 yrs only)a 10 (23.3%) 33 (76.7%) 2 45
aBased on public health risk group variable.
PTO =prior to onset
[Data source: CIDR]
Figure 8.  Salmonellosis notifications by week of notification and travel history, 2011-2013. [Data source: CIDR]
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(20.4%) compared to the proportion of households in 
the general population with non public supplies (22.1% 
-CSO census 2011) was not statistically significant 
(X2=0.2813, P =0.596), suggesting that waterborne 
transmission from lower quality drinking water is not a 
strong risk factor for salmonellosis in Ireland (Table 3).
Similarly, the proportion of indigenous salmonellosis 
cases attending childcare (23.3%) is below the norm 
(42%) [CSO quarterly survey re use of non-parental 
childcare], suggesting that transmission between young 
children at childcare facilities is not a strong risk factor 
either.
The proportion of indigenous cases reporting contact 
with farm animals is lower (15%) than for pathogens 
such as VTEC and Cryptosporidium (38%), both of 
which have a more rural distribution in incidence, 
suggesting that exposure to farm animals is not as 
significant a pathway for Salmonella transmission to 
humans in Ireland.
Contact with pets occurred in 51% of cases, however, 
we are unaware of comparable data for the general 
population. From the literature it would appear that 
particular pets confer a high risk of salmonellosis, 
e.g. reptiles, especially to young children. In 2013, 
6/45 (13%) indigenous cases under 5 years of age 
reported exposure to a reptile compared with 3/132 
(2%) indigenous cases 5 years of age or more. Reptile 
associated salmonellosis is generally associated with 
specific and otherwise unusual variants of salmonella 
which supports the causality of the association.
Outbreaks
Salmonellosis notifications in Ireland are largely 
comprised of sporadic cases; in 2013, only 53 of the 324 
(16.3%) notified cases were linked to outbreaks. The 
18 outbreaks notified in 2013 is a three-fold increase 
on the number notified in 2012 (n=6), but the number 
in 2012 was atypically low. Eight outbreaks in 2013 
were general outbreaks (the highest number of general 
outbreaks since 2008) and ten were family outbreaks 
(Figure 10).
Figure 9.  Salmonellosis notifications by age group and travel history, 2013
 [Data source: CIDR]
Figure 10. Annual number salmonella outbreaks by type, Ireland 2004-2013
[Data source: CIDR]
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These outbreaks resulted in 56 cases of illness 
(median=3, range 2-9 ill per outbreak) and an 
associated hospitalisation rate of 34.0% (n=19 cases). 
Eight outbreaks occurred in private houses, five 
occurred in community settings, three were extended 
family outbreaks, one was in a crèche, and one occurred 
in a summer camp. 
Figure 11 compares the number of outbreaks by 
transmission route with data from previous years. 
Consistently foodborne and person-to-person 
transmission are reported most commonly. This 
year, among the outbreaks with a transmission route 
reported, 45% were reported as foodborne and 55% 
as person-to-person spread. Animal contact outbreaks 
are reported less frequently and none were reported in 
2013.
The largest salmonellosis outbreak in Ireland in 2013 
was a national outbreak of S. Dublin. The outbreak 
consisted of nine cases of salmonellosis with disease 
onsets over a period of six weeks in October –
November 2013. Cases were atypical relative to 
previously identified sporadic S. Dublin cases in Ireland 
in that the ratio of females to males was higher than 
normal (78% vs 33%), and the cases more frequently 
characterised by symptoms of gastrointestinal disease 
rather than bloodstream infections (100% vs 55%). 
The age-sex distribution of cases suggested that the 
exposure which caused the outbreak was more common 
among adults than children, and more common among 
females than males. The wide geographical distribution 
and absence of a common exposure to other possible 
non-food sources suggested the likelihood that the 
outbreak was caused by a widely distributed food item, 
with the shape of the epidemic curve being consistent 
with a continuous source outbreak, possibly a food 
product that was on the market (or had a shelf life) 
of approximately six weeks. The strong association 
between S. Dublin and cattle may suggest that a dairy 
or beef based product is more likely. However despite 
the use of extensive outbreak trawling questionnaires 
and a novel method employing supermarket loyalty 
cards, no single food source was identified which might 
account for the outbreak.
Four other community outbreaks were reported, three 
with transmission route unknown and one reported as 
foodborne although no specific food was implicated. 
The serotypes involved were S. Agama, S. Ball, S. 
Infantis and S. Montevideo, and the outbreaks were 
in all instances recognised in consequence of detailed 
typing at NSSLRL. 
The remaining three general outbreaks were caused 
by S. Typhimurium: they included a person-person 
outbreak in a childcare facility resulted in 4 persons 
ill; a person-person outbreak in a private house, and 
an outbreak of two persons in a summer camp with 
unknown transmission route. 
For the 10 family outbreaks, six were caused by 
S Typhimurium, and one each by S. Enteritidis, S. 
Braenderup, S. Telelkebir and S. Unnamed.  Four were 
transmitted person-person, three were reported as 
foodborne and for three the transmission routes were 
unknown. No evidence implicating any food source 
was reported for any of the three foodborne outbreaks, 
although chicken brought in from abroad by a relative 
was suspected in the family outbreak of S. Enteritidis.
Typhoid/Paratyphoid:
In 2013 there were ten cases of S. Typhi notified and 
two cases of S. Paratyphi, all of whom reported a 
history of recent travel outside Ireland. Of the ten S. 
Typhi cases, five had travelled to Pakistan, three to 
India, and one each to Indonesia and Nigeria. Half of 
typhoid cases were reported in children under 15 years 
of age. 
Among the S. Paratyphi cases, one reported travel to 
Pakistan and one to South America. The isolates were 
identified as Paratyphi A and Paratyphi B respectively. 
Both were adults. 
Summary
The crude incidence rate of human salmonellosis in 
Ireland in 2013 was similar to that reported over the 
previous four years.  The age and regional distribution 
of cases in 2013 was also similar to 2012, however, 
indigenous cases made up a higher proportion of 
Figure 11: Annual number of outbreaks of salmonellosis by reported transmission 
route, Ireland 2004-2013. [Data source: CIDR]
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total case numbers in 2013 than in 2012, in part due to 
a number of indigenous general outbreaks in the last 
quarter of the year. Ireland’s crude incidence rate at 7.1 
per 100 000 is consistently and substantially lower that 
the overall rate for the EU (22.2 per 100,000 population 
in 2012-EFSA report), but the age and seasonal 
distributions mirror those seen for the EU as a whole. 
S. Typhimurium (including monophasic Typhimurium) 
remained the most common serovar in Ireland in 2013 
making up almost 40% of cases. Case numbers of S. 
Enteritidis have been in decline for many years, such 
that, in 2013, S. Enteritidis comprised only 15% of 
cases, with other serovars responsible for 45% of cases. 
This contrasts with the picture across the EU where 
S. Enteritidis remained the top serovar at just over 
40% in 2012, with S. Typhimurium (incl monophasic 
Typhimurium) at just under 30%, and ‘Others’ making 
up the remaining 30%.1 Case numbers of S. Enteritidis 
across Europe are on the decline, contributing to a 
decrease also in overall case numbers over the last five 
years.  New EU legislation concerning salmonella control 
programs for laying hens, which came into effect on 1 
January 2009, is believed to have contributed to the 
reduction in Salmonella contaminated laying hens in the 
EU in recent years.1
In 2013, the transmission routes reported for 
salmonellosis outbreaks in Ireland were consistent with 
previous years: foodborne or person-to-person spread 
only were reported, although the evidence for the 
foodborne route was not strong in any instance, and no 
specific food items were implicated. The EU Zoonoses 
report reports that eggs and egg products continued 
to be the most common vehicles implicated in the 
salmonellosis outbreaks at EU level in 2012, however, 
this was strongly influenced by the fact that half of all 
salmonellosis outbreaks at EU level were associated with 
S. Enteritidis.1 Pork products were the most common 
food vehicle in S. Typhimurium outbreaks in the EU in 
2012. 
In consequence of the increasing recognition in recent 
years of fresh produce as a cause of gastrointestinal 
disease outbreaks, the National Salmonella Outbreak 
Trawling Questionnaire was recently expanded and 
updated. The form is available at 
http://www.hpsc.ie/A-Z/Gastroenteric/Salmonellosis/
SurveillanceInvestigativeForms/ 
References: 
1. EFSA and ECDC. 2013. The European Union Summary Report 
on Trends and Sources of Zoonoses,Zoonotic Agents and 
Food-borne Outbreaks in 2012. . Accessible online at  
http://www.efsa.europa.eu/en/efsajournal/doc/3547.pdf
2. National Salmonella Reference Laboratory of Ireland, Annual 
Report for 2013. Available at:     
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
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Listeriosis 
Eight cases of human listeriosis were notified in 2013, 
lower that the 11 cases reported in 2012. This equates 
to a crude incidence rate of 0.17 (95% CI 0.05-0.30) per 
100,000, below the EU average of 0.41 per 100,000 in 
2012.  
Among these, there were three neonatal cases. This is 
the same as the number of pregnancy-associated cases 
reported in 2012 (Figure 1).  One infant was stillborn.
The number of adult/juvenile cases was lower than 
last year, but similar to the numbers reported in the 
previous five years. Three of the five cases were male. 
Four developed bloodstream infection, while the fifth 
developed meningitis. One case with a predisposing 
condition died, but not as a result of their listeriosis; 
the outcome was unknown or not specified for the 
remaining four adult cases. Four of the five adult cases 
were more than 65 years of age, with the fifth being 
in the 55-64 years age group. Additionally, all were 
receiving treatment for serious underlying illnesses.
Since 2007, the National Salmonella, Shigella and 
Listeria Reference Laboratory in Galway has offered a 
national service for typing of Listeria strains. In 2013, 
isolates from six of the eight notified cases were 
referred. The serotypes for these six cases are listed in 
table 1 below. 
Listeria in Ireland remains a hazard for the elderly, 
persons with underlying illness, and other vulnerable 
groups such as pregnant women and neonates.
3.7  Less common gastroenteric 
 infections
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Figure 1: Number listeriosis notifications by case type, Ireland 2006-2013
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Table 1. Listeriosis notifications by case type and serotype, Ireland 2013 -typing data provided courtesy of Prof Martin Cormican 
and staff at the NSSLRL
Type Serotype 1/2a Serotype 1/2b Serotype 4b
Not referred for 
serotyping
Total
Adult or juvenile 0 0 4 1 5
Pregnancy-related 0 0 0 0 0
Neonatal 0 0 2 1 3
Total 0 0 6 2 8
Giardiasis
In 2013, there were 44 cases of giardiasis notified; 
almost 20% lower than the 54 cases notified in 2012. 
This equates to a crude incidence rate of 0.96 (95% CI 
0.68-1.24) per 100,000. 
Cases ranged in age from 1 month-70 years (median 
age=29 years) with only 10 cases reported in children 
under 15 years of age.  According to CDC, Giardia 
infects nearly 2% of adults and 6% to 8% of children in 
developed countries worldwide so it is likely that there 
is a high degree of underreporting of the illness in 
Ireland.1 Similar numbers of females (n=21) and males 
(n=23) were affected. Hospitalization rates were low 
with five cases admitted out of 44 (11%). 
The number of cases for which travel status was 
reported has improved markedly over the last six years 
from 11% of cases in 2006 to 66% of cases this year 
(Figure 2). Twenty-two cases (50% of all cases; 76% of 
those with known travel status) were reported as being 
associated with foreign travel: the countries of infection 
reported were India (n=10), Ethiopia (n=2), Poland 
(n=2), and there was one case each reported associated 
with travel to Mexico, Pakistan, Mozambique, Russia, 
Nigeria, China, Israel and Sudan. Seven cases were 
reported as being acquired in Ireland, and for the 
remaining 15 cases, country of infection was unknown or 
not specified. 
Two travel-related family outbreaks of giardiasis were 
notified in 2013, one associated with travel to Poland 
and the second with travel to India.  
Giardiasis in Ireland is mainly identified among adults, 
unlike countries such as the United States, Australia and 
the United Kingdom where children are mainly affected. 
And if the travel histories of those with known Country 
of infection are representative of all reported giardiasis 
cases in Ireland, then as many as three-quarters may 
be related to foreign travel. Among these cases, Asia 
and Africa figure most prominently as reported travel 
destinations. 
Yersiniosis 
In 2013, there were four cases of yersiniosis (two 
females and two males), three of whom were less than 
five years of age. All were reported as being infected 
with Y. enterocolitica. The reported incidence of 
yersiniosis in Ireland is low relative to the EU as a whole, 
and to Northern Europe in particular. 
Yersiniosis is commonly associated with consumption of 
pork products however, in Spring 2011, an outbreak was 
reported in Norway associated with salad leaves. 1
1  E MacDonald et al. 2011. Yersinia enterocolitica O:9 infections 
associated with bagged salad mix in Norway, February to April 2011. 
Eurosurveillance, Volume 16, Issue 19, 12 May 2011
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. 
There was one case of infant botulism notified in 2013. 
The causative organism was identified as C. butyricum 
producing the botulism neurotoxin E .This is second 
case of infant botulism in Ireland believed to be due to 
exposure to turtles or to turtle feed, the first being in 
2011.2, 3
There was one case of Clostridium perfringens (type A) 
food-borne disease in an elderly man. 
In 2013, there were no cases or outbreaks of 
staphylococcal food poisoning or Bacillus cereus food-
borne infection/intoxication notified. 
1. CDC. 2012 Giardia -Epidemiology & Risk Factors. Available at 
http://www.cdc.gov/parasites/giardia/epi.html 
2. HPSC. 2013. Reptiles and the risk of Infectious 
Diseases. Available at http://www.hpsc.ie/A-Z/Zoonotic/
ReptilesandRisksofInfectiousDiseases/ 
3. Shelley E. B. et al. 2014. Infant botulism due to C. butyricum type 
E toxin: a novel environmental association with pet terrapins. 
Accepted for publication.
Figure 2: Number Giardiasis Notifications by Travel Status, Ireland 2006-
2013
Note: Travel status is inferred from Country of Infection variable on CIDR
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Summary
Number of confirmed cases: 44
Number of probable cases: 5
Crude incidence rate: 1.1/100,000
In the last twenty years, the number of cases of 
shigellosis in Ireland has been low in comparison to 
the number of cases notified in the early 1990s (Figure 
1). Shigellosis, however, remains a common cause of 
gastrointestinal illness in developing countries, and 
many cases notified in Ireland are now identified as 
being travel-associated.  
While person-to-person spread is an important 
transmission route between children, risks also remain 
from food, with at least four general outbreaks having 
been reported in Scandinavia in 2009 associated with 
imported fresh produce.1-5  Transmission between men 
who had sex with men (MSM) has been reported.  6, 7
Forty-nine cases of shigellosis were notified in Ireland 
in 2013 (CIR 1.1 per 100,000, 95% CI 0.8-1.4), 45 of 
which were laboratory confirmed. This compares to 29 
notifications in 2012, and 42 cases in 2011 (Figure 1). Of 
43 cases where hospitalisation status was recorded, 11 
(26%) were reported as hospital in-patients.
From 2009 to 2012, there was an excess of male cases 
compared to females, contrary to the trend prior to 
that. This trend was reversed again in 2013, with more 
females (n=29) than males (n=20) for the first time since 
2008 (Figure 2). 
In 2013, cases ranged in age from 11 months to 86 
years (median age=28 years). In the age groups 35-44 
and 45-54 yrs, males predominated, whereas females 
were equally or more common in all other age groups 
(Figure 3). 
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
3.8 Shigellosis
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Figure 1: Annual number of notifications shigellosis, Ireland 1991-2013
(Data source: CIDR)
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Table 1: Number of notifications shigellosis by species and country of infection, Ireland 2013
Organism Africa Asia Other Europe Ireland Not specified Total
Shigella boydii 5 5
Shigella flexneri 2 4 1 5 3 15
Shigella sonnei 3 6 1 11 3 24
Species not specified 1 1
Probable epi-linked case 1 1 2 4
Total 7 16 2 18 6 49
(Data source: CIDR)
clusters, and data on country of infection in the national 
dataset continues to improve, being available for 88% 
of shigellosis notifications this year. Historically, the 
country most frequently associated with travel-related 
shigellosis infections is India. Twenty-five cases were 
reported associated with foreign travel in 2013. The 
countries of infection reported were India (n=11), two 
each associated with Nigeria, Pakistan and Ethiopia, 
and one case each associated each with travel to 
Bangladesh, Germany, Rwanda, Sudan, Tanzania, 
Turkey, United Kindom and the United Arab Emirates.  
Eighteen infections were reported as being acquired in 
Ireland, while no country of infection information was 
available for six cases. 
Shigella sonnei was the most common species 
reported (n=24), followed by S. flexneri (n=15), S. 
boydii (n=5) with the species not reported for the 
remaining confirmed case. The species distribution of 
cases by country of infection is reported in Table 1. S. 
boydii cases were exclusively associated with travel 
to Asia, while S. flexneri and S. sonnei infections were 
associated with travel and non-travel associated cases. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains which 
can be used by public health personnel to outrule/
provide evidence for links between cases during 
investigations of case clusters. The National Salmonella, 
Shigella and Listeria Reference Laboratory (NSSLRL) in 
Galway University Hospital provide laboratory services 
for speciation, serotyping, antimicrobial resistance 
profiling, and where appropriate, Pulsed Field Gel 
Electrophoresis (PFGE) of Shigella isolates.
In 2013, 44 human Shigella isolates were referred to the 
NSRL, 98% of the isolates from notifications reported 
as confirmed. This is the highest proportion of isolate 
referrals to NSSLRL (Figure 4). In previous years, the 
proportion of isolates referred to NSSLRL ranged from 
41% to 71%).  
The species/serotype and antimicrobial resistance 
patterns of these cases are reported in Table 2. 
An increase in ciprofloxacin resistance among S sonnei 
isolates has been identified by NSSLRL since 2010; 
this appears to have a significant association with 
exposure in India.8 Further details of Shigella strain 
characterisation performed at NSSLRL can be found in 
the NSSLRL Annual Report.9 
There were four shigellosis outbreaks notified in 2013. 
One general outbreak of shigellosis was reported in a 
Figure 2: Sex distribution shigellosis notifications, Ireland 
2004-2013
(Data source: CIDR)
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Table 2: Species/serotypes and AMR profiles of Shigella isolates 
referred to NSSLRL in 2013 (Data courtesy of Martin Cormican, 
Niall de Lappe and Jean O Connor at NSSLRL)
Serotype
Number 
by 
serotype
AMR profile
Number by 
serotype and 
AMR profile
Shigella boydii 5
ASSuTTm 2
Na 1
SSuTm 1
SSuTmNa 1
Shigella flexneri 1b 2 A 2
Shigella flexneri 2a 7
ACSSuTTm 6
STTmNaCp 1
Shigella flexneri 2b 1 ACST 1
Shigella flexneri 3a 1 CSSuTTmNaCp 1
Shigella flexneri 4a 1 ASSuTTm 1
Shigella flexneri 6 2
SSuTTm 1
SSuTTmNaCp 1
Shigella flexneri X 
variant
2 ASSuTTm 2
Shigella sonnei 23
ACSSuTTm 1
ASSuTm 1
ASSuTTmNaCpCtx 1
ASuTm 1
SSuTm 1
SSuTTm 3
SSuTTmNa 1
SSuTTmNaCp 10
STTmNaCp 1
SuTm 2
Not reported 1
Total 44 Total 44
[Data source: NSSLRL]
Table 3. Notified shigellosis outbreaks, Ireland 2013
HSE-area Outbreak type Location Transmission mode Number ill Serotype
M Family Travel-related Person-to-person 3 Shigella flexneri
MW Family Extended family Unknown 5 Shigella flexneri
MW Family Travel-related FB and WB 2 Shigella sonnei
S General Comm. Hosp/Long-stay unit Person-to-person 9 Shigella sonnei
(Data source: CIDR)
long-stay unit. There were nine people ill over a period 
of four weeks, four of whom were confirmed as being 
infected with S sonnei. The mode of transmission 
was reported as person-to-person. Two small family 
outbreaks were associated with foreign travel, while an 
indigenous extended family outbreak was reported with 
five persons ill. 
Although foreign travel is a major risk factor for 
shigellosis among Irish residents, indigenous risks are 
likely to be through person-to-person spread (in some 
instances from persons who have contracted shigellosis 
abroad), and from food, as demonstrated by the 
Scandinavian outbreaks associated with imported foods 
in recent years. 
References
1.  Shigella sonnei infections in Norway associated with sugar 
peas, May – June 2009. B T Heier , K Nygard, G Kapperud, B A 
Lindstedt, G S Johannessen, H Blekkan     
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19243 
2. Imported fresh sugar peas as suspected source of an outbreak of 
Shigella sonnei in Denmark, April – May 2009. L Müller, T Jensen, R 
F Petersen, K Mølbak, S Ethelberg     
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19241 
3. Lewis HC, Ethelberg S, Olsen KE, Nielsen EM, Lisby M, Madsen 
SB, et al. Outbreaks of Shigella sonnei infections in Denmark 
and Australia linked to consumption of imported raw baby corn. 
Epidemiol Infect 2009;137(3):326-34. 
4. Lewis HC, Kirk M, Ethelberg S, Stafford R, Olsen KE, Nielsen 
EM, Lisby M, Madsen SB, Mølbak K. Outbreaks of shigellosis 
in Denmark and Australia associated with imported baby corn, 
August 2007 – final summary. Euro Surveill. 2007;12(40):pii=3279. 
Available from: http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=3279 
5. M Löfdahl, S Ivarsson, S Andersson, J Långmark, L Plym-Forshell  
2009. An outbreak of Shigella dysenteriae in Sweden, May–June 
2009, with sugar snaps as the suspected source. Eurosurveillance 
14:28        
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19268 
6. Gournis, E. 2010. Shigellosis, changing epidemiology - canada: 
(ontario) request for information. http://www.promedmail.org/pls/
apex/f?p=2400:1001:687576564639::NO::F2400_P1001_BACK_
PAGE,F2400_P1001_PUB_MAIL_ID:1010,81401 
7. HPA. 2011. Outbreak of UK acquired Shigella flexneri in men who 
have sex with men. Volume 5 No 40; 7 October 2011   
http://www.hpa.org.uk/hpr/archives/2011/news4011.htm#shgflx  
8. De Lappe, N., O’Connor, J, Garvey, P, McKeown, P. and 
M.Cormican. Ciprofloxacin-Resistant Shigella sonnei in Ireland with 
some association with travel to India. Submitted for publication.
9. National Salmonella Reference Laboratory of Ireland, Annual 
Report for 2013. Available at:     
http://www.nuigalway.ie/research/salmonella_lab/reports.html 
0
10
20
30
40
50
60
70
80
2007 2008 2009 2010 2011 2012 2013 
nu
m
be
r o
f n
ot
ifi
ca
tio
ns
/is
ol
at
es
 
year of notification/referral 
CIDR NSSLRL 
0
2
4
6
8
10
12
14
<1 yrs 1-4 yrs 5-9 yrs 10-14 
yrs
15-19
yrs
20-24
yrs
25-34
yrs
35-44
yrs
45-54
yrs
55-64
yrs
65+ yrs 
N
um
be
r o
f c
as
es
age group
F M
Figure 4. Annual number of confirmed shigellosis notifications 
compared to the number of isolates referred to NSSLRL, 
Ireland 2007-2013
(Data source: CIDR and NSSLRL)
Figure 3. Age-sex distribution of shigellosis notifications, 
Ireland 2013
(Data source: CIDR)
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Summary:
In 2013, 71 malaria cases were notified in Ireland, an 
increase of 9% compared to 65 cases in 2012 (Figure 
1). The incidence rate now stands at 1.55 per 100,000 
population. Among European Union  (EU) member 
states reporting malaria data to the European Centre 
for Disease Control, Ireland had the third highest 
incidence rate for imported malaria in 2010 (the latest 
year for which comparative data are available); only the 
United Kingdom and Luxembourg had higher reported 
incidence rates.1
In common with the rest of the EU, males predominated 
(male: female ratio 2.1:1), with the highest numbers 
of cases among males aged between 35 and 54. The 
number of paediatric cases reported was 12, an increase 
compared to eight cases reported during 2012 (Figure 
1). 
Six of the paediatric cases reported ‘visiting family in 
country of origin’ as their reason for travel while one 
case was a visitor from outside Ireland who became ill 
during their stay in Ireland. There was no information on 
reason for travel for the remaining five paediatric cases. 
Of the six paediatric cases that travelled to visit family, 
all visited sub-Saharan Africa, staying for between 1 
to 9 months duration. Six of the paediatric cases were 
reported not taking any prophylaxis for their travel while 
the remaining six did not have prophylaxis reported. 
4.1 Malaria 
Summary
Number of cases malaria, 2013: 71
Crude incidence rate malaria 2013: 1.55/100,000
Number of cases malaria, 2012: 65
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Figure 1: Annual number of malaria notifications by age, Ireland 2004-2013
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Table 1: Number of malaria notifications by reason for travel and country of birth, Ireland 2013
Reason for travel Country of Birth
Nigeria Ireland Other Africa Oceania Not reported Total
Visit family country origin 23 5 7 0 1 35
Foreign visitor ill in Ireland 3 0 0 0 0 3
Business/Professional travel 0 2 0 1 0 3
Holiday travel 0 2 0 0 1 3
Irish citizen living abroad 0 2 0 0 0 2
Other 1 1 0 0 0 2
New entrant to Ireland 0 0 1 0 1 1
Child visiting parents 0 1 0 0 0 1
Reason for travel not reported 1 0 1 0 22 21
Total 28 13 9 1 25 71
Among all age groups, the category of traveller most 
affected in Ireland continued to be African immigrants 
and their families who were exposed while returning 
to ‘visit family in country of origin’ (table 1). This 
almost certainly reflects the greater frequency with 
which this group travels to malarious areas, but also 
reflects Ireland’s importance as a destination for those 
emigrating from English speaking West Africa. Where 
the reason for travel was reported in 2013, 70.0% 
cited ‘visiting family in country of origin’, all of whom 
travelled to Africa (table 1).
The second most commonly cited reasons for travel this 
year were ’Business/professional travel’ (n=3), ’Holiday 
travel’ (n=3) and ‘Foreign visitor ill Ireland’ (n=3), each 
making up 6% of cases with known reason for travel in 
2013. 
Figure 2 shows the distribution of cases by reason for 
travel 2006-2013. During that time period ‘visiting 
family in country of origin’ remained the most common 
reason for travel, with new entrant and holidaymaker 
case numbers declining. The numbers of cases in 
persons exposed during business/professional travel has 
increased.
Nigeria remained the country most frequently visited, 
accounting for 52.1% of total cases and 64.9% of cases 
where country of infection was reported (table 2). The 
remaining cases were exposed in other countries within 
Africa. The majority of cases who reported travel to 
Nigeria were ‘visiting family in country of origin’ (29/35 
with known reason for travel).
Plasmodium falciparum accounted for 88.7% of 
infections in 2013, reflecting the dominance of 
exposure in Africa as the source of the majority of 
notifications. One case each of P. ovale and P vivax 
were also reported which remains stable in comparison 
to previous years. The remaining six cases did not have 
Plasmodium species specified.
While this report has highlighted the high incidence 
among persons travelling to ‘visit family in their country 
of origin’, malaria prevention messages should also 
be targeted at tourists, business travellers and other 
travellers with little previous exposure to malaria. 
Children can also be particularly at risk. It is important 
that persons born in Western and Central Africa who 
take up residence in Ireland and who return to their 
country of origin with their Irish-born children are made 
aware of the fact that their children have no innate 
immunity to malaria (and their own immunity will likely 
have waned considerably), and must complete their full 
course of advised chemoprophylaxis while taking steps 
to ensure they avoid mosquito bites. 
-90-HPSC Annual Epidemiological Report 2013 4 Vectorborne and Zoonotic Diseases
0
20
40
60
80
100
120
2006 2007 2008 2009 2010 2011 2012 2013 
N
um
be
r o
f n
ot
ifi
ca
tio
ns
Year of notification
Visit family country origin New entrant to Ireland Holiday travel 
Irish citizen living abroad Other Business/professional ravel 
Foreign visitor ill in Ireland Irish defence forces Child visiting parents
Foreign student study Ireland Not reported 
Figure 2: Annual number of notifications malaria by reason for travel, Ireland 2006-2013
Table 2: Number of cases malaria by infecting species and country of infection
Organism Nigeria Other African country1 Not reported Total
Plasmodium falciparum 33 18 12 63
Plasmodium ovale 0 1 0 1
Plasmodium vivax 1 0 0 1
Plasmodium 3 0 2 5
Malarial parasites 0 1 0 1
Total 37 20 14 71
n=1 each from Angola, Congo DR, Egypt, Ivory Coast, Mozambique, Papua New Guinea, Sierra Leone, South Africa, Sudan and Tanzania n=2 
each from Cameroon, Ghana and Uganda.
HPSC resources for health professional include a poster 
which can be downloaded from the HPSC website for 
display in GP surgeries, maternity hospitals, paediatric 
hospitals and emergency departments, advising 
immigrant families travelling to Africa to consult their 
doctor about malaria before travelling. A leaflet for 
intending travellers, available in English and French, 
highlights the value of antimalarial prophylaxis and 
protection against mosquito bites. The poster and 
leaflet are available here.
Recent developments of note include a case of 
autochthonous falciparum malaria was reported in 
a patient in France during February 2013. The case 
reported no recent travel to malaria-endemic countries 
and it was hypothesised that transmission was likely 
due to an infective Anopheles mosquito carried in 
the luggage of a close contact recently arrived from a 
malaria-endemic area. 2
During 2013, a case of a Plasmodium knowlesi infection 
was reported as imported to Germany from Thailand. 
P. knowlesi was known as a plasmodium of macaques 
until transmission to humans was recognised in Borneo 
and later throughout South-East Asia. The retrospective 
analysis of blood samples from Thailand suggests that 
the prevalence of P. knowlesi infections remained stable 
from 1996 to 2008 so it is likely that the increasing 
number of cases recognised is due to raised awareness 
of the possibility of human P. knowlesi malaria and 
to the application of diagnostic molecular biology 
techniques to differentiate this parasite from other 
malaria parasites. However, due to of the possibility of a 
severe course of P. knowlesi infections, physicians must 
be increasingly aware of this as a human pathogen. 3
Also of note is the recent re-emergence of indigenous 
malaria due to P. vivax in Greece, with continued 
transmission during 2013.4,5,6,7 However, case numbers 
are very low and have been identified in areas not 
usually associated with tourism. In a European Centre 
for Disease Control and Prevention Risk Assessment 
of the situation, the risk to travellers to the country 
was deemed limited, with general advice for travellers 
to take prophylaxis not recommended, although 
travellers to Greece should take standard measures 
against mosquito bites to protect against this and 
other mosquito-borne diseases.7 Moreover, health 
professionals who see cases of febrile illness returning 
from the affected parts of Greece should be alert to the 
possibility of malaria. 
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Fourteen cases of leptospirosis were notified in Ireland 
in 2013, similar to the 15 cases notified in 2012 (Figure 
1). This equates to a crude incidence rate of 0.31 per 
100,000 (95% CI 0.15-0.46). The latest year for which 
data is available across the European Union is 2011. 
Among the 27 countries that reported leptospirosis 
incidence in 2011, Ireland reported the third highest in-
cidence rate after Slovenia and Romania. The incidence 
in the EU as a whole was 0.22 per 100,000. 
The leptospirosis notification dataset is typically domi-
nated by adult males, and this year was no exception 
(Table 1). Ten cases (71.4%) were male and the age 
range was 21-65 (mean age =38 years, median age=46 
years). This is consistent with the exposures most 
commonly associated with leptospirosis in temperate 
regions, e.g. occupational contact with farm animals, 
and watersports.
Among the 12 cases for which hospital admission status 
was reported, nine (75%) required hospitalization. There 
were no deaths reported. 
Six cases (43%) were believed to have acquired their 
illness occupationally –three were either farmers or 
reported contact with farm environments, one reported 
exposure to outdoor environments during the course 
of their work and the source of occupational exposure 
was not specified for the remaining two cases, however 
they were known to have contact with animals. Five 
(36%) cases were reported as being associated with 
recreational activities: two with travel to a tropical des-
tination, two with rowing/kayaking, and one case cited 
contact with river water as the source of their infection. 
One was exposed to a rat in their home, one case had 
accidental exposure to river water and there were no 
risk factors identified for the remaining case.
Figure 2 shows the trend in notifications by exposure 
group. The decrease in case numbers reported over the 
last five years appears to be due to a reduction in the 
number of recreational cases, with occupational cases 
now making up the largest proportion of cases in the 
last three years.
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, around two thirds 
of cases are diagnosed by the National Virus Reference 
Laboratory each year. Positive specimens are generally 
referred to the United Kingdom’s Leptospirosis Refer-
ence Unit (LRU) for confirmation and for typing where 
possible. In 2013, species information was available on 
4.2 Leptospirosis           
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Summary
Number of notifications: 14
Crude incidence rate: 0.31/100,000
Figure 1: Annual number of leptospirosis notifications, Ireland 
1991-2013
(data source: CIDR)
Figure 2: Annual number of leptospirosis notifications by 
exposure group, Ireland 2004-2013
(data source: CIDR)
Table 1: Leptopirosis notifications by age and sex, Ireland 
2013
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 2 3 5
25-44 yrs 2 0 2
45-64 yrs 5 1 6
65+ yrs 1 0 1
Total 10 4 14
CIDR for only two cases (14%)–one Leptospira ictero-
haemorrhagiae, and one L. hardjo. For many cases, 
serovar is not determined. Failure to provide follow-up 
samples is likely to be one contributory factor in this. 
Activities that continue to be associated with leptospi-
rosis risk in Ireland include recreational activities such as 
water sports, and farming. In recent years, travel to Asia 
and other tropical destinations has emerged as a risk 
factor for leptospirosis. 
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Toxoplasmosis
During 2013, 32 cases of toxoplasmosis were notified 
compared to 36 in 2012 and 32 cases in 2011. 15% of 
cases with known patient status were hospitalized (3/20)
One congenital case was reported, the same as in each 
of the last three years. 
The remaining 31 cases ranged in age from 10 to 87 
years (median, 33 years).  As in previous years, female 
cases were more common (53%). The high number of 
cases reported among women of child-bearing age is 
probably a reflection of enhanced testing during preg-
nancy (Table 1). 
Brucellosis
During 2013, there was one case of brucellosis notified, 
an adult female. This compares with between one and 
four cases per annum over the previous five years. The 
case was reported as Brucella species; the country of 
infection was not specified. 
Despite the reporting of this female case this year, the 
age and sex distribution for brucellosis in recent years in 
Ireland has tended towards adult males, suggesting that 
occupational exposure is likely to be a major transmis-
sion route for this disease. 
Echinococcosis
In 2013, there was one notification of echinococcosis; an 
adult female who acquired her illness in Poland. Prior to 
this there have only been four cases of  echinococcosis 
notified in Ireland since the disease became notifiable 
in 2004; in 2008, two adult cases were notified, and one 
adult case was notified each in 2009 and 2010. 
Because of the long incubation period for this disease, 
it is possible that these infections occurred many years 
ago. 
Trichinosis and Q Fever
No cases of either of these zoonotic diseases were noti-
fied in Ireland in 2013. 
Since the disease became notifiable in 2004, there have 
only been two cases of trichinosis; both were associated 
with exposure in Poland, and were linked to the same 
outbreak. For Q fever between 2004 and 2012, annual 
totals of 5 to 17 cases were notified. 
4.3  Other Notifiable Non-IID Zoonotic 
Diseases
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Table 1: Toxoplasmosis notifications by age and sex, Ireland 
2013
Age group Male Female Total
<1 yr 1 0 1
1-4 yrs 0 0 0
5-14 yrs 1 2 3
15-24 yrs 2 1 3
25-44 yrs 5 14 19
45-64 yrs 4 0 4
65+ yrs 2 0 2
Total 15 17 32
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Other Vectorborne Diseases
Four vectorborne diseases were added to the notifiable 
disease list in Ireland from the beginning of 2012. This 
chapter summarises the information gathered on these 
notifications in the second year of formal surveillance. 
The case definitions for these diseases are outlined on 
the HPSC website at http://www.hpsc.ie/hpsc/Notifi-
ableDiseases/CaseDefinitions/.
Lyme neuroborreliosis
Lyme neuroborreliosis is an infection caused by a spiral-
shaped bacterium called Borrelia burgdorferi that is 
transmitted to humans by bites from ticks, generally 
hard-bodied ticks (Ixodidae). 
During 2013, 13 cases of Lyme neuroborreliosis were 
notified in Ireland, seven female and six male. Two pa-
tients were admitted to hospital, five were reported as 
day-patients, two were emergency department patients 
and three were GP patients. The hospitalisation status 
of the remaining case was not specified. No cases were 
reported as being acquired abroad.
Cases were reported from all HSE areas except HSE-M. 
Over half of the 13 cases were reported by HSE-S and –
SE. Table 2 displays the regional distribution of cases by 
age group in years. 
Dengue Fever
Fifteen confirmed cases of dengue fever were notified 
during 2013. Three cases were reported as being admit-
ted to hospital, four were GP patients and patient type 
was not reported for the remaining eight cases. Table 2 
displays the regional distribution of cases by age group 
in years.
Dengue is found commonly throughout the tropics and 
subtropics and is endemic in about 100 countries. Of 
the 15 cases reported in 2013, country of infection was 
reported for four cases, with one each in Cambodia, 
Columbia, Thailand and Viet Nam. The remaining 11 
cases did not have country of infection specified. These 
destinations probably reflect the frequency of travel by 
Irish residents to dengue endemic countries. 
West Nile fever 
One case of West Nile fever was notified in Ireland 
in 2013. Country of infection was reported as United 
States for this case. 
Chikungunya fever: 
No cases of chikungunya were notified in Ireland in 2013
4.4 Other Vectorborne Diseases
Table 1: Lyme neuroborreliosis notifications by age group (years) and HSE-area, 2013
Age group (years) HSE-E HSE-M HSE-MW HSE-NW HSE-SE HSE-S HSE-W Total
10-14 yrs 1 1
15-19 yrs 1 1
20-24 yrs 1 1
25-34 yrs 1 1
35-44 yrs 3 3
45-54 yrs 1 1 2 4
55-64 yrs 1 1
65+ yrs 1 1
Total 1 1 1 1 3 4 2 13
Table 2: Dengue fever notifications by age group (years) and HSE-area, 2013
Age group (years) HSE-E HSE-M HSE-MW HSE-SE HSE-W Total
20-24 yrs 4 1 0 0 2 7
25-34 yrs 2 0 1 0 1 4
35-44 yrs 1 0 0 0 0 1
45-54 yrs 0 0 1 0 0 1
65+ yrs 1 0 0 1 0 2
Total 8 1 2 1 3 15
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Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease caused 
by the hepatitis B virus. It is transmitted through 
percutaneous or mucocutaneous contact with the blood 
or body fluids of an infected person. Over 90% of 
people infected in late childhood and adulthood clear 
the virus within a year of infection, but there is a high 
probability of developing chronic infection if hepatitis 
B is acquired in infancy (approx. 90%) or when aged 
under five years (approx. 30%).1 Between 15 and 40% 
of people with chronic infection ultimately develop 
cirrhosis, liver failure or hepatocellular carcinoma (liver 
cancer).2
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%). Most cases fall into 
defined risk groups such as people with multiple sexual 
partners, household or sexual contacts of known cases, 
injecting drug users and people who were born in 
countries of intermediate (2-7%) or high ( >8%) hepatitis 
B endemicity.
The number of hepatitis B cases reported in Ireland 
decreased by 24% in 2013, with 429 cases (9.3/100,000 
population) notified compared to 566 in 2012. This was 
a continuation of a general downward trend since peak 
levels in 2008 (n=902). Annual hepatitis B notifications 
since 1997 are shown in figure 1. 
Notification rates were highest in HSE E (16/100,000 
population, n=260) and HSE S (11/100,000 population, 
n=52). Geographic trends for the past four years are 
shown in figure 2.
All cases were laboratory confirmed and 99% (n=423) 
contained information on acute/chronic status. Where 
status was known, 8% of cases were acute (n=32, 
0.7/100,000 population) and 92% were chronic (n=391, 
8.5/100,000 population). Both acute and chronic cases 
of hepatitis B are notifiable in Ireland.
Acute cases (recent infections)
The number of acute cases of hepatitis B notified in 
Ireland is relatively low and decreased by 16% in 2013 
5.1 Hepatitis B
Summary
Number of cases, 2013: 429
Crude notification rate, 2013: 9.3/100,000 population
Number of cases, 2012: 566
HPSC Annual Report 2008  
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2013
(n=32) compared to 2012 (n=38) (figure 3). The majority 
of acute cases of hepatitis B in Ireland are sexually 
acquired.
Of the 32 acute cases notified in 2013, 78% (n=25) 
were male and 22% (n=7) were female. The highest 
notification rates were in young to middle aged adults, 
with 91% (n=29) of acute cases aged between 20 
and 54 years (figure 4). Males were older overall, with 
a median age of 40 years compared to 35 years for 
females. The median age at notification increased in 
2013 compared to previous years (figure 3).
Information on risk factor was available for 81% (n=26) 
of acute cases. Of these, 81% (n=21) were likely to have 
been sexually acquired (12 heterosexual and 9 men 
who have sex with men), one case was likely to have 
been infected nosocomially in Ireland and another was 
likely to have been infected through dental procedures 
outside of Ireland. No risk factor was identified for 
remaining three cases despite public health follow up. 
Five further cases had no risk factor information but 
were known to have been born in hepatitis B endemic 
countries.
Country of birth was specified for all of the acute cases 
notified in 2013. Sixty nine percent (n=22) were born in 
Ireland and 16% (n=5) were born in Eastern or Central 
Europe. A further three cases were born in Asia, one 
case was born in Western Europe (excluding Ireland) 
and one case was born in Sub-Saharan Africa. Ninety 
percent of acute cases were tested because they were 
symptomatic.
Chronic cases (long-term infections)  
There was a 24% decrease in chronic hepatitis B 
notifications in 2013 (n=391) compared to 2012 (n=517) 
(figure 5). This was a continuation of a significant 
downward trend in notifications of chronic hepatitis 
B in recent years. The large increase in hepatitis B 
notifications between 1997 and 2008 (figure 1) was 
mostly due to increased numbers of people immigrating 
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Figure 3. Number of acute cases of hepatitis B notified, by sex and median age, 2004 to 2013
Figure 2. Hepatitis B notification rates/100,000 population, by HSE area, 2010-2013
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to Ireland from hepatitis B endemic countries.  The 
current economic climate has most likely contributed to 
reduced immigration to Ireland between 2009 and 2013, 
which correlates with an overall decrease in hepatitis B 
notifications over this time period. 
Of the 391 chronic cases notified in 2013, 57% (n=221) 
were male, 42% (n=165) were female and sex was not 
reported for 1% (n=5). Eighty one percent (n=317) of 
chronic cases were aged between 20 and 44 years when 
notified (figure 6). Males were slightly older overall, with 
a median age at notification of 34 years compared to 30 
years for females (figure 5). 
Although risk factor was reported for a minority of 
chronic cases, some information on country of birth or 
asylum seeker status was available for 54% (n=212). Of 
these, 85% (n=180) were either born in a hepatitis B 
endemic country (hepatitis B surface antigen prevalence 
>2%) or were asylum seekers. Most of these cases are 
likely to have been infected outside Ireland, but the 
actual mode of acquisition of infection is unknown 
for the majority. Where country of birth was available 
(51%, n=198), the most common birth countries were 
in Central or Eastern Europe (34%, n=68), Asia (25%, 
n=49), Sub-Saharan Africa (23%, n=46) and Western 
Europe (12%, n=24). Of those born in Western Europe, 
17 were born in Ireland. 
Risk factors for transmission were provided for 20% of 
the chronic cases notified in 2013. Where data were 
available, the most common risk factors were sexual 
exposure (50%, n=39), vertical transmission (14%, n=11), 
attending an intellectual disability institution (9%, n=7) 
and injecting drug use (9%, n=7). All of the cases with an 
intellectual disability were born in Ireland, but infection 
may have been acquired in the past and only diagnosed 
in 2013 as part of routine testing. 
The reason for testing was known for 71% (n=279) 
of chronic cases. The main reasons were: antenatal 
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Figure 5. Number of chronic cases of hepatitis B notified, by sex and median age, 2004 to 2013
Figure 4. Age and sex-specific notification rates/100,000 population for acute cases of hepatitis B, 2013
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screening (23%, n=65), routine health screening (17%, 
n=46), STI screening (15%, n=43), re-testing of known 
cases (not previously notified) (13%, n=36) and asylum 
seeker screening (12%, n=33).
Co-infections
Co-infection with HIV or hepatitis C can lead to more 
severe liver disease and an increased risk of liver cancer 
in people with hepatitis B infection. Seven of the cases 
of hepatitis B notified in 2013 were co-infected with HIV, 
two were co-infected with hepatitis C and one additional 
case was infected with HIV and hepatitis C.
The figures presented in this summary are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) System on 17th September 2014. These 
figures may differ from those published previously due 
to ongoing updating of notification data on CIDR.
1. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS.A 
mathematical model to estimate global hepatitis B disease burden 
and vaccination impact. Int J Epidemiol. 2005 Dec;34(6):1329-39.
2. Wright TL. Introduction to chronic hepatitis B infection. Am J 
Gastroenterol. 2006;101 Suppl 1:S1-6.
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Figure 6. Age and sex-specific notification rates/100,000 population for chronic cases of hepatitis B, 2013
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Hepatitis C is a major cause of liver disease worldwide. 
The hepatitis C virus is primarily transmitted through 
sharing contaminated equipment when injecting drugs 
or through receipt of unscreened blood or blood 
products (this is no longer a risk in Ireland). Sexual, 
occupational and vertical transmission can also occur but 
are less common. 
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear 
the virus and develop chronic infection. Between 5 
and 20% of chronically infected individuals develop 
cirrhosis of the liver after 20 years of infection. Of 
those with cirrhosis, 1.5 to 2.5% will go on to develop 
hepatocellular carcinoma (liver cancer) each year.1 
Treatment with a combination of pegylated interferon/
ribavirin/telaprevir or pegylated interferon/ribavirin/
boceprevir induces sustained virological response (SVR) 
rates of up to 75% in those with genotype 1 hepatitis 
C.2 Approximately 80% of those with genotype 2 and 
3 infections achieve SVR on pegylated interferon and 
ribavirin alone.3 An SVR is regarded as a virological 
cure and is associated with improved morbidity and 
mortality. Several newer direct acting antiviral therapies 
have achieved high SVRs in clinical trials.4 Some have 
been approved by the European Medicines Agency and 
reimbursement recommendations are currently under 
review by the National Centre for Pharmacoeconomics.
The overall prevalence of chronic hepatitis C in Ireland 
is comparable to other Northern European countries, 
and is estimated to be between 0.5 and 1.2%. Most 
cases fall into defined risk groups such as injecting drug 
users, people who received unscreened blood or blood 
products in the past and people who were born in 
hepatitis C endemic countries.5
Hepatitis C notifications decreased by 12% in 2013 
(n=786, 17.1/100,000 population) compared to 2012 
(n=894, 19.5/100,000 population) (figure 1). This was 
a continuation of a general downward trend since 
peak levels in 2007 (n=1539). There was a strong 
predominance of males: 68% (n=537) of cases were 
male, 31% (n=245) were female and sex was not 
reported for four cases. The highest notification rates 
were in young to middle aged adults. Eighty six percent 
(n=676) of cases were aged between 25 and 54 years 
(figure 2). The median age at notification for females was 
younger (36 years) than that for males (38 years). 
5.2 Hepatitis C
Summary
Number of cases, 2013: 786
Crude notification rate, 2013: 17.1/100,000 population
Number of cases in 2012: 894
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Figure 1. Number of notifications of hepatitis C and median age at notification, by sex, 2004-2013
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The geographical distribution of cases was skewed, 
with the HSE-East reporting 71% of the cases notified in 
2013 (n=556, 34/100,000 population) (figure 3).
Data on most likely risk factor were available for 57% 
of cases (n=445) in 2013. The most common risk 
factors reported were injecting drug use (79%, n=351), 
sexual exposure (7%, n=30), receipt of blood or blood 
products (3%, n=14), tattooing or body piercing (2%, 
n=10) and vertical transmission (2%, n=8) (figure 4). 
The vertically acquired infections do not all represent 
recent births in Ireland. Five were born in Ireland, two 
were born in other countries and country of birth was 
not available for the remaining case. Of those who 
were infected through contaminated blood or blood 
products, seven were infected in Ireland, six were 
infected in other countries and no country of infection 
was available for the remaining case. The Irish infections 
occurred many years in the past, but were notified for 
the first time in 2013. Figure 4 shows recent risk factor 
trends for hepatitis C in Ireland.
Data on country of birth were available for 28% of cases 
(n=223) in 2013. Where information was available, 
46% of cases were born in Ireland and 54% were born 
outside of Ireland. For the non-Irish nationals, the most 
common regions of birth were Central and Eastern 
Europe (34%, n=75), Asia (8%, n=18) and Western 
Europe (excluding Ireland) (6%, n=13). 
Hepatitis C genotype data were collected 
retrospectively from the NVRL and the Molecular 
Diagnostic & Research Laboratory in University College 
Cork and were available for 43% of notifications in 2013. 
Of these, 64% (n=213) were genotype 1, 28% (n=92) 
were genotype 3, 5% (n=16) were genotype 2, 3% 
(n=11) were genotype 4 and 1% (n=2) were genotype 
6.  Subtype was available for 93% (n=197) of genotype 
1 cases. Seventy three percent were genotype 1a and 
27% were 1b.
Co-infections with HIV or hepatitis B can lead to more 
severe liver disease and an increased risk of liver cancer 
in those with hepatitis C infection. Twenty two of the 
hepatitis C cases notified in 2013 were known to be co-
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2010-2013
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2013
0
10
20
30
40
50
60
0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ 
N
ot
ifi
ca
tio
n 
ra
te
s 
pe
r 1
00
,0
00
 
Age group (years) 
Male Female
0
10
20
30
40
50
60
70
E M MW NE NW SE S W 
N
ot
ifi
ca
ito
n 
ra
te
 p
er
 1
00
,0
00
 
HSE area 
2010 2011 2012 2013
infected with HIV and four with hepatitis B. One of these 
was infected with hepatitis B, hepatitis C and HIV. 
Hepatitis C notifications have been decreasing in recent 
years. Some of this decline may be explained by the 
introduction of new case definitions, explicitly excluding 
the notification of resolved cases, in 2012. Data 
completeness has also improved in recent years and 
this has facilitated better deduplication of notifications. 
However, overall indications are that the incidence of 
hepatitis C in Ireland is decreasing. Where risk factor 
information was available, 79% of cases were drug 
users who were likely to have been infected through 
unsafe injecting practices. Anecdotally, the proportion 
of drug users who are injecting is decreasing and the 
incidence of hepatitis C appears to be decreasing in this 
population. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 30th September 
2014. These figures differ from those published 
previously and those reported in the appendices of this 
report due to ongoing updating of notification data on 
CIDR.
1. Global Burden of Hepatitis C Working Group. Global burden 
of disease (GBD) for hepatitis C.J Clin Pharmacol. 2004 
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Figure 4. Most likely risk factor for hepatitis C, 2010-2013
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In 2013, 344 people were newly diagnosed with HIV 
in Ireland giving a rate of 7.5 per 100,000 population. 
Since 2010, the annual rate of new HIV diagnoses has 
been relatively stable in Ireland, ranging from 7.0 to 
7.5 per 100,000 population. Cumulatively, to the end 
of 2013, 6,979 people have been newly diagnosed 
with HIV in Ireland since the early 1980’s. This number 
does not represent the number of people living with 
HIV (PLHIV) in Ireland, as it does not take factors such 
as death and migration into account. The prevalence of 
HIV in the Irish population is currently unknown. A study 
in 2009/2010 found that 3,254 patients accessed HIV 
outpatient care in six centres in Ireland over a 12 month 
period (1). 
A summary of new HIV diagnoses in 2013 is given in 
table 1 and figure 1 shows the number of HIV cases 
diagnosed annually in Ireland from 2003 to 2013, in 
males and females. The rate of new HIV diagnoses by 
HSE area of residence is shown in table 2. In 2013, the 
rate was highest in HSE East (14.6 per 100,000) and 
lowest in HSE Northwest (1.9 per 100,000). 
It is important to note that 55 (16%) of the new 
diagnoses in 2013 were reported to have previously 
tested HIV positive in another country and this should 
be borne in mind when interpreting the 2013 data. A 
further 203 (59%) did not have a previous positive test 
and information on previous positive HIV testing was 
not available for the remaining 86 cases (25%). 
Probable route of transmission
Information on probable route of transmission was 
available for 313 (91%) new diagnoses in 2013. 
The predominant route of transmission was sex 
between men, accounting for 46% of new diagnoses. 
Heterosexual contact accounted for 131 new diagnoses 
(38%); there were 18 new diagnoses among people 
who inject drugs (PWID) (5%) and three cases where the 
route of transmission was identified as mother to child 
transmission (MTCT). Figure 2 shows probable route of 
transmission among the three major risk groups; MSM 
(men who have sex with men), heterosexuals and PWID 
(people who inject drugs) between 2003 and 2013. 
MSM (Men who have sex with men)
MSM are the population most affected by HIV in Ireland, 
and in 2013 accounted for the highest proportion 
(46%) of new diagnoses. This is slightly lower than the 
proportion reported in 2012 (49%). The median age 
among MSM diagnosed in 2013 was 32 years (range 
19-68 years). The median age has decreased in recent 
years (from 37 years in 2005). Just over half (54%) of 
MSM were born in Ireland, 20% in Latin America, 12% in 
central and eastern Europe and 6% in western Europe. 
5.3 HIV
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Figure 1: New HIV diagnoses by year of diagnosis, 2003 to 2013 
0
50
100
150
200
250
300
350
400
450
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
N
um
be
r o
f c
as
es
Year of HIV diagnosis
Females Males Total 
Where CD4 count was reported (92% of cases), 37% 
of MSM were diagnosed late (CD4 count <350 cells/
mm3) including 15% who had advanced HIV infection 
(CD4 count <200 cells/mm3). Seven MSM (4%) were 
diagnosed with an AIDS defining illness at the time 
of their HIV diagnosis in 2013. The most common 
indicative illness among MSM was Pneumocystis Carinii 
Pneumonia (PCP) (57%).
Ten percent of MSM newly diagnosed with HIV were 
co-infected with gonorrhoea and 8% were co-infected 
with chlamydia. Twenty four percent of MSM had 
positive syphilis serology but the proportion of these 
with infectious syphilis was not available. Almost one in 
every four (22%) MSM were infected relatively recently, 
in either 2012 or 2013 (i.e.had a previous negative test 
in either 2012 or 2013). 
Heterosexual transmission
In 2013, 38% of newly diagnosed cases (n=131) were 
infected via heterosexual sex. Among the heterosexual 
cases, 57% were born in countries with generalised 
epidemics (greater than 1% of the general population 
is HIV positive), 14% had a partner from a country with 
a generalised epidemic, 7% had a high-risk partner or 
a partner known to be HIV positive, and a further 22% 
were presumed to be infected heterosexually with 
no further information. Fifty three percent of the new 
diagnoses among heterosexuals were female with a 
median age of 33 years (range 19-55 years) and 47% 
were male with a median age of 39 years (range 24-70 
years). 
Where CD4 count was available (91% of cases), a 
high proportion (59%) of heterosexual cases, were 
diagnosed late and 34% had advanced HIV infection at 
the time of diagnosis. The proportion diagnosed late 
in male heterosexuals decreased from 67% in 2011 to 
59% in 2013. The proportion diagnosed late in female 
heterosexuals increased from 54% in 2011 to 59% in 
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Figure 2: New HIV diagnoses in Ireland by probable route of transmission, 
2003 to 2013
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Table 1: Key points, new HIV diagnoses 2013
Number of new diagnoses 344
Rate (per 100,000 population) 7.5
Age Median Age 34 years
Age range of adult cases 19 to 70 years
Gender Males 258 (75.1%)
Females 86 (24.9%)
Route of Transmission MSM 159 (46.2%)
Heterosexual 131 (38.1%)
PWID 18 (5.2%)
MTCT 3 (0.9%)
Unknown/Other 33 (9.6%)
Geographic origin Born in Ireland 141 (41.0%)
Born Abroad 174 (50.6%)
Unknown 29 (8.4%)
Stage of Infection Late (CD4 <350 cells/mm3) 150/303 (49.5%)
Very late (CD4 <200 cells/mm3) 77/303 (25.4%)
2013. Thirteen percent of heterosexual cases were 
diagnosed with an AIDS defining illness at the time of 
their HIV diagnosis in 2013. 
PWID (People who inject drugs)
Five percent (18 cases) of new diagnoses were among 
PWID. This is similar to the numbers diagnosed in the 
last four years (ranging from 13 to 23 cases since 2010). 
Of the 18 new diagnoses, 12 were men and six were 
women. The median age was 33.5 years (range 25 to 
56 years). Ten were born in Ireland, three in central and 
eastern Europe and one in born in western Europe. 
Over 80% of PWID were co-infected with hepatitis C at 
the time of their HIV diagnosis.
Where CD4 count was reported (89% of cases), 56% 
of PWID were diagnosed late including 19% who had 
advanced HIV infection at diagnosis. The proportion 
diagnosed late in 2013 is lower than in 2012 (63%) and 
2011 (85%). 
MTCT (Mother to Child Transmission)
Three MTCT cases were newly diagnosed in 2013 
with two of the children born in sub-Saharan Africa 
and one in eastern Europe. No MTCT cases were 
identified in children born in Ireland in 2013 (Personal 
Communication; Michelle Goode, Rainbow Clinic, Our 
Lady’s Children’s Hospital, Crumlin).
Discussion
The overall trend in newly diagnosed HIV cases 
in Ireland for the period 2003 to 2013 has been 
relatively stable with most cases occurring in 
specific subgroups of the population, namely MSM, 
heterosexuals from countries with a generalised 
epidemic and PWID. Sex between men is the 
commonest mode of transmission in Ireland since 
2010. It is also reported as the predominant mode of 
transmission in EU/EEA countries and accounted for 
40% of the total number of diagnoses in 2012 (2). The 
number of new diagnoses among heterosexuals and 
PWID in Ireland has been relatively stable since 2010.  
National information on stage of infection improved in 
2013, with information available for 88% of cases, up 
from 73% in 2012. Overall, the number of individuals 
that were diagnosed at a late stage of infection 
remains high: 50% were reported as late presenters 
compared with 48% in 2012 and 52% in 2011. The 
proportion diagnosed late varied by risk group and 
was highest among heterosexuals (59% in males and 
females), followed by 56% among PWID and 37% in 
MSM. The lower levels of late presentation in MSM are 
encouraging, and reflect on-going efforts in improving 
access to testing and promotion of testing in this risk 
group. However, in other risk groups, late presentation 
rates remain high. More emphasis on the benefits 
of early testing and ready access to HIV testing are 
needed to improve the proportions presenting late, 
which will not only benefit the individual detected early, 
but reduce the likelihood of transmission to others. 
The detailed 2013 report and slide set are available at 
http://www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/
SurveillanceReports/  and weekly HIV and STI reports 
are available at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIWeeklyReports/ 
Note: CIDR information is updated on an on-going 
basis with the most up to date information available 
and so numbers reflect the date of extraction from 
CIDR. Data for this chapter were extracted from CIDR in 
May 2014.
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Table 2: Number of new HIV diagnoses and rate by HSE area 
of residence, 2013 
HSE Area Number Rate per 100,000
HSE E 236 14.6
HSE M 10 3.5
HSE MW 23 6.1
HSE NE 14 3.2
HSE NW 5 1.9
HSE SE 12 2.4
HSE S 33 5.0
HSE W 11 2.5
Total 344 7.5
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This chapter describes data from the antenatal HIV 
screening programme in Ireland in 2013. Background 
information on the system and a copy of the HIV 
antenatal data collection form can be found at  
www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/AntenatalHIVTesting/ 
Sixteen of the twenty maternity hospitals and units 
provided antenatal HIV screening data for 2013. Table 
1 describes the data collected from maternity hospitals 
between 2007 and 2013. Table 2 describes the 2013 
data by HSE area. 
In 2013, the national reported uptake of HIV antenatal 
screening was 99.9%, ranging from 99% to 100% among 
participating hospitals. However, antenatal screening 
data were only available for 57,638 women in 2013. 
There were 68,930 births in 2013 and while these 
figures are not directly comparable, there is a shortfall 
in returns for approximately 16% of antenatal women. 
This is a higher figure than that seen in 2012 (10%). Data 
were not available from four hospitals (one with private 
patients only) and a further ten hospitals provided data 
on public patients only. 
Eighty three women tested HIV positive at their 
antenatal screen, giving a HIV prevalence rate of 0.14%, 
slightly lower than the rate in 2011 and 2012 (0.16%). 
The prevalence of HIV infection among pregnant 
women varied among HSE areas, ranging from 0.09% in 
HSE South to 0.19% in HSE Dublin Northeast. Of the 83 
HIV cases, 14 were newly diagnosed at their antenatal 
screen (i.e. HIV infection was not previously known). The 
prevalence of newly diagnosed HIV infection was 0.02% 
in 2013 which is slightly lower than the prevalence in 
2010, 2011 and 2012 (0.03%). 
Some hospitals can only provide estimates or proxy 
measures for the number of women booked and/or the 
number offered HIV testing. Booking data was retrieved 
from a variety of sources including maternity IT systems 
5.4  Voluntary antenatal HIV testing in 
Ireland: 2013
Key Points
National reported uptake rate:  99.9% *
Number HIV positive cases:  83
Prevalence (%): 0.14%
Number new HIV positive cases 14
Prevalence of new HIV positive cases (%):  0.02%
*  Returns not available for approximately 16% of 
antenatal women in 2013
Table 1: Results of the antenatal screening programme, 2007 to 2013
Parameter 2007 2008 2009 2010 2011 2012 2013
No. of hospitals participating 19/20 18/20 19/20 19/20 20/20 18/20 16/20
No. of live births per year (CSO) 71,389 75,173 75,554 75,174 74,650 72,225 68,930
No. of women booked 60,111 66,558 68,378 70,024 68,111 64,803 57,638
No. offered test 60,052 66,558 68,026 69,615 67,849 64,803 57,638
No. tested 59,522 66,210 67,694 69,292 67,135 64,781 57,618
Uptake of HIV antenatal test (%) 99.0 99.5 99.0 99.0 98.6 99.9 99.9
Number HIV positive 117 123 140 118 109 105 83
Prevalence (%) 0.20 0.19 0.21 0.17 0.16 0.16 0.14
No. newly diagnosed HIV positive 38 34 32 21 17 22 14
Prevalence of new diagnoses (%) 0.06 0.05 0.05 0.03 0.03 0.03 0.02
(6 hospitals), maternity unit manual data collection (6 
hospitals), patient administrations systems (4 hospitals), 
and laboratory IT systems (3 hospitals).
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Figure 1: Prevalence of HIV and newly diagnosed HIV among pregnant women, 
2002 to 2013
Technical Note:  
•  Percent uptake is calculated as the number of women tested divided by the number of 
women booked, multiplied by 100
•  Prevalence of HIV infection is calculated as the number of women testing positive 
divided by the number of women tested, multiplied by 100
Table 2: Results of the antenatal screening programme by HSE area, 2013
HSE area Number 
booked
Uptake of test (%) Number HIV 
positive
Prevalence (%) Number newly 
diagnosed 
positive
Prevalence of new 
diagnoses (%)
Dublin Mid Leinster 22,449 100.0 33 0.15 3 0.01
Dublin Northeast 16,233 100.0 31 0.19 6 0.04
South 11,035 100.0 10 0.09 2 0.02
West 7,921 99.7 9 0.11 3 0.04
Ireland 57,638 99.9 83 0.14 14 0.02
Sexually Transmitted Infections (STIs), 2013
Summary
During 2013, a total of 12,753 cases of sexually 
transmitted infections (STIs) were reported. The most 
frequently reported STIs were Chlamydia trachomatis 
infection (n=6,262), ano-genital warts (n=2,133), 
gonorrhoea (n=1,294) and non-specific urethritis 
(n=1,272; table 1). The burden of STIs is greatest among 
those aged less than 25 years and among men who 
have sex with men (MSM).
Chlamydia trachomatis infection
Chlamydia trachomatis infection was the most 
frequently reported STI. There were 6,262 notifications 
in 2013 giving a crude incidence rate (CIR) of 136.5 per 
100,000. The rate has remained steady in recent years 
with rates of 139.6/100,000 and 134.3/100,000 reported 
in 2012 and 2011, respectively (figure 1).There were 
17 cases of Chlamydia trachomatis infection in young 
children (<6 months); three-quarters of these were 
reported as conjunctivitis. 
Gonorrhoea
Following an upsurge in 2012, notifications of 
gonorrhoea continued to rise in 2013. The CIR was 
28.2/100,000 population in 2013, up from 24.2/100,000 
in 2012. While the rates in HSE East stabilised, the CIR 
in most other HSE areas increased in 2013. This increase 
may reflect better surveillance data, with the inclusion 
of all laboratory diagnosed cases in the Computerised 
Infectious Disease Reporting (CIDR) system in 2013. 
Young heterosexuals and MSM were the groups most 
affected by the increase1.  
Ano-genital warts
During 2013, 2,133 cases of ano-genital warts were 
reported in Ireland giving a CIR of 46.5 per 100,000 
population. This represents a slight increase from 2012 
(43.2/100,000) (figure 1). The highest age-specific 
incidence rate was among those aged 20-24 years 
(196.8/100,000). The numbers reported here are likely 
to be an underestimate of the true incidence as data 
were not reported from every STI clinic. Further details 
on the completeness of reporting are available in the 
report Ano-genital Warts in Ireland, 2013, available on 
the HPSC website, www.hpsc.ie.
5.5  Sexually Transmitted Infections  
 (STIs), 2013
Summary
Total number of STI cases in 2013: 12,753
Crude notification rate, 2013: 277.9/100,000
Most frequently reported STI in 2013: Chlamydia 
trachomatis infection (n=6,262)
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Table 1: Number, crude incidence rate (CIR) per 100,000 & median 
age of STIs, 2013
STI Number CIR Median Age (range)
Chlamydia 6,262 136.5 25 yrs. (14 -81 yrs.)*
Ano-genital warts 2,133 46.5 NA
Gonorrhoea 1,294 28.2 26 yrs. (15 - 79 yrs.)**
Non-specific urethritis 1,272 27.7 NA
Herpes simplex (genital) 1,136 24.8 29 yrs. (14-75 yrs.)
Syphilis (all cases) 576 12.6 36 yrs. (19-83 yrs.)
Syphilis (early infectious) 172 3.7 33 yrs. (19-73 yrs.)
Trichomoniasis 75 1.6 33 yrs. (16-52 yrs.)
LGV 5 0.1 31 yrs. (27 -44 yrs.)
Total 12,753 277.9 -
*Excludes those <14 years; **Excludes those <15 years; NA: case-based data 
were not collected
Herpes simplex (genital)
There were 1,136 cases of herpes simplex (genital) 
notified in Ireland during 2013 corresponding to a CIR 
of 24.8 per 100,000 population, a small decrease from 
2012 (28.9/100,000)(see figure 1). Most cases were 
reported as Herpes simplex virus (HSV) type 1 (45%) and 
29% as HSV type 2; subtype was not reported for 26% 
of cases.
Trichomoniasis
During 2013 there were 75 cases of trichomoniasis 
notified in Ireland corresponding to a CIR of 1.6 per 
100,000 population.  While there were similar numbers 
of cases reported in the age groups 25-29 years, 30-34 
years and 45-49 years, the highest age-specific rate was 
among those aged 45-49 years.
Lymphoganuloma venereum (LGV)
There were 5 cases of LGV reported in 2013 compared 
with 4 cases in 2012 and 2 in 2011. All cases were 
reported in HSE East in MSM, three of whom were 
reported as HIV positive. 
Non-specific urethritis
At total of 1,272 cases of non-specific urethritis were 
reported in 2013 compared with 1,539 in 2012. 
More detailed annual reports on STIs are available on 
the HPSC website at http://www.hpsc.ie/A-Z/HIVSTIs/
SexuallyTransmittedInfections/Publications/STIReports/
STIAnnualReports/. Weekly reports on STIs and HIV are 
available on the HPSC website at http://www.hpsc.ie/
A-Z/HIVSTIs/SexuallyTransmittedInfections/Publications/
STIReports/STIWeeklyReports/.
Data on syphilis, HIV and hepatitis B are presented 
elsewhere in this report.
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Figure 1: Trend in CIR per 100,000 population of selected STIs, 1995-2013
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During 2013, there were 576 notifications of syphilis 
made via CIDR giving a crude incidence rate (CIR) in 
2013 of 12.6 per 100,000 population. Rates of early 
syphilis have been steady since 2009 with a slight 
decrease in 2012 (figure 1). The rate for total cases 
in 2013 was 12.6 per 100,000 population and 3.7 per 
100,000 for early cases. 
 
Of the 576 notifications, 172 were early infectious 
syphilis (primary, secondary and early latent), 22 
were late latent syphilis, 153 were latent cases of 
undetermined duration, 13 were of unknown stage 
and the stage of infection was not specified for the 
remaining 216 cases (table 1). No congenital syphilis 
cases were notified in 2013. 
Of the 576 cases, 467 were in males, 105 were in 
females and sex was unknown for 4 cases. Of the 105 
cases in women, 26 were pregnant at diagnosis. 
Early infectious syphilis
Of the 172 early infectious cases notified in 2013:
•   92 (53.5%) were classified as primary, 45 (26.2%) as 
secondary syphilis and 35 (20.3%) as early latent (table 
1).
•   Rates varied throughout the country, with the rate (7.8 
per 100,000) in HSE East (Dublin, Kildare and Wicklow) 
twice the national rate (3.7 per 100,000).
•   The majority of cases occurred in males, with a male to 
female ratio of 16:1. 
•   The highest age specific rate was in 30-34 year olds 
(9.6 per 100,000 population) and the median age was 
33 years (age range: 19-73 years) (table 2).
•   More than three quarters of cases (78%) were identified 
in STI clinics, with 11% being diagnosed in general 
practice. 
•   Nearly two thirds (61.6%) of all cases occurred in men 
who have sex with men (MSM), with rates highest in 
the  30 to 34 year age group.  
•   The proportion of MSM who were co-infected with 
HIV at the time of their syphilis diagnosis continued to 
increase (33% in 2013 compared to 29% in 2012 and 
21% in 2011).
•   Thirteen percent of early infectious cases were among 
heterosexuals, 17% of whom were co-infected with 
HIV. There were no re-infections among heterosexuals.
•   One of the 10 female heterosexual cases was pregnant 
at time of diagnosis (early latent syphilis). 
5.6 Syphilis, 2013
Summary
Total number of syphilis notifications: 576
Number of early infectious syphilis cases: 172
Crude incidence rate of early infectious syphilis: 
3.7/100,000 population
Number of congenital syphilis cases: 0
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Figure 1: Crude incidence rate of total syphilis and early infectious syphilis (per 100,000 
population), 2000-2013
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Discussion
In 2013, the overall crude incidence rate of early syphilis 
increased to 3.7 per 100,000, the same rate as for 2011. 
For the first time in 2013 all laboratories uploaded 
syphilis data to CIDR and this could account for some of 
the increase seen over 2012.
The increase in early syphilis in 2013 was concentrated 
among men (94% of cases). The rate among men 
increased to 7.1 per 100,000 compared to 4.5/100,000 
and 6.8/100,000 in 2012 and 2011, respectively. The 
rate among women continued to decline in 2013 with 
a rate of 0.4 per 100,000 compared to 0.5/100,000 
and 0.7/100,000 in 2012 and 2011, respectively. As in 
previous years, these data demonstrate that MSM are 
disproportionately affected by early infectious syphilis 
(82% of cases where mode of transmission was known). 
This mirrors the pattern seen in UK1 and the United 
States (US)2. 
The increase in the proportion of early syphilis cases 
(29%) co-infected with HIV is particularly concerning 
as co-infection increases the risk of transmitting HIV3. 
The proportion of co-infection was higher among MSM 
(33%) compared to heterosexuals (17%). 
A more detailed analysis of syphilis in Ireland in 2013 is 
available in the report Syphilis in Ireland, 2013, which is 
available on the HPSC website www.hpsc.ie.
Note: CIDR information is updated on an on-going 
basis with the most up to date information available 
and so numbers reflect the date of extraction from 
CIDR. Data for this chapter were extracted from CIDR 
on 28th May, 2014.
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Table 1: Number of syphilis cases by HSE area and stage of infection, 2013 
Stage of infection HSE E HSE M HSE MW HSE NE HSE NW HSE S HSE SE HSE W Total
Congenital 0 0 0 0 0 0 0 0 0
Primary 72 1 4 0 1 7 2 5 92
Secondary 28 3 2 0 0 5 1 6 45
Early latent 27 2 1 1 1 0 2 1 35
Early syphilis 127 6 7 1 2 12 5 12 172
Late latent 8 0 2 0 0 10 1 1 22
Tertiary 0 0 0 0 0 0 0 0 0
Late syphilis 8 0 2 0 0 10 1 1 22
Latent of undetermined duration 136 1 3 0 0 3 5 5 153
Unknown 4 1 1 1 2 0 2 2 13
Not specified 164 3 2 14 1 27 1 4 216
All syphilis 439 11 15 16 5 52 14 24 576
Table 2: Summary of early infectious syphilis cases, 2011, 2012 and 2013
 2011 2012 2013
 No. % No. % No. %
Number of early infectious cases 171 - 116 - 172 -
Male 154 90.1 102 87.9 162 94.2
Men who have sex with men (MSM) 136 79.5 82 70.7 106 61.6
Heterosexuals 28 16.4 24 20.7 23 13.4
Unknown mode of transmission 7 4.1 10 8.6 43 25.0
Median age (years) 31 33 33
Age Range (years) 18-70  19-68  19-73  
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Other infections
Encephalitis due to viruses not otherwise specified 
(NOS) are notifiable under the disease category ‘viral 
encephalitis’. Details of viral encephalitis cases caused 
by other notifiable diseases, if any, are presented in 
other chapters in this report. 
In 2013, only six cases of viral encephalitis (NOS) were 
notified in Ireland (0.1/100.000 population). This was 
12 cases less than the 18 reported during the previous 
year (figure 1). One reason for the sharp reduction 
in numbers is attributable to the late notification of 
15 cases from 2013 (based on their specimen dates) 
reported during weeks 4 to 7 in 2014 and which have 
been excluded from this summary analysis. It should 
also be noted however, that a recent paper has shown 
that there was underreporting of viral encephalitis 
notifications in Ireland between 2005 and 2008.1
There were twice as many viral encephalitis (NOS) 
cases among males (n=4), than females (n=2), a ratio 
of 2:1, which is the reverse of what was recorded in the 
previous year. Cases ranged in age from 18 months to 
79 years with a median age of 61 years. Four of the six 
cases occurred in those aged between 54 and 79 years 
(figure 1, table 1). 
Of the six cases reported in 2013, three were laboratory 
tested positive and case classified as confirmed, the 
remainder were classified as possible. Three of the 
confirmed cases had their causative organism identified, 
of which two were herpes simplex virus type 1 and one 
was human herpes virus type 6.
There were no reported deaths associated with 
viral encephalitis (NOS) in 2013, nor were there any 
imported cases in that year.
6.1 Viral Encephalitis
Summary
Viral Encephalitis, not otherwise specified (NOS)
Number of cases 2013: 6
Number of cases 2012: 18
Number of cases 2011: 23
Crude incidence rate, 2011: 0.1/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by age group, Ireland, 
2013*
* excludes the late notification of 15 cases in 2013 reported in early 2014
 Causative pathogen    
Age Group
Herpes simplex 
virus
Human Herpes 
virus type 6
Not specified Total ASIR % Proportion
<1 0 0 0 0 0.00 0.0
1-4 0 0 2 0 0.70 0.0
5-14 0 0 0 0 0.00 0.0
15-24 0 0 0 0 0.00 0.0
25-44 0 0 0 0 0.00 0.0
45-64 1 0 0 1 0.10 16.7
65+ 1 1 1 2 0.56 33.3
All ages 2 1 3 6 0.13 100
% total cases 33.3 16.7 50.0 100   
ASIR, age specific incidence rate per 100,000 population of total cases
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 27th August, 2014. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
Reference
1. Kelly TA, O’Lorcain P, Moran J, Garvey P, McKeown P, Connell J, 
Cotter S. Underreporting of viral encephalitis and viral meningitis, 
Ireland, 2005-2008. Emerg Infect Dis. 2013;19(9):1428-36
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Figure 1. Number of viral encephalitis (NOS) cases by age group and year, Ireland, 
1992-2013*
* excludes the late notification of 15 cases in 2013 reported in early 2014
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Figure 2. Number of viral encephalitis (NOS) cases by causative pathogen and year, Ireland, 
1992-2013*
* excludes the late notification of 15 cases in 2013 reported in early 2014
Meningitis due to viruses not otherwise specified 
(NOS) are notifiable under the disease category ‘viral 
meningitis’. Details of viral meningitis caused by other 
specified notifiable diseases (such as mumps and 
influenza viruses, if any) are presented in other chapters 
in this report. 
The sharp, steady increase in annual notifications 
which began in 2007 continued in 2013 when 281 were 
reported. The latter number is still less than the 300 
cases notified back in 1990, the highest ever recorded 
in a single year (figure 1). However, a recent paper has 
shown that there was underreporting of viral meningitis 
notifications in Ireland between 2005 and 2008.1 Also, 
the total number of cases reported in 2013 does not 
include the late notification of seven cases (based on 
their specimen dates) reported during weeks 5 and 6 of 
2014.
Since 1997, only seven deaths have been reported with 
cases of viral meningitis (NOS), only one of which was 
attributable to the infection itself. There were none 
reported in 2013.
Of the 281 cases notified in 2013, 266 were classified as 
confirmed (94.7%), six as probable (2.1%) and nine as 
possible (3.2%). There were slightly more cases among 
males (n=142) than in females (n=132), giving a male to 
female ratio of 1.08:1.0. Seven cases were reported with 
unknown gender details in 2013.
6.2 Viral Meningitis
Summary
Viral Meningitis, not otherwise specified (NOS)
Number of cases 2013: 281
Number of cases 2012: 235
Number of cases 2011: 220
Crude incidence rate, 2013: 6.1/100,000
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Figure 1. Number of viral meningitis (NOS) cases by organism type and year, Ireland, 1988-2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
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In 2013 the highest frequency of cases was in children 
aged 1 to 2 months (n=52) and in those aged between 
15 to 39 years (n=113) with an overall median age of 
13.6 years (range one week to 78 years) (figure 2). Over 
67% of cases (n=189) occurred in those under 25 years 
of age (figure 3, table 1). 
The highest age specific incidence rate (ASIR) in 2013 
was in infants <1 year of age (165.7/100,000; n=120). 
The next highest ASIR was in the 20 to 24 year age 
group (9.5/100,000; n=27). The lowest rates were 
reported in the older age groups, 55 to 64 and 65+ 
years with rates of 0.4/100,000 (n=2) and 0.6/100,000 
(n=3), respectively (table 1). 
The national crude incidence rate in 2013 was 6.1 (95% 
CI 5.4–6.8) cases per 100,000 population, a 19.6% 
increase compared with the previous year when 235 
cases were notified (5.1/100,000). The incidence rate 
in 2013 was highest in HSE W at 14.4/100,000 (95%CI 
10.9–17.9) and lowest in HSE S at 2.3/100,000 (95%CI 
1.1-3.4) with both rates significantly different from the 
national rate (figure 4).
In 2013, enteroviruses were the most common 
pathogen associated with viral meningitis, accounting 
for nearly 77.2% (n=217/281) of all notifications (figure 
3, table 1). As a cause of viral meningitis, enteroviruses 
have accounted for more than 60% of all cases each 
year since 2008. In 2013, human herpes virus (type 6) 
(HHV) was the causative pathogen for 11.7% (n=33) 
notifications, herpes simplex virus (HSV) for 2.1% (n=6) 
with varicella virus/varicella zoster virus and echovirus 
each accounting for 0.7% (n=2 each) of cases (figure 3, 
table 1).
Enterovirus was also the most common pathogen in 
infants under one year of age with viral meningitis 
(NOS) in 2013 in 86 out of 120 cases (71.7%). Between 
2007 and 2013 enteroviruses accounted for 71.7% 
(n=852/1188) of all viral meningitis (NOS) cases, with 
typical summer peaks observed each year (figure 5).
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Figure 2. Number of viral meningitis (NOS) cases by age group and gender, 
Ireland, 2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
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Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications by age group and causative 
pathogen, Ireland, 2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
 Causative pathogen    
Age Group
entero-
virus
human herpes 
virus
herpes 
simplex 
virus
varicella virus 
& varicella 
zoster virus
echo-virus
not 
specified
Total ASIR
% 
Proportion
<1 86 28 0 0 0 6 120 165.7 42.7
1-4 2 4 0 0 0 1 7 2.5 2.5
5-9 6 1 0 0 0 1 8 2.5 2.8
10-14 9 0 0 0 0 1 10 3.3 3.6
15-19 23 0 0 0 1 3 27 9.5 9.6
20-24 13 0 0 0 1 3 17 5.7 6.0
25-34 39 0 3 0 0 3 45 6.0 16.0
35-44 32 0 0 1 0 2 35 5.0 12.5
45-54 4 0 1 1 0 1 7 1.2 2.5
55-64 2 0 0 0 0 0 2 0.4 0.7
65+ 1 0 2 0 0 0 3 0.6 1.1
All Ages 217 33 6 2 2 21 281 6.1 100
% Total 77.2 11.7 2.1 0.7 0.7 7.5 100   
ASIR, age specific incidence rate per 100,000 population
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The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 27th August, 2014. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
Reference
1. Kelly TA, O’Lorcain P, Moran J, Garvey P, McKeown P, Connell J, 
Cotter S. Underreporting of viral encephalitis and viral meningitis, 
Ireland, 2005-2008. Emerg Infect Dis. 2013;19(9):1428-36
Figure 5. Monthly number of enterovirus-related meningitis notifications, 2008-2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
Figure 4. Crude incidence rates per 100,000 population with 95% confidence 
intervals for viral meningitis (NOS) cases by HSE area, Ireland, 2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
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Figure 3. Number of viral meningitis (NOS) cases by age group (<25, >25 years 
of age) and year, Ireland, 2000-2013*
* excludes the late notification of seven cases in 2013 reported in early 2014
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Five cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2013, this is identical to 2012 when five cases 
were also notified. Four cases in 2013 were sporadic 
CJD cases and one was iatrogenic. One of the cases 
was in the age group 35-44 years, one was in the age 
group 45-54 years, two were in the age group 55-64 
years and one was in the age group ≥65 years. Four 
cases were female and one was male.
In total, 68 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996 
(figure 1). Figure 2 shows the 68 CJD notifications 
by age group. The majority (79%, n=54) of the cases 
were aged greater than 54 years. Of the 68 cases, 35 
were male and 33 were female. Sixty-four cases were 
sporadic CJD, two were familial CJD and two were 
iatrogenic.
Variant CJD (vCJD) is specified as a separate notifiable 
disease. No cases have been notified since 2006. In 
total, four cases of vCJD were notified since vCJD 
became notifiable in December 1996. A summary of 
these four cases was provided in the 2006 HPSC annual 
report. 
Data presented in this summary are based on 
notifications from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit. Annual 
figures published here are based on the year the 
notification was entered on the Computerised Infectious 
Disease Reporting (CIDR) system and consequently may 
differ from annual figures published by the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2013: 5
Number of cases, 2012: 5
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Figure 1. Number of CJD notifications by year from December 
1996 to 2013
Figure 2. Number of CJD notifications (n=68) from December 
1996 to 2013 by age group
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6. Other Infections
Tetanus
One case of tetanus was notified in 2013. The case 
was in the age group 20-24 years and was classified as 
probable. The case was reported as having received 
one dose of a tetanus vaccine 20 years earlier but it 
was not known if the case had received any previous 
doses (ie primary tetanus vaccines as an infant). The risk 
factors for infection were reported as hand injuries from 
a can and a rusty nail.
Summary of case data since 1981:
Fourteen cases of tetanus were reported since tetanus 
became notifiable in November 1981. The number of 
tetanus cases notified by age group is shown in figure 1. 
Two deaths were reported, both cases were aged >60 
years.
Of the 14 tetanus cases, eight (57%) were male, four 
(29%) were female while gender was unreported for two 
(14%).
The following wound injuries (n=10) were reported 
among the 14 notified cases: wound injuries from a road 
traffic accident (n=1), wound from a fall outdoors (n=1), 
wound associated with a dog bite (n=1), wound from 
a kitchen knife (n=1), gardening associated leg wound 
(n=1), leg scratches in an avid gardener (n=1), hand 
wound associated with a clean piece of wood (n=1), a 
farming associated hand wound (n=1), a foot wound 
from a thorn (n=1), and hand injuries from a can and a 
rusty nail (n=1).
Vaccination data were reported for five of the 14 cases. 
Two cases were unvaccinated. One case, in the age 
group 15-19 years, was reported to have received 
three doses of tetanus vaccine as a child and a booster 
at four years and again at five-six years of age. One 
case was reported to have received a single tetanus 
vaccine around 40 years prior to infection. One case 
was reported as having received one dose of a tetanus 
vaccine 20 years earlier but it was not known if the case 
had received any previous doses (ie primary tetanus 
vaccines as an infant).
Clinical efficacy after a complete series of vaccines 
is almost 100%. However, immunity wanes and after 
10 years may be insufficient to provide protection. 
The childhood immunisation schedule in Ireland 
recommends children receive a dose of tetanus toxoid 
containing vaccine at two, four and six months of age 
6.4 Tetanus
Summary
Number of cases, 2013: 1
Number of cases, 2012: 1
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Figure 1. Tetanus cases notified (n=14) from November 1981 to 2013 by age group
and booster doses at four-five years of age and 11-14 
years of age. For vaccinated persons who have received 
five doses of tetanus toxoid, booster doses may be 
considered every 10 years. This is based on concern 
regarding the decline of antibody levels with age and 
potential failure of single booster doses to produce 
protective levels in older individuals. For more detailed 
information on tetanus immunisations please see the 
document Immunisation Guidelines for Ireland available 
at www.immunisation.ie.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 12th September 
2014. These figures may differ from those published 
previously due to ongoing updating of notification data 
on CIDR. 
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Infectious Disease Outbreaks
Outbreaks
During 2013, 520 outbreaks of infectious diseases 
were reported with 5,886 associated cases of illness, 
including 810 (13.8%) cases hospitalised and 32 deaths* 
Regional variation in outbreaks was observed between 
HSE areas with the highest rates observed in HSE-NW 
(25.9/100,000 population), while the lowest rate was 
observed in HSE-NE at 5.0 per 100,000 population. 
Table 1 details the regional distribution of all outbreaks 
of infectious disease, outbreaks of infectious intestinal 
disease (IID) and outbreaks of non-IID.
General outbreaks accounted for 69.4% (n= 361) of 
all outbreaks notified during 2013. The remaining 
outbreaks (30.6%, n= 159) were reported as family/
household outbreaks. Similar to previous years, 
person-to-person spread†  was reported as the mode 
of transmission for the majority of outbreaks (65.6%, 
n=341). Most of these outbreaks were due to norovirus, 
acute infectious gastroenteritis (AIG), influenza/ 
influenza-like illness and verotoxigenic E. coli (VTEC). 
The most frequently reported outbreak locations were 
private houses (n=138, 26.5%), residential institutions 
(n=106, 20.4%) and community hospital/ long-stay units 
(n=101, 19.4%). The highest numbers ill were reported 
from outbreaks in residential institutions (n=1,607), 
community hospital/long-stay units (n=1,424) and 
hospitals (n=1,408). Table 2 details the number of IID 
and non-IID outbreaks and numbers ill by outbreak 
location. 
Infectious intestinal disease (IID) outbreaks:
During 2013, 372 IID outbreaks were reported, which 
was a decrease of 8.1% compared to the number of IID 
outbreaks reported during 2012 (n=405). However, the 
percentage of IID outbreaks as a proportion of total 
outbreaks remained stable at 71.5% when compared 
to recent years (78.0% in 2012 and 74.4% in 2011). The 
Table 3 details the regional distribution of outbreaks of 
infectious intestinal disease (IID).
Norovirus/ suspected viral outbreaks accounted for 
54.8% of all IID outbreaks reported in 2013. Figure 1 
compares norovirus/ suspected viral outbreaks with 
non-norovirus IID outbreaks by year from 2001 to 2013. 
Norovirus/ suspected norovirus was also responsible for 
four of the six largest outbreaks during 2013. Numbers 
ill ranged from two cases to 287 cases.
After noroviral infection (n=114), the next most 
commonly reported IID outbreaks were VTEC (n=96), 
AIG (n=90), and cryptosporidiosis (n=28). The number 
of general and family outbreaks of IID and numbers ill 
are outlined in Table 4. 
7. Outbreaks
Summary
Number of outbreaks:520
Number of IID outbreaks: 372
Number of non-IID outbreaks:148
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Table 1: Number of outbreaks by HSE area, 2013
HSE area Number of 
outbreaks
Outbreak rate 
per 100,000
Number ill Number 
hospitalised
Number of 
deaths
Number of IID 
outbreaks
Number 
of Non-IID 
outbreaks
HSE-E 119 7.3 2,546 434 9 66 53
HSE-M 42 14.9 277 22 6 35 7
HSE-MW 52 13.7 222 61 0 44 8
HSE-NE 22 5.0 188 34 5 17 5
HSE-NW 67 25.9 560 58 0 43 24
HSE-SE 67 13.5 747 35 3 54 13
HSE-S 70 10.5 654 28 7 48 22
HSE-W 74 16.6 610 102 2 58 16
HPSC 7 - 82 36 0 7 0
Total 520 11.3 5,886 810 32 372 148
*Outbreak data extracted from CIDR on 22/09/2014.
†  Including 78 outbreaks reported as person to person
Figure 1: Number of norovirus/suspected viral outbreaks§ and number of non-norovirus IID outbreaks by year, 2001-2013
§ Includes all norovirus outbreaks and AIG outbreaks where organism was suspected norovirus, suspected viral or not specified
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Table 2: Number of IID and non-IID outbreaks and number ill by outbreak location, 2013
Outbreak location
IID Non-IID Total outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Comm. hosp/long-stay unit 62 776 39 648 101 1,424
Community outbreak 16 152 4 17 20 169
Crèche 7 25 3 13 10 38
Extended family 8 26 6 26 14 52
Hospital 50 1,065 10 343 60 1,408
Hotel 7 190 0 0 7 190
Nursing home 18 261 2 13 20 274
Other 10 57 4 21 14 78
Private house 119 229 19 44 138 273
Public house 1 17 0 0 1 17
Residential institution 61 945 45 662 106 1,607
Restaurant / cafe 2 86 0 0 2 86
School 3 106 11 120 14 226
Travel related 3 7 2 7 5 14
University/college 0 0 2 5 2 5
Workplace 0 0 1 3 1 3
Unknown 3 12 0 0 3 12
Not specified 2 10 0 0 2 10
Total 372 3,964 148 1,922 520 5,886
Table 3: IID outbreak summary by HSE area 2013
HSE area Number of outbreaks Outbreak rate per 100,000 Number ill Number hospitalised Number of deaths
HSE-E 66 4.1 1,580 401 0
HSE-M 35 12.4 121 11 0
HSE-MW 44 11.6 180 40 0
HSE-NE 17 3.9 144 28 1
HSE-NW 43 16.6 361 39 0
HSE-SE 54 10.9 590 21 2
HSE-S 48 7.2 461 8 2
HSE-W 58 13.0 445 71 0
HPSC 7 - 82 36 0
Total 372 8.1 3,964 655 5
-124-HPSC Annual Epidemiological Report 2013 7. Infectious Disease Outbreaks
Figure 2: Number of IID and non-IID outbreaks by month of notification, 2013
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Table 4: Number of general and family IID outbreaks by disease, 2013
Outbreak disease/pathogen
Family outbreak General outbreak Total IID outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
AIG (unspecified) 1 7 89 1,017 90 1,024
Campylobacter infection 6 14 1 2 7 16
C. difficile infection 0 0 5 28 5 28
Cryptosporidiosis 22 55 6 38 28 93
Giardiasis 2 4 0 0 2 4
Hepatitis A (acute) 2 5 4 35 6 40
Noroviral infection 4 151 110 2,310 114 2,461
Rotavirus infection 1 2 0 0 1 2
Salmonellosis 10 26 8 30 18 56
Shigellosis 3 8 1 9 4 17
VTEC infection 80 133 16 88 96 221
Yersiniosis 1 2 0 0 1 2
Total 132 407 240 3,557 372 3,964
Table 5: Non-IID outbreak summary by HSE area, 2013
HSE area Number of outbreaks Outbreak rate per 100,000 Number ill Number hospitalised Number of deaths
HSE-E 53 3.3 966 33 9
HSE-M 7 2.5 156 11 6
HSE-MW 8 2.1 42 21 0
HSE-NE 5 0.0 44 6 4
HSE-NW 24 9.3 199 19 0
HSE-SE 13 2.6 157 14 1
HSE-S 22 3.3 193 20 5
HSE-W 16 3.6 165 31 2
Total 148 3.2 1,922 155 27
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The most frequently reported locations for IID 
outbreaks were private houses (n=119), community 
hospital/long stay facilities (n=62) and residential 
institutions (n=61). The most commonly reported 
outbreaks in private houses were VTEC (n=77) and 
cryptosporidiosis (n=22). In community hospital/long 
stay facilities the most commonly reported outbreaks 
were AIG (n=33) and noroviral infection (n=26). In 
residential institutions the most commonly reported 
outbreaks were norovirus (n=35) and AIG (n=26).
Person-to-person (P-P) spread‡ was the most frequently 
reported mode of transmission implicated in IID 
outbreaks during 2013 (62.6%, n=233). 
During 2013, the number of IID outbreaks peaked 
between March and May. This peak observed was 
mainly due to high numbers of norovirus/ suspected 
norovirus and VTEC outbreaks. Figure 2 illustrates 
the number of IID and non-IID outbreaks by month of 
notification during 2013.
Non-IID outbreaks: 
During 2013, 148 outbreaks of non-IID diseases were 
reported, representing 28.5% of all outbreaks notified 
nationally. The most common non-IID outbreak diseases 
were influenza/ influenza-like illness (50.0%, n=74), 
tuberculosis (8.1%, n=12) and pertussis (6.8%, n=10). 
Table 5 details the regional distribution of non-IID 
outbreaks while the number of general and family 
outbreaks of non-IID disease and numbers ill are 
outlined in Table 6.
The number of non-IID outbreaks peaked during 
March and April 2013. Both peaks were mainly due to 
influenza, influenza-like illness (ILI) and acute respiratory 
outbreaks (figure 2). 
The most frequently reported locations for non-
IID outbreaks were residential institutions (n=45), 
community hospital/long-stay units (n=39) and private 
houses (n=19), as shown in table 2. Non-IID outbreaks 
in these locations were most frequently caused by 
influenza/ILI, acute respiratory outbreaks and pertussis. 
Person-to-person (P-P) spread** was the most 
frequently reported mode of transmission implicated in 
non-IID outbreaks during 2013 (73.0%, n=108). 
The information gathered from outbreaks reported 
is used to inform public health professionals on the 
causes and factors contributing to outbreaks, to target 
prevention strategies and to monitor the effectiveness 
of prevention programmes. For further information on 
disease specific outbreaks, please refer to the individual 
disease chapter.
Table 6: Number of family and general non–IID outbreaks by disease, 2013
Outbreak disease/pathogen
Family outbreak General outbreak Total Non-IID outbreaks
Number 
outbreaks
Number ill
Number 
outbreaks
Number ill
Number 
outbreaks
Number ill
Influenza 0 0 64 1,391 64 1,391
Tuberculosis 6 18 6 23 12 41
Pertussis 9 25 1 3 10 28
Influenza-like illness 0 0 10 126 10 126
Parvovirus/ suspected parvovirus 1 3 6 35 7 38
Mumps 2 4 3 7 5 11
Acute respiratory illness 0 0 5 44 5 44
Measles 2 4 2 29 4 33
Viral meningitis 2 4 2 6 4 10
Parainfluenza 0 0 4 48 4 48
Respiratory syncytial virus infection 2 4 1 15 3 19
Human metapneumovirus 0 0 3 65 3 65
ESBL E. coli 0 0 3 8 3 8
Streptococcus group A infection (invasive) 1 2 1 2 2 4
Suspected Scabies 0 0 2 14 2 14
Pseudomonas/ P. aeruginosa 0 0 2 2 2 2
Meningococcal disease 1 2 0 0 1 2
Malaria 1 5 0 0 1 5
Carbapenem-resistant Enterobacteriaceae infection (invasive) 0 0 1 2 1 2
CFR positive linezolid resistant Staphylococcus epidermidis 0 0 1 2 1 2
Varicella 0 0 1 8 1 8
Human metapneumovirus & parainfluenza 0 0 1 15 1 15
Hand foot and mouth disease 0 0 1 3 1 3
Streptococcus Group A 0 0 1 3 1 3
Total 27 71 121 1,851 148 1,922
‡ Including 40 IID outbreaks reported as person to person and airborne 
transmission and 8 reported as person-to-person and animal transmission.
**Including 38 non-IID outbreaks reported as person to person and airborne 
transmission
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Immunisation Uptake
Summary
In 2013, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area. 
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website. 
The annual immunisation uptake rates presented 
here represent the collation of the 2013 quarterly 
data. The proportion of children who completed the 
recommended childhood immunisation schedule by 12 
months (born between 01/01/2012 and 31/12/2012) 
and 24 months (born between 01/01/2011 and 
31/12/2011) of age in 2013 are reported.
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1). These 
children should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month of 
age; three doses of vaccines against diphtheria (D3), 
tetanus (T3), pertussis (P3), Haemophilus influenzae type 
b (Hib3), polio (Polio3) and Hepatitis B (HepB3) with one 
dose of each given at two, four and six months of age; 
three doses of pneumococcal conjugate vaccine (PCV3) 
given at two, six and 12 months of age and three doses 
of meningococcal group C (MenC3) vaccine given at 
four, six and 13 months of age. Also at 12 months of 
age a dose of MMR (MMR1) is recommended and at 13 
months a dose of Hib (Hibb) is recommended. Further 
vaccinations are recommended for older children and 
adults; please see www.immunisation.ie for complete 
information on the Irish immunisation schedule.
In children who reached 12 months of age in 2013 (born 
between 01/01/2012 and 31/12/2012) uptake of BCG, 
D3, T3, P3, Hib3, Polio3, HepB3 and two doses of PCV 
(PCV2) and MenC (MenC2) were measured. In children 
who reached 24 months of age in 2013 (born between 
8.1  Immunisation uptake at 12 and 24 
months of age
Summary
Among children 12 months of age in 2013 uptake of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 were 
91%
Among children 24 months of age in 2013 uptake of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached or 
exceeded the target of 95%
D3, T3, P3 and Polio3 were 96%
Hib3 and HepB3 were 95%
MMR1 was 93%
PCV3 was 91%
Hibb was 90%
MenC3 was 87%
The childhood immunisation schedule is shown in 
table 1. Five GP visits are required to ensure children 
receive all their recommended doses of vaccine.
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Table 1. Change in primary childhood immunisation schedule (introduced on September 1st 2008)
Age Children born before  01/07/2008                 Children born on or after 01/07/2008
Birth BCG BCG
2 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC
12 months MMR + Hib MMR + PCV
13 months - MenC + Hib
Please see www.immunisation.ie for complete information on the Irish childhood immunisation schedule including vaccinations for older 
children and adults
BCG  Bacille Calmette Guerin vaccine 
DTaP  Diphtheria, Tetanus and acellular Pertussis vaccine
HepB  Hepatitis B vaccine
Hib  Haemophilus influenzae type b vaccine
IPV  Inactivated Polio Virus vaccine
MenC   Meningococcal group C vaccine
MMR  Measles, Mumps and Rubella vaccine
PCV  Pneumococcal Conjugate Vaccine
01/01/2011 and 31/12/2011) uptake of D3, T3, P3, Hib3, 
Polio3, HepB3, MenC3, PCV3, MMR1, Hibb, one dose of 
vaccine against meningococcal group C (MenCb) on or 
after twelve months of age and one dose of vaccine 
against pneumococcal conjugate vaccine (PCVb) on or 
after twelve months of age were measured.
The immunisation uptake rates are reported here 
by HSE Area and LHO. While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
Caveats to data
BCG uptake data at 12 months has been incomplete 
since reporting to HPSC began in Quarter 3 2003. This 
has occurred due to differences in implementation of 
a neonatal BCG programme across the HSE Areas as 
well as difficulties in providing these data to the HPSC 
where the programme was implemented. Prior to the 
establishment of the HSE each former health board 
determined their own BCG vaccination policy and some 
areas (Western and parts of the Southern Health Boards) 
stopped routine neonatal BCG vaccination but provided 
BCG vaccination for adolescents or high risk groups. 
The neonatal programme has now been routinely 
implemented for all neonates in most, but not all, HSE 
areas. Additionally more complete data on neonatal 
BCG vaccination is now available. However, in the HSE 
NE, where a neonatal programme is implemented, 
data is not available for reporting. In the HSE W the 
neonatal programme is not routinely or comprehensively 
implemented in all LHOs. Therefore, data provided 
for the HSE W reflects BCG vaccination for just a small 
proportion of all babies born in this area. 
Data for 2013 are presented in this report and 
compared to 2012 data. Not all HSE Areas were able 
to provide data during 2012 and 2013. BCG uptake 
data were available for the HSE M, HSE MW, HSE NW, 
HSE SE, HSE S and HSE W Areas in Quarters 1-4 2012 
and for all Areas except the HSE NE during 2013. The 
available national BCG cohort data may be around 52% 
of the national birth cohort in 2012 and 90% in 2013 
(these figures are estimates only). In the HSE W BCG 
data were not available by LHO.
As uptake of MenC3 and Hibb were low since Q3 2010 
and as those over 12 months need only one dose of 
MenC and those aged 12-23 months need only one 
dose of PCV, data on MenCb (one dose of MenC on or 
after twelve months of age) and PCVb (one dose of PCV 
on or after twelve months of age) were requested in 
2012 for the first time. Six HSE Areas (HSE E, M, MW, 
NW, SE and S) were able to provide data representing 
approximately 81% of the national birth cohort in 2012 
and 80% in 2013 (these figures are estimates only).
Immunisation uptake rates at 12 months
National immunisation uptake rates, in children 12 
months of age in 2013, were 91% for D3, T3, P3, Hib3, 
Polio3, HepB3, MenC2 and PCV2 (table 2). Compared with 
2012, the uptake rates for D3, P3, T3, Hib3, Polio3, HepB3, 
MenC2 and PCV2 were unchanged. 
The available 2013 BCG cohort data may be around 
90% (estimate only) of the national birth cohort; based 
on these data BCG uptake was 86%. In contrast, the 
available 2012 BCG cohort data may be around 52% 
(estimate only) of the national birth cohort; based on 
these data BCG uptake in 2012 was 80%. 
Among the HSE Areas, uptake rates for D3, T3, P3, Hib3, 
Polio3 and HepB3 ranged from 90% to 95% and MenC2 
and PCV2 ranged from 87% to 95% (table 2). Among 
the LHOs, uptake rates for D3, T3, P3, Hib3, Polio3, PCV2 
and MenC2 ranged from 82% to 97% and HepB3 ranged 
from 82% to 96% (table 3). The target uptake of 95% 
was reached or exceeded in Laois/Offaly, Longford/
Westmeath and Roscommon for D3, T3, P3, Hib3, Polio3, 
HepB3, MenC2 and PCV2 and in Donegal for D3, T3, P3, 
Polio3 and PCV2 (table 3). The target uptake of 95% was 
reached or exceeded for BCG in 14 LHOs reporting 
data (table 3).
Immunisation uptake rates at 24 months
National annual immunisation uptake rates, in children 
24 months of age in 2013 were 96% for D3, T3, P3 and 
Polio3, 95% for Hib3 and HepB3, 93% for MMR1, 91% for 
PCV3, 90% for Hibb and 87% for MenC3 (table 2). This 
is the third year national annual uptake rates reached 
the target of 95% for D3, T3, P3, Hib3, Polio3 and HepB3. 
Compared with 2012, the uptake rates for D3, T3, P3, 
Hibb, Polio3 and MMR1 increased by one percent, MenC3 
increased by two percent while Hib3, HepB3 and PCV3 
were unchanged (figure 1). 
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Table 2. Annual immunisation uptake rates (based on available data) by HSE Area for children 12 and 24 months of age in 2013
% Uptake at 12 months
Cohort born 01/01/2012 - 31/12/2012
% Uptake at 24 months
Cohort born 01/01/2011 - 31/12/2011
D3 HepB3 MenC2 PCV2 BCG D3 Hib3 Hibb HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE E 90 90 90 90 94 95 95 89 95 86 89 91 93 92
HSE M 95 95 95 95 96 98 98 98 98 91 93 94 96 96
HSE MW 93 93 93 93 97 96 96 92 96 89 92 93 94 94
HSE NE 90 90 90 90 na 94 94 86 94 84 na 89 na 90
HSE NW 94 94 94 94 96 97 97 94 96 88 94 91 95 95
HSE SE 92 92 92 93 96 96 96 96 96 90 94 94 95 95
HSE S 90 89 87 87 93 96 95 83 94 84 87 90 91 92
HSE W 93 93 92 93 13 96 96 91 95 87 na 92 na 92
Ireland 91 91 91 91 86 96 95 90 95 87 90 91 93 93
na=not available
Since T3, P3, and Polio3 uptake at 12 and 24 months and Hib3 uptake at 12 months are identical to D3 uptake only D3 uptake figures presented
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Table 3. Immunisation uptake (%) at 12 months of age in 2013 (i.e. cohort born 01/01/2012-31/12/2012) by LHO and HSE Area
HSE Area Local Health Office/HSE Area
Number in 
cohort for 
BCG *
Number in 
cohort for D3, T3 
& P3 †
Immunisation Uptake (%)
BCG D3 Hib3 HepB3 MenC2 PCV2
HSE E
Dublin South 1780 1780 92 92 92 92 91 92
Dublin South East 1673 1673 93 90 90 90 90 90
Dublin South City 1791 1791 92 93 93 93 93 94
Dublin South West 2663 2663 96 93 93 93 93 94
Dublin West 2929 2929 93 93 93 93 93 93
Dublin North West 3971 3971 93 82 82 82 82 82
Dublin North Central 1903 1903 93 89 89 89 89 90
Dublin North 4346 4346 95 91 91 91 91 91
Kildare/West Wicklow 3959 3959 96 92 92 92 92 92
Wicklow 1943 1943 93 91 91 91 90 91
HSE E Total 26958 26958 94 90 90 90 90 90
HSE M
Laois/Offaly 2583 2583 96 95 95 95 95 95
Longford/Westmeath 2078 2078 96 96 96 96 96 96
HSE M Total 4661 4661 96 95 95 95 95 95
HSE MW
Clare 1721 1747 97 94 94 94 94 94
Limerick 1899 1955 98 92 92 92 92 92
Tipperary NR/East Limerick 1812 1849 97 94 94 94 94 94
HSE MW Total 5432 5551 97 93 93 93 93 93
HSE NE
Cavan/Monaghan na 2012 na 91 91 91 92 92
Louth na 1978 na 89 89 89 90 90
Meath na 3377 na 89 89 89 89 89
HSE NE Total na 7367 na 90 90 90 90 90
HSE NW
Donegal 2195 2195 95 95 94 94 94 95
Sligo/Leitrim 1431 1431 96 94 94 94 93 94
HSE NW Total 3626 3626 96 94 94 94 94 94
HSE SE
Carlow/Kilkenny 1988 1988 96 92 92 92 92 92
South Tipperary 1290 1290 98 93 93 93 93 93
Waterford 1908 1908 95 93 93 93 93 93
Wexford 2197 2197 96 92 92 92 92 92
HSE SE Total 7383 7383 96 92 92 92 92 93
HSE S
North Cork 1585 1544 92 91 91 90 88 88
North South Lee 5863 5759 94 89 89 89 87 87
West Cork 784 780 92 88 88 88 85 85
Kerry 1997 1968 93 92 92 92 90 89
HSE S Total 10229 10051 93 90 90 89 87 87
HSE W
Galway na 3889 na 93 93 93 93 93
Mayo na 1734 na 90 90 90 90 91
Roscommon na 884 na 97 97 96 97 97
HSE W Total 6507* 6507 13* 93 93 93 92 93
Ireland 64796 72104 86 91 91 91 91 91
na=not available
* HSE W BCG data were not available by LHO 
†As the denominator/number in cohort varied slightly according to vaccine the most commonly used number is reported here 
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented 
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
Six of the eight HSE Areas were able to provide uptake 
data on MenCb (one dose of MenC at ≥12 months of 
age) and PCVb (one dose of PCV at ≥12 months of age) 
in 2013. These Areas cover approximately 80% of the 
national birth cohort. Where data were available, national 
uptake was 90% for MenCb and 93% for PCVb.
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1); children 
who were 24 months of age in Quarter 3 2010 were 
born between July 1st and September 31st 2008 
and were the first children recommended the new 
immunisation schedule. Under the new immunisation 
schedule children are now recommended HepB vaccine 
and PCV. In addition, there is a change in timing of the 
MenC and Hibb vaccines (table 1). The changes to the 
schedule mean that three injections (6 in 1, PCV and 
MenC vaccines) are now recommended at six months 
of age and two GP visits are required on or after 12 
months; the first dose of MMR and the third dose of 
PCV should be given at 12 months of age and at 13 
months of age the third dose of MenC vaccine and Hibb 
should be given (table 1). MenC3 uptake was 93% in 
Quarter 1 2010 but declined to 80% in Quarter 3 2010 
and was 82% in Quarter 4 2010 (figure 2). During 2011 
and 2012, MenC3 increased from 83% in Quarters 1 and 
2 2011 to 87% in Quarter 4 2012. During 2013, MenC3 
uptake was 86% during Quarters 1-3 and was 88% in 
Quarter 4. Hibb was 87% in Quarters 1 and 2 2010 but 
declined to 84% in Quarters 3 and 4 2010 (figure 2). 
During 2011 and 2012 Hibb uptake increased from 86% 
in Quarter 1 2011 to 91% in Quarter 4 2012. During 
2013, Hibb uptake was 89% during Quarters 1 and 2, 
90% in Quarter 3 and 91% in Quarter 4. There was also 
low uptake of PCV3 in 2010 (combined Quarters 3 and 4 
data was 88%). During 2011 and 2012, PCV3 increased 
from 90% during Quarters 1 and 2 2011 to 92% during 
Quarter 4 2012. During 2013, PCV3 uptake was 91% 
during Quarters 1-3 and 92% in Quarter 4.
Uptake rates among the HSE Areas, for children at 24 
months of age in 2013, for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 94% to 98%, MMR1 ranged from 
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Figure 1. National annual immunisation uptake rates (based on available data) at 24 months, 1999-2013
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE NE during 1999, Quarters 3 and 
4 2000 and Quarter 1 2001 and the HSE NW in 2000 and 2001. The 2002 MenC3  figure is based on uptake rates for Quarter 3 and Quarter 4 2002 only. The 2005 
MMR1 uptake figure is incomplete as the HSE E was unable to provide MMR data for Quarter 4 2005, due to technical problems with extraction of MMR1 data from 
the HSE E database.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE E figure, which is an estimate only due to technical problems with extraction of MMR1 
data from the HSE E database.  The 2007 national Hibb figure is incomplete, as the HSE W data for Quarter 1 2007 and the HSE NW data for Quarter 3 2007 were 
not available.  The 2007 national Hibb figure also includes the HSE SE data which are an underestimate due to data extraction methods.  The 2008 Hibb figure is 
incomplete as the HSE SE data for Q2 2008 and the HSE MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as the HSE 
E and HSE MW MenC3 data for Quarter 3 2008 were not available. The 2009 data are incomplete as the following were unavailable: the Quarter 1 2009 HSE E D3, 
T3, P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE E Dublin North Hibb uptake data and; the Quarter 4 2009 HSE MW data, HSE E 
Dublin North Hibb data and HSE SE Hibb data for those given a Hib dose as part of the five in one or six in one vaccine after 12 months of age.  The 2010 data are 
incomplete as the following were unavailable: the Quarter 1 2010 HSE M and HSE S data and the HSE E Dublin North Hibb data; the Quarter 2 2010 HSE M data 
and; the Quarter 4 2010 HSE NE data. As a new childhood immunisation schedule was introduced in 2008, for those born on or after July 1st 2008, the 2010 HepB3 
and PCV3 data at 24 months are for those born between July 1st and December 31st 2008 (i.e. Quarters 3 and 4 2010 data) only.  The MenCb and PCVb data were 
available for only six of the eight HSE Areas.
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Table 4. Immunisation uptake (%) at 24 months of age in 2013 (i.e. cohort born 01/01/2011-31/12/2011) by LHO and HSE Area
HSE Area
Local Health Office/
HSE Area
Number in 
cohort for D3, 
T3 & P3 *
Immunisation Uptake (%)
D3 Hib3 Hibb Polio3 HepB3 MenC3 MenCb PCV3 PCVb MMR1
HSE E
Dublin South 1788 95 95 89 95 95 86 89 90 92 91
Dublin South East 1766 92 92 88 92 92 86 87 89 90 90
Dublin South City 1737 97 97 91 97 97 87 90 92 94 94
Dublin South West 2790 96 96 93 96 96 88 92 91 94 95
Dublin West 2874 96 96 90 96 96 86 89 91 94 93
Dublin North West 4007 93 93 84 93 93 81 84 87 89 89
Dublin North Central 1795 95 95 89 95 95 85 89 89 92 91
Dublin North 4456 95 95 91 95 95 89 91 92 93 93
Kildare/West Wicklow 4154 96 96 92 96 96 90 92 93 95 94
Wicklow 1901 94 94 85 94 94 81 85 89 91 91
HSE E Total 27268 95 95 89 95 95 86 89 91 93 92
HSE M
Laois/Offaly 2683 98 98 98 98 98 91 93 94 95 96
Longford/Westmeath 1986 97 97 97 97 97 91 94 94 97 97
HSE M Total 4669 98 98 98 98 98 91 93 94 96 96
HSE MW
Clare 1748 96 96 95 96 96 92 95 94 95 95
Limerick 2056 95 95 91 95 95 88 90 92 93 93
Tipperary NR/East 
Limerick
1947 96 96 90 96 96 87 90 93 94 94
HSE MW Total 5751 96 96 92 96 95 89 92 93 94 94
HSE NE
Cavan/Monaghan 2220 95 95 87 95 95 85 na 91 na 92
Louth 2027 92 92 85 92 92 82 na 86 na 88
Meath 3748 95 95 86 95 95 84 na 90 na 91
HSE NE Total 7995 94 94 86 94 94 84 na 89 na 90
HSE NW
Donegal 2279 97 97 93 97 95 88 93 92 95 94
Sligo/Leitrim 1391 97 97 95 97 97 88 95 90 95 96
HSE NW Total 3670 97 97 94 97 96 88 94 91 95 95
HSE SE
Carlow/Kilkenny 2102 96 96 96 96 96 89 94 94 95 96
South Tipperary 1389 98 98 98 98 98 92 96 95 96 95
Waterford 1980 95 95 93 95 95 89 92 93 93 94
Wexford 2246 96 96 98 96 97 91 95 94 96 95
HSE SE Total 7717 96 96 96 96 96 90 94 94 95 95
HSE S
North Cork 1487 95 95 85 95 94 86 88 89 89 91
North South Lee 6040 96 95 83 96 95 83 85 90 91 91
West Cork 763 91 90 75 91 90 76 80 86 86 89
Kerry 2023 97 97 87 97 96 89 92 92 94 94
HSE S Total 10313 96 95 83 96 94 84 87 90 91 92
HSE W
Galway 3964 95 95 89 95 95 86 na 91 na 91
Mayo 1770 95 95 91 95 95 82 na 90 na 90
Roscommon 913 99 99 97 99 98 97 na 98 na 98
HSE W Total 6647 96 96 91 96 95 87 na 92 na 92
Ireland 74030 96 95 90 96 95 87 90 91 93 93
*As the denominator/number in cohort varied slightly according to vaccine. The most commonly used number is reported here.
Since T3 and P3 uptake identical to D3 uptake only D3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here
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Figure 2. National quarterly immunisation uptake rates at 24 months
Note scale ranges from 60-100%
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE NE during 
1999, Quarters 3 and 4 2000 and Quarter 1 2001 and the HSE NW in 2000 and 2001. The Q4 2005 MMR1 figure is based on data from seven 
of the eight HSE Areas.  The Q1 2006 MMR1 figure includes the HSE E figure that is an estimate only.  The Q1 2007, Q3 2007, Q2 2008 and Q3 
2008 Hibb figures are based on data from seven of the eight HSE Areas.  In Q1 2008 the HSE SE changed their Hibb data extraction method 
compared to previous quarters; in Q1 2008 the uptake of Hibb in the HSE SE was 83% compared to 53% in Q4 2007.  The Q3 2008 MenC3 
figure is based on data from six of the eight HSE Areas.  The Q1 2009 HSE E D3, P3, T3, Polio3 and MMR1 uptake figures exclude those born 
on the 31/03/2007.  The Q2 2009 HSE E Hibb uptake figures exclude uptake figures from Dublin North.  The Q4 2009 figures are based on data 
from seven of the eight HSE Areas.  The Q4 2009 Hibb figures also exclude uptake figures from Dublin North and HSE SE Hibb data for those 
given a Hib dose as part of the five in one or six in one vaccine after 12 months of age.   The Q1 2010 figures are based on data from six of the 
eight HSE Areas.  The Q1 2010 Hibb figures also exclude uptake figures from HSE E Dublin North.  The Q2 2010 and Q4 2010 figures are based 
on data from seven of the eight HSE Areas.  MenCb and PCVb figures are based on data form six of the eight HSE Areas.
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90% to 96%, PCV3 ranged from 89% to 94%, MenC3 
ranged from 84% to 91% and Hibb ranged from 83-98% 
(table 2). Among the six Areas in a position to provide 
data MenCb uptake ranged from 87% to 94% and PCVb 
uptake ranged from 91% to 96%. The target uptake of 
95% was reached or exceeded in seven HSE Areas during 
2013 for D3, T3, P3, Hib3 and Polio3, in six Areas for HepB3, 
in three for PCVb and MMR1 and in two for Hibb (table 2).
D3, Hibb, MenC3 and MMR1 uptake rates are mapped 
by LHO in figure 3. Among the LHOs the uptake rates 
ranged from 91% to 99% for D3, T3, P3 and Polio3, 90% 
to 99% for Hib3, 90-98% for HepB3, 88% to 98% MMR1, 
86% to 98% for PCV3, 86% to 97% for PCVb, 80% to 
96% for MenCb, 76% to 97% for MenC3 and 75% to 
98% for Hibb (table 4). The target uptake of 95% was 
reached or exceeded in 26 LHOs for D3, T3, P3, Hib3 and 
Polio3, in 25 LHOs for HepB3, in nine LHOs for PCVb and 
MMR1, in eight LHOs for Hibb, in four LHOs for MenCb, 
in two LHOs for PCV3 and in one LHO for MenC3 (table 
4). Roscommon was the only LHO to reach and exceed 
the target of 95% for D3, T3, P3, Hib3, Polio3, HepB3, Hibb, 
MenC3, PCV3 and MMR1 at 24 months.
There was a large decline in MenC3 and a decline in 
Hibb uptake at 24 months in Quarters 3 and 4 2010 
ie children who were born between July 1st and 
December 31st 2008 and were the first recommended 
the new immunisation schedule. There was a change 
in timing of the MenC and Hibb vaccines under the 
new immunisation schedule (table 1). The uptake of 
MenC3 (87%) in particular and Hibb (90%) in 2013 were 
still lower than the uptake of the other recommended 
vaccines. In addition, to low uptake of MenC3 and Hibb, 
MMR1 (93%) and PCV3 (91%) uptake in 2013 are lower 
than the target uptake of 95%.
In contrast in 2013, annual national uptake rates at 24 
months for D3, T3, P3, Hib3, Polio3 and HepB3 reached 
the target rate of 95%. This is the third year national 
annual uptake rates reached the target of 95% for these 
vaccines. Seven HSE Areas reached or exceeded the 
target uptake of 95% for D3, T3, P3, Hib3 and Polio3 at 24 
months during 2013. Roscommon reached or exceeded 
the target of 95% for D3, T3, P3, Hib3, Polio3, HepB3, 
MenC3, PCV3, Hibb and MMR1 uptake at 24 months of 
age.
 
The immunisation reports for Quarters 1 to 4 2013 are 
available on the HPSC website in Topics A-Z under the 
heading vaccination. 
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D3
MenC3
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Table 5. Local Health Office (LHO) abbreviations used in this chapter
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Figure 3. D3, Hibb, MenC3 and MMR1 immunisation uptake rates (%) in those 24 months of age in 2013 by Local Health Office 
(LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see table 5 to translate LHO abbreviations
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs 
their combined immunisation
Local Health Office Abbreviations Local Health Office Local Health Office Abbreviations Local Health Office
HPV vaccine uptake 2012/2013
Background
Following a recommendation from the National 
Immunisation Advisory Committee, that human 
papillomavirus (HPV) vaccine should be given to 12 
year old girls, a routine Health Service Executive (HSE) 
school HPV vaccination programme began in May 2010 
for girls in first year of second level schools and age 
equivalent in non second level schools (see below for 
cohort details). The aim of the programme is to protect 
girls from their future risk of developing cervical cancer.
A catch-up campaign for girls in sixth year of second 
level schools and their age equivalents in non-second 
level schools (see below for cohort details) was added in 
the academic year 2011/2012, this catch-up campaign 
continued during the academic year 2012/2013.
Quadrivalent HPV vaccine, which protects against HPV 
types 6, 11, 16 and 18 associated with 70% of cervical 
cancer, is used in the school vaccination programme. 
A schedule of three vaccine doses given over a six 
month period was recommended in the academic year 
2012/2013. The HPV vaccine does not protect against 
all cervical cancers, so regular cervical screening is still 
needed.
The vaccinations are provided by vaccination teams 
from the Local Health Offices (LHOs) who go into 
schools in their areas to vaccinate or provide vaccination 
clinics free of charge for girls in the target cohorts. 
Please see the HSE National Immunisation Office (NIO) 
website at www.immunisation.ie for detailed and current 
information on the HPV school vaccination programme.
The target for uptake of three doses of vaccine for the 
routine HPV vaccination programme is >80% and the 
target for the catch-up programme is >60% uptake.
HPV vaccinations provided through the schools 
immunisation programme are entered onto a database. 
Here we report on the uptake of HPV vaccine, provided 
through the school immunisation programme and 
recorded on the database, in the academic year 
2012/2013 in Ireland. This is the second HPV report 
from the database which is the result of collaboration 
between NIO, School Immunisation Teams, 
Immunisation Coordinators, Immunisation System 
Administrators, Immunisation administrative staff, HPV 
vaccine working groups and HPSC.
Cohorts for vaccination in the academic year 
2012/2013
The routine and catch-up cohorts for the 2012/2013 
HPV vaccination programme as agreed with the 
Department of Education and Skills was as follows:
Routine HPV Vaccination programme
 All girls in first year of second level schools
 and their equivalents ie those who were born 
between 01/09/2000 and 31/08/2001
o attending special schools or
o registered with the National Educational 
Welfare Board to be home schooled.
Catch up HPV Vaccination Programme
 All girls in sixth year of second level schools
 and their equivalents ie those  who were born 
between 01/09/1994 and 31/08/1995 and
o attending special schools or
o registered with the National Educational 
Welfare Board to be home schooled or
o attending Youthreach and Community 
Training Centres funded by the Department 
of Education and Skills.
Terminology used in this report
At least stage 1 - means a girl had a stage 1 HPV 
8.2 HPV vaccine uptake 2012/2013
Summary
In the academic year 2012/2013, 84.2% of girls in 
first year and 67.4% of girls in sixth year in second 
level schools were recorded as having received 
at least stage 3 HPV vaccine (considered to have 
completed a three dose HPV vaccine course).
In addition, 286 girls in the first year and sixth year 
age equivalent cohorts in non-second level schools 
(ie special schools, Youthreach, Community Training 
Centres, home schooled or out of school) and 
158 girls outside these cohorts recommended for 
vaccination were recorded as having received at least 
stage 3 HPV vaccine.
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vaccine recorded on the database, this girl may or 
may not have had a stage 2 or a stage 3 HPV vaccine 
recorded on the database.
At least stage 2 - means a girl had a stage 2 HPV 
vaccine recorded on the database, she may or may not 
have had stage 1 or a stage 3 HPV vaccine recorded on 
the database.
At least stage 3 - means a girl had a stage 3 HPV 
vaccine recorded on the database, she may or may not 
have had a stage 1 or a stage 2 HPV vaccine recorded 
on the database.
Girls with at least stage 3 are considered to have 
completed a course of vaccination.
Home schooled - refers to girls registered with the 
National Educational Welfare Board to be educated at 
home. These girls were recorded on the database and 
reported here as home schooled.
Out of school - refers to vaccinated girls who were 
neither enrolled in a second level school, special 
school, Youthreach or Community Training Centre nor 
registered with the National Educational Welfare Board 
as ‘home schooled’.
Local Health Office (LHO) - refers to the LHO the 
school is located in (it does not refer to the LHO the girl 
is resident in).
Outside cohort - refers to those who were vaccinated 
but who were not in first year or sixth year of second 
level schools or their equivalents.
The denominator for girls in second level schools was 
defined as the number of girls on the school roll on 30th 
September 2012 for first year in the routine programme 
and for sixth year in the catch-up programme. The 
denominator for age equivalent to first years in second 
level schools in the routine programme was defined 
as girls born between 01/09/2000 and 31/08/2001 on 
the school roll of special schools or registered with the 
National Educational Welfare Board on 30th September 
2012. The denominator for age equivalent to sixth years 
in second level schools in the catch-up programme 
was defined as girls born between 01/09/1994 and 
31/08/1995 on the school roll of special schools or 
registered with the National Educational Welfare Board 
or attending Community Training Centres or Youthreach 
on 30th September 2012. All the denominator data was 
entered on the immunisation database by the relevant 
System Administrator.
Results
Academic Year 2012/2013
The figures presented in this summary are based on 
data recorded on the immunisation system on the 25th 
June 2014. These figures are provisional and subject 
to change due to ongoing updating of data on the 
database.
First year girls in second level schools
In Ireland, 84.2% of girls in first year in second level 
schools were recorded as having received at least 
stage 3 HPV vaccine (considered to have completed a 
three dose course) (Table 1). This is a decline of 1.3% 
compared to the academic year 2011/2012 when 
85.5% of girls in first year in second level schools were 
recorded as having received at least stage 3 HPV 
vaccine.1 Among the 32 Local Health Offices (LHOs), in 
the academic year 2012/2013, uptake of at least stage 
3 HPV vaccine ranged from 58.4% to 96.0%; with four 
recording ≥90.0% uptake and four recording <80.0% 
uptake.
Sixth year girls in second level schools
In Ireland, 67.4% of girls in sixth year in second level 
schools were recorded as having at least stage 3 HPV 
vaccine (Table 2). This is a decline of 4.1% compared 
to the academic year 2011/2012 when 71.5% of girls 
in sixth year in second level schools were recorded as 
having received at least stage 3 HPV vaccine.1 Among 
the 32 LHOs, in the academic year 2012/2013, uptake 
of stage 3 HPV vaccine ranged from 48.7% to 81.0%; 
with one recording ≥80.0% uptake and seven recording 
<60.0% uptake.
Some girls in the catch-up cohort were vaccinated 
privately by General Practitioners or other medical 
agencies following the licensing of HPV vaccines in 
2006/2007 and prior to the announcement in early 2011 
that there would be a HPV catch-up programme. These 
vaccinated girls would be included in the denominator 
data but not in the numbers vaccinated as they were 
not vaccinated as part of the school programme. Some 
LHOs have highlighted this issue: Donegal, Dublin North 
Central, Limerick, Louth, North Tipperary/East Limerick, 
Tipperary South and Wexford.
First and Sixth year second level equivalent cohorts in 
non-second level schools/Outside cohort/Out of school
An additional 444  girls were recorded as having 
received at least stage 3 HPV vaccine (Table 3); of 
these 286 were recorded in the first year routine and 
sixth year catch up age equivalent cohorts in special 
schools, Youthreach, Community Training Centres, 
home schooled or out of school and 158 were recorded 
as being outside the cohorts recommended for 
vaccination.
The target cohort of girls in special schools, Community 
Training Centres, Youthreach, and home schooled 
were identified by birth cohort either equivalent to first 
years (born between 01/09/2000 and 31/08/2001) or 
equivalent to sixth years (born between 01/09/1994 and 
31/08/1995). For operational reasons HSE vaccinating 
staff did not adhere strictly to these birth cohorts. The 
identification of denominator data for the target birth 
cohorts in these settings was difficult and staff focused 
on vaccinations rather than defining cohort numbers 
accurately. Therefore, this report gives the number of 
girls vaccinated in these settings reflecting activity in 
these settings rather than HPV vaccine uptake.
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Table 1. HPV vaccine uptake in the academic year 2012/2013 among first year girls (routine HPV programme) in 
second level schools
HSE Region
Local Health Office/
HSE Region
2012/2013
First year (routine HPV vaccination programme)**
Denominator
Numbers vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin Mid 
Leinster
Dublin South 932 834 831 822 89.5% 89.2% 88.2%
Dublin South East 597 519 518 517 86.9% 86.8% 86.6%
Dublin South City 800 696 686 668 87.0% 85.8% 83.5%
Dublin South West 758 687 678 660 90.6% 89.4% 87.1%
Dublin West 947 812 806 761 85.7% 85.1% 80.4%
Kildare/West Wicklow 1575 1387 1383 1361 88.1% 87.8% 86.4%
Wicklow 724 646 640 635 89.2% 88.4% 87.7%
Laois/Offaly 942 849 844 839 90.1% 89.6% 89.1%
Longford/Westmeath 1049 925 919 896 88.2% 87.6% 85.4%
Total Dublin Mid Leinster 8324 7355 7305 7159 88.4% 87.8% 86.0%
Dublin 
North East
Dublin North 1479 1355 1342 1292 91.6% 90.7% 87.4%
Dublin North Central 651 558 552 532 85.7% 84.8% 81.7%
Dublin North West 1331 969 956 912 72.8% 71.8% 68.5%
Cavan/Monaghan 892 542 535 521 60.8% 60.0% 58.4%
Louth 1019 871 861 842 85.5% 84.5% 82.6%
Meath 1252 1091 1082 1058 87.1% 86.4% 84.5%
Total Dublin North East 6624 5386 5328 5157 81.3% 80.4% 77.9%
South
North Cork 610 536 530 525 87.9% 86.9% 86.1%
North Lee - Cork 1157 1028 1023 941 88.9% 88.4% 81.3%
South Lee - Cork 1122 975 962 940 86.9% 85.7% 83.8%
West Cork 357 282 282 278 79.0% 79.0% 77.9%
Kerry 930 833 826 804 89.6% 88.8% 86.5%
Carlow/Kilkenny 973 910 896 862 93.5% 92.1% 88.6%
South Tipperary 582 553 550 529 95.0% 94.5% 90.9%
Waterford 756 732 729 723 96.8% 96.4% 95.6%
Wexford 1122 951 946 922 84.8% 84.3% 82.2%
Total South 7609 6800 6744 6524 89.4% 88.6% 85.7%
 
West
Donegal 1152 1018 1012 1004 88.4% 87.8% 87.2%
Sligo/Leitrim 628 559 557 551 89.0% 88.7% 87.7%
Galway 1659 1341 1328 1297 80.8% 80.0% 78.2%
Mayo 848 764 759 754 90.1% 89.5% 88.9%
Roscommon 300 292 290 288 97.3% 96.7% 96.0%
Clare 765 697 691 680 91.1% 90.3% 88.9%
Limerick 912 818 809 789 89.7% 88.7% 86.5%
Tipperary NR/
East Limerick
990 910 904 893 91.9% 91.3% 90.2%
Total West 7254 6399 6350 6256 88.2% 87.5% 86.2%
Ireland 29811 25940 25727 25096 87.0% 86.3% 84.2%
The figures presented in this table are based on data recorded on the immunisation system on the 25th June 2014. These figures are 
provisional and subject to change due to ongoing updating of data on the database.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on the database, this girl may or may not have had a stage 2 or a stage 3 
HPV vaccine recorded on the database.  Similarily, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on the database, she 
may or may not have had stage 1 or a stage 3 HPV vaccine recorded on the database. Similarily, ‘at least stage 3’ means a girl had a stage 3 
recorded on the database, she may or may not have had stage 1 or a stage 2 HPV vaccine recorded.
**Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2012/2013.
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Table 2. HPV vaccine uptake in the academic year 2012/2013 among sixth year (catch up campaign) girls in second level 
schools
HSE 
Region
Local Health Office/
HSE Region
2012/2013
Sixth year (catch up campaign)**
Denominator
Numbers vaccinated with: % Vaccinated with:
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
At least 
Stage 1
At least 
Stage 2
At least 
Stage 3
Dublin Mid 
Leinster
Dublin South 837 526 519 505 62.8% 62.0% 60.3%
Dublin South East 550 353 344 335 64.2% 62.5% 60.9%
Dublin South City 843 604 593 557 71.6% 70.3% 66.1%
Dublin South West 677 563 529 477 83.2% 78.1% 70.5%
Dublin West 742 513 478 415 69.1% 64.4% 55.9%
Kildare/West Wicklow 1271 1029 1016 975 81.0% 79.9% 76.7%
Wicklow 572 474 472 450 82.9% 82.5% 78.7%
Laois/Offaly 894 638 625 603 71.4% 69.9% 67.4%
Longford/Westmeath 823 627 619 605 76.2% 75.2% 73.5%
Total Dublin Mid Leinster 7209 5327 5195 4922 73.9% 72.1% 68.3%
Dublin 
North East
Dublin North 1180 684 660 605 58.0% 55.9% 51.3%
Dublin North Central 668 438 427 389 65.6% 63.9% 58.2%
Dublin North West 1071 755 718 642 70.5% 67.0% 59.9%
Cavan/Monaghan 797 478 469 454 60.0% 58.8% 57.0%
Louth 869 457 442 423 52.6% 50.9% 48.7%
Meath 970 667 660 650 68.8% 68.0% 67.0%
Total Dublin North East 5555 3479 3376 3163 62.6% 60.8% 56.9%
South
North Cork 464 371 363 348 80.0% 78.2% 75.0%
North Lee - Cork 1075 817 803 774 76.0% 74.7% 72.0%
South Lee - Cork 1031 762 752 710 73.9% 72.9% 68.9%
West Cork 340 215 213 211 63.2% 62.6% 62.1%
Kerry 923 733 715 689 79.4% 77.5% 74.6%
Carlow/Kilkenny 815 649 637 599 79.6% 78.2% 73.5%
South Tipperary 519 354 342 322 68.2% 65.9% 62.0%
Waterford 703 551 546 539 78.4% 77.7% 76.7%
Wexford 972 689 681 643 70.9% 70.1% 66.2%
Total South 6842 5141 5052 4835 75.1% 73.8% 70.7%
West
Donegal 947 763 758 739 80.6% 80.0% 78.0%
Sligo/Leitrim 526 438 433 426 83.3% 82.3% 81.0%
Galway 1344 1113 1100 1046 82.8% 81.8% 77.8%
Mayo 775 591 582 568 76.3% 75.1% 73.3%
Roscommon 348 236 233 229 67.8% 67.0% 65.8%
Clare 647 476 467 461 73.6% 72.2% 71.3%
Limerick 921 659 637 606 71.6% 69.2% 65.8%
Tipperary NR/East  Limerick 876 529 524 511 60.4% 59.8% 58.3%
Total West 6384 4805 4734 4586 75.3% 74.2% 71.8%
Ireland 25990 18752 18357 17506 72.2% 70.6% 67.4%
The figures presented in this table are based on data recorded on the immunisation system on the 25th June 2014. These figures are 
provisional and subject to change due to ongoing updating of data on the database.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on the database, this girl may or may not have had a stage 2 or a stage 3 
HPV vaccine recorded on the database.  Similarily, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on the database, she 
may or may not have had stage 1 or a stage 3 HPV vaccine recorded on the database. Similarily, ‘at least stage 3’ means a girl had a stage 3 
recorded on the database, she may or may not have had stage 1 or a stage 2 HPV vaccine recorded.
**Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2012/2013.
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Table 3. HPV vaccinations in the academic year 2012/2013 among those in non-second level schools and those outside the 
recommended cohorts in second level schools
HSE 
Region
Local Health Office/ HSE Region
Recommended cohorts** for vaccination and those outside cohort 
in special schools, Youthreach, Community Training Centres, home 
schooled and out of school and those outside cohort in second 
level schools with:
At least Stage 1 At least Stage 2 At least Stage 3
Dublin Mid 
Leinster
Dublin South 19 17 13
Dublin South East 2 2 2
Dublin South City 9 4 4
Dublin South West 18 15 11
Dublin West 18 16 16
Kildare/West Wicklow 32 31 29
Wicklow 10 9 8
Laois/Offaly 10 9 8
Longford/Westmeath 18 11 10
Total Dublin Mid Leinster 136 114 101
Dublin 
North East
Dublin North 5 2 1
Dublin North Central 23 15 6
Dublin North West 31 30 29
Cavan/Monaghan 1 1 1
Louth 11 10 10
Meath 20 19 14
Total Dublin North East 91 77 61
South
North Cork 9 9 9
North Lee - Cork 37 35 32
South Lee - Cork 22 19 15
West Cork 0 0 0
Kerry 12 11 10
Carlow/Kilkenny 39 36 31
South Tipperary 12 12 12
Waterford 34 29 26
Wexford 35 30 24
Total South 200 181 159
West
Donegal 15 14 13
Sligo/Leitrim 7 6 6
Galway 21 20 15
Mayo 13 13 13
Roscommon 6 6 4
Clare 17 14 10
Limerick 54 50 45
Tipperary NR/East Limerick 19 17 14
Total West 152 140 120
Home schooled 3 2 2
Total of LHOs and home schooled 582 514 443
Out of school 1 1 1
Total of LHOs and home schooled and out of School 583 515 444
The figures presented in this table are based on data recorded on the immunisation system on the 25th June 2014. These figures are provisional 
and subject to change due to ongoing updating of data on the database.
Local Health Office refers to the Local Health Office of the school.
‘At least stage 1’ means a girl had a stage 1 HPV vaccine recorded on the database, this girl may or may not have had a stage 2 or a stage 3 
HPV vaccine recorded on the database.  Similarily, ‘at least stage 2’ means a girl had a stage 2 HPV vaccine recorded on the database, she 
may or may not have had stage 1 or a stage 3 HPV vaccine recorded on the database. Similarily, ‘at least stage 3’ means a girl had a stage 3 
recorded on the database, she may or may not have had stage 1 or a stage 2 HPV vaccine recorded.
 **Please see Background section of report for details of cohorts recommended HPV vaccine during the academic year 2012/2013.
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Total doses administered
A total of 132,925 administered vaccine doses were 
recorded in the academic year 2012/2013. This 
compares to 139,646 administered vaccine doses 
recorded in 2011/2012.1
Academic Years 2009/2010 and 2010/2011
HPV vaccine uptake for 2009/2010 and 2010/2011 
cohorts of first year girls vaccinated from May 2010 was 
measured by manual reports and national uptake for 
the combined cohort was estimated at 81.9%.2
Discussion
The uptake of HPV vaccine in Ireland is very 
encouraging and reflects the huge effort and support 
put in by all staff and schools involved in the school 
vaccination programme. Uptake of HPV vaccine 
compares very favourably with estimates in other 
countries that have introduced HPV vaccination and 
monitored uptake.3,4,5,6,7,8,9,10
Acknowledgements
Many thanks to all HSE staff, Department of Education and Skills staff, 
staff in all educational settings, parents and girls, who implemented, 
participated in and supported the school HPV vaccination 
programme.
References
1. HSE. HPV vaccine uptake in Ireland: 2011/2012. Available 
at http://www.hpsc.ie/A-Z/VaccinePreventable/Vaccination/
ImmunisationUptakeStatistics/HPVImmunisationUptakeStatistics/
File,14255,en.pdf.
2. HSE Press Release Friday 6th January 2012. HPV Cervical Cancer 
Vaccination Programme- 82% uptake rate for first full year of the 
vaccination programme. Available at http://www.hse.ie/eng/services/
news/newsarchive/2012archive/jan2012/hpvcervicalcancervaccination.
html
3. Public Health England. Annual HPV vaccine coverage in England: 
2012-13. HPV coverage data of first, second and third dose for 
the routine cohort at 31 August 2013, by PCT and area team (16 
December 2013). Available at https://www.gov.uk/government/
uploads/system/uploads/attachment_data/file/266207/HPV_
AnnualDataTable2012_13_AT_acc5.pdf. Accessed: 26/06/2014.
4. NHS ISD Scotland. HPV Immunisation Uptake Statistics, HPV 
Immunisation Programme – School Year 2012/13. Available 
at https://isdscotland.scot.nhs.uk/Health-Topics/Child-Health/
Publications/2013-09-24/HPV-Report-September-2013.
pdf?12946718932. Accessed: 26/06/2014.
5. Public HealthWales Health Protection Division. Vaccine uptake in 
Children in Wales, January to March 2014:
COVER report 110, June 2014. Cardiff, Public Health 
Wales. Available at http://www2.nphs.wales.nhs.uk:8080/
VaccinationsImmunisationProgsDocs.nsf/($All)/283778A94860F
6DD80257D0100544B59/$File/Cov14q1%20(Report110%20v1).
pdf?OpenElement. Accessed: 26/06/2014.
6. HPA. White J and Das S (2012) Annual HPV vaccine coverage 
in England in 2010/2011. Available at http://media.dh.gov.uk/
network/211/files/2012/03/120319_HPV_UptakeReport2010-11-
revised_acc.pdf Accessed: 26/06/2014.
7. Potts A, Sinka K, Love J, Gordon R, McLean S, Malcolm 
W, Ross D, Donaghy M. High uptake of HPV immunisation in 
Scotland – perspectives on maximising uptake. Euro Surveill. 
2013;18(39):pii=20593. Available online:    
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20593. 
Accessed: 26/06/2014.
8. Australia National HPV Vaccination Program Register. HPV 
Vaccination Coverage 2012. Available at
http://www.hpvregister.org.au/research/coverage-data. Accessed: 
26/06/2014.
9. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene 
J, O’Flanagan D, Lopalco PL, D’Ancona F, Lévy-Bruhl D, on behalf 
of the VENICE 2 project gatekeepers group. The current state of 
introduction of human papillomavirus vaccination into national 
immunisation schedules in Europe: first results of the VENICE2 
2010 survey. Euro Surveill. 2010;15(47):pii=19730. Available online: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19730. 
Accessed: 26/06/2014.
10. CDC. Human Papillomavirus Vaccination Coverage Among 
Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety 
Monitoring, 2006–2013 — United States. MMWR 2013; 62 (29) 591-
595. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm6229a4.htm?s_cid=mm6229a4. Accessed: 26/06/2014. 
-141-HPSC Annual Epidemiological Report 2013 8. Immunisation Uptake
Summary
Uptake in Hospitals during 2013-2014 Season
•   80.7% (46/59) of hospitals (including six private 
ones) participated 
•   Overall, 24.4% of hospital health care workers 
(HCWs) were reported as vaccinated 
•   Vaccine uptake varied by HSE region (range 
15.6%- 35.2%)
•   Highest uptake was reported in Dublin North East 
region
•   Nationally, vaccine uptake varied by staff category 
(18.2%-33.6%)
•   Highest uptake was reported among ‘medical & 
dental’ staff and lowest among ‘nursing’ staff
Uptake in LTCFs during 2013-2014 Season
•   54.1% (131/242 ) of LTCFs participated
•   Overall, 22.8% of LTCF HCWs were reported as 
vaccinated
•   Vaccine uptake varied by HSE region (range 
13.7%- 28.4%)
•   Highest uptake was reported in Dublin Mid 
Leinster region
•   Nationally, vaccine uptake varied by staff category 
(range 17.7%-30.3%)
•   Highest uptake was reported among ‘medical & 
dental’ staff and lowest among ‘management & 
administration’ staff 
Achieving a high uptake of influenza vaccination among 
HCWs is recognised as an important infection control 
intervention and occupational health issue. Vaccination 
is designed to reduce the risk of influenza transmission 
between patients and HCWs with the potential for 
severe disease in both patients and staff. On 8th 
October 2013, the HSE Leadership team reviewed and 
endorsed an action plan to achieve a national influenza 
vaccination target of 40% among HCWs.
A 2013-2014 season based protocol on measuring 
uptake of influenza vaccine among HCWs was posted 
on to the HPSC website on 1st November 2013. 
Separate online survey forms for hospitals and LTCFs 
were designed to capture aggregate data on eligible 
and vaccinated staff and were based on six categories 
of HSE staff: management & administration; medical & 
dental; nursing; health & social care professionals; other 
patient & client care; and general support staff. 
For hospitals, occupational health departments were 
asked to provide data on the number and category of 
HCWs vaccinated by the service with human resource 
departments requested to provide data on the numbers 
of staff employed. For LTCFs, uptake details were 
sought from nominated coordinators on the number of 
staff, residents and respite care patients present and 
vaccinated. 
For the 2013-2014 season, a link to an online form was 
emailed to each nominated coordinator in 53 known 
public hospitals and separately to identified HSE funded 
LTCFs on 8th November 2013. Each coordinator was 
asked to complete the online form using aggregate 
uptake data relating to the previous month. Further 
monthly requests for cumulative seasonal uptake figures 
were made with new online survey forms between 
December 2013 and February 2014 and a final survey 
8.3  Seasonal Influenza Vaccine Uptake 
in Hospitals & Long Term Care 
Facilities (LTCFs)
Table 1. Vaccine uptake (with 95% CIs) among HCWs in participating hospitals and LTCFs by season (2011-2012, 2012-2013, 
2013-2014)
 Hospitals LTCFs
Season
No. Participating 
Hospitals 
% Uptake
% Uptake 
95% CIs
No. Participating 
LTCFs
% Uptake
% Uptake 
95% CIs
2011-2012 41 18.0 17.1-18.8 70 17.7 15.1-20.2
2012-2013 35 17.4 17.1-17.8 137 14.4 12.9-15.9
2013-2014 46 24.4 24.0-24.7 118 22.8 21.3-24.2
Note: All 46 participating hospitals in 2013-2014 season provided both eligible and vaccinated staff details (including four out of six private 
hospitals), but of the 131 participating LTCFs during the same season, only 118 (90.1%) provided these details to allow vaccine uptake 
to be calculated.
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seeking aggregate data for the for the entire season 
was sent in early May 2014. 
For the 2013-2014 influenza season, vaccination uptake 
among HCWs in hospitals and LTCFs was monitored 
and comparisons made with estimated uptakes for the 
previous 2011-2012 and 2012-2013 seasons (table 1).
Figures 1 to 4 below give details of vaccine uptake 
among HCWs based in hospitals and LTCFs over the 
past three seasons by category of staff and HSE region. 
The highest hospital uptake was reported in Dublin 
North-East region and the lowest in the Western 
region. Overall, a statistically significant increased 
uptake between seasons 2011-2012 and 2013-2014 
was seen across all hospital staff categories: health and 
social care professionals (+10.2%); medical and dental 
staff (+10.1%); management and administration staff 
(+8.1%); nursing (+5.9%); general support staff (+4.5%); 
and other patient and client care professionals (+2.6%). 
The highest LTCF uptake was reported in Dublin Mid 
Leinster region (28.4%) with the lowest in the Southern 
region (13.7%). Only Dublin North East region exhibited 
an increasing uptake trend among LTCFs since the 
2011-2012 season. A statistically significant increased 
uptake across all staff categories, with the exception 
of management and administration, was observed 
between 2012-2013 and 2013-2014: health and social 
care professionals (+18.8%); medical and dental staff 
(+16.5%); nursing (+9.3%); general support staff (+8.2%) 
and other patient and client care professionals (+8.1%). 
Twenty-five (21.2%) of LTCFs in 2013-2014 exceeded 
the 40% national uptake target.
Among the most notable improvements in uptake 
during the 2013-2014 season compared to the previous 
one was:
•   An increase in hospital participation from 35 to 46 
(all of which had provided complete eligible and 
vaccinated staff details)
•   A 7% increase in uptake among hospital staff 
nationally to an overall uptake of 24.4%
•   An 8.4% increase in uptake among staff in LTCFs to 
an overall uptake of 22.8%
•   An 11.3% increase in uptake among long stay 
residents to an overall uptake of 84.3%
•   A 16.4% increase in uptake among respite residents 
(vaccinated either prior to admission or within the 
facility itself) to an overall uptake of 32.1% 
•   An increase in the number of LTCFs with a policy 
recommending vaccination of respite residents prior 
to their admission from 11 to 24 LTCFs reporting such 
policies
Some reductions in uptake were also observed in LTCFs 
between 2012-2013 and 2013-2014 in relation to: 
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Figure 1. Hospital staff uptake by HSE grade category in 
2011-2012 (Hospital n= 41), 2012-2013 (n=35) and 2013-2014 
(n=46) seasons
Figure 2. Hospital staff uptake by HSE region in 2011-2012 
(Hospital n= 41), 2012-2013 (n=35) and 2013-2014 (n=46) 
seasons
Figure 3. LTCF staff uptake by HSE grade category in 2011-
2012 (LTCF n=70), 2012-2013 (n=137) and 2013-2014 (n=118) 
seasons
Figure 4. LTCF staff uptake by HSE region in 2011-2012 (LTCF 
n=70), 2012-2013 (n=137) and 2013-2014 (n=118) seasons
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•   Participation of LTCFs declining from 183 to 131 (a 
fall of 28.4%)
•   Uptake among management and administration staff 
falling from 22.3% to 17.7%
Reasons for failing to meet an overall target of influenza 
vaccine uptake of 40% among staff were not specifically 
sought during the 2013-2014 data collection survey. 
The national uptake among hospital staff was somewhat 
higher that the overall uptake reported among LTCFs. 
This lack of substantial difference occurs against 
different organisational structures for vaccination in 
these services. In theory, one would expect uptake 
to be substantially higher in hospitals that are more 
likely than LTCFs to have their own occupational health 
departments to facilitate staff vaccination clinics. In the 
LTCFs, the absence of site specific vaccination policies, 
despite national recommendations1, may reflect a 
lack of awareness at senior management level about 
the value of having vaccination policies to enable and 
support vaccination for staff. 
The World Health Organization have stated that 
annual  vaccination is especially important for people 
at higher risk of serious influenza complications, and for 
people who live with or care for high risk individuals.2 
In Ireland, more action is required to reach a national 
HSE target of 40% vaccination uptake among HCWs if 
unnecessary disease and mortality is to be prevented. 
Other countries have already achieved uptake rates 
beyond our target. For example, in England during 
the 2013-2014 season, uptake among frontline HCWs 
was 54.8%.3 In the United States, 81.8% of hospital-
based health care professionals were reported to be 
vaccinated during the same season.4
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Vaccine uptake in Junior Infants during the 
2012/2013 academic year
Background
Uptake of the DTaP-IPV* and MMR vaccines in 4 to 
5 year old schoolchildren was monitored across all 
Local Health Offices (LHOs) during the academic 
year 2012/2013 and the findings compared to those 
reported for the previous 2011/2012 season.
HSE- versus GP-vaccine administered LHOs
During both seasons, the administration of the DTaP-
IPV vaccine was performed by GPs based in the 
following LHOs: Louth, Cavan/Monaghan, Meath, 
Dublin North Central, Galway, Mayo, Donegal and 
Sligo/Leitrim. These same LHOs, apart from Galway 
and Mayo, also had GPs administer the MMR vaccine 
to the same cohort of children. In all other LHOs, the 
administration of vaccines was performed by HSE 
public health personnel. Only the Dublin Mid Leinster 
and Southern regions were exclusively HSE-vaccine 
administered regions, unlike the Dublin North East and 
Western regions, which were a combination of HSE- 
and GP-vaccine administered regions.
Target populations in the 2011/2012 and 2012/2013 
academic years
For the 2012/2013 academic year, the target population 
in HSE-vaccine administered LHOs was all children 
in Junior Infants on the school register on the 30th 
September 2012. For GP-vaccine administered LHOs, 
the target population was all children born between the 
1st September 2006 and 31st August 2007. 
In 2011/2012, the target population in HSE-vaccine 
administered LHOs was less well defined as Junior 
Infants on the school register during that academic 
year. Similarly, in GP-vaccine administered LHOs, the 
target population were simply children aged 4 to 5 
years.
The different ways in which the target populations 
have been defined in the HSE- and GP-vaccinated 
administered LHOs has meant that a national uptake 
for either vaccine could not be calculated for the 
2012/2013 or 2011/2012 academic years.
Uptake of DTaP-IPV vaccine
Between 2011/2012 and 2012/2013, the uptake of the 
DTaP-IPV vaccine in HSE-vaccine administered LHOs 
increased from 89.1% to 90.7% in Dublin Mid Leinster, 
from 83.5% to 87.1% in Dublin North East and from 
82.0% to 90.4% in the Southern region, but fell from 
92.1% to 89.7% in the Western region. Overall, DTaP-
IPV uptake across all HSE-administered LHOs increased 
from 86.2% to 90.4%.
During the same period of time, DTaP-IPV uptake in 
GP-vaccine administered LHOs fell from 79.3% to 
73.9% in Dublin North East and from 73.0% to 59.8% in 
the Western region. It should be noted that there was 
no uptake data reported by Louth, Cavan/Monaghan 
and Meath during 2011/2012 or by Mayo during 
2012/2013. Overall, GP-administered DTaP-IPV uptake 
decreased from 73.8% to 67.6%.
Uptake of MMR vaccine
Between 2011/2012 and 2012/2013, the uptake of 
the MMR vaccine in HSE-vaccine administered LHOs 
increased from 89.1% to 90.6% in Dublin Mid Leinster, 
from 82.8% to 86.8% in Dublin North East, from 78.5% 
to 83.1% in the Southern region and from 81.6% to 
92.3% in the Western region. Overall, HSE-administered 
MMR uptake increased from 83.7% to 89.1%.
In GP-vaccine administered LHOs, uptake fell from 
79.3% to 73.2% in Dublin North East, but increased 
from 86.6% to 90.3% in the Western region. During 
2011/2012, no MMR uptake data was available for 
Louth, Cavan/Monaghan and Meath. Overall, GP-
administered MMR uptake decreased from 84.6% to 
78.2%.
It is hoped that the limitation of GP-vaccine 
administered only LHOs to Donegal and Sligo/Leitrim 
in 2013/2014 will lead to further overall increases in 
uptake for both vaccines.
Details of the uptake of the two vaccines in the 
HSE- and GP-vaccinated LHOs during 2012/2013 are 
presented in Table 1 and in the maps in Figure 1.
* DTaP-IPV = Diphtheria, Tetanus, acellular Pertussis 
and Polio vaccine
8.4  Uptake of other childhood and 
adolescent vaccines 
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Figure 1. LHO Maps of DTaP-IPV & MMR vaccine uptake at 
Junior Infants level during the 2012/2013 academic year
HSE-DTaP-IPV Vaccine Administered LHOs HSE-MMR Vaccine Administered LHOs
GP-DTaP-IPV Vaccine Administered LHOs GP-MMR Vaccine Administered LHOs
Tdap vaccine uptake during the 2012/2013 academic 
year
The National Immunisation Advisory Committee 
recommends vaccination with tetanus and low-dose 
diphtheria and acellular pertussis (Tdap) vaccine 
at 11-14 years of age. Tdap vaccine uptake in the 
academic year 2012/2013, provided through the 
school immunisation programme for those in first 
year of second level schools and their equivalents in 
non-second level schools (i.e. special school, home 
schooled and out of school), and recorded on a national 
immunisation IT system are presented in table 2. The 
vaccinations are provided by vaccination teams from 
the Local Health Offices (LHOs) who go into schools in 
their areas to vaccinate. Data on vaccination is inputted 
into the national immunisation IT system at a local level. 
Delays in data inputting may impact on the accuracy 
of uptake data extracted from the system. Please see 
the HSE National Immunisation Office (NIO) website 
at www.immunisation.ie for detailed and current 
information on the school vaccination programme.
The data presented here are the result of collaboration 
between NIO, School Immunisation Teams, 
Immunisation Coordinators, Immunisation System 
Administrators, Immunisation administrative staff and 
HPSC.
The figures presented in this summary are based on 
data recorded on the national immunisation system on 
the 24th September 2014. These figures are provisional 
and subject to change due to ongoing updating of data 
on the database.
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Table 2. Tdap uptake data in the academic year 2012/2013 (provisional data)
HSE Region Local Health Office/HSE Region
2012/2013
First year in second level and equivalent in 
special schools, home schooled and out of 
school (Routine cohort)
Outside cohort
Denominator
Numbers 
vaccinated 
with Tdap:
% Vaccinated 
with Tdap: Denominator
Numbers 
vaccinated 
with Tdap:
Dublin Mid Leinster
Dublin South 1947 1455 74.7% N/A 2
Dublin South East 1164 889 76.4% N/A 9
Dublin South City 1432 1159 80.9% N/A 6
Dublin South West 1707 1355 79.4% N/A 487
Dublin West 1935 1344 69.5% N/A 38
Kildare/West Wicklow 3377 2825 83.7% N/A 20
Wicklow 1483 1187 80.0% N/A 4
Laois/Offaly - - - N/A -
Longford/Westmeath - - - N/A -
Total Dublin Mid Leinster 13045 10214 78.3% N/A 566
Dublin North East
Dublin North 2943 2542 86.4% N/A 8
Dublin North Central 1479 1008 68.2% N/A 1
Dublin North West 2402 1727 71.9% N/A 0
Cavan/Monaghan 1805 1149 63.7% N/A 1
Louth 2036 1398 68.7% N/A 5
Meath 2340 742 31.7% N/A 1665
Total Dublin North East 13005 8566 65.9% N/A 1680
South
North Cork 1208 991 82.0% N/A 2
North Lee - Cork 2472 2147 86.9% N/A 4
South Lee - Cork 2250 1973 87.7% N/A 3
West Cork 728 606 83.2% N/A 0
Kerry 1908 1650 86.5% N/A 0
Carlow/Kilkenny 1927 1800 93.4% N/A 111
South Tipperary 1148 1045 91.0% N/A 8
Waterford 1622 1592 98.2% N/A 7
Wexford 2165 1944 89.8% N/A 20
Total South 15428 13748 89.1% N/A 155
West
Donegal 2289 2025 88.5% N/A 1
Sligo/Leitrim 1229 1175 95.6% N/A 3
Galway 2946 2212 75.1% N/A 1
Mayo 1742 1260 72.3% N/A 132
Roscommon - - - N/A -
Clare 1451 1281 88.3% N/A 3
Limerick 1887 1420 75.3% N/A 96
Tipperary NR/East Limerick 1908 1677 87.9% N/A 6
Total West 13452 11050 82.1% N/A 242
Homeschooled 0 1 0 N/A 1
Total of LHOs and home schooled 54930 43579 79.3% N/A 2644
Out of School N\A 1 N\A N/A 0
Total of LHOs and home schooled and out of school N\A 43580 N\A N/A 2644
Outside cohort refers to those who were vaccinated but who were outside the routine cohort for vaccination
Please note at the time of running this report Tdap vaccinations in Laois/Offaly, Longford/Westmeath and Roscommon were not recorded 
on the national database therefore their denominator numbers (i.e. numbers eligible for vaccination) are excluded here from the total 
denominator and calculation of percentage uptake figures.
Local health office (LHO) refers to the LHO of the school. Therefore, in reports the LHOs of homeschooled and out of school children do not 
appear
N/A-Not applicable
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MMR vaccine catch-up campaign
In Ireland the first dose of MMR vaccine is 
recommended for children at 12 months of age. A 
second dose of MMR is recommended at four to five 
years of age. A MMR catch-up campaign started in 
October 2012 and continued during 2013. During the 
MMR catch up campaign the HSE offered a dose of 
MMR vaccine to second level students and primary 
school children who had not completed (or were 
not sure they had) their two dose MMR vaccination 
schedule. In Ireland this campaign was in response to 
measles and mumps outbreaks among those who had 
not received their recommended two MMR vaccine 
doses. It is also part of the World Health Organization 
campaign to eliminate measles and congenital rubella. 
Please see the NIO website at
www.immunisation.ie for detailed and current 
information on the school vaccination programme.
MMR catch-up data entry was not complete at the 
time of writing this report and therefore MMR catch-up 
uptake data are not reported on here.
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9.1.1 Clostridium difficile Infection
Notifiable C. difficile infection 
In May 2008, new cases of CDI in persons two years or 
older became notifiable in Ireland under the disease 
category “acute infectious gastroenteritis” (AIG). Since 
January 2012, CDI has become a notifiable infection in 
its own category, with both new and recurrent CDI cases 
now notifiable.  
In 2013, 1,835 cases of CDI were notified to Public 
Health Departments via the Computerised Infectious 
Diseases Reporting (CIDR) system. Of those, 1,668 
(91%) were classified as new, 146 (8%) as recurrent, with 
21 (1%) of unknown case type (Table 1).  All cases were 
laboratory-confirmed.
The national crude incidence rate (CIR) of new CDI 
cases in 2013 was 37.5 per 100,000 population, an 
increase of 2.7% from 36.6 per 100,000 population in 
2012 (Table 1). Taking both new and recurrent cases 
into account, the overall CIR for 2013 was 41.3 per 
100,000 population, which is similar to the reported rate 
in 2012 (41.1).
Since surveillance began in 2008, there has been a 
decrease in the incidence of CDI in Ireland (Table 1, 
Figure 1).  Since 2012, the CDI incidence rate has 
remained stable. Fewer recurrent cases were notified in 
2013 (n=146) compared to 2012 (n=179).  Identification 
9.1.0  Healthcare-associated infections 
(HCAI)
Key Points
•   In 2013, 1,835 cases of Clostridium difficile 
infection (CDI) were notified. Of those, 1,668 
(91%) were classified as new cases, 146 
(8%) as recurrent, with 21 (1%) of unknown 
case type. This represents a national crude 
incidence rate of 41.3 cases per 100,000 
population, which is similar to the rate 
reported in 2012 (41.1)
•   Of the 1,835 CDI cases, 1,240 (68%) were 
reported from patients aged 65 years or older
•   The voluntary enhanced CDI surveillance 
scheme received information on 1,801 CDI 
cases from 50 hospitals, covering 89% of all 
cases notified to Public Health Departments. 
Of those, 875 were healthcare-associated, 
representing a national CDI incidence rate of 
2.4 cases per 10,000 bed days used for 2013, 
a decrease from 2.7 in 2012 
•   Data collected on patient location at symptom 
onset highlights that CDI is not confined to 
acute healthcare facilities. It is commonly 
encountered in long term care facilities (11% 
of all CDI) and in the community (29% of all 
CDI) 
•   Of 258 C. difficile isolates with available 
ribotyping data (14% of all cases) reported 
from 19 hospitals, the most frequent ribotypes 
were: 078 (n=45; 17%), 014 and 001/072 
(both n=24; 9%), 005 (n=18; 7%), 015 and 002 
(both n=12; 5%)
Figure 1. Numbers of CDI notifications by month and case 
type, 2008 – 2013. (Source: CIDR)
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of seasonal patterns from CIDR notification data 
is hindered by delayed and batched laboratory 
notifications.
The majority of patients with CDI were female (61%).  
The mean age was 68 years (range: 2 – 99 years), with 
1,240 cases (68%) reported in patients aged 65 years 
and older.  
Regarding patient location at the time of CDI diagnosis, 
most were classified as ‘hospitalised’ (73%), with 14% 
from general practice, 5% from outpatients or day 
patients, 5% from the emergency department and 4% 
from either ‘other’, or ‘unknown’ patient location. This 
is similar to that reported in 2012. However, this data 
does not provide information on the origin or onset 
of CDI, as that information is collected as part of the 
enhanced CDI surveillance scheme. 
In 2013, 28 deaths were reported in patients with CDI, 
which is similar to that reported in 2012. Two deaths 
were attributed to CDI, 16 were not attributed to CDI 
and for the remaining 10 deaths, the contribution of 
CDI to death was unknown. 
Notifiable C. difficile infection: Outbreaks
In 2013, six CDI outbreaks, all healthcare-associated 
and involving 30 patients, were notified to Public Health 
Departments as displayed in Table 2. Five were linked 
to hospitals, and one to a residential institution.
Enhanced surveillance of C. difficile infection
Although notifiable CDI data provides important 
preliminary information on the burden of CDI in Ireland, 
it represents an underestimate of the true burden of 
CDI, as it does not capture information on the origin, 
onset or severity of CDI. National collation of C. difficile 
enhanced surveillance information commenced on a 
voluntary basis on 1st August 2009. Information on case 
type, origin, onset and infection severity is collected 
using the European Society for Clinical Microbiology 
and Infectious Diseases Study Group on C. difficile 
(ESCMID-ESGCD) interim case definitions.  To the end 
of 2013, 50 acute hospitals participated in the voluntary 
enhanced surveillance CDI scheme, comprising 42 
public hospitals [26 general (100%), nine tertiary (100%) 
and seven specialist hospitals (58%)] and eight private 
hospitals (67%). 
In 2013, 1,801 CDI cases were reported to the 
enhanced surveillance scheme (89% of all the CDI 
cases notified via CIDR). Of those, 1,523 (84.5%) were 
classified as new, 154 (8.5%) as recurrent and 124 (7%) 
of unknown CDI case type. 
Of the reported cases, 49% (n=875) originated within 
the reporting healthcare facility. The overall national 
CDI incidence rate of new and recurrent cases 
combined, acquired within the reporting healthcare 
facility was 2.4 cases per 10,000 bed days used (BDU), 
a decrease from 2.7 in 2012. The incidence rate of new 
CDI was 2.2 cases per 10,000 BDU, a decrease from 2.4 
in 2012. The incidence of recurrent cases remained at 
0.2 cases, unchanged from 2012. The CDI rate is based 
on the number of new and recurrent CDI cases that 
originated in the participating healthcare facility (both 
public and private hospitals). The rate is calculated 
using acute public hospital activity data from the HSE 
Business Intelligence Unit, Corporate Planning and 
Corporate Performance (CPCP), with private hospital 
activity data provided directly by participating hospitals. 
Since enhanced surveillance began in 2009, the national 
CDI rate has declined from 3.1 cases per 10,000 BDU 
(2009) to 2.8 (2010), with an increase to 3.0 (2011). 
Since 2011, the rate further decreased from 2.7 (2012) 
to 2.4 (2013) (Figure 2). 
Caution should be taken when interpreting national CDI 
trends, particularly prior to 2012 due to: 
(i)  Changes in the numbers of participating hospitals, 
as displayed in Figure 2. Throughout 2012, the total 
number of hospitals participating in enhanced CDI 
surveillance stabilised. In 2012 and 2013, there was 
complete participation in CDI enhanced surveillance 
by all tertiary and general hospitals
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Table 1. CDI notifications by year and case type, 2008 – 2013
(Source: CIDR)
Number of CDI 
cases notified
CDI rate per 
100,000 population
New Recurren Unknown To al
New CDI 
rateb
Total CDI 
ratec
2008 
(Wks19-53)a
1609 - - 1609 59.2 -
2009 1900 - - 1900 42.8 -
2010 1692 - - 1693 38.1 -
2011 1847 - - 1848 41.6 -
2012 1624 179 25 1828 36.6 41.1
2013 1668 146 21 1835 37.5 41.3
a The CDI rate from 2008 was adjusted for the year; b The new CDI 
rate is based on new cases of CDI only. C The total CDI rate is based 
on both new and recurrent cases of CDI. The CDI rate from 2008 was 
based on the 2006 census data, the data from 2009 onwards was 
based on 2011 census data
Table 2. CDI outbreaks reported in Ireland in 2013 by public 
health region (Source: CIDR)
Public Health Region Outbreak location Total number ill
West Hospital 7
West Hospital 7
West Hospital 6
South Residential insitution 2
South Hospital 5
NorthWest Hospital 3
(ii)  Changes in C. difficile laboratory testing protocols. 
Throughout 2012 and 2013, there were fewer 
changes in laboratory testing protocols. Please 
also refer to the section on laboratory testing of C. 
difficile in Ireland.  
There was a wide range in the incidence of CDI among 
participating hospitals in 2013 (range, 0 – 6.8 cases 
per 10,000 BDU; median = 1.8 cases). In 2013, tertiary 
hospitals (n = 9) had a median CDI rate of 2.6 cases per 
10,000 BDUs (range: 2.1 – 3.8), which was higher when 
compared to that of general hospitals (n = 27), with 
a median rate of 2.0 (range: 0 – 6.8). Since 2011, the 
median CDI rate in both tertiary (3.0 to 2.6 cases per 
10,000 BDU) and general hospitals (2.4 to 2.0 cases per 
10,000 BDU) declined.
The differences in CDI median incidence rates 
may reflect inter-hospital variation with regard to 
patient case mix, C. difficile ribotypes, laboratory 
testing protocols, antimicrobial prescribing policies, 
antimicrobial stewardship interventions and surveillance 
resources. No obvious seasonal trend for CDI is 
distinguishable from enhanced surveillance data in 
2013.
The percentage coverage of acute hospital activity was 
calculated using bed days used data from participating 
hospitals as a percentage of total acute hospital bed 
days used activity in Ireland
Severe CDI
A severe case of CDI is defined as (i) a patient requiring 
admission to an intensive care unit (ICU) for treatment 
of CDI or its complications, (ii) a patient requiring 
colectomy or (iii) death within 30 days after diagnosis, if 
CDI is either the primary or contributory cause of death. 
The enhanced CDI surveillance scheme does not collect 
information on patient outcome. Therefore, surgery and 
ICU admission for CDI are the two markers of severity 
captured via enhanced surveillance. In 2013, 31 (1.7%) 
severe CDI cases were reported, similar to 2012 (1.5%). 
Six patients required both surgery and ICU admission, 
six required surgery only and 19 required ICU admission 
without surgery. 
Onset & Origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
Sixty percent (n=1,088) of patients had CDI symptom 
onset in a healthcare facility (healthcare-onset), 29% 
(n=520) had symptom onset in the community and for 
11% (n=193), location at CDI onset was unknown  
(Table 3). 
Of the 1,088 patients with healthcare onset CDI, 75.3% 
(n=819) had onset in the reporting hospital, 2.4% (n=26) 
in another hospital, 18% (n=196) in a long term care 
facility (LTCF) and for the remaining 4% (n=47) onset 
location was unknown. 
Between 2011 and 2013, there was a decrease in the 
proportion of patients with CDI symptom onset in a 
healthcare facility (71 to 60%), with the exception of 
LTCFs, where an increase was noted (14 to 18%). While 
community onset remained unchanged over this period, 
an increase in the proportion with unknown location of 
symptom onset was observed (2 to 11%) (Table 3). 
Origin: Location where the patient acquired the CDI
For the majority of CDI cases, the infection was acquired 
in a healthcare setting (healthcare-associated) (n=1,145; 
64%). Community-associated cases accounted for 18% 
(n = 324) and in 5% (n = 87) the origin could not be 
assigned as either healthcare or community-associated, 
as the patient had been discharged from a healthcare 
facility between four and 12 weeks prior to the CDI 
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Figure 2. Quarterly national rate of healthcare-associated CDI 
(new and recurrent): 2009 – 2013
The percentage coverage of acute hospital activity was calculated using 
bed days used data from participating hospitals as a percentage of total 
acute hospital bed days used activity in Ireland
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ONSET: Location of where patient 
symptoms occurred
Healthcare-onset 71 64 60
Breakdown of healthcare-onset cases:
Within reporting hospital 78 77 76
Other hospital 6 4 2
Nursing home/LTCF 14 16 18
Unknown 1 3 4
Community-onset 27 30 29
Unknown 2 6 11
ORIGIN: Location of where infection 
was acquired
Healthcare-associated 74 68 64
Breakdown of healthcare-associated 
cases:
Within reporting hospital 78 76 76
Other hospital 8 6 5
Nursing home/LTCF 13 15 17
Unknown 1 3 2
Community-associated 20 17 18
Indeterminate 3 5 5
Unknown 4 10 14
  
Table 3. Origin and onset of CDI, 2011 – 2013
onset date. For the remaining 14% (n = 245) of cases, 
the origin was unknown (Table 3).
Of the 1,145 healthcare-associated CDI cases, 76% 
(n=875) originated in the reporting hospital, 5% (n=53) 
originated in a hospital other than the reporting hospital, 
17% (n=189) originated in a LTCF and 2% (n=28) 
originated in another unspecified healthcare facility or 
were of unknown origin.
Between 2011 and 2013, there was a decrease in the 
proportion of cases associated with a healthcare facility 
(74 to 64%), in particular for the reporting hospital 
and other hospital categories. However an increase in 
cases associated with LTCFs was reported (13 to 17%). 
There was little change in cases classified as community-
associated or indeterminate, while cases classified as 
‘unknown’ increased (4 to 14%) (Table 3).     
Of the 1,145 cases of healthcare-associated CDI:
•   88.5% (n=1,013) experienced onset of CDI symptoms 
at least 48 hours following admission to a healthcare 
facility (healthcare-onset, healthcare-associated)
•   11.2% (n=128) experienced symptom onset in the 
community, within four weeks of discharge from a 
healthcare facility (community-onset, healthcare-
associated)
•   0.3% (n = 4) had no information recorded on symptom 
onset
Of the 324 cases of community-associated CDI: 
•   89% (n=289) experienced CDI symptom onset while 
outside a healthcare facility and without a history of 
discharge from a healthcare facility within the previous 
12 weeks
•   10% (n=33) experienced symptom onset within the 
first 48 hours of admission to a healthcare facility, 
without a history of admission to or residence in a 
healthcare facility within the previous 12 weeks 
•   1% (n = 2) had no information recorded on symptom 
onset
Information was also captured on the location where 
the patient’s faeces specimen was taken. The reporting 
hospital accounted for the majority (76%) of specimens 
(n=1,379), with 10% (n=179) taken in the GP surgery, 
11% (n=203) in LTCF and 2% (n=28) in a hospital other 
than the reporting hospital. For the remaining 1% 
(n=12), no information was provided.
Discussion
The collation of national data on C. difficile through 
CIDR notifications and the enhanced CDI surveillance 
system has provided a valuable insight into the burden 
of CDI in Ireland. Both surveillance systems present 
a similar decreasing trend since 2009. The notifiable 
surveillance system, which reflects total burden of 
disease, shows that the CDI rate stabilised in 2012 
and 2013, while the enhanced surveillance system 
shows a decrease in the CDI rate during this time 
period, including a decrease in the number of new CDI 
cases acquired in an acute hospital. The reasons for 
this decrease are unknown, but may be attributed to 
improved hand hygiene compliance and other infection 
control practices, changes in antimicrobial prescribing or 
changes in laboratory testing practices. 
In 2013, recurrent CDI accounted for 8.5% of 
notifications through the enhanced surveillance scheme, 
a slight decrease from 9.2% in 2012. Recurrent CDI 
may result in severe infection, places a further burden 
on limited hospital isolation resources and results in 
significant patient morbidity. 
CDI is not confined to acute healthcare settings and 
is increasingly common in LTCF and the community. 
In 2013, 11% of cases had onset in LTCF, with 29% 
having onset in the community. Of the 324 community-
associated cases reported in 2013, 89% experienced 
CDI symptom onset in the community, without a 
history of discharge from a healthcare facility within the 
previous 12 weeks. It is important to consider CDI in 
the differential diagnosis of all patients presenting with 
diarrhoea of potentially infectious origin and to send 
specimens in a timely fashion for laboratory diagnosis. 
 
C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are requested to provide 
C. difficile PCR ribotyping information, where available. 
Ireland does not yet have a national C. difficile reference 
laboratory or ribotyping service. Therefore, laboratories 
submit specimens abroad for ribotyping. In 2013, 
ribotyping data was provided for 258 C. difficile isolates 
(14% of all samples) from 19 hospitals. 
The most common ribotypes reported in 2013 were: 
078 (n=45; 17%), 014 and 001/072 (both n=24; 9%), 005 
(n=18; 7%), 015 and 002 (both n=12; 5%) (Figure 3). In 
2013, one tertiary hospital reported that 60% of all C. 
difficile isolates were ribotyped, with a similar pattern of 
ribotypes to the national picture.
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Figure 3. Most frequently reported C. difficile ribotypes in 
Ireland: 2010 – 2013
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Laboratory Testing of C. difficile in Ireland
Since 2010, information on C. difficile testing has been 
collected quarterly as part of the enhanced surveillance 
system. In the first quarter of 2010, the majority of 
hospitals participating in the enhanced surveillance 
project were using a one step Toxin EIA (60%). In 
the last quarter of 2013, this had reduced to 18%. A 
gradual increase in the use of more sensitive testing 
approaches, such as PCR has been observed: 0% (Q1 
2010) versus 61% (Q4 2013) (Figure 4). 
Owing to considerable variations in current Irish 
laboratory C. difficile testing methodologies, inter-
hospital comparison of CDI rates is not recommended 
where testing methods differ, as the data in the 
national quarterly enhanced surveillance reports are 
not adjusted for differences in the sensitivities of the 
different diagnostic methodologies.
Conclusion
The continued excellent participation in the voluntary 
CDI enhanced surveillance scheme ensures that a 
significant amount of information is collected regarding 
the burden of CDI in Ireland. 
The updated National Clinical Guidelines on the 
Surveillance, Diagnosis and Management of CDI in 
Ireland were updated in 2013 and endorsed by the 
National Clinical Effectiveness Committee in 2014. The 
updated guidelines may be accessed on the HPSC 
website at:
www.hpsc.ie/A-Z/Gastroenteric/Clostridiumdifficile/
Guidelines/.
-154-HPSC Annual Epidemiological Report 2013 Healthcare Associated Infections
Figure 4. Changes in C. difficile laboratory testing protocols: 
2010 - 2013
1 STEP: Toxin EIA: EIA for the detection of C. difficile TcdA and/or 
TcdB. 1 STEP: PCR for toxin gene: Polymerase chain reaction (PCR) 
for the detection of TcdA and/or TcdB genes; 2 STEP: GDH AND 
TOXIN EIA: Enzyme immunoassay (EIA) for the detection of glutamate 
dehydrogenase (GDH) of C. difficile as well as or followed by an EIA 
for the detection of C. difficile TcdA and/or TcdB.; 2 STEP: GDH EIA 
AND Toxin PCR: EIA for the detection of GDH of C. difficile as a first 
screening test followed by a PCR for the detection of TcdA and/or 
TcdB genes.
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Summary
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In May 2013, 9,318 residents in 190 Irish long-term 
care facilities (LTCF) were included in a European 
point prevalence survey (PPS) of healthcare-
associated infections (HCAI) and antimicrobial use. 
The survey is also known as the HALT survey. 
•   Of the 190 LTCF, the majority were owned by 
the Health Service Executive (HSE) [n=128; 67%], 
followed by private [n=39; 21%] and voluntary 
services [n=23; 12%]
•   The median capacity of participating LTCF was 
46 beds (range = 5 – 203) and the median bed 
occupancy on the HALT survey date was 94%
•   Overall, single room accommodation accounted for 
a median of 34% of available beds. The proportion 
of single room accommodation was much lower in 
HSE-owned than privately-owned LTCF (21% versus 
76%)
•   For the purposes of data analysis and reporting, 
the 190 LTCF were stratified into the following 
different care type categories, based on the 
characteristics and estimated length-of-stay (LOS) 
for the majority of the residents:
o General nursing homes >12 months 
(GN>12m): 103 long-stay facilities with 5,807 
residents 
o Mixed care type facilities >12 months 
(Mixed>12m): 26 long-stay facilities with 
1,409 residents
o LTCF caring for residents with intellectual 
disabilities (Intellectually disabled): 24 
facilities with 1,060 residents
o LTCF (either general nursing homes or 
mixed care type facilities) <12 months 
(LTCF<12m): 15 short-stay facilities with 374 
residents
o LTCF caring for residents with psychiatric 
conditions (Psychiatric): 11 facilities with 345 
residents
o Other care types: Facilities caring for 
residents with palliative care needs (4 facilities 
with 89 residents), rehabilitation needs 
(3 facilities with 139 residents), physical 
disabilities (2 facilities with 46 residents) 
and ‘other’ care types (2 facilities with 49 
residents)    
 
•   The national crude HCAI prevalence was 5.3% and 
the national median HCAI prevalence was 4.2%. 
The median prevalence was higher in rehabilitation 
(7.8%), LTCF<12m (8.3%), Mixed>12m (6.1%) and 
the lowest median HCAI prevalence was reported 
from GN>12m (4.2%), psychiatric (4.3%) and 
physically disabled LTCF (no HCAI detected in 46 
residents)
•   The most prevalent HCAI types were: respiratory 
tract infections (RTI), urinary tract infections (UTI) 
and skin infections; affecting 1.9%, 1.7% and 1.3% 
of all residents, respectively
•   The national crude antimicrobial use prevalence 
was 9.8% and the national median antimicrobial 
use prevalence was 9.7%. The median prevalence 
was higher in LTCF<12m (11.2%). At 24.5%, the 
prevalence in palliative care was more similar to 
antimicrobial use prevalence reported from acute 
hospital settings
•   The majority of antimicrobials were prescribed 
within the LTCF (81%), mainly by GPs and directly-
employed doctors
•   Whilst the majority of antimicrobials were 
prescribed to treat infection, the proportion 
that were prescribed for infection prevention/
prophylaxis was particularly high in intellectually 
disabled LTCF (49%), GN>12m (39%) and 
Mixed>12m (35%)
•   During HALT 2013, 3.2% of GN>12m, 2.9% of 
Mixed>12m and 2% of intellectually disabled LTCF 
residents were prescribed antimicrobials for UTI 
prophylaxis. Prophylaxis against RTI (1.9%) and skin 
infection (1.4%) was most prevalent in intellectually 
disabled LTCF
•   The full HALT 2013 National Report and the 
recommended future priorities for prevention of 
HCAI and improving antimicrobial stewardship in 
Irish LTCF is available at the following link:
http://www.hpsc.ie/A-Z/
MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Surveillance/
HCAIinlongtermcarefacilities/
HALTReports/2013Report/National2013HALTReport/
9.1.2 HCAI Surveillance 
9.1.2.1 Point Prevalence Survey of Healthcare-
Associated Infections & Antimicrobial Use in European 
Long-Term Care Facilities (HALT): May 2013 
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9.1.3 Hand Hygiene 
9.1.3.1  Alcohol Hand Rub Surveillance 
Summary
Key Points
•  The median rate of alcohol hand rub consumption 
in acute hospital in Ireland increased by 10% to 
26.3 litres per 1,000 bed-days used in 2013, from 
23.9 in 2012
Hand hygiene is one of the most important actions to 
prevent Healthcare Associated Infection (HCAI). Alcohol 
hand rubs (AHR) are an effective and rapid method 
of hand hygiene, and recommended as the primary 
means of hand hygiene in national and international 
guidelines. Measurement, which includes alcohol hand 
gels and foams, of hospital-level consumption of AHR, 
expressed as volume used per 1,000 bed-days, has 
been shown to correlate with overall hand hygiene 
activity in hospitals. It is a recommended process 
measure of hand hygiene activity by both the World 
Health Organisation (WHO) and the US Centers for 
Disease Control & Prevention (CDC). 
HPSC has collated data on AHR consumption in acute 
public hospitals in Ireland since 2006. The data are 
collected quarterly and represent the total volume of 
AHR dispensed to wards, clinics and other hospital 
areas for hospitals that provide the data via their 
pharmacy department, and total volume purchased 
for hospitals that provide the data via their supplies 
department. Quantities used for pre-operative surgical 
hand hygiene were excluded. The rate of usage per 
hospital is calculated as the total volume of AHR 
consumed in litres per 1,000 bed-days used (Table 1).
In 2013, the median rate of AHR consumption 
increased to 26.3 litres per 1,000 bed-days used, from 
23.9 in 2012, an increase of 10%. The wide variation 
in levels of AHR consumption between hospitals 
(16.4 – 132.5 litres per 1,000 bed-days used) may, in 
part, be explained by differences in methodologies 
for collecting and reporting the data, and difference 
in types and range of hand hygiene agents used. One 
limitation of this surveillance system is that the data 
refer to the use of AHR only, and do not take account 
of the other hand hygiene agents (e.g. medicated liquid 
soap) that may also be in use in hospitals. In addition, 
the data do not give an indication of the frequency 
with which hand decontamination is carried out at a 
given hospital, whether or not hand hygiene is carried 
out at the correct time or using the correct technique, 
nor distinguish between who has used the AHR (visitor, 
patient or healthcare worker). Nevertheless, given 
that AHR should be used for the vast majority of 
hand hygiene opportunities in hospital settings, AHR 
consumption remains a useful process measure for hand 
hygiene activity.
The data are prone to reporting artefacts, particularly 
for hospitals that report supplies (rather than pharmacy 
dispensing) data. For example, the hospital with the 
highest reported rate had undergone a change in 
suppliers and the products had been restocked in all 
areas of the hospital over a relatively short period of 
time. It is expected that there will be occasional outliers 
of this nature. Using the median consumption figure 
provides a stable indicator of the national AHR rate 
over time. However, the volume of AHR consumed 
remains a crude measure of hand hygiene activity at 
individual hospital level and must be viewed with other 
indicators such as direct observation of hand hygiene 
compliance.
Further information may be found at: http://www.hpsc.
ie/A-Z/Gastroenteric/Handwashing/
Table 1. National data on AHR consumption in acute public hospitals in Ireland by year, 2006 – 2013.
 2006 2007 2008 2009 2010 2011 2012 2013
Number of participating hospitals 52 50 50 49 45 43 44 44
National consumption rate* 10.3 14.9 18.1 22.1 19.2 21.2 23.9 26.3
Range for participating hospitals 
in litres per 1,000 bed-days used 0.5 - 29.0 5.2 - 47.1 5.9 - 52.5 7.8 - 47.7 7.6 – 36.4
10.6 - 
129.4 12.5 - 160 16.4 - 132.5
*  The consumption rate is the total volume of AHR consumed in the defined time period in litres per 1,000 bed-days used. The national rate 
represents the median of the national sample for each time period.
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9.1.3.2 Hand Hygiene Compliance 
Summary
There were two national hand hygiene compliance 
audits in 2013:
•  For Period 5 (May/June), 49 hospitals participated: 
42 HSE and seven private hospitals. In total, 
10,247 hand hygiene opportunities were observed; 
achieving an average compliance of 86.3% (range 
= 63.8 - 95.7%) 
•  For Period 6 (October/November), 48 hospitals 
participated: 42 HSE and six private hospitals. In 
total, 10,040 hand hygiene opportunities were 
observed; achieving an average compliance of 
87.1% (range = 69 - 98.1%)
•  Overall hand hygiene compliance in HSE hospitals, 
for periods 5 & 6 combined, was 85.7%, which 
was below the 2013 HSE target of 90%. However, 
the underlying trend in hand hygiene compliance 
increased
•  Overall hand hygiene compliance in participating 
private hospitals, for periods 5 & 6 combined, was 
93.4%
Hand hygiene is one of the most important actions 
to prevent healthcare-associated infections (HCAI).  
Measuring hand hygiene compliance by direct obser-
vation is described by the World Health Organisation 
(WHO) as the gold standard. In Ireland, collection of 
biannual hand hygiene compliance audit data from 
acute hospitals commenced in 2011. Healthcare work-
ers (HCWs) are observed for their compliance against 
the ‘5 moments for hand hygiene’ by trained auditors 
using the WHO methodology for hand hygiene audits. 
Each participating hospital is required to measure HCW 
compliance against 30 hand hygiene opportunities 
for each of the seven randomly selected wards in the 
facility, resulting in a maximum of 210 opportunities per 
hospital per audit period.  In 2013, data analysis and 
management moved to the Health Protection Surveil-
lance Centre (HPSC) on-line service: MicroB.
Biannual audits were undertaken in May/June (Period 
5) and October/November 2013 (Period 6).  Within the 
42 participating HSE hospitals, a total of 8,800 hand 
hygiene opportunities were observed in Period 5, with 
8,786 observed in Period 6. Combined results for the 
two periods are displayed in Table 1 and Figure 1. 
In 2013, the overall compliance for HSE and private 
hospitals combined was 86.2%. The compliance of 
85.7% for HSE hospitals alone fell below the HSE 2013 
target of 90%. However, the underlying trend for com-
pliance among HSE hospitals has increased (Figure 2) 
over the last six periods. Participating private hospitals 
had an overall compliance of 93.4% in 2013.  
In 2013, of the four major HCW categories, medical 
staff had the lowest compliance at 75.2% and nursing/
midwifery staff the highest at 90.1%. Based on the 
WHO ‘5 moments for hand hygiene’, compliance for 
‘Moment 5’ (after touching patient surroundings) was 
the lowest at 81.8% and highest for ‘Moment 3’ (after 
body fluid exposure risk) at 91.2%. The proportion of 
hand hygiene actions involving soap and water was 
34.6% versus those involving use of alcohol hand rub at 
65.4%. Data from private hospitals were excluded from 
Table 1 and Figure 1 sections: Staff Categories and 
WHO 5 Moments.
Caveats
While standardised hand hygiene auditor training and 
validation (with inter-rater reliability testing) should 
ensure that measurement of hand hygiene compliance 
is comparable, the results have not been validated by 
external auditors.  Furthermore, all auditors measured 
compliance in the facility in which they work. There-
fore, there may be an element of bias in the results. It 
is therefore possible that hand hygiene auditing may 
not have been performed in a comparable fashion in all 
hospitals. The results may also not be reflective of HCW 
compliance at all times. Compliance with hand hygiene 
is measured by auditors observing HCWs workers un-
dertaking patient care who may change their behaviour 
if aware that they are being observed. However, this 
effect (known as the Hawthorne effect) diminishes over 
time and HCWs under observation may not be aware of 
the presence of the auditor due to the many compet-
ing demands on their attention. Auditors are requested 
to give immediate feedback to ward staff following an 
audit, thereby increasing awareness and knowledge 
of hand hygiene. This risk of bias should be balanced 
by the benefits of increasing local staff knowledge and 
awareness of hand hygiene. 
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and household services; “Allied health/Other” 
includes physiotherapists, radiologists, dieticians, social workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic procedure; Moment 3: After body fluid exposure risk; 
Moment 4: After touching a patient; Moment 5: After touching patient surroundings
Figure 1:  Summary of hand hygiene compliance in acute hospitals in Ireland (combined for the two national audit 
periods in 2013). The 95% confidence intervals are shown in bars and the HSE target for 2013 (90%) is shown as a 
red line. 
Table 1:  Summary of hand hygiene compliance in acute hospitals in Ireland (combined for the two national audit periods in 2013). 
 
Hand Hygiene Op-
portunities
Hand Hygiene Ac-
tions
Percent Compliance
Lower 95% Confi-
dence Interval
Upper 95% Confi-
dence Interval
Overall 20,287 17,591 86.7% 86.2% 87.2%
HSE Hospitals 17,586 15,069 85.7% 85.1% 86.2%
Private Hospitals 2,701 2,522 93.4% 92.4% 94.3%
HSE - South 6,084 5,238 86.1% 85.2% 87.0%
HSE - Dublin North-East 3,746 3,154 84.2% 82.9% 85.5%
HSE - Dublin Mid-Leinster 3,561 3,116 87.5% 86.3% 88.7%
HSE - West 4,195 3,561 84.9% 83.7% 86.1%
Nurse/Midwife 10,274 9,253 90.1% 89.5% 90.7%
Auxiliary 2,638 2,169 82.2% 80.6% 83.8%
Medical 3,411 2,564 75.2% 73.5% 76.8%
Allied health/Other 1,263 1,083 85.7% 83.7% 87.8%
Moment 1 4,614 3,968 86.0% 84.9% 87.1%
Moment 2 1,028 867 84.3% 81.9% 86.8%
Moment 3 1,473 1,343 91.2% 89.7% 92.7%
Moment 4 6,627 5,916 89.3% 88.5% 90.1%
Moment 5 5,275 4,316 81.8% 80.7% 83.0%
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and household services; “Allied health/Other” includes physiotherapists, 
radiologists, dieticians, social workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic procedure; Moment 3: After body fluid exposure risk; Moment 4: After 
touching a patient; Moment 5: After touching patient surroundings
Note that data from private hospitals were excluded for the ‘Staff Categories’ and ‘WHO 5 Moments’.
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Figure 2:  Summary of biannual hand hygiene compliance in HSE acute 
hospitals in Ireland for the first six national audit periods (2011 to 
2013). The annual HSE target for compliance is shown as red lines.
Note that data from private hospitals were excluded for the ‘Staff 
Categories’ and ‘WHO 5 Moments’ sections.
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Ireland participates in ECDC’s European Surveillance of 
Antimicrobial Consumption (ESAC-Net) project which 
aims to collect systemic antimicrobial usage data from 
the outpatient (ambulatory, community or primary 
care) setting and from the hospital (inpatient) setting. 
Antimicrobial consumption is measured in Defined 
Daily Dose (DDD), which is the assumed average 
maintenance dose per day for a drug used for its main 
indication in adults. Rates are calculated in DDD per 
1000 inhabitants per day (DID) for outpatients and DDD 
per 100 bed-days used (DBD) for inpatients. Please 
see “Antimicrobial consumption” and “Denominator 
data” parts of the explanatory notes section for further 
details. In 2013, the analysis and management of data 
were moved to the HPSC online service, MicroB. 
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for 
Ireland in 2013 was 23.8 DID, an increase of 4% from 
the previous year’s rate of 22.9 DID. In the latest interim 
ESAC-Net report (provisional 2013 data), the reported 
range of outpatient antimicrobial usage among 
European countries was 10.8 to 30.1 DID. The median 
for 27 European countries with reliable data was 19.0 
DID, with Ireland ranking as the seventh highest.
The underlying trend for outpatient antimicrobial 
consumption for Ireland (Figure 1) has been increasing 
steadily since 2000. After a decrease in 2009, the rate 
increased again to the highest level so far in 2013. 
There is a marked seasonal fluctuation in usage, with 
the highest levels occurring during periods of increased 
influenza activity.
In Ireland in 2013, outpatient consumption of penicillins 
accounted for the largest class used (55.1% of total 
at 13.1 DID), followed by macrolides (18.5%, 4.4 
DID), tetracyclines (12.5%, 3.0 DID), cephalosporins 
(5.7%, 1.4 DID), sulphonamides/trimethoprim (4.1%, 
1.0 DID) and fluoroquinolones (3.7%, 0.9 DID). Other 
antimicrobial classes accounted for less than 1% of total 
use. Penicillin in combination with a beta-lactamase 
inhibitor (such as co-amoxiclav) accounted for the 
largest proportion of all penicillins at 53% (7.0 DID). 
Broad-spectrum penicillin (such as amoxicillin) usage 
was also high at 29.7% of all penicillins (3.9 DID). See 
Table 1 for a detailed breakdown by pharmacological 
drug groups.
There was considerable variability in the overall 
outpatient antimicrobial usage at county level (18.2 to 
32.6 DID) as shown in Figure 2. 
Hospital Antimicrobial Consumption
Forty-two public acute hospitals provided valid 
antimicrobial usage data for 2013. The median rate 
of antimicrobial consumption was 84.9 DBD (range 
32.8 – 114.8 DBD). This was a 2.5% decrease from the 
previous year’s rate of 89.1 DBD. The overall rate for 
2013 was 84.4 DBD. These levels are mid-to-high in 
Europe.
The largest group of antimicrobials, penicillins 
at 41.8 DBD accounted for 50% of all inpatient 
antimicrobial usage. The use of fluoroquinolones 
such as ciprofloxacin (representing 7% of all inpatient 
antimicrobial usage) was 5.5 DBD. Consumption of 
cephalosporins, monobactams and carbapenems 
(representing 10% of all inpatient antimicrobial usage) 
was 8.1 DBD. Consumption of glycopeptides such as 
intravenous vancomycin, imidazoles such as intravenous 
9.2.0 Antimicrobial Consumption 
Key Points
•  The overall outpatient antimicrobial consumption in 
Ireland for 2013 was 23.8 DID, an increase from the 2012 
rate of 22.9 DID. This rate is mid-to-high in comparison 
with other European countries
•  The median rate of hospital antimicrobial consumption 
in Ireland for 2013 was 84.9 DBD (range 32.8 – 114.8 
DBD), a 2.5% decrease from 2012. This rate is mid-range 
in comparison with other European countries. Forty-two 
public acute hospitals contributed data in 2013
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metronidazole and nitrofurans (representing 10% 
of all inpatient antimicrobial usage) was 8.8 DBD. 
Consumption of erythromycin and related agents 
(representing 14% of all inpatient antimicrobial 
usage) was 11.7 DBD. Less frequently used agents in 
hospitals are tetracyclines, sulfonamides/trimethoprim, 
aminoglycosides and other systemic antimicrobials; 
collectively these drugs represent just less than 10% 
of all inpatient antimicrobial usage. All consumptions 
levels remained proportionately the same as those seen 
2012 (see Figure 3).
Hospital function was the main driver for the differences 
in the rates of antimicrobial consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 84.4 and 87.5 DBD) centred around 
the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
was much lower (median 47.2 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case-mix, compared to other 
hospitals. However it may also reflect the fact that 
DDDs are based on adult dosing and may therefore 
underestimate antimicrobial consumption in paediatric 
settings. 
It should be noted that the data do not indicate 
whether or not the level of antimicrobial use is 
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Figure 1. Outpatient antibiotic consumption in Ireland by quarter, 2000-2013.
2012 Percent of 2012 2013 Percent of 2013
Percent Change 2012 
to 2013
Penicillins 12.5 54.6% 13.1 55.1% 5.0%
Narrow spectrum penicillins 1.0 4.4% 1.1 4.5% 7.2%
Beta-lactamase resistant penicillins 1.0 4.6% 1.2 5.0% 13.6%
Broad spectrum penicillins 3.7 15.9% 3.9 16.4% 6.8%
Penicillin with beta-lactamase inhibitor 6.8 29.7% 7.0 29.2% 2.4%
Macrolides and related drugs 4.2 18.2% 4.4 18.5% 5.7%
Tetracylines 2.9 12.8% 3.0 12.5% 1.6%
Cephalosporins and other beta-lactam drugs 1.2 5.2% 1.4 5.7% 14.6%
First-generation cephalosporins 0.2 0.8% 0.2 0.8% 10.9%
Second-generation cephalosporins 0.9 4.0% 1.1 4.5% 17.9%
Third-generation cephalosporins 0.1 0.4% 0.1 0.4% -8.5%
Quinolones 0.9 3.8% 0.9 3.7% 0.3%
Sulfonamides and Trimethoprim 1.2 5.0% 1.0 4.1% -14.5%
Other antibiotics 0.1 0.5% 0.1 0.4% -8.1%
TOTAL 22.9 100.0% 23.8 100.0% 4.0%
Table 1. Breakdown by pharmacological drug groups for outpatient antibiotic use in Ireland for 2012 and 2013.
appropriate for a given patient population. For example, 
higher levels of antimicrobial consumption among tertiary 
hospitals may be appropriate if such hospitals have 
specific patient populations that are more likely to require 
antimicrobial therapy (e.g. organ transplant, cystic fibrosis 
etc).
More detailed analyses of antimicrobial usage data can 
be found on the www.hpsc.ie website, through “Topics 
A-Z”, under “Antibiotic Consumption Surveillance”. 
Details of the WHO ATC/DDD system of classifying and 
measuring drug consumption can be found at 
www.whocc.no/atc_ddd_index/. The figures presented 
in this report may vary from previously published levels 
owing to methodological changes.
Figure 2. Outpatient antibiotic consumption in Ireland by 
county, in DDD per 1000 inhabitants per day for 2013. 
0
20
40
60
80
100
2007 2008 2009 2010 2011 2012 2013 
R
at
e 
(D
D
D
 p
er
 1
00
 B
D
U
) 
Tetracyclines, Amphicols and Other Systemic 
Antimicrobials
Glycopeptides, Imidazoles and Nitrofurans (J01X) 
Quinolones (J01M) 
Aminoglycosides (J01G) 
Macrolides, Lincosamides and Streptogramins (J01F) 
Sulfonamides and Trimethoprims (J01E) 
Cephalosporins, Monobactams and Carbapemes (J01D) 
Penicillins (J01C) 
Figure 3. Overall hospital antibiotic consumption rate in DDD per 100 BDU by 
pharmacological subgroup (ATC level 3) by year. 
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9.3.0 Antimicrobial Resistance
Key Points
•   There were 2,530 reports of invasive E. coli 
infection, an increase of 3% from 2,450 (2012):  
  m  The proportions of invasive E. coli resistant to 
3rd generation cephalosporins (3GCs) (12.8%), 
ciprofloxacin (25.3%) and aminoglycosides 
(12.8%), those that were extended spectrum 
beta lactamase (ESBL) positive (10.5%) and 
those that exhibited multi-drug resistance 
(14.8%) were at their highest levels since 
surveillance began
•   There were 1,094 reports of S. aureus bloodstream 
infection (BSI), an increase of 3% from 1,060 (2012). 
Of those, 222 (20.3%) were meticillin resistant S. 
aureus (MRSA):
  m  For acute hospitals, the rate of MRSA BSI was 
0.056 cases per 1,000 bed days used (BDU), 
a decrease from 0.060 (2012). Conversely, the 
rate of meticillin susceptible S. aureus (MSSA) 
BSI increased from 0.208 (2012) to 0.218 
(2013)
  m  Enhanced surveillance data revealed that 
21% of S. aureus BSI were associated with 
infection related to central venous catheters 
(CVC) and 7% with peripheral venous catheter 
(PVC) infection
•   There were 409 reports of E. faecium BSI, an 
increase of 4% from 392 (2012):
  m  Vancomycin resistant E. faecium (VREfm) 
accounted for 43.1%, a decrease from 45.4% 
(2012)  
•   There were 326 reports of invasive K. pneumoniae 
infection, a decrease of 5.5% from 345  (2012):
  m  The proportions of invasive K. pneumoniae 
resistant to 3GCs (21.2%) and those that were 
ESBL positive (18.4%) were at their highest 
levels since surveillance began
  m  Two predominant clones have been identified 
among K. pneumoniae that are both ESBL 
positive and non-susceptible to ciprofloxacin 
and gentamicin. Some also produce 
carbapenemases. Together, these are termed 
multi-drug resistant K. pneumoniae (MDRKP) 
and the proportion of invasive K. pneumoniae 
that were MDRKP further increased between 
2012 and 2013: 5.3% (18 of 342 isolates) 
to 12.3% (40 of 325 isolates). An outbreak 
control team was established in October 2013 
to investigate this emerging threat
  m  Two invasive K. pneumoniae isolates were 
carbapenemase producers, also known as 
carbapenem-resistant Enterobacteriaceae 
(CRE)
•   There were 311 reports of invasive S. pneumoniae 
infection, a decrease of 3% from 321 (2012). Of 
those, 64 (20.7%) were penicillin-non-susceptible 
S. pneumoniae (PNSP), an increase from 19.6% 
(2012) 
  m  The national rate of invasive infection was 
6.8 per 100,000 population, compared to 7.0 
(2012)
  m  Serotype data were available for 271 of 
311 invasive S. pneumoniae isolates (87%). 
Results indicate good coverage (71%) for 
the 23-valent pneumococcal polysaccharide 
vaccine (PPV-23) in its target population 
(adults ≥65 years)
 
 •   There were 207 reports of invasive P. aeruginosa 
infection, a decrease of 5.5% from 219 (2012) and 
resistance to all indicator antimicrobials decreased
•   Enhanced surveillance data were provided on  
1,908 cases from 11 laboratories, representing 36% 
of all reported cases in 2013
•   See http://www.hpsc.ie for further details of EARS-
Net, antimicrobial resistance and enhanced BSI 
surveillance in Ireland. European data are available 
at http://ecdc.europa.eu/en/activities/surveillance/
EARS-Net/Pages/Database.aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European 
Antimicrobial Resistance Surveillance System (EARSS), 
collects routinely-generated antimicrobial susceptibility 
testing data on seven important bacterial pathogens 
using the EARS-Net case definition. Participating 
laboratories in Ireland submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter. EARS-Net does not distinguish 
clinically significant isolates from contaminants, 
nor does it distinguish between hospital-acquired, 
healthcare-associated and community-acquired 
infections. EARS-Net primarily serves as a surveillance 
system to measure national levels of antimicrobial 
resistance (AMR). In 2013, all 41 microbiology 
laboratories participated in EARS-Net resulting in 
complete coverage of the Irish population.
Escherichia coli
There were 2,530 reports of invasive E. coli infection 
(2,525 from blood and five from CSF) from 2,480 
patients, an increase of 3.3% from 2,450 reports in 
2012.  Table 1 displays the annual trends since 2004 
in the proportion of E. coli isolates resistant to the 
four “indicator” antimicrobials/antimicrobial classes 
[ampicillin, third-generation cephalosporins (3GCs); 
cefotaxime, ceftriaxone, ceftazidime or cefpodoxime, 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
aminoglycosides (gentamicin, amikacin or tobramycin)]:  
•   Of 2,528 isolates, 323 (12.8%) were resistant to 3GCs 
and of those, 256 were ESBL positive, with 65 ESBL 
negative 
•   Of 2,526 isolates, 640 (25.3%) were resistant to 
ciprofloxacin 
•   Of 2,525 isolates, 247 (9.8%) were resistant 
to gentamicin [325 (12.8%) of 2,530 were 
aminoglycoside-resistant (i.e. resistant to gentamicin, 
tobramycin or amikacin)]
•   Two (0.2%) of 2,254 isolates were resistant to 
carbapenems, but both were confirmed not to be 
carbapenemase producers
In 2013, resistance to 3GCs, ciprofloxacin and 
aminoglycosides were at their highest levels since 
surveillance began (Figure 1). The trend in 3GC 
resistance has been upwards since 2004, which is highly 
significant (Chi2 trend=187, P<0.0001). 
In 2013, Ireland had moderately high levels (10 to 
<25%) of resistance to 3GCs (Figure 2), ciprofloxacin 
and aminoglycosides (ranking 13th, 13th and 11th, 
respectively, out of 30 countries reporting to EARS-
Net). The median proportion for resistance among 
EARS-Net countries was 3GC (11.3%), ciprofloxacin 
(22.9%) and aminoglycosides (9.9%).
ESBLs are enzymes that confer resistance to most 
penicillins and cephalosporins (including 3GCs). ESBL 
positive bacteria (including E. coli and K. pneumoniae) 
are also often resistant to other classes of antimicrobials 
and have emerged as important causes of healthcare 
associated infection (HCAI). ESBLs were detected in 
264 (10.5%) of 2,515 isolates tested. In 2013, ESBL 
production among E. coli isolates was at its highest 
level since surveillance began. The trend in ESBL 
production has been upwards since 2004, which was 
highly significant (Chi2 trend=213, P<0.0001). 
Of 2,524 isolates tested against all four “indicator” 
antimicrobials, 373 (14.8%) reported from 49 hospitals/
institutions were identified as multi-drug resistant 
(MDR); defined as resistance to three or more of 
indicator antimicrobials), an increase from 13.4% (2012):
•   151 resistant to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides. ESBL positive (138), ESBL 
negative (13)
•   105 resistant to ampicillin, 3GCs and 
ciprofloxacin. ESBL positive (87), ESBL negative 
(17)
•   110 resistant to ampicillin, ciprofloxacin and 
aminoglycosides. ESBL positive (1), ESBL 
negative (108)
•   Seven resistant to ampicillin, 3GCs and 
aminoglycosides. ESBL positive (5), ESBL 
negative (2)
In 2013, MDR E. coli was at its highest level since 
surveillance began. Between 2009 and 2013, the trend 
in MDR was upwards, which was highly significant (Chi2 
trend=22.28, P<0.0001).
Females were slightly more likely (1.1-times) to have an 
invasive E. coli infection than males (z=2.63, P=0.01).  
The frequency of invasive E. coli infection increased 
with age, with the majority (n=1,884; 75%) occurring 
in adults aged over 60. The median age was 72 years 
(95%CI, 72-73).
Staphylococcus aureus
There were 1,094 reports of S. aureus BSI from 1,068 
patients, an increase of 3.2% from 1,060 (2012). Of 
those, 222 (20.3%) were MRSA, which represents the 
lowest annual proportion since surveillance began in 
1999. (Table 1). In 2010, the proportion was 24.4%, 
the first year that MRSA accounted for <25% of S. 
aureus BSI in Ireland, thus changing from red to orange 
on the EARS-Net map and 2013 was the seventh 
successive year in which a decrease was observed. The 
overall downward trend over this time period is highly 
significant (Chi2trend=249, P<0.0001) (Figure 3).  Overall, 
there was a 9.2% reduction in the number of reported 
MRSA BSI compared with 2012 (222 versus 242). In 
contrast, the total number of MSSA BSI increased by 
6.6% compared with 2012 (872 versus 818). 
Despite the decrease in numbers and proportion of 
MRSA BSI in 2013, Ireland still had one of the higher 
proportions of MRSA in Europe (see http://ecdc.
europa.eu/en/activities/surveillance/EARS-Net/Pages/
Database.aspx for more detailed European data, 
including EARS-Net tables, charts and maps) (Figure 
4). Ireland ranked 11th out of 30 countries reporting to 
EARS-Net, with the median proportion of MRSA BSI at 
14.9%. All countries with MRSA proportions higher than 
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Table 1. Summary of EARS-Net data by pathogen and year, 2004-2013 
Pathogen Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Number laboratories by year-end 40 41 42 44 42 43 40† 41† 41 41
E. coli
Number of isolates 1256 1445 1656 1785 1926 2064 2170 2210 2450 2530
%Ampicillin-R* 65.0 67.6 70.7 68.3 70.4 68.7 68.4 71.9 69.6 70.9
%3GC-R* 2.6 4.1 4.2 6.7 7.4 7.5 8.3 9.5 10.8 12.8
%ESBL-producers* 1.1 2.4 2.5 4.1 5.0 5.8 6.1 7.5 8.8 10.5
%Ciprofloxacin-R* 12.6 17.3 21.5 22.1 23.3 22.3 23.6 23.8 25.2 25.3
%Gentamicin-R* 5.7 8.5 7.7 9.9 10.2 7.7 9.4 8.7 9.7 9.8
%Gentamicin/Amikacin/Tobramycin-R* 6.1 8.6 8.6 10.6 11.0 9.3 11.8 12.2 12.6 12.8
%Carbapenem1-R* 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
%MDR* 5.6 7.7 9.0 11.3 12.1 10.4 11.7 13.0 13.4 14.8
Number laboratories by year-end 41 42 42 44 43 43 40† 41† 41 41
S. aureus
Number of isolates 1323 1424 1412 1393 1303 1309 1251 1095 1060 1094
Number Meticillin-R (or MRSA) 553 592 592 536 439 355 305 263 242 222
%Meticillin-R (or MRSA) 41.8 41.6 41.9 38.5 33.7 27.1 24.4 24.0 22.8 20.3
Number laboratories by year-end 40 41 42 44 42 43 40† 41† 41 41
E. faecium
Number of isolates 187 224 265 330 406 397 392 364 392 409
%Ampicillin-R* 95.7 92.3 93.9 93.1 95.1 92.9 95.6 95.9 92.9 93.2
%Vancomycin-R (VREfm) 23.2 31.7 37.1 33.4 35.7 38.3 39.3 37.4 45.4 43.1
%HLG-R* 58.0 51.4 44.3 35.2 28.1 39.1 39.6 36.8 39.3 41.4
%MDR* 18.5 25.6 25.6 22.7 16.2 26.7 24.9 21.1 20.3 19.6
Number laboratories by year-end 40 41 42 44 42 43 40† 41† 41 41
E. faecalis
Number of isolates 242 290 294 280 301 289 298 265 298 336
%Ampicillin-R* 0.8 3.5 4.5 2.2 0.7 2.1 0.7 0.8 4.0 2.7
%Vancomycin-R (VREfa) 1.3 2.5 3.7 2.9 3.7 0.7 0.3 4.9 3.0 2.1
%HLG-R* 41.3 44.4 42.4 36.9 30.5 36.7 29.7 29.1 32.9 33.6
Number laboratories by year-end 36 39 41 42 40† 41† 41 41
K. pneumoniae
Number of isolates
No data No data
217 244 310 323 326 312 345 326
%Ampicillin-R* 97.7 99.2 99.7 99.7 99.1 100.0 98.5 99.1
%3GC-R* 10.2 9.9 11.4 11.2 10.5 8.0 11.9 21.2
%ESBL-producers* 8.6 3.7 7.7 8.2 5.0 5.6 8.8 18.4
%Ciprofloxacin-R* 15.3 18.1 12.8 13.0 10.5 13.2 11.9 20.9
%Gentamicin-R* 7.8 9.9 10.7 11.1 6.8 7.4 9.9 16.9
%Gentamicin/Amikacin/Tobramycin-R* 9.2 11.1 10.7 11.1 7.1 8.3 9.6 17.5
%Carbapenem1-R* 0.0 0.6 0.0 0.0 0.0 1.6 0.3 1.2
%MDRKP2* 1.7 2.9 3.9 4.3 2.2 4.6 5.3 12.3
%MDR* 11.2 11.9 10.6 11.9 8.0 8.4 9.9 19.4
Number laboratories by year-end 41 42 42 44 42 43 40† 41† 41 41
S. pneumoniae
Number of isolates 400 401 407 438 447 356 314 327 321 311
%Penicillin-NS* 10.3 11.7 15.7 17.4 23.1 20.2 18.2 19.6 19.6 20.7
of which:   %HLR 1.8 3.0 2.9 5.7 6.0 5.6 4.8 6.1 4.7 2.3
 %Int 7.0 8.7 12.5 11.0 16.8 13.8 12.7 13.5 15.0 18.3
%Erythromycin-R* 14.4 12.1 16.1 16.4 16.7 17.3 15.7 18.9 16.9 17.9
%Penicillin-NS/Erythromycin-R 3.1 3.2 7.4 7.9 10.2 11.9 12.6 13.8 12.1 13.0
Number laboratories by year-end 36 39 41 42 40† 41† 41 41
P. aeruginosa
Number of isolates
No data No data
128 177 199 248 222 184 219 207
%Piperacillin/tazobactam-R* 9.4 12.6 9.7 8.9 10.0 2.8 17.4 15
%Ceftazidime-R* 10.6 11.8 8.7 11.8 9.2 8.2 15.2 11
%Imipenem/meropenem-R* 11.8 12.2 9.3 10.2 8.3 12.0 19.6 12
%Ciprofloxacin-R* 18.0 22.9 21.8 12.1 13.2 12.6 20.6 15
%Gentamicin-R* 10.2 13.3 9.0 7.7 8.7 6.5 11.9 12
%Gentamicin/Amikacin/Tobramycin-R* 10.2 13.3 9.0 7.7 8.7 6.5 11.9 12
%MDR* 9.5 12.4 11.1 6.4 6.5 4.0 13.0 9
Number laboratories by year-end 41
Acinetobacter spp.
Number of isolates
No data No data No data No data No data No data No data No data No data
91
%Ciprofloxacin-R* 3
%Gentamicin-R* 0
%Gentamicin/Amikacin/Tobramycin-R* 1
%Carbapenem1-R* 4
%MDR* 0
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VREfm, Vancomycin-Resistant E. faecium; VREfa, Vancomycin-Resistant E. faecalis
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime 
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
† The number of laboratories processing blood cultures has changed on a number of occasions between 2006 and 2014; however, coverage of acute hospitals has remained at 100%
1 Carbapenems include imipenem, meropenem and ertapenem
2 MDRKP, MDR K. pneumoniae phenotype (ESBL-producer plus non-susceptibility to Ciprofloxacin and Gentamicin) OR carbapenemase-producer (e.g. KPC, OXA-48)
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Ireland are located in Southern and Central/Eastern 
Europe.
No MRSA isolates with reduced susceptibility to 
vancomycin were detected at the National MRSA 
Reference Laboratory.  
The MRSA rate for all acute hospitals in 2013 was 0.056 
cases per 1,000 BDU, a decrease from 0.060 in 2012, 
while the MSSA rate increased from 0.208 to 0.218 
[Rates are calculated from denominator data (bed days 
used) obtained from the HSE Business Intelligence Unit 
(BIU) for all acute public hospitals; and directly from 
private hospitals where available, where both numerator 
(S. aureus numbers) and denominator data have been 
provided]. 
Males were approximately 1.7-times more likely to have 
invasive S. aureus infection (2.3-times for MRSA, z=6.26, 
P<0.0001; 1.5-times for MSSA, z=6.38, P<0.0001) than 
females (z=8.43, P<0.0001).  The frequency of invasive 
S. aureus infection increased with age, with the majority 
of infections (n=650; 60%) occurring in adults aged over 
60.  The median age for MRSA infection was 71 years 
(95%CI, 69-73) and for MSSA infection was 63 years 
(95%CI, 61-64). This was considered to be a significant 
difference, as the confidence intervals did not overlap.
Enterococcus faecium
There were 409 reports of E. faecium BSI from 399 
patients, an increase of 4.3% from 392 (2012). Table 1 
displays the annual trends since 2004 in the proportion 
of E. faecium isolates resistant to the three “indicator” 
antimicrobials (ampicillin, vancomycin and high-level 
gentamicin).  
•   Of 399 isolates, 165 (41.4%) were resistant to 
high-level gentamicin (Figure 5) 
•   Of 408 isolates, 176 (43.1%) were resistant to 
vancomycin, with a decrease in the proportion 
of vancomycin resistant E. faecium (VREfm) from 
45.4% (2012). Since 2008, Ireland has had the 
highest proportion of VREfm in Europe. In 2013, 
countries with the next highest proportions of 
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3rd 
generation cephalosporins (3GCs), ciprofloxacin/ofloxacin (CIP/OFX), gentamicin (GEN) and 
gentamicin/amikacin/tobramycin (GEN/AMK/TOB) with 95% confidence intervals
.
Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from laboratories participating 
in enhanced surveillance for 2013). Proportion of isolates detected <48 hours and >5 days post-admission is also shown.
Total for  
2013
Percent 
female
Mean age in 
years
Detected <48 hours 
after admission
Detected >5 days 
after admission
Staphylococcus aureus
Meticillin Resistant (MRSA) 97 25% 69.0 59% 34%
Meticillin Susceptible 327 37% 57.7 66% 23%
Streptococcus pneumoniae
Penicillin non-Susceptible 21 29% 59.3 67% 19%
Penicillin Susceptible 89 52% 61.5 90% 4%
Enterococci Vancomycin Resistant 84 45% 66.2 18% 76%
Vancomycin Sensitive 196 40% 65.3 41% 47%
Escherichia coli
Fluoroquinolone Resistant 234 46% 72.1 73% 22%
Fluoroquinolone Susceptible 672 56% 67.7 77% 16%
Klebsiella pneumoniae 117 37% 65.7 49% 41%
Pseudomonas aeruginosa 71 44% 67.5 54% 34%
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VREfm were; the United Kingdom (23%), Greece 
(23%) and Portugal (22%) (Figure 6), while 
the median proportion of VREfm in EARS-Net 
countries was just 5.6%.
•   Of 398 isolates tested against the three 
“indicator” antimicrobials, 78 (19.6%) reported 
from 18 hospitals were resistant to all three and 
termed MDR, which represents a slight decrease 
from 20.3% (2012) 
Males were approximately 1.4-times more likely to 
have invasive E. faecium infection than females (z=3.36, 
P<0.001). The frequency of invasive E. faecium infection 
increased with age, with the majority of infections 
(n=290; 71%) occurring in adults aged over 60. The 
median age was 68 years (95%CI, 65-70).
Klebsiella pneumoniae
There were 326 reports of invasive K. pneumoniae 
infection (323 from blood and three from CSF) from 317 
patients, a decrease of 5.5% from 345 (2012).  Table 1 
displays annual trends since 2004 in the proportion of 
K. pneumoniae isolates resistant to the four “indicator” 
antimicrobials (as for E. coli above) plus carbapenems 
(imipenem, meropenem or ertapenem). 
•   Of 326 isolates, 69 (21.2%) were resistant to 
3GCs, 60 (18.4%) were ESBL positive and nine 
were ESBL negative. In 2013, the proportion of 
invasive ESBL positive K. pneumoniae infection 
was at its highest level since surveillance began, 
with an increase from 8.8% in 2012 (Figure 7)
•   Of 325 isolates, 68 (20.9%) were resistant to 
ciprofloxacin
•   Of 326 isolates, 55 (16.9%) were resistant 
to gentamicin [57 (17.5%) of 326 were 
aminoglycoside-resistant (i.e. resistant to 
gentamicin, tobramycin or amikacin)]
•   Of 326 isolates, four (1.2%) were resistant 
to carbapenems, with two confirmed to be 
carbapenemase producers, both reported from 
the same hospital (both OXA-48 type CRE) 
and two confirmed not to be carbapenemase 
producers. The two invasive OXA-48 K. 
pneumoniae isolates in 2013 followed the last 
reported invasive CRE isolates in 2011: OXA-48 
(3) and KPC (1)
In 2013, resistance to 3GCs, ciprofloxacin and 
gentamicin/aminoglycosides were all at their highest 
levels since surveillance began.
Three invasive K. pneumoniae isolates were reported as 
susceptible to ampicillin, an unexpected finding as all K. 
pneumoniae is inherently resistant to ampicillin.
Of 326 isolates, 63 (19.4%) reported by 17 hospitals 
that were tested against all four “indicator” 
antimicrobials were identified as MDR, a large increase 
from 9.9% (2012):
•   42 resistant to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides. ESBL positive (38), ESBL 
negative (4). This represented a large increase 
from 16 isolates reported as resistant to all four 
antimicrobials in 2011
•   Seven resistant to ampicillin, 3GCs and 
ciprofloxacin. All ESBL positive
•   Six resistant to ampicillin, 3GCs and gentamicin. 
ESBL positive (5), ESBL negative (1)
Figure 2. Distribution of 3rd-generation cephalosporin resistant E. coli in EARS-Net 
countries in 2013
Map downloaded from ECDC’s TESSy database on 28/07/2014:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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•   Eight resistant to ampicillin, ciprofloxacin and 
aminoglycosides. All ESBL negative 
In 2013, the Antimicrobial Resistance and Microbial 
Ecology (ARME) group at NUI Galway alerted HPSC to 
the presence of two predominant K. pneumoniae clones 
implicated in both patient infection and colonisation 
in a number of Irish hospitals. Both clones were 
simultaneously ESBL positive and non-susceptible to 
ciprofloxacin and gentamicin. Some were also found to 
produce carbapenemases. Together, these are termed 
multi-drug resistant K. pneumoniae (MDRKP) and the 
proportion of invasive K. pneumoniae that were MDRKP 
further increased between 2012 and 2013: 5.3% (18 of 
342 isolates) to 12.3% (40 of 325 isolates), as displayed 
in Figure 8. An outbreak control team was established 
in October 2013 to evaluate this emerging threat.
Antimicrobial resistance in invasive K. pneumoniae 
isolates in Ireland were previously among the lowest 
in Europe, but this appears to be changing. In 2013, 
at 21.2% 3GC resistance, Ireland ranked 18th of 30 
countries (up from a rank of 26th in 2012; 11.9%). At 
21.2% fluoroquinolone resistance, Ireland ranked 21st 
(up from a rank of 25th in 2012; 11.9%). Aminoglycoside 
resistance in Ireland has also increased from 9.9% 
(ranking 19th of 29 countries) in 2012 to 17.5% (ranking 
18th of 30 countries) in 2013. With only two reports 
of carbapenemase-producing K. pneumoniae, Ireland 
ranked 19th of 29 countries in 2013, with the median 
proportion among EARS-Net countries being 1.0% 
(Figure 9).
Males were approximately 1.5-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=3.85, P=0.0001).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=220; 67%) occurring in adults 
aged over 60.  The median age was 68 years (95%CI, 
66-70).
Streptococcus pneumoniae
There were 311 reports of invasive S. pneumoniae 
infection (304 from blood and seven from CSF) from 
310 patients, a decrease of 3.1% from 321 (2012). Table 
1 displays annual trends since 2004 in the proportions 
of S. pneumoniae isolates non-susceptible/resistant to 
penicillin and erythromycin.  
Penicillin-non-susceptible S. pneumoniae (PNSP) 
accounted for 20.7% (n=64) of all isolates tested against 
penicillin (n=309) in 2013. Of the PNSP isolates, 56 
were intermediately-resistant (Int; MIC=0.1-1 mg/L for 
laboratories following the Clinical Laboratory Standards 
Institute (CLSI) old/oral guidelines and MIC=0.1-
2mg/L for those following European Committee on 
Antimicrobial Susceptibility Testing (EUCAST)  non-
meningitis guidelines) and eight were high-level 
resistant (HLR; MIC >1.0mg/L for CLSI and >2mg/L for 
EUCAST) to penicillin. Penicillin susceptibility was not 
determined for two isolates. Fifty-four (17.9%) of 302 
isolates were resistant to erythromycin.  
There was a slight increase in the proportion of PNSP 
isolates from 19.6% (2012) to 20.7% (2013) as displayed 
in Figure 10. However, the proportion that displayed 
penicillin HLR decreased from 4.7% (2012) to 2.6% 
(2013).  
In 2013, Ireland remained among European countries 
with the highest proportions of PNSP (ranking 10th of 
30 countries overall; and 6th of 22 countries reporting 
≥50 isolates). In 2013, the median proportion among 
EARS-Net countries was 9.2%. However, it is important 
to consider that comparison with other EARS-Net 
countries is increasingly problematic due to the 
possibility of different interpretive criteria being applied 
to the data from different countries (and indeed from 
different laboratories within a country). Many Irish 
microbiology laboratories have recently switched or 
are currently in the process of switching from CLSI to 
EUCAST guidelines: 27 laboratories had switched by the 
Figure 3. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage 
MRSA with 95% confidence intervals
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end of 2013, an increase from 15 by the end of 2012. 
•   CLSI provides three sets of breakpoints 
for interpreting penicillin susceptibility of 
S. pneumoniae isolates: meningitis, non-
meningitis and oral
•   EUCAST provides two sets of breakpoints: 
meningitis and infections other than meningitis 
In Ireland, EARS-Net data are reported using the “oral” 
CLSI breakpoints (which correspond to the original CLSI 
breakpoints) or the EUCAST breakpoints for infections 
other than meningitis, as these are broadly similar for 
epidemiological purposes and thus facilitate a more 
meaningful analysis of the data. This also permits a 
relatively consistent approach for comparing historical 
data. 
Moderately high levels of erythromycin resistance were 
seen, with Ireland ranking 18th of 30 countries overall 
and 10th of 22 countries reporting 50 or more isolates. 
This is similar to the situation observed in much of 
Southern and Central/Eastern Europe. In 2013, the 
median proportion among EARS-Net countries was 
18.0%.
Of 299 isolates tested against both penicillin and 
erythromycin, 39 (13.0%) were simultaneously PNSP (33 
Figure 5. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
vancomycin (VREfm) and high-level gentamicin (HLG) with 95% confidence intervals
Figure 4. Distribution of MRSA in EARS-Net countries in 2013
Map obtained from ECDC on 28/07/2014:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Int, 6 HLR) and erythromycin-resistant in 2013, which 
is the highest proportion of penicillin/erythromycin co-
resistance since surveillance began.
In early 2007, a national pilot project was established 
as a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple 
St and HPSC, with the aim of providing baseline 
serotyping data on invasive S. pneumoniae isolates.  
This project pre-dates the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) into the 
childhood immunisation schedule in September 2008 
and PCV13 replaced PCV7 from September 2010. 
In 2013, serotype data were available for 271 
pneumococcal isolates reported by 31 of the 33 
laboratories reporting pneumococcal isolates to EARS-
Net, representing 87% of all pneumococcal isolates 
reported: 
•   Of 138 isolates from patients aged ≥65 years, 98 
(71%) belonged to serotypes included in the PPV-
23 vaccine 
•   Only 12 isolates were referred for typing from 
patients aged <2 years (the target population for 
the PCV13 vaccine) and eight of these were non-
vaccine serotypes
The most common serotypes identified were; 7F (n=48), 
19A (n=33), 3 and 22F (n=18 each), 8 (n=11), 14 and 
23B (n=10 each) representing 55% of all isolates typed. 
Of the 64 PNSP isolates, 55 were serotyped: 
•   Of 36 isolates from patients age ≥65 years, 24 
(67%) belonged to serotypes included in the PPV-
23 vaccine
•   None of the serotyped PNSP isolates came from 
children <2 years (note: one PNSP isolate from a 
child in this age group was not serotyped)
Ongoing surveillance of the predominant serotypes is 
required, as strains with non-vaccine serotypes have 
been reported to increase in prevalence following the 
introduction of conjugate vaccines in other countries, 
hence the need for a fully-resourced Irish pneumococcal 
reference laboratory. The separate chapter on invasive 
pneumococcal disease (IPD) in Ireland in 2013 contains 
additional information on pneumococcal serotyping.
In 2013, the rate of IPD in Ireland was estimated at 6.8 
cases per 100,000 population, compared with 7.0 in 
2012 (Note that both rates were calculated using 2011 
census data). The highest rates of IPD were observed 
at extremes of age; children aged <1 year (11.0 per 
100,000) and 1 year (10.5 per 100,000) and adults aged 
65-74 (20.3 per 100,000), 75-79 (39.2 per 100,000) and 
≥80 (40.5 per 100,000) as displayed in Figure 11. The 
IPD rates in all age groups were broadly similar to 2012, 
with the exception of ages 1 year (increase from 5.5 to 
10.5) and ≥80 years (decrease from 53.7 to 40.5).  
Males were approximately 1.1-times more likely to have 
an invasive S. pneumoniae infection than females, but 
this was not statistically significant (z=0.97, P=0.33). The 
frequency of invasive S. pneumoniae infection increased 
with age, with the majority (n=182; 59%) occurring in 
adults aged over 60. The median age was 64 years 
(95%CI, 62-67).
Enterococcus faecalis
There were 336 reports of E. faecalis BSI from 327 
patients, an increase of 12.8% from 298 (2012). Table 
1 displays annual trends since 2004 in the proportions 
of E. faecalis isolates resistant to the three “indicator” 
antimicrobials (as for E. faecium):  
•   Of 334 isolates, seven (2.1%) were resistant to 
vancomycin (VREfa), with Ireland ranking 7th 
Figure 6. Distribution of vancomycin-resistant E. faecium (VREfm) in EARS-Net countries in 2013
Map downloaded from ECDC’s TESSy database on 28/07/2014:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 7. Trends for K. pneumoniae – total numbers of K. pneumoniae and percentage 
resistance to 3rd generation cephalosporins (3GCs) and ESBL-positivity with 95% 
confidence intervals
among European countries for resistance. The 
median proportion in Europe was 0.4%, although 
the proportion of VREfa in Ireland has decreased 
from the highest reported proportion of 4.9% in 
2011 
•   Of 318 isolates, 107 (33.6%) were resistant to 
high-level gentamicin 
Nine isolates were reported resistant to ampicillin, 
which is suggestive of misidentification of species or 
misclassification, as resistance to ampicillin is rare in 
E. faecalis.
Males were approximately 2.1-times more likely to 
have invasive E. faecalis infection than females (z=6.74, 
P<0.0001). The frequency of invasive E. faecalis 
infection increased with age, with the majority of 
infections (n=236; 70%) occurring in adults aged over 
60.  The median age was 69 years (95%CI, 67-71).
Pseudomonas aeruginosa
There were 207 reports of invasive P. aeruginosa 
infection (206 from blood and one from CSF) from 205 
patients, a decrease of 5.5% from 219 (2012).  Table 1 
displays annual trends since 2006 in the proportion of 
P. aeruginosa isolates resistant to the five “indicator” 
antimicrobials/antimicrobial classes [piperacillin-
tazobactam, ceftazidime, carbapenems (meropenem or 
imipenem), fluoroquinolones (ciprofloxacin or ofloxacin) 
and gentamicin].  In 2013, resistance to all five indicator 
antimicrobials decreased.
•   Of 204 isolates, 31 (15.2%) were resistant to 
piperacillin-tazobactam 
•   Of 206 isolates, 22 (10.7%) were resistant to 
ceftazidime
•   Of 206 isolates, 25 (12.1%) were resistant to 
imipenem or meropenem
•   Of 207 isolates, 31 (15.0%) were resistant to 
ciprofloxacin
•   Of 207 isolates, 24 (11.6%) were resistant to 
gentamicin [no additional isolates were resistant 
to the other aminoglycosides (amikacin or 
tobramycin)] 
Nineteen (9.4%) of 203 isolates reported from 13 
hospital and that were tested against all five “indicator” 
antimicrobials were identified as MDR, the highest since 
surveillance began:
•   Three resistant to all five antimicrobial classes
•   Ten resistant to four of five antimicrobial classes
•   Six resistant to three of five antimicrobial 
classes
Antimicrobial resistance levels among P. aeruginosa 
isolates in Ireland are at moderately low levels in 
comparison with other European countries, with Ireland 
ranking 18th – 23rd of 30 countries for all five indicator 
antimicrobials.
Males were approximately 1.5-times more likely to 
have invasive P. aeruginosa infection than females 
(significant; z=2.91, P=0.004). The frequency of invasive 
P. aeruginosa infection increased with age, with the 
majority of infections (n=155; 75%) occurring in adults 
aged over 60. The median age was 71 years (95%CI, 
69-73).
Acinetobacter spp.
In 2013, surveillance of invasive Acinetobacter spp. 
Infection began in Ireland, with 91 reports of invasive 
infection caused by Acinetobacter spp. (90 from blood 
and one from CSF) from 90 patients.  Table 1 displays 
the proportion of Acinetobacter spp. isolates resistant 
to the three “indicator” antimicrobials/antimicrobial 
classes [carbapenems (meropenem or imipenem), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
gentamicin]:  
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•   Of 86 isolates, three were resistant to imipenem 
or meropenem
•   Of 89 isolates, three were resistant to 
ciprofloxacin
•   None of 89 isolates were resistant to gentamicin 
[no additional isolates were resistant to the other 
aminoglycosides (amikacin or tobramycin)] 
Enhanced Surveillance
The voluntary EARS-Net enhanced surveillance 
programme was established in 2004. Laboratories that 
participate in EARS-Net are invited to provide additional 
demographic, risk factor and clinical data on invasive 
pathogens causing BSI.
In 2013, enhanced surveillance data on 1,908 individual 
records (cases or isolates under the EARS-Net definition) 
were submitted from 11 participating laboratories, 
representing 36% of all reports to EARS-Net. In late 
2013, the layout of the enhanced surveillance data 
collection form was revised and piloted. The field 
structures were simplified to allow greater participation.  
Table 2 displays demographic and other basic data for 
the major resistance profiles of pathogens reported to 
EARS-Net enhanced surveillance. 
1. S. aureus BSI
•   Healthcare associated infection was reported for the 
majority of MRSA (69%) and MSSA (63%) BSI
•   From 2010 to 2012, a reduction in the proportion 
of S. aureus BSI due to CVC infection was observed 
(from 23% to 15%). However, the proportion 
increased to 21% in 2013. The proportion of S. 
aureus BSI due to PVC infection declined from 11% 
(2012) to 7% (2013)
  m  MRSA BSI = 23% CVC & 3% PVC infection
  m  MSSA BSI = 20% CVC & 8% PVC infection
•   The most common risk factors reported were recent 
surgery, malignancy and stay in an intensive care 
unit
2. Enterococcal BSI 
•   Healthcare associated infection was reported for 
the vast majority of vancomycin resistant (92%) and 
vancomycin susceptible (74%) enterococcal BSI
•   The most common primary sources of BSI were: 
CVC and intra-abdominal or gastrointestinal tract 
infection
3. S. pneumoniae BSI 
•   The proportion of PNSP detected within two 
days after admission decreased from 95% (2012) 
to 67% (2013), while the proportion of penicillin 
susceptible S. pneumoniae (PSSP) increased from 
77% (2012) to 90% (2013). However, the number of 
PNSP BSI isolates for which enhanced information 
was reported was small, thus the results must be 
interpreted with caution
•   Respiratory tract infection remained the most 
common source of pneumococcal BSI
4. E. coli BSI 
•   Healthcare associated infection was reported for 
the majority of fluoroquinolone resistant E. coli 
BSI, which contrasts with 44% for fluoroquinolone 
susceptible E. coli 
•   The most common source of E. coli bloodstream 
infection was urinary tract infection, with 5% 
reported in association with the presence of a 
urinary catheter
Figure 8. Trends for K. pneumoniae isolates with the MDRKP phenotype (simultaneously 
ESBL-producers and non-susceptible to both ciprofloxacin and gentamicin and/or a 
carbapenemase producer) –– numbers and percentage with MDRKP phenotype with 
95%CIs
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Further information is available on the HPSC website: 
http://www.hpsc.ie/A-Z/MicrobiologyAntimicrobialRe-
sistance/EuropeanAntimicrobialResistanceSurveillanc-
eSystemEARSS/EnhancedBacteraemiaSurveillance/
Conclusion
For the seventh consecutive year, the proportion of S. 
aureus BSI attributable to MRSA further declined to 
20.3%, the lowest reported level since Ireland joined 
EARS-Net. Unfortunately, antimicrobial resistance in 
other important BSI causative pathogens increased 
further and remains a cause for concern. 
For the sixth consecutive year, Ireland remained the 
European country with the highest proportion of VREfm 
BSI (43.1%), which was far in excess of the countries 
reporting the second highest proportion (UK and 
Greece, both at 23%). 
Additionally, the proportions of ESBL positive and 
multi-drug resistant Enterobacteriaceae (E. coli 
and K. pneumoniae) reached the highest reported 
levels to date. In 2013, the ARME research group at 
NUI Galway alerted the HPSC to the detection of 
two K. pneumoniae clones causing both infection 
and colonisation in patients attending a number of 
Irish hospitals. These clones exhibited a multi-drug 
Figure 9. Distribution of carbapenem-resistant K. pneumonie in EARS-Net countries in 2013
Map downloaded from ECDC’s TESSy database on 28/07/2014:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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Figure 10. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and 
percentage PNSP with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
resistant phenotype, involving both ESBL production 
and non-susceptibility to both ciprofloxacin and 
gentamicin and have been termed MDRKP, with a 
smaller proportion also producing carbapenemases, 
hence the term CRE. Further analysis of EARS-Net data 
revealed a large increase in invasive K. pneumoniae 
that were MDRKP between 2012 and 2013 (from 5.3% 
to 12.3%), supporting the hypothesis of emergence 
and dissemination of MDRKP in Ireland. Given the 
extent of antimicrobial resistance exhibited by MDRKP, 
coupled with increasing concerns worldwide on 
both dissemination of multi-drug resistant organisms 
and paucity of effective antimicrobial treatments, in 
response to this data, a national outbreak control team 
was established by HPSC in October 2013 to evaluate 
this emerging threat. 
In 2013, there were two reported cases of invasive 
carbapenemase-producing K. pneumoniae (CRE) 
infection in Ireland, with 24 of 29 EARS-Net participant 
countries reporting one or more cases and 15 countries 
reporting five or more cases. Greece (60%) and Italy 
(36%) remained the European countries with the 
largest proportion of invasive CRE infections (among 
K. pneumoniae). Additionally, significant increases 
were reported by Romania (22%) and Malta (15%). This 
clearly illustrates the successful dissemination of these 
highly resistant microorganisms in Europe, which may 
be contributed to by suboptimal infection prevention 
and control and antimicrobial stewardship practices 
in both acute and non-acute healthcare settings. To 
address the threat of MDR-Enterobacteriaceae, such 
as MDRKP, ESBLs and CRE to Ireland, it is vital that 
control measures are strengthened in both acute and 
non-acute healthcare settings, with implementation 
of the recommendations contained in the Guidelines 
for the prevention and control of multi-drug resistant 
organisms, other than MRSA, published in 2013 and the 
Guidelines for antimicrobial stewardship in hospitals, 
published in 2009. 
The decline in the burden of MRSA BSI in recent 
years may be partly attributable to improvements in 
infection prevention and control interventions, such 
as increased emphasis on and improved healthcare 
worker awareness of the importance of compliance 
with standard and contact precautions, screening 
of patients for MRSA carriage and the availability of 
decolonisation regimens to eradicate MRSA carriage. 
The development of and strengthening of hospital 
antimicrobial stewardship programmes and restricted 
prescribing of certain broad spectrum antimicrobials, 
particularly in response to other healthcare associated 
infections, such as Clostridium difficile infection, may 
also have positively contributed to the decreasing 
proportion of MRSA BSI. 
Since 2008, pneumococcal conjugate vaccines have 
been a component of the childhood immunisation 
programme, an intervention which has already resulted 
in a reduction in the burden of paediatric invasive 
pneumococcal disease (IPD) in Ireland. However, 
pneumococcal antimicrobial resistance remains a 
major problem in Ireland and the increasing number of 
reported invasive infections due to multi-drug resistant 
strains is of particular concern. Clearly, IPD manifesting 
as BSI or meningitis reflects the most severe form 
of pneumococcal infection and data on other more 
common manifestations of infection (e.g., pneumonia, 
sinusitis and otitis media) are not captured by EARS-
Net.  While data from invasive infections is extremely 
valuable in comparing national levels of AMR, the true 
burden of infection caused by antimicrobial resistant 
pneumococci may be underestimated.
The enhanced EARS-Net surveillance data are 
particularly useful in informing infection prevention 
and control programmes, both nationally and in those 
hospitals that participate in the surveillance scheme. 
Participation in enhanced surveillance can also help 
to identify risk factors and potentially preventable 
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Figure 11. Numbers and age-specific incidence rates of patients with invasive 
S. pneumoniae infection in 2013 compared with 2012
healthcare associated infections that can be targeted as 
part of preventative programmes (e.g., invasive medical 
device related infections).
Infections caused by antimicrobial resistant bacteria 
result in excess patient mortality, morbidity and costs 
to the healthcare system. Rising levels of AMR threaten 
many aspects of healthcare that we currently take 
for granted. It is critical that comprehensive infection 
prevention and control and antimicrobial stewardship 
programmes continue to be developed and maintained 
at all levels and settings within the Irish health service. 
To this end, it is vital that recommendations and 
guidelines produced by the HSE RCPI Clinical Advisory 
Group on HCAI and AMR are implemented.
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 1st September 2014.
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9.3.0.1 Enhanced surveillance of Carbapenem 
Resistant Enterobacteriaceae (CRE) in Ireland – 2013
Summary:
•   In 2013, enhanced surveillance data was 
received on 24 CRE cases. This represented a 
decrease compared with 2012, when enhanced 
surveillance data was received on 32 CRE 
cases. In contrast, the National Carbapenemase 
Producing Enterobacteriaceae (CPE) Reference 
Laboratory Service (CPEaRLS) at Galway 
University Hospital confirmed carbapenemase 
production in 48 Enterobacteriaceae isolates in 
2013 
•   Just one patient (4%) had a history of 
hospitalisation in another jurisdiction (Northern 
Ireland: KPC-type CRE isolated)
•   The clinical significance of the CRE isolate was 
reported for 20 patients (83%), representing 
colonisation in the majority (n=13). CRE 
infection was reported for the remaining seven 
patients
 
Carbapenem resistant Enterobacteriaceae (CRE) are 
multi-drug resistant Gram-negative bacteria that can be 
easily spread between patients in healthcare settings 
and have the ability to cause infections for which 
effective antimicrobial therapy may be lacking. Most 
CRE produce carbapenemase, an enzyme that breaks 
down the carbapenem class of antimicrobials (e.g. 
imipenem, meropenem). Carbapenemase production 
has spread worldwide in the past 15 years and is now 
a prominent resistance mechanism reported in many 
countries. 
Detection of confirmed carbapenemase-producing CRE, 
hereafter known as CRE, became notifiable in Ireland 
in March 2011, under the category of ‘unusual cluster 
or changing pattern of illness’. Upon amendment to 
the Infectious Diseases Regulations in September 
2011, invasive CRE infection (blood, CSF or normally 
sterile site) became notifiable in its own category. The 
CRE enhanced surveillance scheme was established in 
June 2011 and reporting of CRE isolates from any site, 
whether colonisation or infection is encouraged.
 In 2013, enhanced surveillance data was received 
from 11 laboratories on 24 confirmed cases of 
carbapenemase-producing CRE and one tertiary 
hospital reported a CRE outbreak. Figure 1 displays 
annual trends in CRE cases and types reported to 
enhanced surveillance since 2011. Of the 24 patients, 
15 were male (63%). The average age was 67 years 
(range: 31 – 95). At the time of CRE detection, 21 
patients (88%) were hospitalised, two were in the 
community (8%) and one was a nursing home resident 
(4%). Of the 21 hospitalised patients, 10 (48%) had 
been admitted from home, eight (38%) were transfers 
from another acute hospital, one had been admitted 
from long-term care (4%) and the source of admission 
was not provided for the remaining two patients (10%). 
Of the eight patients who had been transferred from 
another acute hospital, one was repatriated from a 
hospital in another jurisdiction (Northern Ireland). 
At the time of CRE detection, nine patients (38%) were 
already known to be colonised or infected with one or 
more other multi-drug resistant organisms (MDRO) and 
seven of those were inpatients. 
Nine patients (38%) reported no foreign travel in the 
last 12 months and the travel history was unknown for 
the remaining 15 (62%). 
Two patients had no identifiable risk factors for CRE 
colonisation or infection and risk factor data was not 
provided for two patients. Of the remaining 20 patients, 
17 (85%) had more than one risk factor. Reported risk 
factors included; Hospitalisation in the past 12 months 
(15; 75%), history of surgery in the past six months (9; 
45%), history of admission to intensive care in the last 
12 months (3; 15%). Reported underlying co-morbidities 
included: immunocompromise (7 patients), renal 
disease (5 patients), diabetes mellitus (4 patients), liver 
disease (3 patients), chronic lung disease (1 patient) and 
urological abnormality (1 patient). 
Antimicrobial exposure history prior to isolation of CRE 
was provided for 10 patients (42%), all of whom were 
hospitalised. Of those, nine had recent antimicrobials, 
with six having received more than one antimicrobial 
class: 
• β lactam - β lactamase inhibitor combination agents;  
9 (100%) 
• Carbapenems; 3 (33%) 
• Aminoglycosides; 3 (33%)
• Cephalosporins; 2 (22%)
• Fluoroquinolones; 2 (22%) 
The clinical significance of the CRE isolate was reported 
for 20 patients (83%), representing colonisation in the 
majority (n=13). CRE infection was reported for the 
remaining seven patients, with three cases of urinary 
tract infection, two cases of surgical site infection and 
one case each of respiratory tract and intra-abdominal 
infection. 
Half of CRE (n=12) were isolated from screening swabs 
(rectal or stoma). Five isolates were detected from urine 
(21%), two each from vascular catheter tips, respiratory 
specimens and tissue specimens and one from a 
superficial swab. 
Outcome was reported for one of the three non-
hospitalised patients (who survived) and for 17 of the 
21 hospitalised patients (81%). Of those, nine (53%) 
were discharged home, two (12%) remained inpatients 
at the time the surveillance form was returned, one 
of whom had already had CRE infection and it is not 
known whether or not the second CRE colonised 
patient subsequently went on to develop CRE infection 
later in the hospital admission. Six patients died (35%). 
For two of the six deaths, the patient was reported 
to have had CRE infection. The potential contribution 
of CRE to patient death was not collected. Date of 
death was provided for four patients. Thus the interval 
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between CRE positive specimen date and death could 
be calculated for four patients and was four, 17 and 
19 days, respectively with CRE isolated from a post 
mortem specimen obtained from the final patient.
Length-of-stay could be calculated for all nine admitted 
patients. The median length-of-stay was 18 days (range: 
3 – 77).
Klebsiella pneumoniae accounted for 20 CRE isolates. 
There were two cases each of Escherichia coli CRE 
and Citrobacter freundii CRE reported to enhanced 
surveillance.  
The carbapenemase enzyme types reported to 
enhanced surveillance in 2013 were; OXA-48 (11), 
KPC (11) and NDM-1 (2). This contrasts with 48 CPE 
confirmed by the CPEaRLS in 2013, subdivided as 
follows: KPC (14), OXA-48 (29), NDM-1 (3), IMI (1) and 
IMP (1). Therefore, a significant proportion of confirmed 
CPE cases in 2013 were not reported to the enhanced 
surveillance scheme.
• Carbapenems; Reported minimum inhibitory 
concentrations for meropenem and ertapenem ranged 
from 0.38 to >32 mg/L 
• Gentamicin; Reported on 23 isolates, with 9 resistant 
(39%)
• Amikacin; Reported on 18 isolates, with 7 resistant 
(39%)
• Fluoroquinolones; Reported on 21 isolates, with 15 
resistant (71%) and one of intermediate susceptibility 
• Tigecycline; Reported on 16 isolates; with 5 resistant 
(31%) and 4 with intermediate susceptibility (25%)
• Colistin; Reported on 15 isolates, with none resistant
In response to the emergence of CRE, Irish guidelines 
for the prevention and control of multi-drug resistant 
organisms, excluding MRSA, in the healthcare setting 
were developed under the auspices of the Royal Col-
lege of Physicians of Ireland (RCPI) Clinical Advisory 
Group on Healthcare-Associated Infections and Anti-
microbial Resistance and were first published in early 
2013. In response to the changing epidemiology of 
CRE and other types of multi-drug resistance in Entero-
bacteriaceae in Ireland, the guidelines on screening for 
carriage of resistant Enterobacteriaceae were further 
updated in July 2014. The latest versions of the guide-
lines are available on the HPSC website at the following 
link: http://www.hpsc.ie/A-Z/MicrobiologyAntimicrobi-
alResistance/StrategyforthecontrolofAntimicrobialResis-
tanceinIrelandSARI/CarbapenemResistantEnterobacte-
riaceaeCRE/ScreeningforCREinIreland/
Please note that in the reduction in reported cases 
between 2012 and 2013 reflects under-reporting 
rather than a true decline in CRE. Twice as many 
isolates were confirmed by the CPEaRLS, Galway 
University Hospital (n=48) than were reported to the 
voluntary CRE enhanced surveillance scheme (n=24) 
in 2013.
Acknowledgements: 
Sincere thanks to colleagues working in microbiology 
laboratories and infection prevention and control teams 
across Ireland for submitting enhanced surveillance data 
on patients with CRE.
Sincere thanks also to colleagues in the CPEaRLS, 
Galway University Hospital for data on confirmed 
carbapenemase producing Enterobacteriaceae in 2013 
(Source: CPEaRLS annual report). 
Figure 1. Annual trends in CRE cases and types reported to 
HPSC since enhanced surveillance of CRE commenced in 2011. 
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HPSC Annual Epidemiological Report 201310
Computerised Infectious Disease 
Reporting System (CIDR)
OMPUTERISED INFECTIOUS DISEASE REPORTING – 
CIDR OPERATIONS
SEXUALLY TRANSMITTED INFECTION 
SURVEILLANCE ON CIDR
Initiated at the end of 2012, implementation of 
the notification of case-based laboratory-identified 
notifiable sexually transmitted infections using CIDR 
was completed in 2013.  The completion of this 
implementation led to significant improvements in 
accuracy and timeliness of notification, analysis and 
reporting of these diseases.  The inclusion of STI 
surveillance on CIDR resulted in an expected increase 
in the total number of infectious disease notifications 
made through CIDR in 2013 and represents the highest 
annual number of notifications recorded on CIDR to 
date.
INFRASTRUCTURE AND SOFTWARE UPGRADE FOR 
CIDR
Building on the virtualisation of the CIDR architecture 
in 2012, the infrastructure and software were upgraded 
from the CIDR2 (32-bit) to CIDR3 (64-bit) virtual 
environment in 2013.  Use of the 64-bit server, database 
and CIDR Application software improved system 
performance by maximising the use of additional 
memory available in the CIDR infrastructure.  The 
upgrade also ensured that the latest 64-bit tools and 
applications can be used in the CIDR architecture where 
required.
INFORMATION SECURITY ACCREDITATION
Following a full re-accreditation audit as required 
every four years, HPSC and CIDR retained ISO 
27001 accreditation in 2013.  The HPSC Information 
Governance Framework, which includes CIDR, provides 
re-assurance to users and partners of the CIDR system, 
the Data Protection Commissioner and the data 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of  statutory infectious disease notifications and corresponding number 
of diseases in CIDR per year, since 2005 when national implementation commenced (as of 18th 
September 2014)
Summary
STI surveillance on CIDR was implemented nationally
•  The highest ever annual number of notifications was 
recorded on CIDR in 2013
•  Major infrastructure and software upgrade from CIDR2 
(32 bit) to CIDR3 (64 bit) virtual environment was 
completed
•  IS27001 Information Security accreditation was retained
• The number of active CIDR users in 2013 was 246
•  Delivery of CIDR user training transferred from central 
delivery at HPSC to local delivery in Public Health 
Departments and Laboratories
•  Outbreak management functionality was improved
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subjects relating to sensitive data stored and managed 
by the system.  Maintenance of this accreditation 
standard is vital to information security.
CIDR USER TRAINING
Delivery of CIDR User training was transferred from 
central delivery at HPSC to local delivery in Public 
Health Departments and Laboratories.  The de-
centralisation of CIDR training became necessary as 
a result of reduced resources in Public Health and 
Laboratories where staff were finding it increasingly 
difficult to travel to HPSC for training and at HPSC 
where availability of trainers was reduced due to 
other duties.  Local training by previously trained 
and experienced users was made possible by the 
virtualisation of the CIDR environment and the 
availability of the CIDR Test / Training system on the 
Government Virtual Private Network.
OUTBREAK MANAGEMENT FUNCTIONALITY 
IMPROVED
The outbreak management functionality of CIDR was 
re-designed according to end-user specification in 2013 
for delivery early in 2014.  The changes to the system 
were extensive and designed to simplify and streamline 
the use of the outbreak functions.  The enhanced 
surveillance data associated with outbreak management 
was expanded significantly in this re-design.
GOVERNANCE AND COMMUNICATIONS
The National CIDR Steering Group continued to provide 
guidance and oversight of CIDR through 2013 and met 
by teleconference on four occasions during the year. 
The wider National CIDR User Group convened on four 
occasions throughout the year, also by teleconference, 
to discuss the ongoing use of CIDR and associated 
developments.
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Figure 2. The number of users of the CIDR system in 
Departments of Public Health, in diagnostic and reference 
laboratories and in HPSC in 2013 (total=246)
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29
Public Health 
Labs
HPSC
HPSC Annual Epidemiological Report 2013  
Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures for the year 2013 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on the 12th September, 2014. Please note that some figures may differ from figures 
published previously or other chapters in this report, due to ongoing updating of notification data on CIDR.
Figures on EARS-Net pathogens and certain sexually transmitted infections (specifically, ano-genital warts and non-
specific urethritis) are not presented here, since these diseases were not reported via the CIDR system during 2013; 
separate databases are used to collate data on these diseases.
Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2013) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Ano-genital warts Human papilloma virus
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)  
Botulism Clostridium botulinum
Brucellosis Brucella spp.
Campylobacter infection Campylobacter spp.
Carbapenem-resistant Enterobacteriaceae infection 
(invasive) 
Carbapenem-resistant Enterobacteriaceae (blood, CSF or other normally 
sterile site)
Chancroid Haemophilus ducreyi
Chickenpox – hospitalised cases Varicella-zoster virus
Chikungunya disease Chikungunya virus
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium difficile infection Clostridium difficile
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease  
variant Creutzfeldt Jakob disease  
Cryptosporidiosis Cryptosporidium parvum, hominis
Cytomegalovirus infection (congenital) Cytomegalovirus
Dengue fever Dengue virus
Diphtheria Corynebacterium diphtheriae or ulcerans (toxin producing)
Echinococcosis Echinococcus spp.
Enterococcal bacteraemia Enterococcus spp. (blood)
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale Klebsiella granulomatis
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) infection Hepatitis A virus
Hepatitis B (acute and chronic) infection Hepatitis B virus
Hepatitis C infection Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Human immunodeficiency virus infection Human immunodeficiency virus
Influenza Influenza A and B virus
Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF)
Legionellosis Legionella spp.
Leprosy Mycobacterium leprae
Leptospirosis Leptospira spp.
Listeriosis Listeria monocytogenes
Lyme disease (neuroborreliosis) Borrelia burgdorferi
Lymphogranuloma venereum Chlamydia trachomatis
Malaria Plasmodium falciparum, vivax, knowlesi, ovale, malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis  
Noroviral infection Norovirus
Paratyphoid Salmonella Paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Pseudomonas aeruginosa infection (invasive) Pseudomonas aeruginosa (blood or CSF)
Q Fever Coxiella burnetii
Rabies Rabies virus
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Respiratory syncytial virus infection Respiratory syncytial virus
Rotavirus infection Rotavirus
Rubella Rubella virus
Salmonellosis Salmonella spp. other than S. Typhi and S. Paratyphi
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella spp.
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus group B infection (invasive) Streptococcus agalactiae (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella spp.
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella Typhi
Typhus Rickettsia prowazekii
Verotoxigenic Escherichia coli infection Verotoxin producing Escherichia coli
Viral encephalitis  
Viral haemorrhagic fevers  
Viral meningitis  
West Nile fever West Nile virus
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
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Table A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2013) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2011 (S.I. No. 452 of 2011)
(Continued)
Infectious Disease Causative Pathogen(s)
Table A1.2 Number of notifiable infectious diseases, 2011-2013 and crude incidence rates of diseases, 2013
Infectious Disease 2011 2012* 2013 CIR 2013
Acute anterior poliomyelitis 0 0 0 0.00
Anthrax 0 0 0 0.00
Bacillus cereus food-borne infection/intoxication 0 0 0 0.00
Bacterial meningitis (not otherwise specified) 35 29 21 0.46
Botulism 1 0 1 0.02
Brucellosis 1 2 1 0.02
Campylobacter infection 2427 2388 2276 49.60
Carbapenem-resistant Enterobacteriaceae infection (invasive) NA 0 0 0.00
Chancroid NA NA 0 0.00
Chickenpox - hospitalised cases NA 80 53 -
Chikungunya disease NA 0 0 0.00
Chlamydia trachomatis infection (genital)† NA NA 6261 136.46
Cholera 0 0 0 0.00
Clostridium difficile infection‡ 1847 1822 1814 39.54
Clostridium perfringens (type A) food-borne disease 0 0 1 0.02
Creutzfeldt Jakob disease 7 5 5 0.11
Creutzfeldt Jakob disease (variant) 0 0 0 0.00
Cryptosporidiosis 428 556 514 11.20
Cytomegalovirus infection (congenital) NA 8 7 0.15
Dengue fever NA 7 15 0.33
Diphtheria 0 0 0 0.00
Echinococcosis 0 0 1 0.02
Giardiasis 57 54 44 0.96
Gonorrhoea NA NA 1293 28.18
Granuloma inguinale NA NA 0 0.00
Haemophilus influenzae disease (invasive) 44 41 41 0.89
Hepatitis A (acute) 19 30 50 1.09
Hepatitis B (acute and chronic) 520 566 429 9.35
Hepatitis C 1241 998 841 18.33
Herpes simplex (genital) NA NA 1136 24.76
Human immunodeficiency virus infection NA 340 341 7.43
Influenza 2077 743 1602 34.92
Legionellosis§ 7 15 14 0.31
Leprosy NA 0 2 0.04
Leptospirosis 16 15 14 0.31
Listeriosis 7 11 8 0.17
Lyme disease NA 8 13 0.28
Lymphogranuloma venereum NA NA 5 0.11
Malaria 61 65 71 1.55
Measles|| 267 103 51 1.11
Meningococcal disease 94 66 81 1.77
Mumps 165 163 223 4.86
Noroviral infection† 990 1704 1489 32.45
Paratyphoid 2 5 2 0.04
Pertussis 229 458 174 3.79
Plague 0 0 0 0.00
Q fever 5 6 0 0.00
Rabies 0 0 0 0.00
Respiratory syncytial virus infection† NA 1972 1283 27.96
Rotavirus infection† 2451 2651 2514 54.79
Rubella 4 9 0 0.00
Salmonellosis 310 313 324 7.06
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0.00
Shigellosis 42 29 49 1.07
Smallpox 0 0 0 0.00
Staphylococcal food poisoning 0 0 0 0.00
Streptococcus group A infection (invasive) 67 122 168 3.66
Streptococcus group B infection (invasive)¶ NA 77 66 -
Streptococcus pneumoniae infection (invasive) 425 427 637 13.88
Syphilis** NA 494 555 12.10
Tetanus 0 1 1 0.02
Toxoplasmosis 32 36 32 0.70
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Trichinosis 0 0 0 0.00
Trichomoniasis NA NA 75 1.63
Tuberculosis 413 359 380 8.28
Tularemia 0 0 0 0.00
Typhoid 14 8 10 0.22
Typhus 1 0 0 0.00
Verotoxigenic Escherichia coli infection 284 554 702 15.30
Viral encephalitis 23 18 6 0.13
Viral haemorrhagic fevers 0 0 0 0.00
Viral meningitis 220 235 281 6.12
West Nile fever NA 0 1 0.02
Yellow fever 0 0 0 0.00
Yersiniosis 6 2 4 0.09
Total 14839 17595 25982
Notes: 
1. NA: Indicates that data not available in CIDR for the diseases and years indicated above
2. CIR, Crude incidence rate per 100,000 total population
*  In 2012, new notifiable diseases were introduced on January 1st 2012 along with the revised versions of case definitions of certain diseases at 
that time
†  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
‡  Since 01/01/2012 both new and recurrent cases of Clostridium difficile infection are notifiable, prior to this only new cases were notifiable; 
please interpret comparisons between current and historical data with caution 
§  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to 
a confirmed measles case
¶ Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
**  Syphilis data were reported via CIDR from May 2011, but syphilis data for 2011 are excluded from this appendix as they represent only a 
portion of the cases notified in 2011
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Infectious Disease 2011 2012* 2013 CIR 2013
Table A1.2 Number of notifiable infectious diseases, 2011-2013 and crude incidence rates of diseases, 2013
(Continued)
Table A1.3 Number of notifiable infectious diseases by HSE area, 2013
Infectious Disease
HSE 
E
HSE 
M
HSE 
MW
HSE 
NE
HSE 
NW
HSE 
SE
HSE 
S
HSE 
W
Total
Bacterial meningitis (not otherwise specified) 9 1 4 0 2 3 1 1 21
Botulism * * * * * * * * 1
Brucellosis * * * * * * * * 1
Campylobacter infection 697 160 214 155 108 343 383 216 2276
Chickenpox - hospitalised cases 32 2 6 2 1 1 7 2 53
Chlamydia trachomatis infection (genital)† 3346 247 465 334 242 659 498 470 6261
Clostridium difficile infection‡ 816 39 159 87 94 175 206 238 1814
Clostridium perfringens (type A) food-borne disease * * * * * * * * 1
Creutzfeldt Jakob disease 3 0 0 0 0 2 0 0 5
Cryptosporidiosis 25 43 74 34 60 88 86 104 514
Cytomegalovirus infection (congenital) 3 0 0 3 0 0 1 0 7
Dengue fever 8 1 2 0 0 1 0 3 15
Echinococcosis * * * * * * * * 1
Giardiasis 14 6 4 5 1 2 8 4 44
Gonorrhoea 830 43 67 53 35 90 119 56 1293
Haemophilus influenzae disease (invasive) 10 4 3 6 3 5 6 4 41
Hepatitis A (acute) 20 1 0 12 3 2 9 3 50
Hepatitis B (acute and chronic) 260 14 20 30 7 19 52 27 429
Hepatitis C 607 27 35 44 9 27 58 34 841
Herpes simplex (genital) 694 33 64 27 13 105 97 103 1136
Human immunodeficiency virus infection 235 10 21 14 5 12 33 11 341
Influenza 645 64 165 148 104 129 138 209 1602
Legionellosis§ 10 1 1 0 0 2 0 0 14
Leprosy * * * * * * * * 2
Leptospirosis 6 0 1 2 0 1 2 2 14
Listeriosis 1 2 2 0 1 1 0 1 8
Lyme disease 1 1 1 0 1 3 4 2 13
Lymphogranuloma venereum 5 0 0 0 0 0 0 0 5
Malaria 41 4 1 7 2 6 2 8 71
Measles|| 19 1 2 1 1 22 2 3 51
Meningococcal disease 28 6 7 7 5 12 9 7 81
Mumps 101 13 17 13 10 30 20 19 223
Noroviral infection† 712 75 167 179 60 72 70 154 1489
Paratyphoid * * * * * * * * 2
Pertussis 68 4 11 8 8 39 23 13 174
Respiratory syncytial virus infection† 520 93 144 95 125 162 54 90 1283
Rotavirus infection† 502 330 170 211 169 419 414 299 2514
Salmonellosis 98 23 39 37 18 30 46 33 324
Shigellosis 17 3 15 1 0 1 9 3 49
Streptococcus group A infection (invasive) 67 7 16 14 6 21 18 19 168
Streptococcus group B infection (invasive)¶ 35 3 0 13 2 1 8 4 66
Streptococcus pneumoniae infection (invasive) 199 11 91 38 38 169 56 35 637
Syphilis 420 11 13 16 5 14 52 24 555
Tetanus * * * * * * * * 1
Toxoplasmosis 13 8 2 1 1 1 3 3 32
Trichomoniasis 37 7 6 9 4 5 4 3 75
Tuberculosis 151 16 32 30 16 31 68 36 380
Typhoid 5 0 0 1 0 1 2 1 10
Verotoxigenic Escherichia coli infection 89 70 151 15 16 148 111 102 702
Viral encephalitis 1 0 0 0 2 2 0 1 6
Viral meningitis 98 13 28 27 16 20 15 64 281
West Nile fever * * * * * * * * 1
Yersiniosis * * * * * * * * 4
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these 
diseases in 2013
*  Data not reported to HSE area level when total number in Ireland <5 cases
†  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
‡  C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2013 epidemiological calendar year as shown here
§  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to 
a confirmed measles case
¶ Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
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Table A1.4 Number of notifiable infectious diseases by HSE region, 2013
Infectious Disease
Dublin Mid 
Leinster
Dublin 
North East
South West
HSE E LHO area 
unspecified
Total
Bacterial meningitis (not otherwise specified) 7 3 4 7 0 21
Botulism * * * * * 1
Brucellosis * * * * * 1
Campylobacter infection 617 395 726 538 0 2276
Chickenpox - hospitalised cases 16 20 8 9 0 53
Chlamydia trachomatis infection (genital)† 566 632 1157 1177 2729 6261
Clostridium difficile infection‡ 591 351 381 491 0 1814
Clostridium perfringens (type A) food-borne disease * * * * * 1
Creutzfeldt Jakob disease 1 2 2 0 0 5
Cryptosporidiosis 59 43 174 238 0 514
Cytomegalovirus infection (congenital) 2 4 1 0 0 7
Dengue fever 8 1 1 5 0 15
Echinococcosis * * * * * 1
Giardiasis 15 10 10 9 0 44
Gonorrhoea 692 234 209 158 0 1293
Haemophilus influenzae disease (invasive) 7 13 11 10 0 41
Hepatitis A (acute) 18 15 11 6 0 50
Hepatitis B (acute and chronic) 143 161 71 54 0 429
Hepatitis C 399 279 85 78 0 841
Herpes simplex (genital) 528 226 202 180 0 1136
Human immunodeficiency virus infection 141 118 45 37 0 341
Influenza 411 446 267 478 0 1602
Legionellosis§ 10 1 2 1 0 14
Leprosy * * * * * 2
Leptospirosis 4 4 3 3 0 14
Listeriosis 3 0 1 4 0 8
Lyme disease 2 0 7 4 0 13
Lymphogranuloma venereum 2 3 0 0 0 5
Malaria 27 25 8 11 0 71
Measles|| 6 15 24 6 0 51
Meningococcal disease 22 19 21 19 0 81
Mumps 69 58 50 46 0 223
Noroviral infection† 359 293 142 381 314 1489
Paratyphoid * * * * * 2
Pertussis 47 33 62 32 0 174
Respiratory syncytial virus infection† 279 215 216 359 214 1283
Rotavirus infection† 447 265 833 638 331 2514
Salmonellosis 81 77 76 90 0 324
Shigellosis 15 6 10 18 0 49
Streptococcus group A infection (invasive) 51 37 39 41 0 168
Streptococcus group B infection (invasive)¶ 21 30 9 6 0 66
Streptococcus pneumoniae infection (invasive) 100 148 225 164 0 637
Syphilis 288 159 66 42 0 555
Tetanus * * * * * 1
Toxoplasmosis 17 5 4 6 0 32
Trichomoniasis 19 34 9 13 0 75
Tuberculosis 104 93 99 84 0 380
Typhoid 3 3 3 1 0 10
Verotoxigenic Escherichia coli infection 152 22 259 269 0 702
Viral encephalitis 1 0 2 3 0 6
Viral meningitis 79 59 35 108 0 281
West Nile fever * * * * * 1
Yersiniosis * * * * * 4
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these 
diseases in 2013
*  Data not reported to HSE region level when total number in Ireland <5 cases
†  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
‡  C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2013 epidemiological calendar year as shown here
§  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
||  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to 
a confirmed measles case
¶ Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants
Table A1.5 Number of notifiable infectious diseases by age group (years), 2013
Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Bacterial meningitis (not otherwise 
specified)
7 0 0 3 3 2 2 0 2 2 0 21
Botulism 1 0 0 0 0 0 0 0 0 0 0 1
Brucellosis 0 0 0 0 0 0 0 1 0 0 0 1
Campylobacter infection 524 118 72 121 166 331 205 211 204 322 2 2276
Chickenpox - hospitalised cases 35 7 3 0 0 2 1 0 1 4 0 53
Chlamydia trachomatis infection 
(genital)*
¬ ¬ ¬ 746 2640 2279 410 111 38 6 12 6261
Clostridium difficile infection† 27 10 7 21 29 100 82 132 183 1223 0 1814
Clostridium perfringens (type A) food-
borne disease
0 0 0 0 0 0 0 0 0 1 0 1
Creutzfeldt Jakob disease 0 0 0 0 0 0 1 1 2 1 0 5
Cryptosporidiosis 295 103 56 16 8 23 8 0 1 3 1 514
Cytomegalovirus infection (congenital) 7 0 0 0 0 0 0 0 0 0 0 7
Dengue fever 0 0 0 0 7 4 1 1 0 2 0 15
Echinococcosis 0 0 0 0 0 1 0 0 0 0 0 1
Giardiasis 6 1 3 0 8 12 5 4 2 3 0 44
Gonorrhoea ¬ ¬ ¬ 136 424 488 164 48 21 4 4 1293
Haemophilus influenzae disease 
(invasive)
10 1 0 0 1 5 2 0 7 15 0 41
Hepatitis A (acute) 3 2 3 1 2 15 12 4 7 1 0 50
Hepatitis B (acute and chronic) 1 2 1 7 39 190 114 45 17 12 1 429
Hepatitis C 5 1 2 6 28 276 291 161 52 18 1 841
Herpes simplex (genital) ¬ ¬ ¬ 126 318 402 191 59 28 7 2 1136
Human immunodeficiency virus infection 1 2 0 3 37 130 100 48 16 4 0 341
Influenza 165 95 57 49 44 174 239 188 141 444 6 1602
Legionellosis‡ 0 0 0 0 0 0 2 5 1 6 0 14
Leprosy 0 0 0 0 0 1 1 0 0 0 0 2
Leptospirosis 0 0 0 2 3 2 0 4 2 1 0 14
Listeriosis 3 0 0 0 0 0 0 0 1 4 0 8
Lyme disease 0 0 1 1 1 1 3 4 1 1 0 13
Lymphogranuloma venereum ¬ ¬ ¬ 0 0 3 2 0 0 0 0 5
Malaria 3 3 6 2 3 7 24 16 3 3 1 71
Measles§ 29 14 3 2 1 1 1 0 0 0 0 51
Meningococcal disease 47 8 2 9 3 0 3 1 3 5 0 81
Mumps 40 20 21 23 33 35 25 13 6 7 0 223
Noroviral infection* 221 39 10 11 25 59 47 61 113 896 7 1489
Paratyphoid 0 0 0 0 0 2 0 0 0 0 0 2
Pertussis 72 23 9 8 4 14 14 20 4 6 0 174
Respiratory syncytial virus infection* 1194 9 6 1 5 11 3 8 11 35 0 1283
Rotavirus infection* 2402 87 7 1 1 5 0 2 2 6 1 2514
Salmonellosis 74 16 17 10 22 49 46 22 35 33 0 324
Shigellosis 7 4 3 0 7 12 6 6 2 2 0 49
Streptococcus group A infection 
(invasive)
23 14 6 6 10 17 13 14 15 50 0 168
Streptococcus group B infection 
(invasive)||
66 0 0 0 0 0 0 0 0 0 0 66
Streptococcus pneumoniae infection 
(invasive)
44 12 2 5 6 28 40 45 105 350 0 637
Syphilis 0 0 0 3 54 182 178 91 32 15 0 555
Tetanus 0 0 0 0 1 0 0 0 0 0 0 1
Toxoplasmosis 1 0 3 0 3 14 5 3 1 2 0 32
Trichomoniasis ¬ ¬ ¬ 3 7 31 15 19 0 0 0 75
Tuberculosis 7 2 0 11 37 89 80 55 45 54 0 380
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Typhoid 1 2 2 0 0 4 1 0 0 0 0 10
Verotoxigenic Escherichia coli infection 303 55 28 25 20 55 53 28 43 92 0 702
Viral encephalitis 2 0 0 0 0 0 0 1 0 3 0 6
Viral meningitis 127 8 10 27 17 45 35 7 2 3 0 281
West Nile fever 0 0 0 0 0 0 0 0 0 1 0 1
Yersiniosis 3 0 0 0 0 0 0 1 0 0 0 4
Total 5756 658 340 1385 4017 5101 2425 1440 1149 3647 38 25982
Notes: 
1.  This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these 
diseases in 2013
*  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
†  C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2013 epidemiological calendar year as shown here
‡  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to 
a confirmed measles case
||  Streptococcus group B infection (invasive) infections in infants <90 days old or stillborn infants 
¬  Data for the age groups 0-4 years, 5-9 years and 10-14 years are not presented here, but data for the age group 0-14 years are available in 
the STI annual slide-set at www.hpsc.ie  
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Infectious Disease 0-4 5-9 10-14 15-19 20-24 25-34 35-44 45-54 55-64 65+ Unknown Total
Table A1.5 Number of notifiable infectious diseases by age group (years), 2013
(Continued)
Table A1.6 Number of notifiable infectious diseases by gender, 2013
Infectious Disease Male Female Unknown Not Specified Total
Bacterial meningitis (not otherwise specified) 13 8 0 0 21
Botulism 1 0 0 0 1
Brucellosis 0 1 0 0 1
Campylobacter infection 1196 1072 8 0 2276
Chickenpox - hospitalised cases 28 24 1 0 53
Chlamydia trachomatis infection (genital)* 2750 3421 89 1 6261
Clostridium difficile infection† 696 1117 1 0 1814
Clostridium perfringens (type A) food-borne disease 1 0 0 0 1
Creutzfeldt Jakob disease 1 4 0 0 5
Cryptosporidiosis 298 216 0 0 514
Cytomegalovirus infection (congenital) 2 5 0 0 7
Dengue fever 7 8 0 0 15
Echinococcosis 0 1 0 0 1
Giardiasis 23 21 0 0 44
Gonorrhoea 1021 261 11 0 1293
Haemophilus influenzae disease (invasive) 11 30 0 0 41
Hepatitis A (acute) 23 27 0 0 50
Hepatitis B (acute and chronic) 247 177 5 0 429
Hepatitis C 573 263 5 0 841
Herpes simplex (genital) 305 821 10 0 1136
Human immunodeficiency virus infection 255 86 0 0 341
Influenza 678 922 2 0 1602
Legionellosis‡ 9 5 0 0 14
Leprosy 1 1 0 0 2
Leptospirosis 10 4 0 0 14
Listeriosis 4 4 0 0 8
Lyme disease 6 7 0 0 13
Lymphogranuloma venereum 5 0 0 0 5
Malaria 48 22 1 0 71
Measles§ 25 26 0 0 51
Meningococcal disease 44 37 0 0 81
Mumps 126 97 0 0 223
Noroviral infection* 649 838 2 0 1489
Paratyphoid 1 1 0 0 2
Pertussis 84 90 0 0 174
Respiratory syncytial virus infection* 720 561 2 0 1283
Rotavirus infection* 1342 1163 9 0 2514
Salmonellosis 172 152 0 0 324
Shigellosis 20 29 0 0 49
Streptococcus group A infection (invasive) 95 73 0 0 168
Streptococcus group B infection (invasive)|| 37 20 9 0 66
Streptococcus pneumoniae infection (invasive) 315 322 0 0 637
Syphilis 446 105 4 0 555
Tetanus 0 1 0 0 1
Toxoplasmosis 15 17 0 0 32
Trichomoniasis 1 74 0 0 75
Tuberculosis 239 139 2 0 380
Typhoid 7 3 0 0 10
Verotoxigenic Escherichia coli infection 324 378 0 0 702
Viral encephalitis 4 2 0 0 6
Viral meningitis 142 132 7 0 281
West Nile fever 1 0 0 0 1
Yersiniosis 2 2 0 0 4
Total 13023 12790 168 1 25982
Notes: 
1. This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these diseases 
in 2013
*  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
†  C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2013 epidemiological calendar year as shown here
‡  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to a 
confirmed measles case
|| Streptococcus group B infection (invasive) infections in infants <90 days  old or stillborn infants
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Table A1.7 Number of notifiable infectious diseases by case classification, 2013
Infectious Disease Confirmed Probable Possible Not Specified Total
Bacterial meningitis (not otherwise specified) 6 5 10 0 21
Botulism 1 0 0 0 1
Brucellosis 1 0 0 0 1
Campylobacter infection 2276 0 0 0 2276
Chickenpox - hospitalised cases 37 3 13 0 53
Chlamydia trachomatis infection (genital)* 6261 0 0 0 6261
Clostridium difficile infection† 1814 0 0 0 1814
Clostridium perfringens (type A) food-borne disease 1 0 0 0 1
Creutzfeldt Jakob disease 5 0 0 0 5
Cryptosporidiosis 511 3 0 0 514
Cytomegalovirus infection (congenital) 7 0 0 0 7
Dengue fever 15 0 0 0 15
Echinococcosis 1 0 0 0 1
Giardiasis 44 0 0 0 44
Gonorrhoea 1293 0 0 0 1293
Haemophilus influenzae disease (invasive) 41 0 0 0 41
Hepatitis A (acute) 47 3 0 0 50
Hepatitis B (acute and chronic) 429 0 0 0 429
Hepatitis C 841 0 0 0 841
Herpes simplex (genital) 1061 75 0 0 1136
Human immunodeficiency virus infection 341 0 0 0 341
Influenza 1582 6 14 0 1602
Legionellosis‡ 14 0 0 0 14
Leprosy 2 0 0 0 2
Leptospirosis 13 1 0 0 14
Listeriosis 8 0 0 0 8
Lyme disease 13 0 0 0 13
Lymphogranuloma venereum 5 0 0 0 5
Malaria 71 0 0 0 71
Measles§ 33 10 8 0 51
Meningococcal disease 74 1 6 0 81
Mumps 80 6 137 0 223
Noroviral infection* 1489 0 0 0 1489
Paratyphoid 2 0 0 0 2
Pertussis 112 9 53 0 174
Respiratory syncytial virus infection* 1283 0 0 0 1283
Rotavirus infection* 2514 0 0 0 2514
Salmonellosis 324 0 0 0 324
Shigellosis 45 4 0 0 49
Streptococcus group A infection (invasive) 158 10 0 0 168
Streptococcus group B infection (invasive)|| 66 0 0 0 66
Streptococcus pneumoniae infection (invasive) 344 0 293 0 637
Syphilis 531 24 0 0 555
Tetanus 0 1 0 0 1
Toxoplasmosis 32 0 0 0 32
Trichomoniasis 75 0 0 0 75
Tuberculosis 287 37 56 0 380
Typhoid 10 0 0 0 10
Verotoxigenic Escherichia coli infection 571 128 3 0 702
Viral encephalitis 3 0 3 0 6
Viral meningitis 266 6 9 0 281
West Nile fever 1 0 0 0 1
Yersiniosis 4 0 0 0 4
Total 25045 332 605 0 25982
Notes: 
1. This table does not include details of diseases for which a zero number of cases were notified; see Appendix A1.1 for details of these diseases 
in 2013
2. The case definitions booklet, available at http://www.hpsc.ie has been updated since 2012; case classifications are assigned to notifications as 
per the Case Definitions for Notifiable Diseases during 2013
*  Since 17/03/2013, due to a change in business process in HSE E, figures for Chlamydia trachomatis infection, Noroviral infection, Respiratory 
syncytial virus infection and Rotavirus infection may refer to notifications rather than events
†  C. difficile figures in the C. difficile chapter are presented by quarter rather than using the 2013 epidemiological calendar year as shown here
‡  Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
§  These tables exclude two measles cases that are on CIDR but were laboratory negative for measles and were not epidemiologically linked to 
a confirmed measles case
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Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system. During 2013, notification data were inputted 
directly by areas using the system. Enhanced 
surveillance was undertaken for certain diseases 
and these data are collated on CIDR. Outbreak data 
were also collated on CIDR using the same process 
outlined above. Weekly Reports on infectious disease 
notifications (including a separate report for Clostridium 
difficile associated disease, HIV & STIs) and outbreaks 
were produced by HPSC and published on the HPSC 
website, www.hpsc.ie. Throughout the year data were 
cleaned and validated on an ongoing basis and final 
data checks and cleaning were undertaken following 
year end by HPSC and the Departments of Public 
Health. Data analysis was performed using CIDR 
Business Objects Reporting and MS Excel. Figures for 
the relevant chapters within this report were extracted 
from CIDR between February and September 2014. 
These figures may differ from those previously published 
due to ongoing updating of data on CIDR.
HIV
HIV was made a notifiable disease in Ireland in 
September 2011. Since 1st January 2012, CIDR has been 
used to record notifications of HIV, thereby allowing 
the replacement of HIV case based reporting. Since 1st 
January 2012, AIDS diagnoses are only reported if they 
occur at the time of HIV diagnoses. 
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
Sexually Transmitted Infections (STIs)
Clinicians notified their respective Departments 
of Public Health of cases of ano-genital warts and 
non-specific urethritis. Data for 2013 were collated 
and analysed by Departments of Public Health and 
aggregated data were reported quarterly to HPSC. 
National data were collated on an MS Access database, 
analysis preformed and reports produced by HPSC.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and the 
Departments of Public Health on the influenza sentinel 
surveillance project. Sixty-one general practices 
(located in all HSE-Areas and representing 5.8% of the 
population) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI).  ILI is defined using 
the Irish case definition for ILI which is sudden onset 
of symptoms AND at least one of the following four 
systemic symptoms: fever, malaise, headache, myalgia; 
AND at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on one ILI patient per week to the 
NVRL. The NVRL also tested respiratory non-sentinel 
specimens, referred mainly from hospitals. Other 
surveillance systems set up to monitor influenza/ILI 
activity include a network of sentinel hospitals reporting 
admissions data. The Departments of Public Health also 
notified HPSC weekly of all cases of influenza (including 
hospitalisation status), all influenza/ILI outbreaks and 
enhanced surveillance data on all hospitalised cases of 
confirmed influenza in 0-14 year olds. HPSC was notified 
of all registered deaths on a daily basis from the General 
Register Office.
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during subsequent influenza seasons:
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
These data were provided by HSE-NE.  
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza in all critical care units and enhanced 
surveillance of all severe acute respiratory infections 
(SARI) in two pilot ICU sites.  
•  Enhanced surveillance of all confirmed influenza 
deaths.
Other routine surveillance include the monitoring of 
the uptake of the seasonal influenza vaccine among 
residents in long term care facilities (LTCFs) and that 
of the health care workers in both LTCFs and hospitals 
since the 2011/2012 season. Uptake levels by different 
categories of staff over time, along with other details 
are presented in the influenza chapter of this report.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
Explanatory Notes
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www.hpsc.ie. Aggregated clinical and virological data 
and annonymised data on confirmed influenza cases 
admitted to hospital were reported weekly to the 
European Centre for Disease Prevention and Control 
(ECDC).
Immunisation Uptake
•  Immunisation uptake among children at 12 and 24 
months of age
Each HSE Area maintains a childhood immunisation 
database. In 2012, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis. National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website. 
For further details on methods used, please see the 
immunisation uptake chapter within this report.
•  HPV uptake
Following a recommendation from the National 
Immunisation Advisory Committee, that human 
papillomavirus (HPV) vaccine should be given to 12 
year old girls, a routine HSE school HPV vaccination 
programme began in May 2010.  HPV vaccinations 
provided through the schools immunisation programme 
are now collated on a national database.  Uptake of 
HPV vaccine, provided through the school immunisation 
programme in the academic year 2012/2013 and 
recorded on the database, is reported in the HPV 
uptake chapter within this report. For further details 
please see the HPV uptake chapter.
•  Other school immunisations excluding HPV
Since the 2011/2012 academic year, the uptake of the 
DTaP and MMR vaccines in 4-5 year old schoolchildren 
(at Junior Infant level) has been monitored across 
all Local Health Offices (LHOs) each year. Each LHO 
provides details of the cohort size and the number 
of vaccinated children and the returns collated to 
calculate uptake levels which are also presented in 
maps in the ‘other school immunisations’ chapter. 
Uptake of the Tdap vaccine, provided through the 
school immunisation programme in the academic year 
2012/2013 and recorded on a national database, is also 
reported in this chapter.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2012 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF). Data were 
reported quarterly to HPSC, via WHONET software, 
and collated in an MS Access database. Quarterly and 
annual reports were produced.
Note: Invasive infections due to K. pneumoniae and P. aeruginosa 
became notifiable as of 13th September 2011.
Antimicrobial consumption
•   Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the 
support of the Irish Antimicrobial Pharmacists 
Association. Quarterly and annual consumption 
trends by named public acute hospitals are published 
on the HPSC website. All data were interpreted 
using the WHO Anatomical Therapeutic Chemicals 
index (www.whocc.no/atcddd/) in line with European 
Surveillance of Antimicrobial Consumption (ESAC-
Net) methodology, which is now managed by 
the ECDC. See relevant section for notes on the 
denominator data.
Healthcare associated infections
•   Clostridium difficile: Data on C.difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to the HPSC and stored in an MS 
Access database. Quarterly and annual reports were 
produced. 
•   Data were also collected on the total volume of 
alcohol-based hand rub used per hospital per year/
quarter, excluding that used for pre-operative surgical 
“scrub”. See relevant section for notes on the 
denominator data. The rate of usage per hospital was 
calculated as the total volume of hand rub consumed 
(in litres) per 1000 bed days used, and quarterly and 
annual reports were produced for publication on the 
HPSC website.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, 
http://www.cso.ie).  Population figures were applied as 
follows: 
•   Census 2011 for analysis of 2009-2013 data 
•   Census 2006 for analysis of 2004-2008 data
•   Census 2002 for 2000-2003 data 
•   Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2013 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rate. 
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA, 
hospital antibiotic consumption and rates used in other 
hospital-based surveillance systems. Similar activity data 
were obtained directly from private acute hospitals.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas). This is because operationally 
the surveillance, prevention and control of infectious 
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diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
Regional Directors of Operations (RDO’s)
The range of health and personal social services 
provided by the HSE and its funded agencies are 
managed within four regions known as RDOs. Details of 
the four RDOs and their relationship with the eight HSE 
areas are shown below.
1.  Dublin Mid Leinster (HSE-Midland plus CCA1-5 and 
CCA9-10 of HSE-East)
2.  Dublin North East (HSE-North East plus CCA6-8 of 
HSE-East)
3.  South (HSE-South and HSE-South East)
4.  West (HSE-Midwest, HSE-North West and HSE-West)
-195-HPSC Annual Epidemiological Report 2013 Explanatory Notes
Glossary of Terms 
CIDR Computerised Infectious Disease Reporting
DoHC Department of Health
EARS-Net European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
MRSA Meticillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NSRL National Salmonella Reference Laboratory
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organization
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